Mechanisms of Resistance to EGFR Inhibition in HNSCC by Ludwig, Megan





A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy 
(Cellular and Molecular Biology) 




Assistant Professor Chad Brenner, Chair  
Professor Thomas E Carey   
Associate Professor Hui Jiang 
Associate Professor Mukesh Nyati 




































As I’ve learned during my course of study, it takes a team to train a graduate student. To 
my mentors, to my lab mates, to my friends, to my family – thank you all for your generous and 
unending support. I would not be the scientist or the person I am today without you.  
First, to Chad. Thank you for letting me join your team. Thank you for your insight, your 
patience, your continual optimism, and your calm in the midst of chaos. It’s been a special 
privilege to be your first graduate student.   
I would also like to thank my committee members, Drs. Thomas Carey, Hui Jiang, 
Mukesh Nyati, and Andrew Tai. Dr. Carey, thank you for your encouragement, your support, and 
your insightful questions over the course of my training. Thank you to Dr. Jiang for your 
strategies and feedback on tackling data analytics, and thank you to Dr. Nyati and Dr. Tai for 
your thoughtful questions that moved my project forward. I walked out of committee meetings 
inspired with new approaches and new questions to tackle, and I greatly appreciate all of your 
support and guidance during my training.  
Thank you to the CMB graduate program, whose diversity in research topics and event 
participation made for an enjoyable program. Thank you to Dr. Robert Fuller and Dr. Kathy 
Collins as well as the CMB support staff (Cathy Mitchell, Margarita Bekiares, Jim Musgrave, 
Jessica Kijek, Pat Ocelnik, and Lauren Perl) for helping me navigate the stages of graduate 
school.  
 iii 
Also, a big collective thank you to the members of the Brenner and Carey labs, past and 
present. Working alongside you at the bench has made science a joy. Brittany and Sue, thank you 
for everything you do to keep the lab running smoothly. Aditi and Apurva, thank you for being 
fantastic bay-mates. Nicole, Jackie, and Elizabeth, thank you for the scientific and non-scientific 
discussions as we collectively dealt with graduate school. Thank you to Dr. Andrew Birkeland 
for your clinical insights and research. Thank you to Collin and Jingyi for your insight and 
support during lab meetings. Thank you to the many undergraduate students who trained me as I 
trained them. Sai Nimmagadda, Dylan Genouw, Lindsay Remer, Juliet Gunther, Michelle 
Nyugen, Zechariah Diaz-Grace, Xavier Garcia, Rasika Patel, and Lydia Weykamp, thank you for 
all the science that you’ve accomplished, and I wish you the best of luck in your bright futures. I 
would also like to thank Dr. Heather Walline for jump-starting this project during your time at 
the Brenner lab and for your continued support beyond, and Dr. Todd Festerling whose continual 
insight and training helped develop me into the scientist I am today.  
I would also like to thank my previous scientific mentors during my undergraduate 
training. Drs. Maria Burnatowska-Hledin and Joseph Stukey at Hope College, thank you for your 
teachings and trainings in both the lecture halls and labs during my time at Hope. To Dr. Eric 
Hendrickson at the University of Minnesota, thank you for the opportunity to learn and train in 
your lab, and thank you to Eu Han for training me from the beginning. I am grateful for your 
time and investment into my training.  
Thank you to my friends for your support throughout graduate school. The happy hours 
and the coffee breaks and the Marvel movie nights kept me sane when the pressures were high.  
Finally, last but certainly not least, thank you to my family. It’s only with your 







Table of Contents 
 
Acknowledgements ii 
List of Tables vii 
List of Figures ix 
Abstract xii 
Chapter 1 : Exploring the Potential for Targeted Therapies in LSCC and the Generation of 
CRISPR/Cas9 Screening Libraries 1 
Chapter Summary 1 
1.1 Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma 1 
Abstract 1 
Introduction 2 
Historical Treatment of LSCC 3 
Genetic Landscape of LSCCs 6 
Common Mutations and Copy Number Variations 6 
Human Papillomavirus (HPV) in LSCC 8 
Translating Genetics into Targeted Therapies 9 
Immunotherapy 15 
Overcoming Challenges for Targeted Therapy 17 
Algorithms for Integrating LSCC Organ Preservation/Treatment 19 
Conclusion 21 
1.2 Generation and utilization of CRISPR/Cas9 screening libraries in mammalian cells 22 
Introduction 22 
Methodology 23 





Chapter 2 : The Genomic Landscape of UM-SCC Oral Cavity Squamous Cell Carcinoma 
Cell Lines 57 
Abstract 57 
Introduction 58 







Chapter 3 : Using CRISPR/Cas9 Screening Libraries to Identify Mechanisms of Resistance 









Chapter 4 : Investigating FGFR as a Common Resistance Mechanism to EGFR Inhibition 











Chapter 5 : Summary and Perspectives 232 
Summary 232 
Section 1: Challenges to precision medicine in HNSCC 232 
Section 2: Utilizing CRISPR screens to identify co-dependent genes and/or pathways 235 
Section 3: Identifying & Validating Resistance Mechanisms 238 
Section 4. Future Directions 243 
Bibliography 245 
 vii 
List of Tables 
 
Table 1-1. Frequently mutated genes in LSCC samples ............................................................... 40 
Table 1-2. Common copy number variations ............................................................................... 41 
Table 1-3. UM-SCC cell lines derived from LSCC patients ........................................................ 42 
Table 2-1. Clinical statistics of patients from which the oral cavity SCC cell lines were derived.
....................................................................................................................................................... 81 
Table 2-2. Genomic variants in UM-SCC lines, part one ............................................................. 82 
Table 2-3. Genomic variants in UM-SCC cell lines, part two ...................................................... 83 
Table 2-4. Karyotyping results from UM-SCC-69 ....................................................................... 85 
Table 2-5. Karotyping results from UM-SCC-92 ......................................................................... 87 
Table 2-6. Estimated copy numbers for UM-SCC oral cavity cell line panel .............................. 89 
Table 2-7. Antibody information .................................................................................................. 90 
Table 3-1. Genomic primers ....................................................................................................... 132 
Table 3-2. Antibodies.................................................................................................................. 133 
Table 3-3. qPCR primers ............................................................................................................ 134 
Table 3-4. CRISPR library statistics ........................................................................................... 135 
Table 3-5. Significance of six nominated genes across all library screens ................................. 136 
Table 3-6. Gene sets enriched in individual Kinase library screens ........................................... 142 
Table 3-7. Gene sets enriched in individual GeCKO library screens ......................................... 150 
Table 4-1. Antibodies used for immunoblotting ......................................................................... 195 
 viii 
Table 4-2. Primers used for qPCR and genomic amplification .................................................. 196 
Table 4-3. Sequencing statistics for samples from patients receiving cetuximab ...................... 197 
Table 4-4. Non-synonymous mutations in EGFR K/O cell line ................................................. 199 
Table 4-5. Kinases and receptors upregulated in the EGFR K/O cell line ................................. 200 
Table 4-6. Upregulated gene sets enriched in each of the 13 cetuximab-treated gene sets and 
EGFR K/O gene sets ................................................................................................................... 213 
Table 4-7. Downregulated gene sets enriched in each of the 13 cetuximab-treated gene sets and 






List of Figures 
 
Figure 1-1. Key components of the PI3K pathway and possible thereapuetics ............................ 35 
Figure 1-2. Major oncogenic mechanisms in LSCC and thereapuetic opportunities ................... 36 
Figure 1-3. Decision algorithm for treating LSCC patients .......................................................... 37 
Figure 1-4. Diagram of gRNA in complex with Cas9 enzyme..................................................... 38 
Figure 1-5. Schematic of CRISPR library generation .................................................................. 39 
Figure 2-1. Mutation load in UM-SCC lines ................................................................................ 71 
Figure 2-2. Single nucleotide variants identified in the UM-SCC oral cavity cell line panel ...... 72 
Figure 2-3. Single nucleotide variants for non-UM-SCC oral cavity cell lines............................ 73 
Figure 2-4. Sanger sequencing validation of mutations................................................................ 74 
Figure 2-5. Genetic heterogeneity of UM-SCC oral cavity cell lines characterized by copy 
number alterations ......................................................................................................................... 75 
Figure 2-6. Genome-wdie view of copy number alterations for oral cavity UM-SCC cell lines . 76 
Figure 2-7. Copy number calls from normalized keratinocytes HEKa ........................................ 77 
Figure 2-8. Expression of TCGA related genes in the UM-SCC oral cavity cell lines ................ 78 
Figure 2-9. FISH confirmation of cell line heterogeneity ............................................................. 79 
Figure 2-10. Summary of the oncogenic pathways genetically disrupted in the UM-SCC oral 
cavity cell line panel ..................................................................................................................... 80 
Figure 3-1. CRISPR library constructs ....................................................................................... 116 
Figure 3-2. Workflow schematic of the CRISPR library screen ................................................ 117 
 x 
Figure 3-3. Response of UM-SCC-49 to cisplatin ...................................................................... 118 
Figure 3-4. Library coverage plots for cisplatin and vehicle treated libraries ............................ 119 
Figure 3-5. Cisplatin CRISPR screen nominates Notch signaling pathway ............................... 120 
Figure 3-6. Response of NOTCH1 K/O model to cisplatin ........................................................ 121 
Figure 3-7. UM-SCC resistance to EGFR inhibitor gefitinib ..................................................... 122 
Figure 3-8. Library coverage plots for GeCKO libraries ............................................................ 123 
Figure 3-9. Overlap of GeCKO libraries .................................................................................... 124 
Figure 3-10. Overlap of GeCKO library for each inhibitor ........................................................ 125 
Figure 3-11. Library coverage for Kinase libraries .................................................................... 126 
Figure 3-12. Overlap of Kinase CRISPR library ........................................................................ 127 
Figure 3-13. Overlap of Kinase CRISPR library for each inhibitor ........................................... 128 
Figure 3-14. Gene set enrichment analysis of Kinase and GeCKO CRISPR screens ................ 129 
Figure 3-15. Response of MARVELD3 K/O clone to EGFR inhibition .................................... 130 
Figure 3-16. Response of FGFR3 K/O clones to EGFR inhibition ............................................ 131 
Figure 4-1. Cell line responses to EGFR and FGFR combination treatment ............................. 176 
Figure 4-2. Cell death by annexin V+ staining ........................................................................... 177 
Figure 4-3. Immunoblot of UM-SCC lines, 24 hour post-treatment .......................................... 178 
Figure 4-4. Copy number analysis of UM-SCC lines ................................................................. 179 
Figure 4-5. Expression analysis of UM-SCC lines ..................................................................... 180 
Figure 4-6. Immunoblot of UM-SCC cell lines, 1 hour post-treatment...................................... 181 
Figure 4-7. FGFR transcript analysis during EGFR inhibition .................................................. 182 
Figure 4-8. Genetic and protein confirmation of EGFR K/O cell line ....................................... 183 
Figure 4-9. Phenotype of EGFR K/O cell line ............................................................................ 184 
 xi 
Figure 4-10. Transcript analysis of EGFR K/O compared to WT .............................................. 185 
Figure 4-11. Signaling changes in EGFR K/O model by immunoblot ....................................... 186 
Figure 4-12. Response of EGFR K/O cell line to FGFR monotherapy ...................................... 187 
Figure 4-13. No response of EGFR K/O to EGFR inhibition..................................................... 188 
Figure 4-14. Cell signaling effects of inhibitors in mouse xenograft model .............................. 189 
Figure 4-15. Tumor volumes of mouse xenografts ..................................................................... 190 
Figure 4-16. Representative pictures of mouse xenograft tumors harvested at 21 days ............. 191 
Figure 4-17. Mouse weights during xenograft experiment ......................................................... 192 
Figure 4-18. Gene set enrichment analysis of 13 HNSCC tumors treated with cetuximab and 
EGFR K/O cell line ..................................................................................................................... 193 




Head and neck squamous cell carcinoma (HNSCC) remains a deadly disease with poor 
prognosis. Developing novel, effective combination therapies have the potential to improve 
patient survival. However, advancing biomarkers in conjunction with combination therapy will 
also be essential for efficacy so as to match treatment to the patient. In my thesis, I investigated 
the hypothesis that co-targeting a specific mechanism of resistance with combination therapy 
would be more effective than either therapy alone. I focused on identifying resistance 
mechanisms to cisplatin and EGFR inhibition, which are common HNSCC treatments, in UM-
SCC cell lines using CRISPR/Cas9 screening libraries. This approach identified genetic 
knockouts that sensitized cell lines to either cisplatin or EGFR inhibition.  
The results of a CRISPR/Cas9 screen nominated NOTCH pathway knockouts and 
specifically NOTCH1 knockouts as capable of sensitizing cisplatin-resistance cells. Further 
results suggest that the combination of Notch inhibitors and cisplatin therapy are capable of 
overcoming cisplatin resistance, and that inactivating mutations in NOTCH1 may be a biomarker 
of cisplatin sensitivity. I also used genome and kinome CRISPR libraries to identify genetic 
knockouts that sensitized resistant models to the EGFR inhibitors gefitinib and erlotinib. I 
observed that PIK3C2A may be an important linchpin in the PI3K pathway for mediating 
resistance, as well as identified an unexpected set of genes associated with KRAS signaling, 
nominating KRAS as a potential mediator of resistance to EGFR inhibition in HNSCC. 
Furthermore, my CRISPR/Cas9 screens also nominated FGF/FGFR knockouts as sensitizing 
cells to EGFR inhibition.  
 xiii 
Extending these discoveries, I investigated the potential of dual EGFR and FGFR 
inhibition by testing multiple UM-SCC cell lines. I observed that FGFR may be a more common 
compensatory mechanism that previously realized, with 14/22 (63%) of cell lines undergoing 
cell death when challenged with combination therapy. Surprisingly, neither copy number or 
expression of FGFRs predicted responsiveness to the combination of EGFR and FGFR 
inhibition. To explore the mechanism behind this response, I generated an EGFR K/O model and 
showed that FGFR signaling increases when EGFR protein is lost. Evaluation of the discovery in 
vivo demonstrated that dual inhibition of EGFR and FGFR was able to significantly decrease 
tumor volume in a xenograft mouse model, supporting the in vivo relevance of this combination 
for HNSCC. Consistent with the literature, dual EGFR and FGFR inhibition caused weight loss 
in animals suggesting a high level of toxicity; thus, this data suggests that new ways to target the 
pathway are critical to future clinical success. Finally, to evaluate potential clinical relevance, we 
analyzed transcriptome profiles of tumors from patients who received the EGFR inhibitor 
cetuximab. We observed changes in the FGFR receptors, KRAS signaling, and PI3K-mTOR 
signaling, consistent with our profiling data.  
Overall, my thesis work supports the hypothesis that there are specific and common 
compensatory pathways to EGFR inhibition and cisplatin, and that co-targeting EGFR or 
cisplatin with this compensatory pathway is more effective than monotherapy treatments. The 
CRISPR/Cas9 screens and transcriptome analysis have generated a wealth of data that can 
continue to be explored to develop novel, effective strategies for combination therapy. 
Collectively, this body of work represents a step forward in the understanding of how HNSCC 
tumors compensate in response to two prevalent therapies, and may provide the foundation for 
opportunities to advance combination therapies and improve survival of HNSCC patients.  
 1 
Chapter 1 : Exploring the Potential for Targeted Therapies in LSCC and the Generation of 
CRISPR/Cas9 Screening Libraries 
 
Chapter Summary 
In this chapter, I review the potential for implementing targeted therapy approaches in laryngeal 
squamous cell carcinoma, using the laryngeal subsite as a model for head and neck squamous 
cell carcinoma. I discuss opportunities as well as obstacles for implementing targeted therapies in 
this cancer. Then, I discuss the utility and generation of CRISPR/Cas9 screening libraries, with 
the goal of using CRISPR/Cas9 screens to identify further opportunities for targeted therapy 
approaches that will be discussed in later chapters.  
  
1.1 Changing the paradigm: the potential for targeted therapy in laryngeal 
squamous cell carcinoma1  
Abstract 
Laryngeal squamous cell carcinoma (LSCC) remains a highly morbid and fatal disease.  
Historically, it has been a model example for organ preservation and treatment stratification 
paradigms.  Unfortunately, survival for LSCC has stagnated over the past few decades.  As the 
era of next generation sequencing and personalized treatment for cancer approaches, LSCC may 
be an ideal disease for consideration of further treatment stratification and personalization.  Here, 
                                                 
1 This section was published in Cancer Biology & Medicine in collaboration with the following authors: Andrew 
Birkeland, Rebecca Hoesli, Paul Swiecicki, Matthew Spector, and J. Chad Brenner 
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we will discuss the important history of LSCC as a model system for organ preservation, unique 
and potentially targetable genetic signatures of LSCC, and methods for bringing stratified, 
personalized treatment strategies to the 21st century. 
 
Introduction 
 Laryngeal squamous cell carcinoma (LSCC) remains a prevalent disease, accounting for 
over 150,000 new cases annually across the world(1).  Previous clinical trials in LSCC 
demonstrated the potential for non-surgical, organ-preservation treatment options for LSCC, with 
similar survival rates to surgery(2, 3).  While these initial organ-preserving paradigms have 
gradually become the predominant treatment choice for LSCC(4), no new treatment options have 
surfaced in the ensuing decades.  For recurrent LSCC after chemotherapy, radiation, or surgery, 
treatments are limited. This is particularly concerning given the continued poor survival in 
advanced or recurrent LSCC, where 5-year survival is less than 50%(5) and has not improved in 
decades(6).    
 Whole exome and genome sequencing studies have recently provided valuable insight 
into dysregulated pathways and potential drivers of disease in multiple cancers, including head 
and neck cancers(7-10).  These early studies have identified novel genetic mutations and 
pathway dysregulations across a variety of head and neck cancers.  Importantly, LSCCs have 
constituted a significant portion of the tumors in these studies.  
 Cancer treatment is entering an exciting new era, combining the information gained from 
next-generation sequencing studies with targeted therapeutics to allow for models of 
personalized cancer care.  Indeed, cancer sequencing and targeted therapy trials are being 
launched globally, and with some encouraging initial results(11-13).  LSCC may prove to be an 
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ideal model for further investigation into personalized targeted therapies given its successful 
history in response to nonsurgical techniques, previous paradigms for treatment 
stratification(14), and the need to improve survival in this important cohort. 
Here, we will discuss the important history of LSCC as a model system for organ 
preservation, current knowledge of the genomic landscapes, targeted therapies for LSCC, and 
potential strategies for developing stratified, personalized treatment strategies for LSCC. 
 
Historical Treatment of LSCC  
 For early stage LSCC, single modality therapy (surgery or radiation) achieves cure for a 
majority of patients. However, patients with locally advanced disease had historically required 
total laryngectomy followed by adjuvant radiation as the gold standard treatment. Unfortunately, 
many of these surgeries are accompanied by significant morbidity and many patients are left with 
significant swallowing difficulties, communication difficulties, and poor cosmetic outcomes(15). 
Thus, in the 1990s, investigations began into equally effective but less morbid therapies.  
 As a result, the Veterans Affairs (VA) Laryngeal Cancer Study(2) was performed.  In this 
prospective randomized controlled study, 332 patients with advanced LSCC were stratified 
between induction chemotherapy (three cycles of cisplatin and 5-FU) followed by definitive 
radiation versus laryngectomy followed by postoperative radiation. Patients in the chemotherapy 
group were assessed after two cycles of chemotherapy; those that showed clinical response to 
therapy went on to receive one final cycle of chemotherapy followed by radiation. Those that had 
no response to therapy or disease progression after two cycles went on to immediate 
laryngectomy and then post-operative radiation.  There was no difference in two-year survival 
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between the chemotherapy and surgery groups, and laryngeal function was preserved in 64% of 
the patients in the chemotherapy group. This study established that organ preservation in LSCC 
was a feasible goal of treatment, while still providing equivalent overall survival.   
 These findings were confirmed with data from a randomized study in Europe (EORTC 
trial 24891)(16), where patients with cancers of the hypopharynx underwent either induction 
chemotherapy consisting of cisplatin and 5-FU followed by irradiation, or surgical resection 
followed by post-operative radiotherapy. In this study, again overall survival was equivalent, and 
laryngeal preservation was achieved in greater than 50% of patients after 5 years. A third study 
(RTOG 91-11)(17) compared concurrent chemotherapy and radiation, induction chemotherapy 
followed by radiation, and standard radiation therapy. This study found that laryngeal 
preservation was significantly higher in patients receiving concurrent chemoradiation. It is 
important to note this study did exclude large volume T4 tumors with cartilage invasion or 
extension into the base of the tongue. Finally, investigators at the University of Michigan studied 
the utility of a single cycle of induction chemotherapy in LSCC as stratification for further 
treatment in a phase II clinical trial(14). Over 75% of patients had response to induction 
chemotherapy, and overall larynx preservation was achieved in 70% of patients.  This study 
verified that paradigms of treatment stratification could be utilized in LSCC. 
 These trials together demonstrated the efficacy of combined chemotherapy and radiation 
therapy in treating locally advanced LSCC while maintaining the functional status of the larynx. 
Additionally, they showed that treatment with induction chemotherapy did not increase 
complications for surgical treatment or radiotherapy administered afterwards. Finally, although 
there was no benefit in overall survival, a significant reduction in the rate of distant metastasis 
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was shown in the chemotherapy group as compared with primary surgery or radiation therapy 
alone(2, 16-19).  
 Although there was significant improvement in organ preservation gained by treatment 
with induction chemotherapy, unfortunately overall outcomes in LSCC remain poor. In the 
European study, disease free survival at 5 years remained at 25% and 27% for the chemotherapy 
arm and immediate surgery arm respectively(16). Additionally, patients who responded poorly to 
chemotherapy were likely to respond poorly to radiation(20). As such, research began into 
molecular markers to predict radiosensitivity and chemosensitivity in order to better personalize 
therapy and more accurately predict which patients would be eligible for laryngeal preservation. 
 Several studies have evaluated various molecular biomarkers in an attempt to better 
predict a response to therapy. Malecki looked at EGFR, p53, and Ki-67, which are biomolecular 
markers found to be altered in patients with HNSCC. In his retrospective trial, only patients 
without the presence of EGFR expression were noted to have a significantly improved response 
to induction chemotherapy(21). In LSCC specifically, it has been recently found that levels of 
BAK, a gene involved in apoptosis, is associated with response to induction chemotherapy. The 
same study identified cyclin D1 as a predictor of LSCC overall and disease-specific survival, and 
over expression of EGFR as associated with risk of death(22).  
 These biomarker studies have led to clinical trials to evaluate novel therapies with the 
potential to improve outcomes in LSCC. For examples, we previously showed that AT-101, 
which inhibits the anti-apoptotic genes Bcl-2 and Bcl-XL, effectively blocks proliferation in 
LSCC models(23) and have now initiated an on-going trial specifically targeted LSCC 
evaluating the use of AT-101, in combination with induction chemotherapy with platinum and 
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docetaxel ( NCT01633541). Further combinations of traditional chemotherapy, radiation and 
targeted therapies may be applicable for LSCC.  While traditional biomarker studies have been 
limited in identifying additional targetable options, recent whole-genome sequencing studies 
have shed more light into potential key pathways in LSCC.  
 
Genetic Landscape of LSCCs 
Along with the possibility of identifying additional biomarkers of LSCCs, genomic 
sequencing offers the potential to identify drivers of tumorigenesis and targets for new therapy. 
Initial exome sequencing studies have already produced valuable insights into the underlying 
genetic processes, nominating multiple pathways as potential targets for LSCC treatment.  
 
Common Mutations and Copy Number Variations 
Initial exome-sequencing studies by Agrawal(7) and Stransky et al(8) contained some 
LSCCs in their chosen HNSCC cohort (n=2 and n=15 respectively), but the smaller sample size 
did not give a broad view of genetic alterations in LSCC. The Cancer Genome Atlas (TCGA) has 
now whole-genome sequenced 29 HNSCC tumor-normal pairs (low coverage, 30x) and whole 
exome sequenced 279 HNSCC tumor-normal pairs (high coverage), of which 72 are primary 
LSCCs(9). These LSCC samples are predominantly Caucasian (n=57, 79.2%), male (n=58, 
80.6%), and older (mean age = 61). Additionally, most patients had a smoking history (n=50, 
69.4%) and were diagnosed at Stage III or IV (n=55, 76.4%)(9) , with very few 
epidemiologically low risk patients in the cohort(24). The initial studies by Agrawal and 
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Stransky had similar cohort characteristics. Publicly available databases compiling clinical, 
mutation, and copy number data were used for the analysis of this manuscript(25, 26).  
Previously, evaluating the existence of distinct mutation profiles in LSCCs from other 
subsites has been limited from lack of power. The significant contribution of the HNSCC cohort 
from the TCGA has allowed the question to begin to be addressed. Many genes that are 
frequently mutated are common to all HNSCC subsites such as TP53, CDKN2A, FAT1, and 
NOTCH1 (Table 1-1). CASP8, a gene whose product plays a central role in the cell carrying out 
apoptosis, is frequently mutated in other HNSCCs. However, CASP8 has significantly less 
mutations in LSCCs compared to the other subsites (p<0.005). Studies have suggested that 
CASP8 mutations indicate a distinct molecular profile of SCCs(27, 28), but this subset does not 
seem to exist in LSCCs. Additionally, mutations in PIK3CA trend towards occurring more 
frequently in LSCCs than other subsites (p=0.058), and copy number amplification of 3q26 
which contains PIK3CA is found at significantly higher frequency in LSCCs compared to other 
HNSCCs (p<0.001, Table 1-2). Additionally, amplifications of 3q28 and 9q34 occur at 
significantly higher frequency in LSCCs (p<0.001, p<0.007).  
While it is clear that many of the aberrations in HNSCC are common across subsites, 
differences are beginning to emerge as more LSCC samples are being sequenced. By sequencing 
more LSCCs, we will begin to understand if these differences are due to anatomical subsite or 
epidemiologic variation between tumors. Likewise, as genome-wide information continues to 
become available, no doubt distinct subsets of molecular mechanisms will be identified.   
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Human Papillomavirus (HPV) in LSCC 
The link between HPV status and HNSCC has been well established at some anatomical 
subsites(29, 30); for example, HPV appears to be a common initiating event in oropharyngeal 
SCCs . The oncogenic potential of high-risk HPVs in LSCCs is not as clear. Studies with larger 
sample sizes (where n>80) over the past thirty years have shown HPV prevalence in LSCC 
tumors from as low as 1% to as high as 50%(31). However, studies have also found HPV DNA 
in up to 19% of normal laryngeal mucosa samples(32-35), indicating that a significant portion of 
HPV positive LSCCs that have been reported may be latent HPV infections, and more specific 
techniques should be used to truly determine HPV positivity. In contrast to many of the PCR-
based studies, the HNSCC TCGA project relied on multiple methods of detection including 
RNA-sequencing and identified only one HPV positive LSCC case (1.4%)(9). The low 
prevalence of HPV in this study indicates that HPV rates may have been historically 
overestimated in some LSCCs cohorts with similar epidemiology to the TCGA cohort, and 
unfortunately the low number of samples detected in LSCC will make it difficult to study the 
extent of the oncogenic role of HPV in LSCC until more studies are performed.  This significant 
variance between studies is most likely due to both the method of detection and the differential 
rates of HPV infection in each region. For example, HPV DNA PCR assays are capable of 
detecting very few copies of the viral DNA and some have argued that these assays are too 
sensitive, able to pick up viral DNA from a transient infection rather than an integrated event35,36.  
Consequently, many additional assays have been developed that rely on detecting 
common downstream events of HPV biology or directly sequencing across genomic insertion 
sites. For example, when HPV integrates into the genome, early genes E6 and E7 are highly 
 9 
expressed(36). E7 then inactivates pRb, causing increased levels of p16INK4A  which can be 
detected by immunohistochemistry(37). Thus, using the downstream protein expression of p16 
as a surrogate marker for HPV has become a widely acceptable method and clinically relevant 
method(38). Likewise, a second method of detecting HPV integration is to directly sequence the 
genomic breakpoints between the viral and human genomes. This method is usually cost 
prohibitive at this point, due to the high cost of whole genome sequencing, but may become 
more routine in the future. Regardless as the methods for rapid detection and location of HPV 
insertion sites in the genome improve, so will our understanding of the prevalence and 
pathogenic role for this virus in LSCC.   
 
Translating Genetics into Targeted Therapies 
The potential to improve patient survival by using genetic information to match optimal 
treatments can be seen in a growing number of successes in other cancers: imatinib for chronic 
myelogenous leukaemia(39), trastuzumab for breast cancer with ERBB2 amplification(40), and 
erlotinib and gefitinib for lung cancers that express mutant EGFR(41). Here, we will review a 
few specific molecular lesions that are altered in a large percentage of LSCC cases and have a 
similar potential for molecularly driven clinical trials.  
 
PI3K Pathway 
PIK3CA mutations and amplifications frequently occur in LSCCs. PIK3CA encodes 
p110α, the alpha catalytic subunit to the phosphoinositide 3-kinase (PI3K) which plays a central 
role in pathways involved in cell growth, survival, and metabolism(42). PI3K receives signals 
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from activated receptor tyrosine kinases such as EGFR and VEGFRs, and phosphorylates the 
lipid PIP2 on the cell membrane to create PIP3. AKT is then activated by PIP3, resulting in a 
downstream cascade through multiple effectors including GSK-3 and mTOR (Fig 1-1). This 
pathway has been noted to be frequently overactive in other cancers including gastric, breast, and 
lung(43), and developing therapies targeting this pathway are underway(44).  
The majority of mutations found in PIK3CA have been defined as ‘hotspot’ mutations, 
where the specific amino acid residue is recurrently altered in multiple tumor types(45). These 
hotspot mutations, such as E542K, E545K, and H1047L/R, have functional consequences of 
increasing the lipid activity resulting in overactive AKT signaling and downstream effector 
pathway activation(46). The over activation of the PI3K pathway in these cancer cells could 
make the cells reliant on these signals(47). For example, Garnett et al(48) found that PIK3CA 
mutations were a significant biomarker of sensitivity for several drugs targeting the PI3K 
pathway after screening over 600 cancer cell lines, including 23 HNSCC lines, against 130 drugs 
at clinical and preclinical stages. HNSCC cell lines with hotspot PIK3CA mutations 
demonstrated sensitivity to PI3K/mTOR inhibitors compared to PIK3CA wildtype cells, in both 
in vitro(49) and in vivo models(50). These preclinical results are now being tested in early 
clinical trials for patients with a variety of advanced cancers, including HNSCCs. In a phase I 
trial, patients containing PIK3CA mutations had significantly greater partial response rates to 
PI3K/AKT/mTOR therapy (6/17, 35%) than those without PIK3CA mutations (6/241, 6%)(51). 
A following early-phase trial indicated that only the H1047R mutation predicted partial response 
(6/16, 38%) compared to other PIK3CA mutations (5/50, 10%) or PIK3CA wildtype (23/174, 
13%)(52). However, this study also noted that other hotspot PIK3CA mutations, such as E542K 
and E545K, had a strong association with KRAS mutations whereas the H1047R mutation did 
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not. As members of the Ras signaling pathway (KRAS, HRAS) have been known to mediate 
resistance to PI3K inhibition(53, 54), it is unsurprising that patients with both gene mutations 
may not respond to PI3K-targeting monotherapies. Notably, KRAS mutations are rare in 
HNSCCs(55-57), and there are no KRAS mutations present in the recent exome sequenced 
LSCCs(7-9). HRAS mutations occur with more prevalence(50), and of the 2 HRAS mutations in 
sequenced LSCCs both occur in tumors with additional PIK3CA hotspot mutations11,12. 
However, 68.4% (13/19) of the PIK3CA mutations in LSCCs are hotspot mutations without Ras 
mutations, and PI3K-targeted therapies could be a well-matched choice for this patient 
population. 
 In contrast, amplification of 3q26 with the PIK3CA gene has not been found to indicate 
sensitivity to PI3K-targeted therapy(48, 49). It is still unclear how the amplification of the 
PIK3CA gene affects the signaling of the PI3K pathway. While it has been shown that 
amplification of PIK3CA correlates with increased mRNA and protein expression of p110α(58), 
it does not necessarily lead to increased levels of phosphorylated Akt and mTOR as would be 
expected for increased pathway activation(49). Given the significant amplification of 3q26 in 
LSCCs specifically, it is crucial to understand the effects this amplification has on tumorigenesis 
whether PIK3CA or another nearby gene is the cause. 
 
EGFR & HER2 
The important role that the Epidermal Growth Factor Receptor (EGFR) plays in HNSCCs 
has been known for several decades(59, 60) as it has been shown to be overexpressed in >90% of 
HNSCCs. A tyrosine kinase receptor, EGFR belongs to the ERBB family of cell-surface 
receptors. Upon ligand binding to the receptor, EGFR homodimerizes or heterodimerizes with 
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other ERBB family receptors such as HER2 and initiates a signaling cascade(61). Potential 
activated pathways include Ras-MEK and PI3K/AKT/mTOR as discussed above, as well as 
signal transducers and activators of transcription (STATs). EGFR signaling can contribute to 
tumorigenesis by driving cell proliferation, evasion of apoptosis, angiogenesis, and 
metastasis(62).  
Consistent with the molecular role of EGFR, Cetuximab, a monoclonal antibody 
targeting EGFR, is currently the only approved targeted molecular therapeutic for HNSCCs. The 
combination of cetuximab and radiation therapy has been shown to extend patient survival by 
19.3 months compared to radiation alone in patients with recurrent or metastatic disease(63). 
However, contrasting the clear story of EGFR mutations in lung adenocarcinomas predicting 
sensitivity to EGFR-targeted therapies(41), there are still no biomarkers that predict response to 
cetuximab.   
Part of the reason for the lack of biomarkers in HNSCC as compared to lung 
adenocarcinomas may be due to the differential genetic lesions. On contrast to lung cancers 
where EGFR mutation is a common event, EGFR mutations are rare in HNSCCs (13/279, 
4.7%)(9), while amplifications have been reported to vary between 10-30% (64). In HNSCC 
TCGA data, LSCCs had a similar frequency of amplification as other subsites at around 12% 
(Table 1-2). However, amplification of EGFR correlated with worse overall survival in LSCCs 
specifically(65). Additionally, in a phase II trial advanced LSCC patients received a single cycle 
of induction chemotherapy before stratification into surgery and radiation or chemoradiation 
treatments. Here, EGFR expression predicted increased risk of death(22). While there is no 
evidence for any biological difference in EGFR signaling between HNSCC subsites, the 
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prognostic role of EGFR in LSCCs specifically suggests an especially critical role of this 
receptor and pathway.  
Activating similar pathways is the HER2 receptor which heterodimerizes with EGFR as 
well as other members of the ERBB family. While HER2 amplifications seem rare (3/72, 
4.2%)(9), experiments in LSCC cell lines have shown response to anti-HER2 therapy in models 
with HER2 over-expression(66). Targeting HER2 in this distinct subset of patients looks 
promising as research continues, and significant improvements to patient survival might be made 
through focusing on targeting this pathway for LSCCs. 
Notch Signaling 
The frequency of NOTCH1 mutations in HNSCCs was surprising when first discovered, 
additionally so as many of the mutations were predicted to be loss-of-function(7). Traditionally, 
the Notch signaling pathway has been studied in an oncogenic role as activating mutations in 
NOTCH1 have been shown to significantly contribute to tumorigenesis for several malignances 
including chronic lympocytic leukemia (CLL)(67) and prostate cancer(68). However, solid 
tumors such as lung squamous cell carcinoma, cutaneous squamous cell carcinoma(69), and 
HNSCC display loss-of-function mutations indicative of Notch signaling have a role as a tumor 
suppressor.  
The Notch signaling pathway is a direct cell-cell communication network, where a 
signaling cell displays a ligand that binds and activates the receptor on the receiving cell 
membrane. There are four receptors, NOTCH1-4, which upon activation are cleaved by gamma 
secretase, following which the intracellular domain (ICD) of the receptor is translocated to the 
nucleus resulting in transcriptional activation of target genes.  
 14 
In keratinocytes, it has been shown that Notch activity controls cell cycle exit as well as 
commitment to differentiation(70), where loss of NOTCH1 promotes tumorigenesis(71). 
Importantly, the loss of Notch signaling leads to an accumulation of β-catenin expression and an 
increase in Wnt pathway activity(72), and Wnt signaling has been shown to have an oncogenic 
role in multiple cancers(73). The possibility of addiction to Wnt signaling resulting from a loss 
of Notch signaling creates the opportunity for therapeutic intervention. Indeed, the PORCN 
inhibitor (this gene palmitoylates WNT ligands enabling their secretion into the tumor niche) 
called WNT974 has shown inhibition of growth of HNSCC models with loss-of-function 
mutations in NOTCH1(74). Accordingly, we have now opened a phase II clinical trial for 
metastatic HNSCC patients that will be enriched for NOTCH-deficient cancer to receive 
WNT974 (NCT02649530). As 17% of LSCCs contained mutations in NOTCH1, WNT974 is a 
potential targeted therapeutic that will be evaluated for further clinical advancement.  
 In contrast to inactivating NOTCH mutations, a small subset of studies have also reported 
that over-activation of Notch signaling can contribute to HNSCC(75). As LSCCs have a 
significant amplification of NOTCH1 compared to other HNSCC subsites (p-value<0.007, Table 
1-2), Notch signaling may also act as an oncogene for a defined subset. A role as both an 
oncogene and tumor suppressor suggests Notch signaling can have a bimodal effect in HNSCCs, 
dependent on timing and order of mutations. These roles will need to be further elucidated to 
directly target Notch signaling or any of its modulators.  
 
Cyclin D1 (CCND1) 
The CCND1 gene encodes cyclin D1, a member of a highly conserved cyclin family. 
Cyclin D1 regulates cyclin-depending kinases (CDKs) 4 and 6 which control the G1/S phase 
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transition of the cell cycle. The amplification or gain of 11q13, which contains CCND1, is a 
frequent event in LSCCs specifically (36.1%, Table 1-2). Importantly, high expression of cyclin 
D1 correlated with increased risk of death in advanced LSCC patients(22). The efficacy of CDK 
inhibitors to prevent cell cycle progression by overexpressed cyclin D1 is an area of active 
investigation in LSCC. Currently, multiple clinical trials investigating CDK4/6 inhibitors in 
HNSCC are underway(76), where the inhibitor palbociclib has already shown efficacy in breast 
cancer(77). The extent of correlation between high expression of cyclin D1 and patient response 
to CDK inhibitors will be critical to clarifying the potential biomarker role of CCND1 
amplification status.    
 
Immunotherapy 
An additional novel treatment option for LSCC that has rapidly advanced in recent years 
involved immune modulating agents. Immune dysregulation and escape have been increasingly 
recognized as a hallmark of cancer and potential therapeutic target over the past several 
years(78).  It is believed that the adaptive immune system recognizes and eliminates pre-
malignant cells. Progressive derangements in the immune system driven by transformed cells 
gradually leads to immune escape and widespread tumor proliferation(79). Observed 
derangements include inflammatory cytokine expression and activation of inflammatory 
transcription factors in tumor cells(80, 81).  LSCC and other subsites of HNSCC have been 
demonstrated to be markedly immunosuppressive via numerous mechanisms, including 
downregulation of antigen presenting via human leucocyte antigen (HLA) class I molecules(9, 
82-84), development of T-cell tolerance to overexpressed antigens(85, 86), inhibitory cytokine 
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production(87, 88), and increased programmed death-ligand 1 (PD-L1)/ programmed death-1 
(PD-1) expression(89-91). 
 Based on these preclinical findings, numerous potential targets and interventions have 
been proposed. Monoclonal antibodies targeting cytotoxic T-lymphocyte-associated protein-4 
(CTLA-4) (ipilimumab), PD-1 (pembrolizumab), or PD-L1 (nivolumab) have been developed 
with the goal of manipulating mechanisms of tumor escape and eliciting an adaptive immune 
system response targeted towards the tumor(92).  Therapy in patients refractory to standard 
therapy has been well-tolerated and yielded favorable response rates(93-100). However, of more 
excitement, there are a few patients that appear to achieve lasting complete disease response.  
These durable responses are being observed in patients who previously would have had a rapidly 
terminal disease. PD-1/PD-L1 inhibitors have now been approved for metastatic non-small cell 
lung cancer, renal cell cancer, and melanoma. 
 Given the clinical efficacy in other malignancies and the immunologic underpinnings, 
immunotherapy is an avenue of significant interest in LSCC.  Various modalities are under 
development, including vaccine therapy and targeted monoclonal antibodies.  Although many of 
these trials are ongoing, preliminary data has been presented of the Phase I/II KEYNOTE-012, 
where a cohort of 132 HNSCC patients with unresectable recurrent or metastatic tumors were 
treated with the PD-1 inhibitor pembrolizumab.  This cohort was heavily pretreated with 59% of 
patients having received 2 or more previous lines of therapy for recurrent or metastatic disease. 
The overall response rate was observed to be 24.8% with an additional 24.8% achieving stable 
disease.  At the time of the interim report, the median duration of response was not reached and 
86% of responding patients appeared to have an ongoing response(101).  Correlative analysis 
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suggested that an inflamed genotype gene expression was able to predict 6 month progression 
free survival and response to anti-PD-1 therapy(102).  
 A few trials are examining the incorporation of immunotherapy in the management of 
locoregional HNSCC, including LSCC.  These include neoadjuvant vaccine administration 
(NCT02002182, NCT02609386), concomitant cetuximab and ipilimumab with intensity 
modulated radiation therapy (IMRT) (NCT01860430), and addition of nivolumab to concomitant 
cisplatin and IMRT (RTOG3504).  Although the majority of trials are targeting recurrent or 
metastatic HNSCC (all subsites), the preliminary promise of immunotherapy in advanced and 
recurrent HNSCC cases suggest that LSCC patients could benefit from this novel therapeutic 
approach. 
 
Overcoming Challenges for Targeted Therapy 
 While targeted therapies have had several clinical successes in other cancers, these are 
often in tumors with relatively few “actionable” aberrations. In contrast to tumors with low 
genetic complexity, the relatively high number genomic alterations in LSCCs coupled with the 
complex level of intra-tumor genetic heterogeneity will make distilling the critical pathways 
disrupting tumor growth difficult to identify. Moving forward, additional LSCC genetic 
information and models for tumors associated with both under-represented epidemiologic-risk 
groups and genetic landscapes are needed to improve our ability to predict the response of 
tumors to genetic lesion-matched therapeutics. 
 18 
 As mentioned above, the available genetic information for LSCC tumors is currently 
largely limited to previously untreated, stage III/IV tumors from Caucasian patients with a 
history of tobacco and/or alcohol use. Genetic information from untreated early stage (I/II) 
LSCC tumors would be beneficial to isolating initial aberrational events that drive tumorigenesis. 
Likewise, as patients are most likely to enroll in personalized medicine trials with advanced or 
recurrent tumors, genomic landscapes of advanced tumors following relapse from frontline 
therapy would be the most beneficial for designing novel interventional strategies. 
Unfortunately, large sequencing studies of tumors from previously treated, advanced LSCC 
tumors have not yet been published, with the exception of a few small cohorts demonstrating that 
advanced and recurrent LSCCs typically have higher numbers of genetic aberrations than 
untreated counterparts(10). These studies are critical because they demonstrate proof-of-principle 
that the genomic landscape of LSCC tumors evolve with therapeutic course. Thus, an important 
goal for the immediate future is to build a comprehensive understanding of the genetic and 
molecular interaction between the highly recurrent disruptive genomic events found at each stage 
of tumor progression.  
 Importantly, several LSCC models already exist that can be used to dissect the genetic 
and molecular mechanisms of LSCC pathogenesis, but these are also limited to a few 
epidemiologic subsets and few genetic landscapes. For example, LSCC cell line models from 
primary, metastatic, and recurrent tumors(103), including two pairs of primary and metastatic 
cell lines from the same patient(104) and an HPV-positive line(105) (Table 1-3). While the 
value of these existing cell lines is clear, more models of various stages and pre/post-treatment 
status consistent with normal interventional progression are still needed to fully explore 
therapeutic responses at various points in the normal pathogenic course.  
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 In addition to cell lines, models in which surgically excised tissue from patients is 
implanted into immunocompromised mice called patient-derived xenograft (PDX) models have 
recently gained traction as powerful tools for assessing therapeutic responses in pre-clinical 
studies. In fact, HNSCC studies using PDX models in this manner have already been used to 
support the translation of targeted strategies into clinical trials(106), supporting the utility of 
these models. Early studies have indicated that HNSCC PDX models represent parental tumors 
by histology(107, 108), gene expression profiles(109), single-nucleotide polymorphisms(110), 
copy number variants(110, 111) and proteome profiles(112) and there also has not been an 
indication that engraftment of the tumor is biased by either genetic or clinical factors, including 
HNSCC subsite(113). Unfortunately the expense as well as the variable grafting rate (30-80% 
reported for HNSCC) is currently limiting the wide-spread use(114), but once the PDX model is 
established, the tumor can be propagated and expanded into additional mice for parallel, 
sequential, and long-term therapeutics experiments(115). Moving forward, the establishment and 
characterization of LSCC PDX models from both untreated and pretreated tumors will be 
essential for the advancement of therapeutics for different epidemiologic and genetic subsets of 
LSCC.   
 
Algorithms for Integrating LSCC Organ Preservation/Treatment  
 As noted above, LSCC historically has been a unique and successful model for treatment 
selection and for organ preservation.  However, with the current evolving state of genetics and 
targeted agents in cancer, we will need to revisit treatment algorithms for this disease. 
 While existing selection paradigms have been focused on objective clinical response to 
induction chemotherapy(14), future goals would be to identify these potential responders to 
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organ-preservation therapy without the need for an induction chemotherapy cycle. Through next 
generation sequencing studies, we have already identified specific genetic pathways that may be 
of interest for targeted therapy in LSCC (Fig 1-2).  Further incorporating patient genetic 
information into treatment algorithms for LSCC could serve to further stratify and improve 
patient outcomes (Fig 1-3). As the cost and turnaround for targeted next generation improves, 
valuable time could be saved to initiation of definitive treatment, and patients could be treated 
more specifically and effectively.   
 Specific issues should be considered as treatment algorithms are adapted to include new 
agents and genomic sequencing. An important decision in use of targeted therapies is whether 
they should be used irrespective of mutational status (as cetuximab is currently used in HNSCC), 
or whether targeted therapies should be employed only in those patients with genetic aberrations.  
Additionally, protocols will need to be designed and implemented investigating these agents in 
different clinical scenarios (i.e. neoadjuvant vs. adjuvant, monotherapy vs. combination therapy, 
early vs. late stage tumors, primary vs. recurrent tumors, Fig 1-3). Likewise, we must consider 
when and where to add immunotherapy into LSCC treatment algorithms. In a similar fashion to 
targeted therapy, we must identify predictive biomarkers to allow for treatment 
stratification(116).  
 Another key group of LSCC patients in need of additional treatment options are those 
with recurrent disease after both chemoradiation and surgery. These patients have poor outcomes 
(5-year overall survival 49% and disease-free survival 58%; our unpublished data). Moreover, 
these recurrences are often untreatable, as patients will have exhausted all other avenues of 
treatments. Currently, there are no other available options for these patients, and their care is 
often palliative. Interestingly, patients with recurrent HNSCCs may have different mutational 
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signatures(10).  Thus, identifying these patients (through predictive genetic biomarkers) and 
intervening with additional therapies (targeted agents, immunotherapy) earlier in their disease-
course may lead to modified treatment algorithms and improve outcomes.  
 Currently, targeted therapy clinical trials are aimed towards recurrent and advanced stage 
cancers.  In the future, the possibility of expanding these agents to early-stage tumors will be 
important.  Potentially, early-stage LSCC may be more responsive to targeted therapies, given 
they may have a lower overall mutational burden, and fewer potential targetable dysregulated 
driver mutations.  
 As with all next-generation sequencing trials, ethical considerations must be 
addressed(117).  Thus, future programs for personalized medicine in LSCC should have well-
established guidelines for pretest counseling on disclosure of genetic information, and have 
genetic counselors actively involved throughout the process. 
 
Conclusion 
 With the increasing implementation of next-generation sequencing and personalized 
medicine protocols for cancer, LSCCs may be a particularly useful and successful model disease 
for novel treatment paradigms.  Given the long history and relative success of LSCC and organ-
preservation protocols, there will be an inevitable evolution towards adopting targeted and 
immune modulating agents for this disease.  While identification of prognostic genetic 
biomarkers, therapeutic targets and models to perform molecular studies specific to LSCC 
remains incomplete, this field is rapidly advancing.  Ultimately, these novel strategies will 
increasingly be investigated and applied to LSCC, which will hopefully improve both organ 
preservation and overall survival for patients with this disease. 
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1.2 Generation and utilization of CRISPR/Cas9 screening libraries in mammalian 
cells2 
Introduction 
The adaptation of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
system to generate knockouts in mammalian cells has resulted in significant scientific advances. 
By choosing any 20 base pair sequence guide RNA (gRNA), as long as it is next to a protospacer 
adjacent motif (PAM) of 5'-NGG-3', to direct the Cas9 endonuclease and establish knockouts has 
resulted in unmatched speed and flexibility for creating these genetic models than other gene 
editing methods. This power and efficiency of has allowed researchers to apply this technology on 
a genome-wide scale that was previously infeasible using TALENs or zinc finger nucleases. Since 
late 2013, several CRISPR screening libraries have been developed targeting anywhere from 
several hundred to thousands of genes and discovering genes essential to cell proliferation, 
resistance to clinical treatments, and involved in processes of toxicity(118-120).  
To date, the generation of genome-wide knockout libraries is the predominant application for 
CRISPR-Cas9 in large-scale screening, but other methods are being actively developed.  CRISPR 
interference, or CRISPRi, has also been used to transcriptionally repress target genes.  While 
inactive Cas9 (dCas9) alone can sterically inhibit transcription of targets, robust silencing can be 
achieved by fusing dCas9 with a known transcriptional repressor, such as the repressor domain of 
KRAB(121, 122).  dCas9 fusion proteins have also been applied in large scale gene activation 
                                                 
2 This section was published as a chapter in Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs 
to Molecular Surgery at Cambridge University Press in collaboration with the following authors: Nicole 
Michmerhuizen, Rebecca Hoesli, Jacqueline Mann, Samantha Devenport, Aditi Kulkarni, Andrew Birkeland, and J. 
Chad Brenner. 
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screens(122, 123).  Konermann et al optimized a CRISPR-Cas9 mediated activation method 
(CRISPRa) utilizing dCas9 fusions with multiple activation domains to maximize transcriptional 
activation (123).  This strategy, combined with a 70,290 gRNA pool, was used to identify genes 
for which gain-of-function perturbations could confer resistance to BRAF inhibition.  As 
predicted, known BRAF resistance pathway members, such as EGFR, were enriched following 
pharmacological BRAF inhibition(123).  As CRISPRi/CRISPRa technology continues to develop, 
broader applications are envisioned, including manipulation of multiple genes in single cells in 
order to unveil novel interaction networks(124). 
This chapter will focus on the creation and use of a CRISPR/Cas9 screening library for large 
scale genetic studies. Here, we discuss important considerations in design and methodology to 
these screens.  
 
Methodology 
Deciding library coverage 
The first consideration in designing or using a CRISPR screening library is the number of 
genetic targets, whether genome-wide or a targeted panel.  The size of the library is critical to 
establishing optimal parameters in future steps, such as how many cells to screen, sequencing 
depth, and calling statistical significance. Many recent CRISPR screens in human cells have 
utilized whole genome gRNA libraries targeting 7,000 to 25,000 genes(118-120, 122, 123, 125). 
However, it is also necessary to have multiple gRNAs targeting each gene. While the whole 
genome gRNAs target up to 25,000 genes, the actual library size is around 300,000 gRNAs which 
results in up to 10X coverage (that is, 10 unique gRNAs per target gene). Coverage of 3-6X, or 3-
6 unique gRNAs for each gene is currently most common.  
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Designing guide RNAs 
Effective gRNA design hinges first on targeting an appropriate site within the gene of 
interest that has as few off-target binding sites as possible.  In general, a large portion of the coding 
region of a given gene is targetable. While the design of each gRNA/CRISPR complex can be 
dependent on the specific experimental needs, for effective knockouts, most gRNAs are designed 
to target early exons such that they induce insertions or deletions (indels) after the start codon. 
Targeting sequences near the 3' end of the gene is less favorable since frameshift mutations that 
occur near the end of a protein are less likely to alter expression (118, 126).  
 To improve target cleavage, the efficacy and/or stability of the gRNA sequence must be 
optimized (127). The protospacer adjacent motif (PAM) is a critical element to consider.  The 
PAM sequence is directly adjacent to the 20 base pair gRNA, and generally given as a motif of 5'-
NGG-3'. However, it has been noted that cytosine is favored and thymine is disfavored as the 
variable nucleotide in the PAM for effective gRNA design.  The preference for cytosine may be a 
result of RNA polymerase III termination at U-rich regions (since the downstream transcript is U-
rich). The gRNA nucleotide located directly adjacent to the PAM is also very important; in this 
site, guanine is preferred and cytosine is undesirable (126), see Figure 1-4.  Various other changes 
to specific nucleotides within the gRNA sequence have also been shown to significantly affect 
efficacy although these requirements are not necessarily generalizable across gRNAs, gene targets, 
and cell types (128). 
Other characteristics of the gRNA sequence are also important to consider when designing 
gRNAs for experiments.  For example, gRNAs with a G/C content that is too high or too low are 
often less effective (118, 126).  Additionally, if the target sequence displays high nucleosome 
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occupancy or is typically in the coiled (or closed) chromatin state, gRNA efficacy will suffer (129). 
While the gRNA features described here apply in most CRISPR applications, other more 
specialized characteristics differ between individual cell lines, organisms, and techniques.  
Ongoing work seeks to better understand these differences in order to improve the selectivity of 
gRNAs at their intended target sites.  
 
Minimizing off-target effects of gRNAs 
Because the gRNA does not have to match perfectly with the target DNA sequence to 
effectively induce genetic alterations, there is a possibility for off-target effects when using 
CRISPR.  Even though gRNAs are often most effective when perfectly matched to the target 
sequence, some degree of mismatch is tolerated by the CRISPR enzyme. In fact, the distance of 
the mismatch from the PAM site may be one variable in determining off-target efficiency as it has 
been suggested that nucleotide differences generally do not decrease efficacy as substantially if 
they are found at sites more distant from the PAM.  As might be expected, multiple mismatches 
decrease efficacy further than single mismatches, particularly if they are close to each other (127). 
In fact, gRNAs have been shown to bind to and cleave DNA regions with as many as 5 mismatches 
and in some cases the mutation frequency is as high at an off-target site as it is at the intended 
target site (130).  In other genomic “hotspots,” located at some centromeres and telomeres, off-
target effects are especially common (131); however, attributes of these hotspot regions have not 
yet been fully described, and it is still relatively unclear as to how often gRNAs cause genomic 
alterations in off-target regions.   
Consequently, when utilizing CRISPR for screening, increasing the number of guide RNAs 
per target should mitigate undesirable off-target effects and reduce bias since each gRNA has a 
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different sequence and cleavage profile (126).  In order to decrease non-specific effects further, 
other efforts are necessary and are an active area of investigation.  Shorter gRNAs, with 17 or 18 
nucleotides rather than 20, have shown improved specificity, at least in human cells (132).  While 
nickases have also been proposed to improve efficacy, this technology is currently not useful in a 
knockout screening format (133-135). Furthermore, although the ratio of Cas9 to gRNA is not a 
direct feature of gRNA design, this parameter can also be modulated to improve specificity (127). 
Consequently, as the field continues to evolve gRNA libraries may be modified to alter specificity 
and design parameters that can be adapted to meet the needs of diverse experimental questions. In 
order to predict which gRNAs might be functional, recent work has developed gRNA and CRISPR 
library design software.  Many of these programs are publicly available and their early evaluation 
has been promising(136, 137).   
 
Choosing gRNA and Cas9 expression system 
There are multiple methods for introducing the gRNA and Cas9 endonuclease into cells, 
with transient or stable expression. Currently, the most common method of gRNA library 
expression is using lentiviral vectors. Lentiviral constructs are effective across a wide variety of 
cell types, and give stable long-term expression of the gRNA and/or Cas9 (138). Additionally, as 
lentiviral constructs integrate into the genome, the gRNA can be used as a unique identification of 
the knockout that was established in the cell. 
Lentiviral constructs expressing a gRNA and a Cas9 together are common, but a two-vector 
system where Cas9 and a library of gRNAs are introduced separately has also been established, 
see Figure 1-5.  The two-vector system allows for an initial selection of a stable pool of cells 
expressing Cas9, and then subsequent introduction of the gRNA library with a secondary means 
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of selection (either different antibiotic of fluorescent marker) (118, 139). It is possible that a one-
vector system that contains the gRNA, Cas9, and all the needed expression machinery creates a 
large lentiviral construct that might be difficult to virally package. The two-vector system also has 
experimental flexibility, with the ability to have a stable pool of Cas9 expressing cells against a 
variety of smaller, targeted gRNA libraries (120). However, the one-vector system has been 
successfully used in a variety of cell types for a variety of screens (119, 140, 141). The 
disadvantage of using lentiviral vectors are that the long-term expression of the gRNA and Cas9 
has unknown effects on off-target regions on the DNA or other cell functions. While short term 
expression has been shown to be enough to induce knockouts, it has been suggested that continual 
long-term expression increases the chances of off-target effects (138). 
Other vector based systems, such as adeno-associated vectors or plasmid expression 
vectors allow for Cas9 and gRNA expression, but do not integrate. This makes it difficult to 
determine successful hits from the screen, as there is currently no method for identifying the gRNA 
or target region without a depth of next generation sequencing that is cost prohibitive and 
analytically infeasible. Other transient methods of expressing gRNAs or Cas9, while potentially 
successful in establishing a knockout, activation, or suppression cell phenotypes, result in the 
inability to screen for successful events and testing of a pooled library.  
 
Introducing library into mammalian cells 
Introducing the CRISPR screening library into cells is as simple as a lentiviral transduction. 
However, an important concern is introducing the library into the cells at a low multiplicity of 
infection (MOI) so that there is a low chance of multiple constructs integrating into one cell. 
Generally, small-scale tests are run to determine an optimal MOI (5-30%) before the conditions 
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are repeated for a large-scale transduction. Coverage is again a concern. For example, a library of 
65,000 gRNAs can be covered at >400X if a population of 30 million cells are maintained. If the 
MOI is 30%, then 100 million cells need to be transduced. After lentiviral transduction, then a 
selective process of either antibiotics or sorting by fluorescent marker depending on vector choice 
is done. While the kinetics of CRISPR/Cas9 activity are largely unknown and most likely vary per 




Pooled CRISPR screens can be classified as either positive or negative selection. Positive 
selection screens use a strong selective pressure, such as a toxin, to eliminate the majority of cells 
from the population, enriching for cells with genetic perturbations conferring protection from the 
toxin.  For example, to identify genes functioning in DNA mismatch repair (MMR), Wang et al 
cultured cells in the presence of 6-thioguanine (6-TG), which induces cell cycle arrest via the 
MMR pathway. Cas9-inducible KBM7 cells were transduced with a pool of 73,000 gRNAs 
targeting 7031 genes, and incubated with 6-TG.  Sequencing of the surviving population revealed 
that gRNAs targeting the four known MMR pathway components, MSH2, MSH6, MLH1, and 
PMS2, were greatly enriched when compared with the original library(118). This type of screen 
can be powerful in identifying genes that convey resistance to drugs or other death-inducing 
treatments.     
CRISPR-Cas9 mediated knockout libraries can also be used in negative selection screens, 
aimed at identifying genes essential for survival under the chosen experimental condition by 
monitoring the population for depletion of certain gRNAs.  To verify that their methods are also 
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appropriate for negative selection screening, Wang et al assessed representation of gRNAs in 
library-infected Cas9-KBM7 cells at initial seeding and after 12 cell doublings.  As expected, 
gRNAs targeting ribosomal protein genes were dramatically depleted in the final population, 
demonstrating the efficacy of this strategy in identifying essential genes (118).  Negative selection 
screens can also be used to identify targets that convey sensitivity to a low selection process, which 
could identify possible combinations of inhibitors for future clinical use. It is important to note 
that negative selection screens have additional technical concerns. For successful identification of 
a loss of gRNAs, then the CRISPR pool must have each gRNA represented in many cells (>300) 
with many gRNAs targeting the same gene. Deep sequencing coverage of the treated library is 
also needed to be able to successfully identify the low frequency events or drop-outs.  
 
Experimental conclusion 
At the conclusion of the experiment, each gRNA can be PCR-amplified and sequenced to 
identify the surviving population because of the integrated lentiviral gRNA construct. However, 
there are an unknown number of gRNAs and targeted genes, making it difficult to determine proper 
sequencing coverage for the treatment. Library size as well as choosing a positive or negative 
selection screens are the main considerations. Additionally, for either screen type, the gRNA 
coverage needs to be compared to an initial library or a non-treated pool for which the general 
assumption is that full coverage has been established.   
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Results & Discussion 
Identification of significant gRNAs and genes 
In most CRISPR/Cas-9 screens, the general idea is to compare two or more populations of 
cells being subjected to a particular condition or treatment. The effects of the condition or treatment 
are measured by quantifying levels of gRNAs in the different cell populations. An increase in 
gRNA quantity after treatment is indicates a disruption of the function of a target gene that provides 
some benefit to the cells. On the other hand, a decrease of gRNA numbers indicates that the 
disruption of the target gene function is not beneficial to the cell for survival. 
Many software analysis pipelines, modules, and packages are available for computational 
analyses of CRISPR/Cas9 screening data sets.  Although these software packages use different 
algorithms, their common output is a list of significant gRNAs and genes. The first step of these 
analysis pipelines is to obtain read counts from each of the cell population samples in the study. 
These read counts are then normalized to account for library size, read count distribution, read 
depth, and other factors. For example, the study design may need to decide if reads with one or 
more mismatches from gRNAs in the reference library will be used to quantify total read numbers. 
If there are biological or technical replicates in the experiment, variance estimation is performed 
to capture the variance across replicates. By incorporating the normalized read counts, variance 
estimation and other parameters, the statistical significance of each gRNA is calculated. These 
gRNAs are then ranked and the top gRNAs are chosen for further investigation of pathways and 
genes of interest. 
Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) is one of the most 
popular tools for analyzing data from CRISPR/Cas9 screens. MAGeCK uses the median 
normalization method for read count normalization followed by mean-variance estimation to 
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compare replicates in an experiment. Using this mean-variance estimation model, each gRNA is 
assigned a statistical significance. Genes are considered essential if their gRNAs are repeatedly on 
the top of the ranking list after applying the robust rank aggregation (RRA) algorithm. Based on 
RRA results, both positively and negatively selected essential genes can be identified. To identify 
pathways that are enriched, the same RRA algorithm is then applied to the list of top ranked 
essential genes (142). 
MaGeCK-VISPR is an improvised version of MAGeCK with many advanced capabilities. 
Quality control measures are incorporated to help in assessing the quality of the experiment. 
Another important feature is the ability to test if genes are essential under multiple conditions at 
the same time. To estimate gene significance, an expectation maximization (EM) algorithm is used 
instead of the RRA. This EM based method can also estimate the efficiency of the gRNA knockout 
along with estimating gene ranking and significance. Another very beneficial feature is the ability 
to visualize as well as interactively explore the QC as well as analysis results. (45).  
Other data analysis pipelines include the shALIGN(143) and BiNGS!SL-seq(144), both 
which use different R packages for the statistical data analysis. Empirical Analysis of Digital Gene 
Expression Data in R (edgeR) is a popular R package commonly used for various types of gene 
expression data such as RNA-Seq, microarrays etc. A customized workflow in edgeR can be used 
for analyzing data from CRISPR/Cas9 screens (145). 
 
Comparing CRISPR libraries to siRNA & shRNA screens 
The development of the CRISPR/Cas system for precise-genome editing has significantly 
advanced functional genomics screening; however, its import and to understand the utility of 
traditional functional genetics screening approaches. Previously, functional genomics studies 
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relied upon small interfering RNA (siRNA) and short hairpin RNA (shRNA) technologies to 
explore gene function through loss of function studies. Although the usage of siRNA and shRNA 
revolutionized the field at its introduction, the introduction of CRISPR to the field of functional 
genomics has provided several advantages over siRNA and shRNA techniques, but also has some 
limitations where siRNA and/or shRNA approaches may still be advantageous.  
In one study, Feng et al showed that CRISPR techniques resulted in improved gene 
inactivation efficiencies as compared with shRNA(139). This translates to improved sensitivity in 
evaluating gene function, as a complete knockout of a gene can reveal gene effects that are not 
adequately demonstrated by the knockdown of expression achieved by shRNA or siRNA screens 
(146). CRISPR additionally has the advantage of being able to create permanent cell line pools, 
which can be used to perform repeated experiments to further delineate gene function (146). 
Likewise, high density gene saturation editing has also enabled functional genomics screens that 
assess biochemical activity of proteins, whereas shRNA based approaches required complex multi-
step rescue approaches.  
Like shRNA or siRNA, CRISPR also has the ability to reduce gene expression by 
recruitment of transcriptional repressors or direct transcriptional interference, as well as increase 
gene expression by recruiting transcription activators (146). CRISPR also has the benefit of being 
able to explore effects of non-transcribed genes, as it directly acts on a DNA and does not rely 
upon transcription or translation like siRNA and shRNA screens (146). Finally, pooled CRISPR 
screens are cheaper than siRNA due to the transfection agents required to carry out siRNA screens 
(146), but may have similar cost points to shRNA pooled screens. Functional genomic approaches 
leveraging plate formats and transfection assays are beginning to emerge for CRISPR technology, 
but these are still in the early phases of development.  
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Despite the advantages of CRISPR, siRNA and shRNA screens will likely remain an 
important tool in functional genomics screening, as siRNA and shRNA screens often provide 
complementary information to CRISPR, and do maintain some advantages over CRISPR. For 
example, siRNA and shRNA screens are still ideal for targeting essential genes, as complete 
knockdown of essential functioning genes will result in cell death (147). siRNA and shRNA 
screens also have a larger target pool than CRISPR, as they can essentially target any existing 
RNA. CRISPR, on the other hand, requires particular sequences in addition to the gRNA site to 
recruit the necessary machinery to cause double stranded breaks (147). This limits the number of 
cut sites in the genome; however, modified Cas9 enzymes are being rapidly developed to overcome 
this issue, regulate differential cut site specificity and enzyme efficiency. In fact, in the near future, 
we may perform pooled CRISPR screens with high density gRNA libraries and multiple different 
Cas9 enzymes to analyze different effects and compare off-target and on-target activities of 
multiple different Cas9 enzymes.  
Researchers have previously gained significant experience with siRNA and shRNA 
screens, allowing ample time for protocol refinement and an improvement in the rate of off-target 
effects (OTEs) in siRNA and shRNA screens (146), but one current limitation of CRISPR-based 
screens are the unknown consequences of false negatives due to variations in guide RNA accuracy, 
and due to improved efficiency of NHEJ resulting in accurate repair of the double-stranded breaks 
(146). Other technical limitations that will need to be overcome include the fact that CRISPR 
screens require lysis of the host cell populations in order to identify the genes of interest, and thus 
does not allow for screening for any image-based phenotypic screen (146) and Cas9 is also 
constitutively active, and while this has not been shown to harm the cell, it can result in increasing 
OTEs (147). Finally, as mentioned above, the CRISPR screens require complete knockout of the 
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gene of interest, and thus if there are many copies of the gene like in cancer cells, CRISPR may 
not efficiently demonstrate loss of function in that gene (147). As such, knockouts of genes, such 
as lncRNAs, without open reading frames or genes with high copy number in the cell population 
remains challenging for CRISPR, but not for si/shRNA-mediated approaches.   
Consequently, while we have entered an era where knockout-based functional genomics 
screens are viable in almost any cell population, si/shRNA screening approaches will continue to 
complement CRISPR-based technology. These alternative approaches can be easily leveraged for 
performing secondary or tertiary screens on nominated targets advancing from CRISPR screens or 
to simply provide companion methodology that may enhance the chances of a successful screen 
under particular experimental conditions (e.g. assessing the effect of genes with high copy number 
in cancer cell lines).   
Collectively, CRISPR technology is rapidly advancing and quickly becoming a standard 
tool in cell and molecular biology labs across the world. Our early experience with pooled CRISPR 
screening and creation of individual gene knockout lines has complemented the rapidly evolving 
knowledge base building around the technology. It is clear that knockout screening technology 
will lead to new medical and translational advances that were simply not possible before Cas9 was 
advanced into human models, and represents a clear story of how truly basic research can make a 





Figure 1-1. Key components of the PI3K pathway and possible therapeutics   
Drugs targeting individual components are either in trials as noted, or were effective in vitro with 
cell lines containing PI3KCA mutations. The RAS/MEK/ERK pathway, which has been noted to 




Figure 1-2. Major oncogenic mechanisms in LSCC and thereapuetic opportunities 
Dysregulated pathways common to LSCCs with targeted therapies in clinical trials for HNSCCs 






Figure 1-3. Decision algorithm for treating LSCC patients 
Current practice is shown with black arrows, with traditional treatments such as 
surgery/radiation/chemotherapy. The red arrows incorporate HPV status and patient genetics to 






Figure 1-4. Diagram of gRNA in complex with Cas9 enzyme 
Diagram of gRNA (orange) in complex with Cas9 enzyme targeting a gene to create a knockout 
(A). The PAM sequence, with preferred bases emphasized are marked. For CRISPRi libraries, 






Figure 1-5. Schematic of CRISPR library generation 
Overview of steps needed to introduce lentiviral CRISPR library into cells, either using a one or 
two vector system. After selection, the pooled library can then screened by positive selection, 
where the hits are observed at high frequency (circled cells), or by negative selection, where the 






















1 (6.7%) 19 (21.6%) 
53 
(22.4%) 












2 (13.3%) 15 (17.0%) 
44 
(18.6%) 
CASP8 1 (1.4%) 0 (0%) 1 (1.1%)* 
29 
(12.2%) 
Table 1-1. Frequently mutated genes in LSCC samples 
The total (non-SCC) column represents mutations from oral cavity, oral pharynx, and 
hypopharynx samples. Only HPV-negative samples are included. ǂ p-value =0.058, * p-value 










3q26 (PIK3CA, SOX2) Amp 37.5%** 12.8% 
11q13 (CCND1, FGF3/4/19) Amp 36.1% 29.1% 
9p21 (CDKN2A/B) Del 31.9% 32% 
3q28 (TP63, ETV5) Amp 34.7%** 12.8% 
8q24 (MYC, PTK2) Amp 16.7% 12.2% 
7p12 (EGFR) Amp 12.5% 12.2% 
9q34 (NOTCH1, TRAF2) Amp/Del 4.2%**/1.4% 0%/0% 
Table 1-2. Common copy number variations 
Common copy number variations (CNV), either amplifications or deletions, in HPV negative 










Patient-derived cell lines from LSCC patients at University of Michigan Comprehensive Cancer 






















UMSCC-10A 57 M T3N0M0 III True Cord Primary - 
UMSCC-10B 58 M T3N1M0 III Lymph Node Metastasis - 
UMSCC-17A 47 F T1N0M0 I Supraglottis Primary - 
UMSCC-17B 47 F T1N0M0 I Soft Tissue Metastasis - 
Primary: 
UMSCC-11A 65 M T2N2aM0 IV Epiglottis Primary - 
UMSCC-23 36 F T2N0M0 II Supraglottis Primary - 
UMSCC-28 61 F T1N0M0 I True Cord Primary - 
UMSCC-41 78 M T2N1M0 III Arytenoid Primary - 
UMSCC-81B 53 M T2N0M0 II True Cord Primary - 
UMSCC-105 51 M T4N0M0 IV True Cord Primary Positive 
Recurrent and Metastases: 
UMSCC-12 71 M T2N1M0 III Larynx Recurrence - 
UMSCC-13 60 M T3N0M0 III Esophagus Recurrence - 
UMSCC-25 50 M T3N0M0 III Neck Metastasis - 
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Objectives: We sought to describe the genetic complexity of 14 UM-SCC oral cavity cancer cell 
lines that have remained uncharacterized despite being used as model systems for decades.  
Materials and Methods: We performed exome sequencing on 14 oral cavity UM-SCC cell lines 
and denote the mutational profile of each line. We used a SNP array to profile the multiple copy 
number variations of each cell line and use immunoblotting to compare alterations to protein 
expression of commonly amplified genes (EGFR, PIK3CA, etc.). RNA sequencing was 
performed to characterize the expression of genes with copy number alterations.  
Results: The cell lines displayed a highly complex network of genetic aberrations that was 
consistent with alterations identified in the HNSCC TCGA project including PIK3CA 
amplification, CDKN2A deletion, as well as TP53 and CASP8 mutations, enabling genetic 
stratification of each cell line in the panel. Copy number FISH and spectral karyotyping analysis 




Conclusions: Collectively, we developed an important resource for future oral cavity HNSCC 
cell line studies and highlight the complexity of genomic aberrations in cell lines.3   
Introduction 
Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer 
worldwide and consist of malignant tumors of the oral cavity, oropharynx, hypopharynx, and 
larynx (1), which are thought to arise due to a variety of etiologic factors including tobacco-
exposure, alcohol consumption and high risk human papilloma virus (HPV) infection. 
Importantly, clinical outcome and treatment course vary by anatomic site with 5-year survival 
rates ranging from 40-80% depending on stage, subsite, and HPV status. As such, it is important 
to build models representing each specific HNSCC subsite in order to model differences between 
subsites. This is especially true for HNSCCs of the oral cavity, which are the most common 
HNSCCs, have less than 60% overall survival at 5 years (2), and are not currently associated 
with a high rate of HPV infection. With the results of The Cancer Genome Atlas (3) and other 
genomic sequencing studies (4-7), the mutational landscape of primary untreated HNSCCs is 
beginning to be characterized (8).  However, there is still a need for follow-up in vitro studies to 
investigate key regulatory pathways, confirm malignant drivers, and discriminate potential 
therapeutic targets in genetically characterized models.  
Indeed, it is clear from early precision medicine literature that the effectiveness of 
“matched” or “companion” therapies (e.g. those that target specific molecular lesions such as 
Imatinib and BCR-ABL gene fusions) can be tissue type specific, which may be due to the 
                                                 
3 This chapter was published in Oral Oncology and completed in collaboration with the following authors: Aditi 
Kulkarni, Andrew Birkeland, Nicole Michmerhuizen, Susan Foltin, Jacqueline Mann, Rebecca Hoesli, Samantha 




inherent genetic complexity or unique compensatory pathways of each cancer type (9).  In order 
to assess potential compensatory pathways for advancing matched therapies across different 
tissues, cell line models have historically have been valuable tools for investigating the role of 
focused genetic alterations in tumor behavior and response to therapy, especially for HNSCC 
(10-13).  In particular, the University of Michigan has created a repository of HNSCC cell lines 
(UM-SCC) (14), which have been extensively used for in vitro and in vivo modeling of HNSCCs 
(15). Despite the extensive use of UM-SCCs in the literature and characterization of some lines 
using cytogenetics and loss of heterozygosity assessments (16-18), full genetic characterization 
of these cell lines has not yet been performed.  Given the potential for wide phenotypic 
variations based on genetic mutations (19) as well as the move towards genetics based 
personalized medicine approaches (20-22), it is increasingly important to understand the genetic 
architecture of cell lines used for in vitro studies.  While studies have started characterizing the 
genetic implications of therapeutic response in other cell line models (19, 23-25), this analysis 
has been limited in HNSCC.   
Accordingly, whole exome characterization of UM-SCC cell lines is critical to accurately 
understand critical pathways and mechanistic factors that may be involved in UM-SCC 
phenotypes and therapeutic response to advancing precision therapies.  In this study, we sought 
to catalog the mutational landscape of oral cavity UM-SCC cell lines.  To identify genetic 
subsets of the disease that are well- or under-represented by our models, we then classified UM-
SCCs based on disruptive genomic events and compared the mutational and copy number 
profiles in our panel with those of other HNSCC cell lines and primary HNSCCs.  Ultimately, 




genetic biomarkers for applicability to specific targeted therapies (12) in translational models of 
HNSCCs.   
 
Materials and Methods 
UM-SCC models. Cell lines were derived and characterized in the Head and Neck Oncology 
laboratory at the University of Michigan after consent of the patient donors (14).  The oral cavity 
cell lines studied in this report were selected from this panel.  Cell lines were grown in DMEM 
with 10% FBS, 7µg/mL penicillin/streptomycin and 1% Non-essential amino acids in 5% CO2 
incubator. Cell lines were maintained in exponential growth phase and whole genomic DNA was 
isolated using the Qiagen DNeasy kit according to manufacturer’s instructions. All cell lines 
were genotyped as previously described (14).  
 
Exome Sequencing. Exome Capture Library Construction was done using the Roche 
NimbleGen V2 (44.1 Mbp) Exome Enrichment Kit as described (12) or by using the Roche 
NimbleGen V3. Paired-end sequencing (2 × 100 bp) of the captured exons was carried out on an 
Illumina Genome Analyzer IIx Platform. Paired-end sequencing (2 × 150 bp) for NimbleGen V3 
libraries on an Illumina HiSEQ 4000 at the University of Michigan DNA sequencing core 
according to standard protocol.  
 
Variant Calling. Read quality was assessed using FastQC (26). Reads were aligned to hg19 
reference genome using BWA v0.7.8 (27). Mapping was followed by marking duplicates using 
PicardTools v1.79 (Broad Institute). INDEL realignment and base quality score recalibration was 




Genotype GVCFs following the GATK best practices workflow guideline (29) for jointly calling 
variants across all samples. To filter low quality calls, Variant Quality Score Recalibration 
(VQSR) was applied to the variant call set. Since the suggested sample size for applying VQSR  
is 30, samples from the 1000 genomes project (30) were combined along with our cell lines to 
reach this sample size. Varseq v1.4.0 (Golden Helix, Inc., Bozeman, MT) was used to annotate 
and filter the variants of interest. Filters were set to eliminate false positive variant calls due to 
sequencing artifacts. The variants were required to have 5 or more reads supporting the alternate 
allele and be found in less than 1% in a normal population according to the 1000 genomes 
project (30).  Additional annotations were included to annotate each alterations with COSMIC 
and dbSNP, which are provided in the supplement. Intronic and intergenic variants were filtered 
out with the exception of the variants in splice donor or accepter regions. 
  
Sanger Sequencing Validation. Genomic DNA was isolated following Gentra PureGene 
protocol (Qiagen) and PCR amplified with Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen) according to manufacturer’s instructions. Primer sequences for CASP8 are listed in 
SFig2. PCR products were cloned out using pCR8 TOPO vector (Invitrogen) and submitted for 
Sanger sequencing at the University of Michigan DNA Sequencing Core on the 3730XL DNA 
Sequencer (Applied Biosystems).  Sequences were aligned using the DNASTAR Lasergene 
software suite. 
 
Copy Number Analysis. The OncoScan FFPE Assay Kit (Affymetrix) was used to analyze copy 
number variations in our samples. Due to a lack of matched normal samples for the cell lines, a 




comparison to make copy number variation calls. CEL files generated from the kit were 
combined using the OncoScan Console software to generate OSCHP files. These OSCHP files 
were then analyzed using the TuScan algorithm of the Nexus Express for OncoScan Software. 
We also used keratinocyte DNA (ATCC® PCS-200-011) to generate additional OncoScan results 
as an additional control. We noted that in case of some homozygous deletion calls (CN=0), the 
B-Allele Frequency plot did not agree with the copy number estimate made by the TuScan 
algorithm. To provide more accurate copy number calls, we used the presence or absence of 
exome sequencing reads to validate complete loss of the gene. In cases that we observed a copy 
number call of zero but the presence of exome sequencing reads, we modified the copy number 
in Table 2-6 to one copy, noted with an asterisk.  
 
Western blot Analysis. Western blot analysis was performed as previously described (31). 
Briefly, UM-SCC cell lines at 70-80% confluency were rinsed with PBS and lysed in buffer (150 
mM NaCl, 10% Glycerol, 1% NP40, 0.1% Triton X-100, 1 mM PIPES, 1 mM MgCl, 50 mM 
Tris) containing protease and phosphatase inhibitors (Thermo 186129, 1861277) as described 
(32).  See Table 2-7 for primary and secondary antibodies used. 
 
Spectral Karyotyping, Cell lines in exponential growth phase were treated with Colcemid to 
capture metaphases. SKY images of UM-SCC-69 and UM-SCC-92 were then prepared and 
imaged by the Molecular Cytogenetic Core at Albert Einstein College of Medicine using Applied 





Fluorescent In-Situ Hybridization. Cell lines UM-SCC-92 ad UM-SCC-97 were treated with 
Colcemid to arrest cells in metaphase as previously described by our group (31). Slides were 
prepared and then probed for EGFR or RB1 with respective chromosome controls (Empire 
Genomics). Representative images were taken on Leica SP8 confocal.  
 
RNA Sequencing and Bioinformatic Analysis. RNA isolated with the Qiagen Allprep kit was 
submit to the University of Michigan DNA Sequencing core and processed using the Illumina 
HiSeq 4000 by paired end 75nt sequencing.  Libraries were prepared according to 
manufacturer’s protocols with the Illumina Total RNA kit.  Read quality was assessed for each 
cohort using FastQC (v0.11.5). No quality issues were detected in the sample set. Read 
alignment was performed using STAR (v2.5.3a) according to the two-step alignment protocol 
recommended in the user manual. Cufflinks (v2.2.1) was used to compute FPKM and values 
were loaded into MEV for visualization of relative expression between models.  
 
Results 
We first performed exome sequencing on 14 UM-SCC cell lines from patients with oral cavity 
SCC. This patient cohort consists of a mix of seven men and seven women with stage II through 
stage IV oral cavity cancers arising at a variety of oral cavity sites. Six patients (4 female, 2 
male) were under age 40 (range 26-39yrs) and eight patients (5 male, 3 female) were 58 years of 
age or older (range 58-76) (Table 2-1). Our analysis found a large mutational load with over 
1300 non-synonymous variants per cell line (Fig 2-1, Table 2-2, Table 2-3), but as with many 
cell line studies was limited by a lack of normal controls for each cell line model accounting for 




Nonetheless, we characterized common aberrations found in oral cavity HNSCC tumors in the 
data set. Similar to TCGA HNSCC tumor studies, we found high frequencies of mutations in 
13/14 (93%) affecting TP53, 6/14 (43%), affecting NOTCH1, and 5/14 (36%) affecting 
CDKN2A (Fig 2-2). Mutations found in other oral cavity lines from  a previous study (25) are in 
provided Fig 2-3. In our panel, we observed a range of mutations occurring in the coding regions 
and in splice sites as well as several frameshift alterations in common tumor suppressor genes 
like NOTCH1 and CASP8. We validated a set of these mutations by Sanger sequencing for 
CASP8 and CDKN2A (Fig 2-4). To then define copy number alterations in these models, we 
performed high density SNP arrays on all 14 oral cavity cell lines. Analysis of all 14 cell lines by 
summing copy number alterations at each specific SNP probe site demonstrated copy number 
common in oral cavity HNSCC. These include amplifications of chromosome 3q, 11q13 and 20, 
and loss of 3p, 8p, and 18q (Fig 2-5A). Genome wide analysis was performed for each cell line 
and demonstrated numerous differences in each cell line model (Fig 2-6), and held true when 
compared to an additional keratinocyte control (Fig 2-7). At the gene level, we identified 
frequent focal copy number variations in several canonical HNSCC genes, including 
amplifications of EGFR and deletions of CDKN2A. The copy number calls of our panel in 
relation to a list of commonly altered genes in HNSCC as identified from TCGA is shown in Fig 
2-5B, and shows complex copy number profiles for each of our cell lines.  
To then associate copy number outliers with protein expression in the cell line panel, we 
performed Western blot analysis on several proposed HNSCC oncogenic drivers with substantial 
copy number alterations across the panel. We observed that cell lines with the highest copy 
number amplification of EGFR, UM-SCC-59 and -69, also had the highest protein expression 




functional protein p110α. As PIK3CA is contained within the larger 3q amplicon, and focal 
PIK3CA amplifications are rare in HNSCC tumors, these data suggest that 3q amplification is 
not necessarily a marker for PIK3CA protein overexpression in the cell line models. Importantly, 
signaling downstream of these common tyrosine kinase aberrations through AKT, ERK, and 
MEK pathways were present in all cell lines assessed (Fig 2-5C). Accordingly, p53 expression is 
generally associated with mutations as wild type p53 is degraded by MDM2 in normal culture 
conditions. Our protein expression data was consistent with this postulate as the wild type cell 
line and those with splice site mutations did not express p53 protein. Similarly, the RNAseq data 
further validated our copy number calls from above as cell lines with at least one copy of 
CDKN2A, such as UM-SCC-43, -110 expressed CDKN2A, and cell lines with no copies of 
CDKN2A (UM-SCC-49, -55) did not express the gene (Fig 2-8). 
Surprisingly, the copy number analysis revealed that some chromosomes had uneven 
distributions in each cell line. For example, in UM-SCC-92, EGFR located on chromosome 7 
was found an average of 2.33 times suggesting that some cells may contain 3 copies or more and 
others just 2 or fewer copies. Similarly, UM-SCC-69 contained 15.67 copies of EGFR.  Given 
the apparent mixed chromosome content of some cell lines, it is likely that the cell lines contain 
heterogeneous populations with genetic diversity within each cell line population. We postulate 
that within the populations, driving genetic lesions will be found in all cells while passenger 
mutations would reside in only sub-populations. Thus, we analyzed the chromosomal content 
and fusion status of two representative cell lines from our collection, UM-SCC-69 and UM-SCC-
92, by spectral karyotyping to determine the distribution on chromosome content between 
individual cells in each model (Fig 2-5D). This analysis demonstrated that UM-SCC-69 cells 




These data were also consistent with the complexity of copy number data from the SNP arrays. 
For example, while most cells analyzed from the UM-SCC-92 population contained 3 copies of 
chromosome 1, 2/10 cells had 4 copies, 1/10 cells had 2 copies, and 2/10 cells harbored unique 
translocations of chromosome 1 to chromosomes 9 and 15, respectively t(1;9;15)(Table 2-4, 2-
5). We also identified a recurrent chromosome 5 to 17 translocation t(5;17) that was present in 
10/10 UM-SCC-92 cells, though we did not identify any additional translocations that were 
present in all cells from the population in UM-SCC-69. This suggests that no initiating 
translocations were responsible for transformation of this model, though we did identify highly 
recurrent translocations in both models such as t(17,1) in 6/10 UM-SCC-69 cells and t(7,8) in 
9/10 UM-SCC-92 cells. In addition, we performed FISH to evaluate the potential heterogeneity 
of two genes, EGFR and RB1, in two of our cells lines and found that we indeed had cells with 
differing copy numbers of genes, suggesting heterogeneity persisting in the cell lines (Fig 2-9). 
Collectively, these data support the concept that the UM-SCC cell lines contain heterogeneous 
populations of tumor cells even after several passages in long term cell culture.  
With this understanding, we then summarized the overall representation of genetic events 
in our cell line panel as compared to the representation of events in the HNSCC TCGA data. 
This demonstrated that the disruptive genomic events found in our UM-SCC oral cavity 
collection represent a highly complex genetic distribution than is generally not found in primary 
untreated tumors, but could be more consistent with advanced HNSCC cases. In analyzing key 
pathways of oncogenesis similar to TCGA, we found that while there are some commonalities 
across all models (PIK3CA, E2F1, and TP63 amplifications were common) most events are a 




suppressor FAT1, an inhibitor of Wnt/β-catenin signaling, is found to be amplified, deleted, or 
mutated across multiple cell lines. 
 
Discussion 
 The UM-SCC cell line panel was developed over the past 40 years at the University of 
Michigan from over 100 different donors (14, 33-37) and has available citations dating back to 
1983. Here, we have characterized the molecular landscape of 14 of the most highly utilized oral 
cavity UM-SCC models. In the precision medicine era, comprehensive genetic sub-stratification 
of known driver mutations is critical in order to identify how and where to strategically plan 
targeted therapies (38). In vitro experiments with cell lines are critical to identifying genetic 
profiles and connecting subsets to therapeutic responses. Until now, however, genetic 
characterization of the UM-SCC cell line panel has been limited despite their wide-ranging use 
as models for HNSCCs.  
An important finding of this study is the limited genetic diversity observed amongst the 
existing cell line panel as compared to global distributions of common genetic drivers. For 
example,  PIK3CA alterations in HNSCC range from 0-70% globally depending on cohort (39), 
but occur in 100% of our models. In contrast, we and others have recently described activating 
genetic alterations to ERBB2 (HER2) and FGFR1 that occur in both epidemiologically low risk 
and high risk HNSCC populations (31, 40-44); interestingly, these genes harbored activating 
genetic alterations in 10/14 and 3/14 cell lines, respectively. This data suggests a need to 
continue deriving cell lines representative of different ethnic and genetic sub-groups to more 




Moving forward, studies of genetic heterogeneity and tumor evolution are becoming 
increasingly prevalent as sequencing and single cell technologies become more tenable. The data 
generated in this report suggest that the UM-SCC cell lines retain a high level of genetic 
heterogeneity which has both advantages and disadvantages for in vitro experiments. The use of 
CRISPR technology to knockout multiple alleles of a gene, for example, could produce clones 
that may not represent the whole cell line population. In short term experiments, genetic 
heterogeneity is unlikely to play a major role in outcomes, which may be hypothesized to relate 
to the primary driver mutations with which each cell line is characterized. However, in long-term 
culture experiments, such as selection of therapy resistant clones, genetic heterogeneity of the 
cell lines may play a profound effect similar to the in vivo clonal evolution of tumors following 
treatment.  Further follow up from single cell analysis techniques (45, 46) could be very 
interesting in exploring this cell line heterogeneity we observed, especially over time. 
Nonetheless, these consequences of the genetic heterogeneity in the HNSCC remain to be 
explored, though previous work has shown that cell lines reflect the cytogenetic changes that are 
present in the tumor tissue from which they were developed (47, 48).  
 The data collected here suggest that many of the highly recurrent aberrations found in the 
HNSCC TCGA project are well represented in the UM-SCC oral cavity cell line panel. 
Interestingly, the distribution of mutations is distinctive. Whereas most primary untreated 
HNSCC tumors contain a single aberration in multiple pathways (e.g. EGFR amplification OR 
PIK3CA amplification plus CDKN2A deletion OR CCND1 (Cyclin D1) amplification), the 
majority of cell lines harbor multiple aberrations in a single pathway (e.g. EGFR amplification 
AND PIK3CA amplification plus CDKN2A deletion AND CCND1 (Cyclin D1) amplification). 




the evolution of the tumor within the patient is unknown, but suggests that the cell lines represent 
a highly complex and genetically distinct subset of HNSCC tumors. This subset may be of 
particular use in representing responses in a more metastatic setting, in which the tumor may 
have acquired additional mutations, than of modeling the phenotypes of primary patient tumors. 
Sequencing patients in a metastatic setting, and understanding the genomic landscape of those 
tumors, will be particularly interesting in comparison. Despite this observation of mutation 
accumulation, a subset of cell lines such as UM-SCC-108, contain fewer established “driver” 
aberrations than other models and begin to add to the genetic diversity of the panel. 
 Collectively, this panel of UM-SCC oral cavity cell lines has immense utility for studies 
of HNSCC as evidenced by the vast array of publications from labs around the world over the 
past four decades. We report comprehensive genetic characterizations on the models that can be 
leveraged to validate cell line identity and just as importantly to put individual studies in the 
context of genetic alterations. Our study shows that UM-SCC oral cavity cell lines contain 
models with an array of genetic alterations that are commonly found in HNSCC, and suggests 
that the field may benefit from the derivation of additional models with unique genetics. As we 
strive towards improved personalized medicine protocols for HNSCC patients, the cell lines 
continue to represent important models for discovery of both HNSCC pathogenesis and 
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Figure 2-1. Mutation load in UM-SCC lines  
For each UM-SCCC cell line, exome sequencing identified many synonymous (blue) and non-
synonymous (mutations). The total number of mutations for each category is normalized by 






Figure 2-2. Single nucleotide variants identified in the UM-SCC oral cavity cell line panel 
(A) Mutations in oral cavity UM-SCC cell lines were annotated by color code as indicated as 
called from Nimblegen capture-based exome sequencing. The mutation list contains the common 
single nucleotide variants identified in the HNSCC TCGA project, and the percentage of cell 
lines with mutation in each gene is shown on the right. Schematics were created to show the 
distribution of mutations found in (B) CDKN2A or (C) CASP8 in the UM-SCC oral cavity cell 
lines (top) or in the HNSCC TCGA data set (bottom). Numbers next to individual mutations 
indicate the number of independent tissue samples in which each specific mutation was 






Figure 2-3. Single nucleotide variants for non-UM-SCC oral cavity cell lines 
Mutation calls for other publicly availably oral cavity cell lines. The genes chosen are the same 






Figure 2-4. Sanger sequencing validation of mutations 
Sanger sequencing validation of CASP8 and CDKN2A mutations. The UM-SCC cell line and 
identified genetic mutation is shown in the left column. The primer sequences and a section of 
the chromatograms from aligning PCR products with wildtype CASP8 are shown. Only the 






Figure 2-5. Genetic heterogeneity of UM-SCC oral cavity cell lines characterized by copy 
number alterations 
 (A) Genomic DNA from low passage cell lines was analyzed with high density SNP arrays and 
compared to a commercially available pooled control. Copy number alterations were called using 
Affymetrix software and average copy number calls were annotated. This panel shows a 
summary of genetic alterations summed across the entire UM-SCC oral cavity cell line panel. 
Amplifications (blue) and deletions (red) were annotated. (B) Copy number variations of genes 
commonly altered in the HNSCC TCGA project are shown for each of the oral cavity cell lines 
using the probe medians. (C) Protein isolated from the cell line panel was used to perform 
Western blot analysis for several highly recurrent genetic drivers that are amplified in the cell 
lines including EGFR, PIK3CA and their downstream effectors as indicated. Estimated copy 
number values by the TuScan algorithm for EGFR and PIK3CA are shown above the Western 
blots. Representative blots are shown for each image. (D) Spectral Karyotyping (SKY) of UM-
SCC-69 and UM-SCC-92 cells (top panel) and respective high density copy number plots from 
SNP array data (bottom panel). We performed SKY analysis on 10 individual cells from both 





Figure 2-6. Genome-wdie view of copy number alterations for oral cavity UM-SCC cell 
lines 
Genome-wide view of copy number alterations for each UM-SCC cell line. Each plot depicts the 
intensities of the probes from OncoScan. The zero centered on the y-axis of each plot represents 






Figure 2-7. Copy number calls from normalized keratinocytes HEKa 
Genome-wide view of copy number alterations normalized keratinocytes HEKa . Plot depicts the 
intensities of the probes from OncoScan. The zero centered on the y-axis of each plot represents 







Figure 2-8. Expression of TCGA related genes in the UM-SCC oral cavity cell lines 
Heatmap of FPKM values for genes of interest that are displayed across each row, with the cell 






Figure 2-9. FISH confirmation of cell line heterogeneity  
Images from FISH for RB1 in UM-SCC-97 (A) and EGFR in UM-SCC-92 (B) with respective 
chromosomal controls. For both lines, the gene is red, the chromosome in green, and DAPI in 







Figure 2-10. Summary of the oncogenic pathways genetically disrupted in the UM-SCC 
oral cavity cell line panel  
Alterations (mutations and copy number alterations) in common oncogenic pathways in the UM-
SCC oral cavity cell lines were broken down by pathway classification, e.g. Cell Cycle pathway, 
Receptor Tyrosine Kinases, etc. as in the HNSCC TCGA project. Color shades indicate the 















Table 2-2. Genomic variants in UM-SCC lines, part one 
The list of genomic variants is too large to put into this thesis. Please see link above for ability to 






Table 2-3. Genomic variants in UM-SCC cell lines, part two 
The list of genomic variants is too large to put into this thesis. Please see link above for ability to 






UM-SCC-69          
Cell 1 2 3 4 5 6 7 8 9 10 
Chr. 
No. 122 140 118 134 131 120 130 133 130 131 
Chr. 1 
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UM-SCC-92          
Cell 1 2 3 4 5 6 7 8 9 10 
Chr. 
No. 70 72 73 73 72 74 71 58 71 74 
Chr. 
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EGFR 2 4 3.67 4 3,2.5 5 1.67 23 15.67 2.33 3 2.33 3 4 
PIK3CA 3 4 2.67 4 3 5 2.67 5 6 3 4 3 4 3 
TP63 3 4 2.67 4 3 5 2.67 5 6 3 4 3 3 3 
CCND1 1 3 5.33 4 2 5 1.67 12 2.33 12 3 1.67 11 2 
BIRC2 2 4 1.67 4 3 5 1.33 3 2.33 1.67 4 2.33 2 3 
YAP1 2 4 1.67 4 3 5 1.33 3 2.33 1.67 4 2.33 2 3 
ERBB2 2 3 2.33 5 1 4 2.33 4 3 4 2 2.33 2 4 
FGFR1 1 2 2.67,2,2.33 2 1* 1* 1.33 1.5 2.67 3.67 1* 1.33 2 1 
TP53 2 3 2.33 4 1 3 2 4 3.33 2 1 1.33 3 3 
CDKN2A 0,1 0,3 1 2 2 0 0.33 4 2,3.33 1.33 1 0.67 1 1 
FAT1 1 1 1.33 2 1 1* 2.33 3 2 2 1* 1.33 3 1 
NOTCH1 3 5 2 4 1 2.5 3 4 3.33 2,2.33 1 2.33 3 3 
TRAF3 2 4 1.67 4 2 6 2.33 3 4 2.67 2 2.67 4 2 
CASP8 2 3 2 4 1 1 1.67 3 3.33 1.67 1* 2 1.5 4 
KEAP1 1 3 1.67 2 2 2 1.33 3 3 2 1* 2 3 3 
MYH9 3 3 2 2 2 2 2 2 3 1.33 1* 1.67 3,2 2 
IGF1R 2 3 1.67 4 1 3 2 3 3.67 2 1 1.67 3 3 
EPHA2 2 3 1.67 2 1 2 1.33 3 3 2 1 2 3 2 
DDR2 2 2 2 4 1 2 1.67 3 3.67 2 1 1.67 3 2 
FGFR2 2 3 2.33 4 1 2 2.33 2 3 2.33 2 2 2 2 
FGFR3 2 3 1.33 4,3 1 2 1.67 2 3.33 3 1 2.67,2 2.5 3 
MET 2 2.5 1.33 2 2 3 2.33 3 4 2.33 1 2 3 2.5 
MYC 3 4 2.67 7 4 4 3.33 2 2.67 3.67 1 3.33 6 8 
HRAS 2 2.5 2 3 1 3 2 4 2.67 2 1 1.67 2.5 2 
PTEN 2 3 2.33 5 1 2 2.33 3 3 2.33 2 2 2 2 
PIK3R1 2 3 1.33 1* 1 1 1.67 1.5 3 2.33 1* 1.33 1.5 3 
NF1 2 3 2.33 4 1 4 2.33 2 3.33 1.33 1* 2.33 2 3 
BCL6 3 4 2.67 4 3 5 2.67 5 6 3 4 3 3 3 
CDK6 2 2.5 5 2 2 2 2.33 3 5 2.33 1 2 3 3 
JAK2 2 4 3 3 4 3 1.67 3 5 1.33 1 1.33 1.5 5 
GATA6 2 3 3 4 1 5 2 5 2 2 2 1.67 3 6 
SRC 2 3 3 4 3 7 3 4 4 3 3 2.33 4 9 
CDKN2B 1 3 1 2 2 4 0 4 3.33 1.33 1 0.67 1 1 
STK11 1 2 2 2 1,2 2 2 3 3 2 1 2 2 2 
TCF3 1 3 2 2 1 2.5 2 3 3 2 1 2 2 2 




Table 2-6. Estimated copy numbers for UM-SCC oral cavity cell line panel 
Estimated copy numbers as noted by the TuScan algorithm for cell lines for panel of genes. For 
copy numbers with a comma, multiple values were reported over the course of the gene. For cell 
lines with a copy number of 1*, the TuScan algorithm estimated a complete deletion (CN=0), 
however, we observed those genes had exome sequencing reads. We felt it more accurate to 





Primary Company Catalog # 
EGFR OriGene TA312545 
PI3K p110α Cell Signaling 4249 
PTEN Cell Signaling 9559 
pAKT (S473) Cell Signaling 40605 
AKT Cell Signaling 46855 
pERK1/2 (T202, Y204) Cell Signaling 4370 
ERK1/2 Cell Signaling 4695 
pMEK1/2 (S217, S221) Cell Signaling 9121 
MEK1/2 Cell Signaling 8727 
p53 Neo Markers MS-187-P0 
HSP90 Cell Signaling 4877 
pRb (S807, S811) Cell Signaling 8516 
pRb (S780) Cell Signaling 8180 
pRb (S795) Cell Signaling 9301 
Rb Cell Signaling 9313 
Beta-actin Cell Signaling 4970 
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Chapter 3: Using CRISPR/Cas9 Screening Libraries to Identify Mechanisms of Resistance 
to HNSCC Therapeutics 
Abstract 
Head and neck squamous cell carcinoma remains a deadly disease with poor prognosis. 
Developing novel, effective combination therapies can improve patient survival. To identify 
genes that mediate resistance to HNSCC therapies and are therefore prime targets for 
combination therapy, we developed CRISPR libraries in multiple UM-SCC lines. Using the 
CRISPR screens, we identified that loss of NOTCH1 and inhibition of Notch signaling drove 
sensitivity to cisplatin treatment, nominating Notch inhibitors and cisplatin therapy as an 
effective combination treatment. We also used our genome and kinome CRISPR libraries to 
identify genetic knockouts that created sensitivity to the EGFR inhibitors gefitinib and erlotinib. 
We observed that the gene PIK3C2A may be an important linchpin in the PI3K pathway for 
mediating resistance to EGFR inhibition, and that FGFR3 and FGF signaling may be a 
compensatory mechanism to EGFR signaling such that dual EGFR and FGFR inhibition may be 
an effective therapy in HNSCC.  
 
Introduction 
Patients with head and neck squamous cell carcinoma (HNSCC) have seen limited 
improvement in overall survival despite advances in standard therapies such as surgery, 
radiation, and chemotherapy (1). Likewise, while recent advances in immunotherapy have the 




10-15% of patients respond to the therapy (3). A promising option is combination therapy, 
meaning a treatment plan that includes two or more agents, which is a staple of cancer therapy. 
Where monotherapy treatment can often fail, a multi-dimensional therapy plan can be effective 
to reduce toxicity and cancer recurrence (4). However, the discovery of effective combinations 
remains a limiting factor.  
The adaptation of the CRISPR/Cas9 genetic engineering platform for mammalian 
systems has allowed for a new approach to discover effective drivers of drug resistance, making 
the generation of arrays of genetic knockouts more feasible. Upon challenging a CRISPR library 
with a therapy, we can screen hundreds of genes simultaneously to identify genetic knockouts 
that create sensitivity to the treatment and nominate potential targets for combination therapy (5-
7).   Cisplatin is likely candidate to be one of the combination arms, as cisplatin is frequently 
used in HNSCC and specifically for recurrent and metastatic cases (8). Cisplatin crosslinks DNA 
which makes the process of DNA repair impossible, leading to activation of apoptosis 
mechanisms and resulting in cell death for quickly dividing cells (9). However, only 10-25% of 
patients will respond to cisplatin therapy (10), with few therapeutic options after failure. 
Resistance to cisplatin therapy remains an unfortunately common challenge in HNSCC (11). 
An additional therapeutic treatment for HNSCC is the epidermal growth factor receptor 
(EGFR) inhibitor cetuximab. Cetuximab is a monoclonal antibody that binds and inhibits EGFR, 
and was approved for treatment in HNSCC in 2006 when the combination of cetuximab and 
radiation improved patient survival over radiation alone (12). However, cetuximab has limited 
effectiveness as monotherapy (13), despite that the majority of patients with HNSCC exhibit 
EGFR overexpression (14, 15). Indeed, there are no biomarkers of response to cetuximab 




Because of recurrence, several resistance mechanisms for EGFR inhibition have already 
been nominated.  Activation of MET has been noted to cause resistance to cetuximab (16), 
potentially through the reactivation of the PI3K pathway (17). The PI3K pathway is frequently 
altered in HNSCC, specifically PIK3CA, either through activating mutations or gene 
amplification (18). However, while dual inhibition of EGFR and PI3K is currently ongoing in 
clinical trials, initial results from the pan-PI3K inhibitor PX-866 with cetuximab showed no 
improvement to patient survival (19). To improve efficacy, it will be important to use biomarkers 
to nominate specific compensatory pathways within a tumor to better rationalize combinational 
approaches.    
In this chapter, we sought to identify mechanisms of resistance to cisplatin and EGFR 
inhibition using CRISPR libraries. We generated genome-wide and kinome-wide CRISPR 
libraries in UM-SCC cell line models that are resistant to cisplatin and EGFR inhibition, and then 
screened for genetic knockouts that generated sensitivity to these therapies. Here, we used the 
tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib to inhibit EGFR. While gefitinib and 
erlotinib have had limited effectiveness in HNSCC, the TKIs have had in vitro activity (20). As 
gefitinib and erlotinib have had success in other EGFR-driven cancers (21-23), we propose that 
resistance mechanisms prevent these EGFR TKIs from being effective in HNSCC. In identifying 
these resistance mechanisms with our CRISPR screen, we expect to nominate combinational 








Cell Culture. Cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Invitrogen #11965) containing 10% fetal bovine serum (FBS, Sigma), 1% NEAA (Invitrogen 
15140122) and 7 µL/mL penicillin-streptomycin (Invitrogen 15140122) in a humidified 
atmosphere of 5% CO2 at 37°C.  Cells were tested for mycoplasma contamination using the 
MycoAlert detection kit (Lonza).  
UM-SCC lines were transduced with the Human GeCKO CRISPR knockout pooled library, 
either version 1 (Addgene plasmid #49535) or version 2 (Addgene plasmid #52961) which were 
both gifts from Feng Zhang, or the Human Kinase Lentiviral CRISPR Pool (Sigma Aldrich 
HKCRISPR) (Fig 3-1). Conditions for transduction were established for a multiplicity of 
infection (MOI) of 0.3. After 7 days of puromycin selection, the cells were expanded and seeded 
per treatment. To preserve at least 300x coverage, 30 million cells were seeded per treatment for 
the GeCKO libraries while only 3 million cells per treatment were needed for the Kinase Library. 
At the end of treatment, genomic DNA was extracted from the remaining cells using Gentra 
Puregene Cell Kit (Qiagen).  
Cisplatin treatment: Cells were dosed with 0.125 µM cisplatin (Selleckchem S1166) or DMSO 
(Sigma Aldrich) for 24 hours, once a week for two weeks.  
Gefitinib and erlotinib treatment: Cells were dosed with 1 µM gefitinib (Selleckchem S1025) or 
1 µM erlotinib (Selleckchem S7786) in triplicate. For the Kinase Library samples, the DMSO 
control was also in triplicate, while the GeCKO Library samples had one DMSO control 





GeCKO Library Preparation. To preserve coverage of the GeCKO library, 130 µg of genomic 
DNA was used to PCR amplify the gRNA sequence using the Herculase ii Fusion DNA 
Polymerase (Agilent # 600675). 13 reactions with 10 µg input DNA were amplified with the 
following primers: 
PCR #1 Fwd: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
PCR #2 Rev: GGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAG 
The 13 reactions were combined, and then 5 µL were used to set up the second round PCR 
reactions with the following primers: 
PCR #2 Fwd: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
T(1-9bp stagger)AAGTAGAGtcttgtggaaaggacgaaacaccg 
PCR #2 Rev: 
CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTataacggactagccttattttaac 
Uppercase sequence represents Illumina adapters. The forward primer has the TruSeq Universal 
Adapter, and the reverse primer consists of Illumina P7, 8bp index, and multiplexing PCR primer 
2.0. The underlined sequence represents an 8bp barcode. Lowercase letters are the priming sites 
for the lentiviral construct. 
The PCR product was gel extracted and purified using Gel Extraction PCR Purification Kit 
(Qiagen) before submission to the University of Michigan DNA Sequencing Core for sequencing 
with Illumina MiSeq V3 Kit for cisplatin samples or Illumina HiSeq 2500 High-Output with V4 





Kinase Library Preparation. To preserve coverage of the Kinase Library, 12 µg of DNA was 
used to PCR amplify the gRNA sequence using the Herculase ii Fusion DNA Polymerase 
(Agilent # 600675). 2 reactions with 6 µg input DNA was amplified with the following primers: 
PCR #1 Forward : AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
PCR #2 Reverse: CTCGATTAATTAAGGTTGCTCACTTGTCGACTAATGC 
The two reactions were then combined, and 5 µL were used to set up the second round of PCR 
reactions. PCR #2 primers are same as listed above in the GeCKO Library Preparation section, 
as this adds on Illumina adaptor sequences and barcodes.  
The PCR products were gel extracted and purified using Gel Extraction PCR Purification Kit 
(Qiagen). Samples were then submitted to the University of Michigan DNA Sequencing Core for 
sequencing with Illumina MiSeq V3 Kit. 
 
Analysis of CRISPR libraries. Reads were demultiplexed by barcode and then mapped to the 
corresponding reference library using an in-house python script. gRNA counts were input into 
Model-based Analysis of Genome-wide CRISPR/Cas9 knockouts (MAGeCK, v0.5.2) (24). 
MAGeCK algorithms calculated significant gRNAs and genes, and genes with an α-RRA score 
of ≤0.05 were advanced to GSEA analysis. GSEA was then performed using the Molecular 
Signatures Database (v5.1) with the GSEA3.0.jar module to identify overlap with “Hallmark”, 
“C3_motif”, “Go-BP” and “Oncogene” gene set databases. Analysis was performed with 1000 
permutations and gene sets with false discovery rate of less than 0.05 were considered significant 
(max of 20 gene sets per reference database) as described [PMIDs:16199517, 12808457] and 
advanced for network analysis of representative and recurrent gene sets using the 





EGFR resistance analysis. Gefitinib IC50 values for non-UM-SCC cell lines were downloaded 
from The Genomics of Drug Sensitivity in Cancer Project (cancerrxgene.org) (25-27), using data 
version 17.3. 
 
Venn diagrams. Venn diagrams were modified from the output of Galaxy’s Venn Diagram 
program (28).  
 
Generation of Clonal Knockout Lines. UM-SCC-49 was transduced with a lentiviral CRISPR 
construct targeting NOTCH1 (Sigma Aldrich, HS0000408729) and after antibiotic and GFP 
selection, individual clones were isolated. MARVELD3 and FGFR3 gRNA sequences were 
ordered as TrueGuide Modified Synthetic crRNA (ThermoFisher Scientific) and prepared 
according to manufacturer recommendations. The gRNAs were co-delivered with TrueCut Cas9 
Protein v2 (ThermoFisher, A36496) using Lipofectamine CRISPRMAX Cas9 transfection 
reagents (ThermoFisher, CMAX00003) and then individual clones were isolated.  
Individual clones were screened for knockout by sanger sequencing. DNA was extracted from 
clones (Qiagen, Gentra Puregene Cell Kit) and the gRNA region amplified by PCR using 
Platinum HiFi Taq (Invitrogen). Primers for amplification are in Table 3-1. PCR products were 
then ligated into pCR8 vector (ThermoFisher, K250020), transformed, and plasmid DNA 
extracted from individual colonies (Qiagen, QIAprep Spin Miniprep Kit) and submitted for 
sanger sequencing at the University of Michigan DNA Sequencing Core. Sequences were 





Immunoblotting. Western blot analysis was performed as previously described (29, 30). Briefly, 
UM-SCC cell lines at 70-80% confluency were rinsed with PBS and lysed in buffer (150 mM 
NaCl, 10% Glycerol, 1% NP40, 0.1% Triton X-100, 1 mM PIPES, 1 mM MgCl, 50 mM Tris) 
containing protease and phosphatase inhibitors (Thermo 186129, 1861277) as described (31).  
See Table 3-2 for primary and secondary antibodies used.  
 
Clonogenic Cell Survival. Cells received cisplatin for 24 hours. Cells were then plated in 
triplicate and allowed to grow for two weeks, before being fixed and stained with 6% 
glutaraldehyde/0.5% crystal violet.  Colonies with greater than 50 cells were counted and percent 
survival was calculated as number of colonies divided by number of plated cells.  Survival 
fraction was calculated by dividing treatment cells by untreated controls. 
 
Cell viability assays. 2,000 cells per well were seeded in 384-well microplates using a Multiflo 
liquid handling dispensing system.  After 24 hours, cells were treated with compound or DMSO 
in a 10-point two-fold dilution series in quadruplicate.  96-well plates were prepared with 
compounds in 200X concentration and then diluted to 10X concentration in media in a second 
96-well plate using the Agilent Bravo Automated Liquid Handling Platform and VWorks 
Automation Control Software.  These compounds were then used to treat the cells with the 
desired drug concentration, again using liquid handling robotics.  Cells were stained with 
resazurin (Sigma) in PBS for 12-24 hours before fluorescent signal intensity was quantified 72 
hours after treatment using the Cytation3 fluorescence plate reader enabled with automatic 




compounds were purchased from Selleck Chemicals.   10 mM aliquots were stored -80 °C.  Each 
compound was subjected to no more than 5 freeze-thaw cycles.  
 
Trypan blue assays. 32,000 cells were seeded in 24-well plates. After 24 hours, cells were 
treated with compound or DMSO. All compounds were purchased from Selleck Chemicals. 
After 72 hours, cells were harvested and counted with trypan blue reagent (Invitrogen) using the 
Countess II Automated Cell Counter (ThermoFisher). Statistical analysis on trypan data was 
conducted by using a t-test to compare between wildtype and knockout cell lines and with 
Bonferroni correction to adjust p-value for multiple comparisons. For statistical analysis on 
comparing a dual inhibition treatment to the vehicle or monotherapy treatments, linear regression 
with interaction was used with Bonferroni correction to adjust p-value.  
 
Transcript analysis by qPCR. Cells were rinsed with PBS and then preserved in Qiazol 
(Qiagen) at -80°C until RNA extraction was performed using RNeasy Spin Kit (Qiagen) 
according to manufacturer recommendations. cDNA templates were then synthesized using 
random primers and SuperScript III Reverse Transcriptase (Invitrogen) according to 
manufacturer recommendations. Primers used for qPCR analysis are listed in Table 3-3. 
Amplification by qPCR was performed with Quantitech Sybr Green (Qiagen) on QuantStudio5 
(Applied Biosystems) under the cycling conditions recommended by manufacturer. 
 
Results 
With our goal being to nominate potential combination therapies that can block resistance 




screens. The schematic in Figure 3-2 outlines the creation, expansion, and experimental design 
to identify genetic knockouts that result in sensitivity to the treatment, and as such nominates 
potential dual therapy combinations for effective cell death. To test out our hypothesis that 
genetic knockouts in the CRISPR library could drive sensitivity to a monotherapy, we chose to 
use cisplatin due to its prevalence in treatment for head and neck cancer and the relative 
resistance of UM-SCC-49 cells to cisplatin monotherapy.  
Thus, we transduced UM-SCC-49 cells with the GeCKO v2A CRISPR library, then 
selected and expanded this pool before treating with cisplatin or vehicle control. The low dose of 
cisplatin every 7 days was chosen based on minimal impact to wildtype UM-SCC-49 cells 
(Figure 3-3). At the end of treatment, we isolated genomic DNA from the remaining cell pools 
and used Next Generation Sequencing (NGS) to sequence the gRNAs. We observed that over 
80% of the original GeCKO v2A library was represented in both control and treatment 
populations (Fig 3-4).  
We then compared the gRNA sequences from the cisplatin treatment to the vehicle 
control using the MAGeCK algorithm for CRISPR knockout screens (24). This analysis pipeline 
identified gRNAs (Fig 3-5A) and genes (Fig 3-5B) that were significantly depleted in the 
cisplatin treatment compared to the control. We then advanced significant genes (p-value ≤ 
0.005) for GSEA analysis which nominated several pathways as candidate drivers of cisplatin 
resistance (Fig 3-5C). To our surprise, the most significant pathway enriched in the gene set was 
the Notch signaling pathway. Genetic knockouts in the Notch signaling pathway targeting genes 
such as NOTCH1, SSPO, NCOR1, MARK2, and MYCBP were underrepresented in the UM-SCC-




colorectal cancer (33) have found that inhibition of the Notch signaling pathway sensitized cells 
to cisplatin, which gave us confidence that our screening method provided valid targets.  
We then went on to further validate that a genetic knockout in the Notch signaling 
pathway would sensitize UM-SCC-49 cells to cisplatin. We used CRISPR/Cas9 to knockout 
NOTCH1 in UM-SCC-49, where the gRNA was targeted to exon 25 as shown in Fig 3-6A. The 
resulting deletions in both alleles of NOTCH1 resulted in no detectable expression of Notch1 
protein in the NOTCH1 knockout (K/O) (Fig 3-6B). There are moderate decreases in expression 
of downstream effectors such as Hes1, Hey1, and c-Myc. It is also interesting to note the 
increase in Notch2 expression, potentially to compensate for the knockout of NOTCH1. Then, 
we wanted to test if the NOTCH1 K/O cell line was more sensitive to cisplatin than wildtype 
UM-SCC-49 cells as expected from the results of the CRISPR library screen. Clonogenic assays 
showed that the NOTCH1 K/O cell line is more sensitive to cisplatin than the wildtype UM-
SCC-49 cells and we observed a similar sensitivity in the NOTCH1 K/O as when Notch 
signaling is inhibited by the γ-secretase inhibitor DAPT (Fig 3-6C).  
With the successful identification of a genetic knockout that sensitized a UM-SCC model 
to cisplatin, we then moved on to test the hypothesis that genetic knockouts could drive 
sensitivity to EGFR inhibition. In addition to the UM-SCC-49 model, we also transduced 
GeCKO libraries into two additional cell lines resistant to EGFR inhibition, UM-SCC-58 and -
108 (Fig 3-7), and then challenged all three GeCKO pools with gefitinib or erlotinib alongside 
vehicle controls. We maintained a broad coverage of library diversity across libraries and 
treatments with the exception of UM-SCC-49 GeCKO v2A that was treated with erlotinib (Fig 
3-8). As the loss of ~50% coverage applies to both the vehicle control and erlotinib treatments, 




the diversity of the library was lost, we continued the analysis for the knockouts that were 
maintained in the library pool.  
We expected that the similar mechanism of actions between gefitinib and erlotinib would 
produce similar hits and so first looked at the overlap between these inhibitors. For UM-SCC-49, 
the gefitinib treatment had 1,877 genes as significant and erlotinib treatment had 969 genes (p-
value ≤ 0.05). This difference in number of hits called, almost two-fold, is most likely due to the 
loss of diversity in the erlotinib libraries. However, there were still 132 genes that overlapped in 
the gefitinib and erlotinib treated libraries in UM-SCC-49. UM-SCC-108 had 1,887 genes called 
as significant for gefitinib and 1,658 genes for erlotinib (p-value ≤ 0.05) with 539 genes 
overlapping between these two treatments. UM-SCC-58 had 1,908 significant genes in the 
gefitinib treatment and 2,050 genes for the erlotinib treatment (p-value ≤ 0.05), with 310 genes 
overlapping. To further prioritize targets, we then looked for genes that overlapped between the 
cell lines (Fig 3-9). To our surprise, few genes were found to be the same across cell lines. Two 
genes, TSPAN7 and CYP39A1, were found in UM-SCC-49 and UM-SCC-108 libraries. Four 
genes, BBS9, RHO, NARF, and ZCCHC14, were found in both UM-SCC-49 and UM-SCC-58 
libraries, and 9 genes, ZNF449, CALCR, NUBPL CYP2C18, DEK, AKZF1, AURKB, FAM19A5, 
and DPY19L4 were found in both UM-SCC-58 and UM-SCC-108 libraries. There were no genes 
in common between all three cell lines for both the gefitinib and erlotinib treatments. We saw 
similarly low numbers of overlap when analyzing only gefitinib or only erlotinib results between 
all three lines (Fig 3-10).  
As we identified few genes in common between all GeCKO screens, we sought to use a 
parallel strategy to add additional statistical support to the candidates advanced for validation. 




targets for knockout is smaller than the GeCKO libraries, but allowed for more gRNAs per gene 
to provide more statistical power in analysis (Table 3-4). We transduced the cell lines UM-SCC-
49, -97, and -108 with this Kinase library and repeated the pool expansion for treatment with 
vehicle control, gefitinib or erlotinib with the same doses of inhibitor and conditions as the 
GeCKO screen above. After sequencing the surviving cell population, we again analyzed the 
diversity content of the library which was maintained at above 80% coverage for the majority of 
conditions (Fig 3-11).  
We then used the MAGeCK algorithm to identify significant gRNA and gene depletion 
in the gefitinib or erlotinib treatments compared to their respective controls. For UM-SCC-49, 
111 genes were significantly depleted in the gefitinib treatment and 116 genes in the erlotinib 
treatment (p-value ≤ 0.05), with 65 genes in common between both treatments. UM-SCC-108 
had 109 significant genes in the gefitinib treatment and 113 genes in the erlotinib treatment (p-
value ≤ 0.05), with 31 genes overlapping. UM-SCC-97 had 155 significant genes for gefitinib 
and 119 genes for Erlotinib (p-value ≤ 0.05), with 72 genes in common. There were 9 genes in 
common between UM-SCC-49 and UM-SCC-97 (PHKG2, PINK1, PIP4K2B, CAMK1D, 
RAB32, SLK, TRIM33, CDKL1, MAP3K8), 3 genes in common between UM-SCC-49 and UM-
SCC-108 (CDK5R1, ULK4, PDK4), and 3 genes in common between UM-SCC-108 and UM-
SCC-97 (RPS6KB1, BTK, CDK12). The gene PIK3C2A was the only gene called as significant 
for both gefitinib and erlotinib treatments across all three lines (Fig 3-12). We also noted 8 genes 
overlapping between the gefitinib treatments across all three cell lines (PIK3C2A, MIP, PINK1, 
CAMK1D, KIAA1804, TRIM33, CAMK1G, FRK), and 3 for the erlotinib treatments (PIK3C2A, 




We next performed gene set enrichment analysis to evaluate similar pathways between 
the gefitinib and erlotinib treatments across the three lines. As expected, the 
PI3K/mTOR/FOXO4 pathway was enriched, as the PI3K pathway is a frequent combinational 
target with EGFR inhibition (31, 34-36) (Fig 3-14A). We also noted enrichment for several 
transcription factors (SP1, MAX, PAX4) and, interestingly, the Notch signaling pathway. 
Surprisingly, we also noted enrichment in the KRAS pathway, suggesting that KRAS signaling 
may play more of a role in resistance to EGFR inhibition than previously thought for HNSCCs. 
We then looked at gene enrichment in the GeCKO libraries, where the KRAS pathway was also 
enriched (Fig 3-14B). Similar to the results of the Kinase libraries, transcriptional regulation and 
PI3K and Notch signaling pathways were also enriched. In addition, the GeCKO libraries 
nominated cell death and DNA damage pathways, WNT signaling, cell cycle genes, interferon 
gamma and TGF-beta pathways, and genes involved in estrogen response. GSEA outputs for the 
individual cell line and inhibitor treatments for the Kinase and GeCKO libraries are in Table 3-6, 
3-7. 
From this analysis, we nominated 6 candidate genes to generate individual CRISPR/Cas9 
knockout clones for further validation of their role in compensatory EGFR inhibitor resistance 
(Table 3-5). We chose PIK3C2A as it was a significant hit in all six of the Human Kinase 
libraries and represented a potential mechanism of activation of the PI3K/mTOR gene set node. 
Further, we chose to focus on highly recurrent kinases identified in the screens as we postulated 
that these may represent more easily druggable targets including both CDK12 and PINK1, which 
were depleted in 5/6 of the Kinase screens, PDXK, depleted in 4/6 of the Kinase screens 
including all the erlotinib treatments, and MARVELD3, depleted in 3/6 screens including both 




treatments, as FGFR signaling has been noted as a promising target for HNSCC (37, 38). PINK1 
and PDXK were also significant hits in 2 and 1 of the GeCKO screens respectively, further 
supporting the potential role for these kinases in EGFR inhibitor resistance.  
At the time of writing this dissertation, only knockout clones for FGFR3 and 
MARVELD3 were successfully isolated in the UM-SCC-49 model. The MARVELD3 K/O clone 
displayed loss-of-function deletions in each of the three MARVELD3 alleles in UM-SCC-49 (Fig 
3-15A). However, the MARVELD3 K/O cell line did not display any additional sensitivity to the 
EGFR inhibitors gefitinib or erlotinib compared to the UM-SCC-49 wildtype cell line after 72 
hours (Fig 3-15B). We successfully engineered two independent FGFR3 knockout clones, 
though both clones contain the same 7bp deletion in one allele (Fig 3-16A). Interestingly, 
FGFR3 K/O #2 contains an allele with a 7bp deletion and 192bp insertion in which the insertion 
matches an intronic region in SLC4A4 before resuming FGFR3 sequence. Both FGFR3 K/O 
clone #1 and #2 display a significant sensitivity to gefitinib after 72 hours (p-value ≤ 0.05, p-
value ≤ 0.01) as compared to UM-SCC-49 wildtype (Fig 3-16B). We also challenged UM-SCC-
49 and the FGFR3 K/O clones with a pan-FGFR inhibitor in combination with EGFR inhibition. 
As no specific FGFR3 inhibitors were available, we choose a pan-FGFR inhibitor with two goals 
in mind. First, we postulated that if FGFR3 was the main driver of sensitivity to EGFR inhibitors 
and there was no additional compensation from FGFR1 or FGFR2, then the FGFR3 K/O clones 
would display no additional sensitivity to a pan-FGFR inhibitor. Second, we postulated that the 
combination of EGFR and FGFR3 (and/or pan-FGFR inhibition) may lead to cell death in UM-
SCC-49 wildtype which could nominate the dual inhibition of EGFR and FGFR as an effective 
therapeutic combination. Fig 3-16B also shows that while neither UM-SCC-49 WT or the 




undergo cell death with the combination of the pan-FGFR inhibitor and EGFR inhibitor. 
Furthermore, both FGFR3 K/O clones have significantly more cell death with the combination of 
EGFR and pan-FGFR inhibition (p-value ≤ 0.01), indicating that there may be additional 
compensation from FGFR1 and FGFR2. However, under normal cell growth conditions the 




 Here, we present the results of two CRISPR screening libraries used in negative selection 
screens with UM-SCC cell lines as well as the subsequent validation of prioritized candidates 
from each screen. Our results nominate candidate genes that potentially drive resistance to two 
common HNSCC therapies. Because a large number of patients are treated with cisplatin and 
will eventually develop resistance to the therapy (10, 11), we first focused on identifying 
knockouts that sensitized cisplatin-resistant cells to the therapy. Our genome-wide CRISPR 
screen identified the Notch signaling pathway as the most significant pathway that, when 
inhibited, was sensitive to cisplatin. Importantly, these data are consistent with previous results 
in other models (32, 33), and this finding is particularly interesting for HNSCC given the 
prevalence of inactivating NOTCH mutations (39, 40). In addition, others have found that higher 
expressions of Notch1 correlated with cisplatin resistance (41, 42). 
Given this relationship between NOTCH signaling and cisplatin resistance, we went on to 
validate our findings by generating a syngeneic NOTCH1 knockout model. Our targeted 
knockout model corroborated the results of our CRISPR screen, showing that knocking out 




changes in the Notch signaling pathway after knocking out NOTCH1, both in downstream 
effectors and the Notch2 receptor, these responses did not compensate for the lack of Notch1. 
Indeed, the NOTCH1 knockout model had a similar sensitivity to cisplatin as the DAPT 
treatment which would have inhibited all 4 of the Notch receptors. Findings from Lee et al. in 
other HNSCC models suggest that inhibiting Notch1 leads to a reduction of cancer stem cell 
traits which augments sensitivity to cisplatin (43), which is one potential mechanism consistent 
with our observation.  
Our results nominate Notch inhibitors as potential combination therapies alongside 
cisplatin treatment. Unfortunately, this combination is unlikely to be feasible in translation. 
Gamma-secretase inhibitors (GSIs) have undergone clinical trials, most notably for patients with 
activating Notch mutations in T-ALL (44, 45), and have dose limiting gastrointestinal toxicity 
from inhibition of Notch signaling (46). Additionally, a GSI clinical trial for Alzheimer’s 
patients led to the occurrence of both basal cell and squamous cell carcinoma (47). While the 
inhibition of Notch signaling may sensitize HNSCCs to cisplatin, the current therapeutic options 
to inhibit the Notch pathway are not clinically beneficial to make this combination an effective 
therapeutic option.  
Our other 12 CRISPR screens, 6 of which were genome-wide and 6 of which targeted the 
kinome, were setup to nominate genes and pathways that would sensitize HNSCC to EGFR 
inhibition.  While the small molecule inhibitors gefitinib and erlotinib are not currently approved 
for HNSCCs, we postulated that these EGFR inhibitors may be effective in combination with 
another therapy. Our 6 genome-wide screen nominated hundreds of genes that could sensitize 
our HNSCC models to gefitinib or erlotinib. Unfortunately, very few of these genes overlapped 




then acquired the kinome library, which given its more limited target size in comparison to the 
genome-wide library, allowed for more gRNAs per gene without becoming technically 
infeasible. With the additional statistical power, the kinome library provided more confidence in 
choosing targets for validation. For example, the gene PIK3C2A was significantly depleted in all 
six of the kinome screens. While PIK3C2A was not significantly depleted in any of the genome-
wide screens, the kinome screens nominated PIK3C2A as a potentially important node for the 
PI3K pathway’s contribution to resistance to EGFR inhibition.  
 Concordantly, our analysis of critical pathways that contribute to resistance to EGFR 
inhibition nominated the PI3K/mTOR/FOXO4 pathway for both the genome-wide and kinome 
screens. More surprising, the results of both screens also nominate the Notch signaling pathway 
as a potential resistance mechanism to EGFR inhibition. However, we anticipate the same 
difficulties as discussed above in advancing a combination with Notch inhibitors. Of particular 
interest to us was the significant depletion of genes in the KRAS pathway across both genome-
wide and kinome screens. While the KRAS pathway is a known resistance mechanism to EGFR 
inhibition in other cancers such as colon (48) and lung (49, 50), it is frequently due to activating 
mutations in KRAS. However, KRAS activating mutations are rare in HNSCC (18) and are not 
present in the UM-SCC cell lines used in the screens (30). The result of the KRAS pathway may 
speak more generally to Ras activity, though again these UM-SCC cell lines do not have 
activating mutations in KRAS, HRAS, or NRAS.   
From our CRISPR screens we nominated six genes for further validation. At the time of 
writing this dissertation, we successfully isolated clonal CRISPR knockout lines for FGFR3 and 
MARVELD3. From the results of the CRISPR screen, we expected these knockout lines to show 




MARVELD3 K/O clone did not display sensitivity. As the CRISPR screen was conducted with 
multiple doses of EGFR inhibitor over the course of two weeks, it is possible that the 
MARVELD3 K/O cell line may have a greater sensitivity to EGFR inhibition that is not 
observable over the course of three days. A longer term experiment, such as dosing for two 
weeks and monitoring cell proliferation as well as cell viability, would be informative on any 
potential sensitivity that the MARVELD3 K/O clone may have. However, both FGFR3 K/O 
clones showed a statistically significant sensitivity to EGFR inhibition over a shorter 3-day 
experiment, and the UM-SCC-49 wildtype cell line underwent cell death in response to dual 
EGFR and FGFR inhibition. Interestingly, the combination of EGFR and FGFR inhibition has 
shown effectiveness in a model without FGFR1 amplification, a frequently used biomarker for 
possible response to this therapy.  
In summary, we used multiple CRISPR screens to identify genetic knockouts that may 
drive sensitivity to HNSCC therapies. Our results nominated the Notch signaling pathway and 
specifically NOTCH1 as a co-target with cisplatin therapy, suggesting that the combination of 
Notch inhibition and cisplatin could be clinically beneficial for HNSCC if and when therapeutics 
targeting Notch have decreased side-effects. When using EGFR inhibitors, our results identified 
FGFR3 and the FGF signaling pathway as a potential compensatory pathway. The combination 
of EGFR and FGFR inhibition has shown promise in other cancer types, and we propose that this 
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Figure 3-1. CRISPR library constructs 
Schematics of lentiviral vectors used in CRISPR screens. A) GeCKO version 1 B) GeCKO 






Figure 3-2. Workflow schematic of the CRISPR library screen 
Schematic of negative selection screen from CRISPR library. First a library is established, taking 
a wildtype cell line and adding the lentiviral library at 30% MOI and then undergoing antibiotic 
selection. Here, different knockouts from gRNAs are represented in different colors. Then the 
CRISPR library pool is expanded and split for treatment, either vehicle control or compound. At 
the end of treatment, DNA is harvested from the surviving populations, and next generation 






Figure 3-3. Response of UM-SCC-49 to cisplatin 
Percent survival of the UM-SCC-49 cell line after treatment with cisplatin as determined by 






Figure 3-4. Library coverage plots for cisplatin and vehicle treated libraries 
Cumulative percentage of library coverage for UM-SCC-49 GeCKO v2A treated with vehicle or 
cisplatin. The incline of the curve from 20-80% of cumulative total represents the bulk of the 
library has an average of 100 reads representing each gRNA, indicating good depth of 






Figure 3-5. Cisplatin CRISPR screen nominates Notch signaling pathway 
A) gRNA read counts plotted for vehicle verses control treatment. gRNAs in blue indicate a 
significant depletion (0.01 ≤ p-value ≥ 0.05) and gRNAs in red indicate a significant depletion 
with p-value ≤ 0.01. B) The –log10(p-value) for each gene is plotted, where the p-value 
represents the significance of depletion in the cisplatin treatment as compared to the vehicle 
control. A dotted line representing a p-value cut off of 0.005 is shown, where everything above 
the line has a p-value ≤ 0.005. Significantly depleted genes in the Notch pathway are bolded and 
values colored red. C) GSEA results from genes with a p-value ≤ 0.005, where the enriched 







Figure 3-6. Response of NOTCH1 K/O model to cisplatin 
A) Schematic of sanger sequencing results from NOTCH1 K/O, showing a 32bp deletion and 
239bp deletion + 6bp insertion for both allelic copies of NOTCH1. The gRNA (red) and PAM 
sequence (blue) were in exon 25 of NOTCH1. B) Western blot images of UM-SCC-49 line (WT) 
and NOTCH1 K/O. C) Bar graph shows percent survival of UM-SCC-49 WT (blue), UM-SCC-







Figure 3-7. UM-SCC resistance to EGFR inhibitor gefitinib 
Responses of cell lines to the EGFR inhibitor gefitinib, plotting log10 of the IC50 value in µM. 
Black dots are from cell line responses downloaded from The Genomics of Drug Sensitivity in 
Cancer Project. UM-SCC cell lines are in red as tested by cell viability assays using resazurin.  
IC50 values were determined from the mean and standard deviation of at least quadruplicate 







Figure 3-8. Library coverage plots for GeCKO libraries 
Coverage plots for each replicate of the GeCKO library CRISPR screens for each cell line tested. 
Read counts per each gRNA are across the x-axis. Notably, there are few gRNAs with low read 
counts (<10) or high read counts (>1000), as indicated by the strong incline ~100 reads. The 







Figure 3-9. Overlap of GeCKO libraries 
Venn diagram of overlap of the significantly depleted genes (p-value ≤ 0.05) for each GeCKO 






Figure 3-10. Overlap of GeCKO library for each inhibitor 
Venn diagrams showing the overlap of significantly depleted genes (p-value ≤ 0.05) between cell 






Figure 3-11. Library coverage for Kinase libraries 
Coverage plots for each replicate of the Kinase library CRISPR screens for each cell line tested. 
Read counts per each gRNA are across the x-axis. Notably, there are few gRNAs with low read 
counts (<10) or high read counts (>1000), as indicated by the strong incline ~100 reads. The 







Figure 3-12. Overlap of Kinase CRISPR library 
Venn diagram of overlap of the significantly depleted genes (p-value ≤ 0.05) for each Kinase 







Figure 3-13. Overlap of Kinase CRISPR library for each inhibitor 
Venn diagrams showing the overlap of significantly depleted genes (p-value ≤ 0.05) between cell 







Figure 3-14. Gene set enrichment analysis of Kinase and GeCKO CRISPR screens 
Cytoscape network plot shows significant enrichments of gene sets identified in each of the 6 
CRISPR kinome screens (A) or GeCKO screens (B) (with each gene set represented by blue 
circular nodes) with annotated gene sets downloaded from the molecular signatures data bases 
v5.1 (red nodes = “Hallmark” gene sets, black nodes = “Motif” gene sets, green nodes = “Go-
biological process” gene sets and yellow nodes = “Oncogene” gene sets). The size of each node 
is proportional to the number of genes in the gene set. Lines connecting each node are 
proportional to the significance of overlap between the gene sets, determined by false discovery 
rate (FDR), with more significant interactions represented by thicker edge weights. All 
interactions shown have FDR < 0.05. Recurrent and selected concepts are grouped within the 






Figure 3-15. Response of MARVELD3 K/O clone to EGFR inhibition 
A) Schematic of sanger sequencing results from MARVELD3 K/O clone as compared to 
wildtype (WT) sequence. The gRNA sequence is underlined in red, targeted to exon 2 of 
MARVELD3. UM-SCC-49 has 3 copies of MARVELD3, and the MARVELD3 K/O has 1bp, 
10bp, and 20bp deletions. B) Cell viability response of UM-SCC-49 wildtype or MARVELD3 







Figure 3-16. Response of FGFR3 K/O clones to EGFR inhibition 
A) Schematic representation of sanger sequencing data from FGFR3 K/O clones as compared to 
wildtype (WT) sequence. The gRNA is underlined in red, targeted to exon 9 of FGFR3. FGFR3 
clone #1 has a 34bp and 7bp deletion, and FGFR3 clone #2 has a 7bp deletion and a 192bp 
insertion of intronic SLC4A4 sequence + 7bp deletion for a combined resulted insertion of 
185bp. B) Cell viability as determined by trypan blue assay for UM-SCC-49 (black), FGFR3 
K/O clone #1 (red) or FGFR3 K/O clone #2 (blue) at 72hour timepoint. Asterisks denote p-value 
(*p-value ≤ 0.05, **p-value ≤0.01) according to statistical analysis detailed in methods section. 
C) Transcript expression levels as detected by qPCR as compared to the fold change of UM-











Table 3-1. Genomic primers 
Genomic primers used for sanger sequencing of CRISPR knockout clones as indicated. 
 
   
 
  














Antibody Target Catalog # 
NOTCH1 CST 3608 
ICN-1 CST 4147 
NOTCH2 CST 5732 
NOTCH3 CST 5276 
Hes1 CST 11988 
c-Myc CST 5605 
Axin2 CST 2151 
Beta-actin CST 4970 
Anti-Rabbit Secondary Jackson Research 111-035-045 
Anti-Mouse Secondary  Jackson Research 715-035-151 
Table 3-2. Antibodies 





























Table 3-3. qPCR primers 





  GeCKO v1 GeCKOv2 (A or B) Kinase 
Gene targets 18,080 19,050 684 
miRNA targets 0 1,864 0 
gRNA/gene ~3-4 3 ~9 
Cells/treatment 30 million 30 million 3 million 
Table 3-4. CRISPR library statistics 
Table depicting the number of targets, gRNAs, and recommended cells plated per treatment for 






  Kinase Libraries   GeCKO Libraries 
  










































































PIK3C2A 0.0005 0.0019 0.0006 0.0324 0.0282 0.0244   0.5458 0.9953 0.3398 0.1086 0.6822 0.0914 
CDK12 0.0565 0.1755 0.0361 0.0026 0.0340 0.0301   0.0767 - 0.7889 0.3910 0.2189 0.1416 
PINK1 0.0102 0.0215 0.0355 0.3252 0.0298 0.0014   0.6011 0.0353 0.1162 0.6672 0.8318 0.0458 
PDXK 0.1184 0.0223 0.0767 0.0006 0.0063 0.0405   0.9624 - 0.0719 0.0131 0.1262 0.4262 
MARVELD3 0.0008 0.0028 0.1082 0.0068 0.1848 0.4968   0.2190 0.7358 0.9380 0.9406 0.2563 0.4117 
FGFR3 0.0110 0.0150 0.1758 0.2505 0.8514 0.9566   0.8124 0.4790 0.0789 0.1088 0.0691 0.3059 
Table 3-5. Significance of six nominated genes across all library screens 
Table of p-values from MAGeCK output by gene for both Kinase and GeCKO library screens. P-







































49_kinome_erl 116 GO_PHOSPHORYLATION 1228 7.08E-147 
49_kinome_erl 116 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 5.28E-125 
49_kinome_erl 116 GO_PROTEIN_PHOSPHORYLATION 944 2.34E-108 
49_kinome_erl 116 GO_PROTEIN_AUTOPHOSPHORYLATION 192 5.52E-57 
49_kinome_erl 116 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 6.18E-43 
49_kinome_erl 116 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 3.75E-35 
49_kinome_erl 116 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 4.11E-32 
49_kinome_erl 116 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 1.42E-31 
49_kinome_erl 116 GO_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 689 4.53E-30 
49_kinome_erl 116 GO_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1036 1.37E-29 
49_kinome_erl 116 GO_POSITIVE_REGULATION_OF_KINASE_ACTIVITY 482 5.43E-29 
49_kinome_erl 116 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 1.06E-27 
49_kinome_erl 116 GO_REGULATION_OF_KINASE_ACTIVITY 776 3.50E-27 
49_kinome_erl 116 
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALI
NG_PATHWAY 498 3.50E-27 
49_kinome_erl 116 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 3.64E-27 
49_kinome_erl 116 GO_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 616 4.33E-26 
49_kinome_erl 116 GO_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1135 7.23E-26 
49_kinome_erl 116 GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1492 2.10E-25 
49_kinome_erl 116 GO_SIGNAL_TRANSDUCTION_BY_PROTEIN_PHOSPHORYLATION 404 3.44E-25 
49_kinome_erl 116 GO_PEPTIDYL_SERINE_MODIFICATION 148 6.66E-25 
49_kinome_gef 111 GO_PHOSPHORYLATION 1228 3.78E-134 
49_kinome_gef 111 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 4.70E-116 
49_kinome_gef 111 GO_PROTEIN_PHOSPHORYLATION 944 4.46E-111 
49_kinome_gef 111 GO_PROTEIN_AUTOPHOSPHORYLATION 192 1.14E-55 
49_kinome_gef 111 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 5.88E-44 
49_kinome_gef 111 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 8.49E-36 
49_kinome_gef 111 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 5.59E-35 
49_kinome_gef 111 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 2.09E-29 
49_kinome_gef 111 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 4.72E-29 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1036 1.01E-27 
49_kinome_gef 111 GO_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 689 1.50E-26 
49_kinome_gef 111 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 3.11E-26 
49_kinome_gef 111 GO_SIGNAL_TRANSDUCTION_BY_PROTEIN_PHOSPHORYLATION 404 1.52E-25 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1135 2.92E-25 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_KINASE_ACTIVITY 482 3.55E-25 
49_kinome_gef 111 
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALI
NG_PATHWAY 498 7.73E-25 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 1.36E-24 
49_kinome_gef 111 GO_REGULATION_OF_MAPK_CASCADE 660 1.69E-24 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 1.82E-24 
49_kinome_gef 111 GO_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 616 5.87E-24 
97_kinome_erl 119 GO_PHOSPHORYLATION 1228 4.71E-149 
97_kinome_erl 119 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.00E-133 
97_kinome_erl 119 GO_PROTEIN_PHOSPHORYLATION 944 2.35E-117 
97_kinome_erl 119 GO_PROTEIN_AUTOPHOSPHORYLATION 192 2.86E-36 
97_kinome_erl 119 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 3.51E-33 
97_kinome_erl 119 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 2.31E-25 
97_kinome_erl 119 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 3.34E-19 
97_kinome_erl 119 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 5.65E-19 
97_kinome_erl 119 GO_PEPTIDYL_SERINE_MODIFICATION 148 5.81E-19 
97_kinome_erl 119 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 1.01E-17 
97_kinome_erl 119 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 8.34E-16 
97_kinome_erl 119 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 8.49E-16 
97_kinome_erl 119 GO_REGULATION_OF_KINASE_ACTIVITY 776 2.01E-15 
97_kinome_erl 119 GO_REGULATION_OF_CELL_DEATH 1472 2.94E-15 
97_kinome_erl 119 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 5.73E-15 
97_kinome_erl 119 GO_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1036 6.18E-15 
97_kinome_erl 119 GO_SIGNAL_TRANSDUCTION_BY_PROTEIN_PHOSPHORYLATION 404 7.22E-15 




97_kinome_erl 119 GO_REGULATION_OF_MAPK_CASCADE 660 1.06E-14 
97_kinome_erl 119 GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1492 2.85E-14 
97_kinome_gef 155 GO_PHOSPHORYLATION 1228 1.77E-190 
97_kinome_gef 155 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 5.54E-166 
97_kinome_gef 155 GO_PROTEIN_PHOSPHORYLATION 944 3.37E-151 
97_kinome_gef 155 GO_PROTEIN_AUTOPHOSPHORYLATION 192 1.31E-51 
97_kinome_gef 155 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 1.46E-42 
97_kinome_gef 155 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 3.87E-42 
97_kinome_gef 155 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 5.48E-30 
97_kinome_gef 155 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 4.58E-25 
97_kinome_gef 155 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 8.07E-24 
97_kinome_gef 155 GO_PEPTIDYL_SERINE_MODIFICATION 148 8.55E-24 
97_kinome_gef 155 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 5.91E-22 
97_kinome_gef 155 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 1.48E-19 
97_kinome_gef 155 GO_REGULATION_OF_KINASE_ACTIVITY 776 2.49E-19 
97_kinome_gef 155 GO_REGULATION_OF_TRANSFERASE_ACTIVITY 946 3.53E-19 
97_kinome_gef 155 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 3.61E-19 
97_kinome_gef 155 GO_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1036 3.67E-19 
97_kinome_gef 155 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 4.65E-19 
97_kinome_gef 155 GO_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 689 1.58E-18 
97_kinome_gef 155 GO_ORGANOPHOSPHATE_METABOLIC_PROCESS 885 6.13E-18 
97_kinome_gef 155 GO_REGULATION_OF_CELL_CYCLE 949 3.83E-17 
108_kinome_erl 118 GO_PHOSPHORYLATION 1228 1.06E-139 
108_kinome_erl 118 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 5.18E-128 
108_kinome_erl 118 GO_PROTEIN_PHOSPHORYLATION 944 7.82E-108 
108_kinome_erl 118 GO_PROTEIN_AUTOPHOSPHORYLATION 192 5.99E-47 
108_kinome_erl 118 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 1.53E-43 
108_kinome_erl 118 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 1.19E-30 
108_kinome_erl 118 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 6.08E-30 
108_kinome_erl 118 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 1.29E-26 
108_kinome_erl 118 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 9.29E-26 
108_kinome_erl 118 
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALI
NG_PATHWAY 498 5.82E-23 
108_kinome_erl 118 GO_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 689 3.45E-22 
108_kinome_erl 118 GO_REGULATION_OF_CELL_DEATH 1472 3.82E-20 
108_kinome_erl 118 GO_PEPTIDYL_SERINE_MODIFICATION 148 1.68E-19 
108_kinome_erl 118 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 1.21E-18 
108_kinome_erl 118 GO_REGULATION_OF_KINASE_ACTIVITY 776 1.89E-18 
108_kinome_erl 118 GO_REGULATION_OF_TRANSFERASE_ACTIVITY 946 1.28E-17 
108_kinome_erl 118 GO_REGULATION_OF_MAPK_CASCADE 660 1.28E-17 
108_kinome_erl 118 GO_NEGATIVE_REGULATION_OF_CELL_DEATH 872 2.54E-17 
108_kinome_erl 118 GO_REGULATION_OF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY 470 1.74E-15 
108_kinome_erl 118 GO_SIGNAL_TRANSDUCTION_BY_PROTEIN_PHOSPHORYLATION 404 2.35E-15 
108_kinome_gef 109 GO_PHOSPHORYLATION 1228 1.18E-128 
108_kinome_gef 109 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.25E-115 
108_kinome_gef 109 GO_PROTEIN_PHOSPHORYLATION 944 4.71E-110 
108_kinome_gef 109 GO_PROTEIN_AUTOPHOSPHORYLATION 192 2.13E-41 
108_kinome_gef 109 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 1.02E-40 
108_kinome_gef 109 GO_PEPTIDYL_AMINO_ACID_MODIFICATION 841 9.38E-37 
108_kinome_gef 109 GO_PEPTIDYL_TYROSINE_MODIFICATION 186 1.80E-28 
108_kinome_gef 109 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 2.50E-27 
108_kinome_gef 109 GO_REGULATION_OF_KINASE_ACTIVITY 776 1.38E-26 
108_kinome_gef 109 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 1.63E-26 
108_kinome_gef 109 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 6.89E-26 
108_kinome_gef 109 GO_REGULATION_OF_TRANSFERASE_ACTIVITY 946 2.00E-25 
108_kinome_gef 109 GO_PEPTIDYL_SERINE_MODIFICATION 148 2.88E-25 
108_kinome_gef 109 GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1492 4.77E-24 
108_kinome_gef 109 GO_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1036 1.43E-20 
108_kinome_gef 109 GO_POSITIVE_REGULATION_OF_KINASE_ACTIVITY 482 1.29E-19 
108_kinome_gef 109 GO_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1135 1.55E-19 
108_kinome_gef 109 GO_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 616 1.09E-18 
108_kinome_gef 109 GO_REGULATION_OF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY 470 1.60E-18 
108_kinome_gef 109 GO_ACTIVATION_OF_PROTEIN_KINASE_ACTIVITY 279 1.63E-18 
49_kinome_erl 116 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.49E-05 
49_kinome_erl 116 HALLMARK_APICAL_JUNCTION 200 3.14E-04 




49_kinome_erl 116 HALLMARK_ALLOGRAFT_REJECTION 200 1.42E-02 
49_kinome_erl 116 HALLMARK_COMPLEMENT 200 1.42E-02 
49_kinome_erl 116 HALLMARK_MYOGENESIS 200 1.42E-02 
49_kinome_erl 116 HALLMARK_ANDROGEN_RESPONSE 101 1.56E-02 
49_kinome_erl 116 HALLMARK_PANCREAS_BETA_CELLS 40 2.89E-02 
49_kinome_erl 116 HALLMARK_UV_RESPONSE_UP 158 4.15E-02 
49_kinome_erl 116 HALLMARK_TGF_BETA_SIGNALING 54 4.15E-02 
49_kinome_erl 116 HALLMARK_G2M_CHECKPOINT 200 4.49E-02 
49_kinome_erl 116 HALLMARK_HYPOXIA 200 4.49E-02 
49_kinome_erl 116 HALLMARK_INFLAMMATORY_RESPONSE 200 4.49E-02 
49_kinome_erl 116 HALLMARK_KRAS_SIGNALING_DN 200 4.49E-02 
49_kinome_erl 116 HALLMARK_P53_PATHWAY 200 4.49E-02 
49_kinome_erl 116 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 4.49E-02 
49_kinome_gef 111 HALLMARK_COMPLEMENT 200 3.08E-05 
49_kinome_gef 111 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.50E-04 
49_kinome_gef 111 HALLMARK_SPERMATOGENESIS 135 3.38E-04 
49_kinome_gef 111 HALLMARK_UV_RESPONSE_DN 144 3.46E-04 
49_kinome_gef 111 HALLMARK_APICAL_JUNCTION 200 1.31E-03 
49_kinome_gef 111 HALLMARK_TGF_BETA_SIGNALING 54 2.59E-03 
49_kinome_gef 111 HALLMARK_INFLAMMATORY_RESPONSE 200 1.04E-02 
49_kinome_gef 111 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 49 3.75E-02 
49_kinome_gef 111 HALLMARK_UV_RESPONSE_UP 158 3.75E-02 
97_kinome_erl 119 HALLMARK_HYPOXIA 200 7.27E-04 
97_kinome_erl 119 HALLMARK_APICAL_JUNCTION 200 2.27E-03 
97_kinome_erl 119 HALLMARK_E2F_TARGETS 200 2.27E-03 
97_kinome_erl 119 HALLMARK_IL2_STAT5_SIGNALING 200 2.27E-03 
97_kinome_erl 119 HALLMARK_TGF_BETA_SIGNALING 54 3.81E-03 
97_kinome_erl 119 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 1.17E-02 
97_kinome_erl 119 HALLMARK_GLYCOLYSIS 200 1.17E-02 
97_kinome_erl 119 HALLMARK_MITOTIC_SPINDLE 200 1.17E-02 
97_kinome_erl 119 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.45E-02 
97_kinome_erl 119 HALLMARK_UV_RESPONSE_DN 144 3.16E-02 
97_kinome_erl 119 HALLMARK_APOPTOSIS 161 3.90E-02 
97_kinome_gef 155 HALLMARK_HYPOXIA 200 3.21E-03 
97_kinome_gef 155 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 5.57E-03 
97_kinome_gef 155 HALLMARK_E2F_TARGETS 200 7.65E-03 
97_kinome_gef 155 HALLMARK_G2M_CHECKPOINT 200 7.65E-03 
97_kinome_gef 155 HALLMARK_TGF_BETA_SIGNALING 54 8.23E-03 
97_kinome_gef 155 HALLMARK_MYC_TARGETS_V2 58 8.45E-03 
97_kinome_gef 155 HALLMARK_APICAL_JUNCTION 200 2.20E-02 
97_kinome_gef 155 HALLMARK_COMPLEMENT 200 2.20E-02 
97_kinome_gef 155 HALLMARK_GLYCOLYSIS 200 2.20E-02 
97_kinome_gef 155 HALLMARK_IL2_STAT5_SIGNALING 200 2.20E-02 
97_kinome_gef 155 HALLMARK_MYOGENESIS 200 2.20E-02 
97_kinome_gef 155 HALLMARK_PANCREAS_BETA_CELLS 40 3.38E-02 
108_kinome_erl 118 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.19E-08 
108_kinome_erl 118 HALLMARK_UV_RESPONSE_DN 144 7.53E-04 
108_kinome_erl 118 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.55E-02 
108_kinome_erl 118 HALLMARK_MITOTIC_SPINDLE 200 1.55E-02 
108_kinome_erl 118 HALLMARK_MYOGENESIS 200 1.55E-02 
108_kinome_gef 109 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 2.74E-04 
108_kinome_gef 109 HALLMARK_UV_RESPONSE_DN 144 9.96E-03 
108_kinome_gef 109 HALLMARK_GLYCOLYSIS 200 1.13E-02 
108_kinome_gef 109 HALLMARK_HEME_METABOLISM 200 1.13E-02 
108_kinome_gef 109 HALLMARK_KRAS_SIGNALING_DN 200 1.13E-02 
108_kinome_gef 109 HALLMARK_MYOGENESIS 200 1.13E-02 
108_kinome_gef 109 HALLMARK_ANDROGEN_RESPONSE 101 1.30E-02 
49_kinome_erl 116 CAGGTG_E12_Q6 2485 4.13E-07 
49_kinome_erl 116 GGGAGGRR_MAZ_Q6 2274 9.17E-07 
49_kinome_erl 116 GGGCGGR_SP1_Q6 2940 4.51E-06 
49_kinome_erl 116 HNF4ALPHA_Q6 271 6.94E-06 
49_kinome_erl 116 PAX4_01 262 6.26E-05 
49_kinome_erl 116 AATGTGA_MIR23A_MIR23B 419 1.80E-04 
49_kinome_erl 116 CACTTTG_MIR520G_MIR520H 237 3.06E-04 
49_kinome_erl 116 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 3.06E-04 




49_kinome_erl 116 TTGTTT_FOXO4_01 2061 3.56E-04 
49_kinome_erl 116 HNF4_DR1_Q3 261 3.58E-04 
49_kinome_erl 116 GGGTGGRR_PAX4_03 1294 3.58E-04 
49_kinome_erl 116 HNF4_01 269 3.79E-04 
49_kinome_erl 116 CCTGTGA_MIR513 125 1.03E-03 
49_kinome_erl 116 TGTTTGY_HNF3_Q6 738 1.06E-03 
49_kinome_erl 116 RYTTCCTG_ETS2_B 1085 1.07E-03 
49_kinome_erl 116 
AGCACTT_MIR93_MIR302A_MIR302B_MIR302C_MIR302D_MIR372_MIR373_M
IR520E_MIR520A_MIR526B_MIR520B_MIR520C_MIR520D 343 1.31E-03 
49_kinome_erl 116 CTGAGCC_MIR24 231 1.31E-03 
49_kinome_erl 116 AAGTCCA_MIR422B_MIR422A 71 1.45E-03 
49_kinome_erl 116 PEA3_Q6 255 1.80E-03 
49_kinome_gef 111 CAGGTG_E12_Q6 2485 2.60E-08 
49_kinome_gef 111 TTGTTT_FOXO4_01 2061 2.95E-07 
49_kinome_gef 111 GGGAGGRR_MAZ_Q6 2274 1.27E-06 
49_kinome_gef 111 GGGCGGR_SP1_Q6 2940 5.72E-06 
49_kinome_gef 111 AACTTT_UNKNOWN 1890 2.24E-05 
49_kinome_gef 111 PAX4_01 262 3.72E-05 
49_kinome_gef 111 CTGCAGY_UNKNOWN 765 3.89E-05 
49_kinome_gef 111 RTAAACA_FREAC2_01 919 3.89E-05 
49_kinome_gef 111 MEF2_Q6_01 244 2.15E-04 
49_kinome_gef 111 PEA3_Q6 255 2.54E-04 
49_kinome_gef 111 ATF4_Q2 258 2.54E-04 
49_kinome_gef 111 HNF4ALPHA_Q6 271 2.85E-04 
49_kinome_gef 111 E2F_Q2 176 2.85E-04 
49_kinome_gef 111 GTGACGY_E4F1_Q6 658 2.85E-04 
49_kinome_gef 111 TGTTTGY_HNF3_Q6 738 7.18E-04 
49_kinome_gef 111 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 7.62E-04 
49_kinome_gef 111 TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497 601 7.62E-04 
49_kinome_gef 111 GTGCAAA_MIR507 131 7.62E-04 
49_kinome_gef 111 RNGTGGGC_UNKNOWN 766 7.62E-04 
49_kinome_gef 111 AAGCCAT_MIR135A_MIR135B 335 7.62E-04 
97_kinome_erl 119 CTTTGT_LEF1_Q2 1972 5.78E-06 
97_kinome_erl 119 PAX2_02 258 7.89E-06 
97_kinome_erl 119 GGGCGGR_SP1_Q6 2940 7.89E-06 
97_kinome_erl 119 TTGTTT_FOXO4_01 2061 1.45E-05 
97_kinome_erl 119 AACTTT_UNKNOWN 1890 1.45E-05 
97_kinome_erl 119 RTAAACA_FREAC2_01 919 1.75E-05 
97_kinome_erl 119 TTAYRTAA_E4BP4_01 265 5.93E-05 
97_kinome_erl 119 GGGTGGRR_PAX4_03 1294 1.44E-04 
97_kinome_erl 119 GGGAGGRR_MAZ_Q6 2274 1.47E-04 
97_kinome_erl 119 SP3_Q3 245 3.17E-04 
97_kinome_erl 119 CAGGTG_E12_Q6 2485 4.55E-04 
97_kinome_erl 119 TTANTCA_UNKNOWN 952 4.82E-04 
97_kinome_erl 119 OLF1_01 272 4.82E-04 
97_kinome_erl 119 TGACATY_UNKNOWN 665 5.81E-04 
97_kinome_erl 119 E4BP4_01 223 1.49E-03 
97_kinome_erl 119 RNGTGGGC_UNKNOWN 766 1.50E-03 
97_kinome_erl 119 E2F1DP1_01 235 1.50E-03 
97_kinome_erl 119 E2F1DP2_01 235 1.50E-03 
97_kinome_erl 119 E2F4DP2_01 235 1.50E-03 
97_kinome_erl 119 E2F_02 235 1.50E-03 
97_kinome_gef 155 GGGCGGR_SP1_Q6 2940 1.88E-09 
97_kinome_gef 155 GGGTGGRR_PAX4_03 1294 1.29E-06 
97_kinome_gef 155 GGGAGGRR_MAZ_Q6 2274 3.24E-06 
97_kinome_gef 155 CAGGTG_E12_Q6 2485 3.83E-06 
97_kinome_gef 155 AACTTT_UNKNOWN 1890 1.68E-05 
97_kinome_gef 155 TTGTTT_FOXO4_01 2061 1.68E-05 
97_kinome_gef 155 RYTTCCTG_ETS2_B 1085 2.14E-05 
97_kinome_gef 155 TTAYRTAA_E4BP4_01 265 3.47E-05 
97_kinome_gef 155 CTATGCA_MIR153 216 6.71E-05 
97_kinome_gef 155 CTTTGT_LEF1_Q2 1972 6.71E-05 
97_kinome_gef 155 TTANTCA_UNKNOWN 952 6.71E-05 
97_kinome_gef 155 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 6.71E-05 
97_kinome_gef 155 TGCACTT_MIR519C_MIR519B_MIR519A 448 2.10E-04 




97_kinome_gef 155 CCTGTGA_MIR513 125 2.40E-04 
97_kinome_gef 155 CTTTGA_LEF1_Q2 1232 2.40E-04 
97_kinome_gef 155 TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P 579 2.40E-04 
97_kinome_gef 155 RGAGGAARY_PU1_Q6 502 3.90E-04 
97_kinome_gef 155 TATAAA_TATA_01 1296 3.90E-04 
97_kinome_gef 155 E4BP4_01 223 4.75E-04 
108_kinome_erl 118 TTGTTT_FOXO4_01 2061 1.48E-07 
108_kinome_erl 118 GGGTGGRR_PAX4_03 1294 8.23E-06 
108_kinome_erl 118 GGGCGGR_SP1_Q6 2940 1.11E-05 
108_kinome_erl 118 AATGTGA_MIR23A_MIR23B 419 1.87E-05 
108_kinome_erl 118 TGACAGNY_MEIS1_01 827 1.87E-05 
108_kinome_erl 118 CAGGTG_E12_Q6 2485 1.87E-05 
108_kinome_erl 118 TGCACTT_MIR519C_MIR519B_MIR519A 448 1.87E-05 
108_kinome_erl 118 AACTTT_UNKNOWN 1890 1.87E-05 
108_kinome_erl 118 TGAATGT_MIR181A_MIR181B_MIR181C_MIR181D 484 3.35E-05 
108_kinome_erl 118 ATTCTTT_MIR186 272 3.40E-05 
108_kinome_erl 118 TTANTCA_UNKNOWN 952 5.17E-05 
108_kinome_erl 118 CTTTGCA_MIR527 235 1.42E-04 
108_kinome_erl 118 TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497 601 1.62E-04 
108_kinome_erl 118 CAATGCA_MIR33 92 2.04E-04 
108_kinome_erl 118 PAX2_02 258 2.10E-04 
108_kinome_erl 118 TTGCACT_MIR130A_MIR301_MIR130B 403 3.91E-04 
108_kinome_erl 118 TACTTGA_MIR26A_MIR26B 300 4.91E-04 
108_kinome_erl 118 CEBP_C 200 4.91E-04 
108_kinome_erl 118 GGGAGGRR_MAZ_Q6 2274 4.91E-04 
108_kinome_erl 118 ACAGGGT_MIR10A_MIR10B 123 5.89E-04 
108_kinome_gef 109 GGGCGGR_SP1_Q6 2940 5.34E-07 
108_kinome_gef 109 YTATTTTNR_MEF2_02 697 5.34E-07 
108_kinome_gef 109 CAGGTG_E12_Q6 2485 9.23E-07 
108_kinome_gef 109 AACTTT_UNKNOWN 1890 3.92E-06 
108_kinome_gef 109 GGGAGGRR_MAZ_Q6 2274 1.34E-05 
108_kinome_gef 109 MEF2_Q6_01 244 1.88E-05 
108_kinome_gef 109 TGAATGT_MIR181A_MIR181B_MIR181C_MIR181D 484 2.71E-05 
108_kinome_gef 109 TCCCCAC_MIR491 57 2.71E-05 
108_kinome_gef 109 CACTTTG_MIR520G_MIR520H 237 1.42E-04 
108_kinome_gef 109 TTGTTT_FOXO4_01 2061 1.42E-04 
108_kinome_gef 109 PTF1BETA_Q6 244 1.47E-04 
108_kinome_gef 109 MYOD_Q6 245 1.47E-04 
108_kinome_gef 109 HNF4_01_B 253 1.68E-04 
108_kinome_gef 109 ACCAAAG_MIR9 499 1.90E-04 
108_kinome_gef 109 AP1_Q6_01 264 1.92E-04 
108_kinome_gef 109 HNF4_01 269 2.04E-04 
108_kinome_gef 109 RTAAACA_FREAC2_01 919 5.44E-04 
108_kinome_gef 109 TATAAA_TATA_01 1296 5.44E-04 
108_kinome_gef 109 RSRFC4_Q2 214 5.44E-04 
108_kinome_gef 109 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 5.44E-04 
49_kinome_erl 116 CYCLIN_D1_KE_.V1_DN 194 2.00E-03 
49_kinome_erl 116 CYCLIN_D1_KE_.V1_UP 190 8.18E-03 
49_kinome_erl 116 RAPA_EARLY_UP.V1_DN 191 8.18E-03 
49_kinome_erl 116 CRX_DN.V1_UP 136 1.92E-02 
49_kinome_erl 116 KRAS.600_UP.V1_UP 287 2.85E-02 
49_kinome_erl 116 STK33_NOMO_DN 292 2.85E-02 
49_kinome_erl 116 ESC_J1_UP_EARLY.V1_UP 183 2.88E-02 
49_kinome_erl 116 CYCLIN_D1_UP.V1_DN 191 2.88E-02 
49_kinome_erl 116 NOTCH_DN.V1_UP 193 2.88E-02 
49_kinome_erl 116 PIGF_UP.V1_DN 194 2.88E-02 
49_kinome_gef 111 CYCLIN_D1_KE_.V1_DN 194 1.55E-03 
49_kinome_gef 111 STK33_DN 289 5.10E-03 
49_kinome_gef 111 STK33_NOMO_DN 292 5.10E-03 
49_kinome_gef 111 IL2_UP.V1_UP 192 5.11E-03 
49_kinome_gef 111 KRAS.600_UP.V1_UP 287 2.40E-02 
49_kinome_gef 111 ESC_J1_UP_EARLY.V1_UP 183 2.40E-02 
49_kinome_gef 111 SRC_UP.V1_UP 188 2.40E-02 
49_kinome_gef 111 CYCLIN_D1_KE_.V1_UP 190 2.40E-02 
49_kinome_gef 111 CYCLIN_D1_UP.V1_DN 191 2.40E-02 




97_kinome_erl 119 TBK1.DN.48HRS_UP 50 1.12E-03 
97_kinome_erl 119 DCA_UP.V1_DN 193 1.12E-03 
97_kinome_erl 119 TBK1.DF_DN 287 6.82E-03 
97_kinome_erl 119 JNK_DN.V1_DN 191 6.92E-03 
97_kinome_erl 119 PDGF_ERK_DN.V1_UP 147 2.27E-02 
97_kinome_erl 119 CSR_LATE_UP.V1_UP 172 2.99E-02 
97_kinome_erl 119 CYCLIN_D1_KE_.V1_UP 190 2.99E-02 
97_kinome_erl 119 IL15_UP.V1_UP 192 2.99E-02 
97_kinome_erl 119 JNK_DN.V1_UP 192 2.99E-02 
97_kinome_erl 119 NOTCH_DN.V1_UP 193 2.99E-02 
97_kinome_erl 119 MTOR_UP.N4.V1_UP 196 2.99E-02 
97_kinome_gef 155 JNK_DN.V1_UP 192 4.99E-03 
97_kinome_gef 155 PRC2_EED_UP.V1_DN 193 4.99E-03 
97_kinome_gef 155 BMI1_DN_MEL18_DN.V1_UP 145 8.78E-03 
97_kinome_gef 155 RB_P130_DN.V1_UP 133 4.32E-02 
97_kinome_gef 155 RB_DN.V1_UP 137 4.32E-02 
97_kinome_gef 155 ATM_DN.V1_DN 149 4.32E-02 
97_kinome_gef 155 PKCA_DN.V1_DN 167 4.32E-02 
97_kinome_gef 155 AKT_UP.V1_UP 172 4.32E-02 
97_kinome_gef 155 TBK1.DF_DN 287 4.32E-02 
97_kinome_gef 155 TBK1.DF_UP 290 4.32E-02 
97_kinome_gef 155 SNF5_DN.V1_UP 177 4.32E-02 
97_kinome_gef 155 E2F1_UP.V1_UP 189 4.32E-02 
97_kinome_gef 155 CYCLIN_D1_KE_.V1_UP 190 4.32E-02 
97_kinome_gef 155 JNK_DN.V1_DN 191 4.32E-02 
97_kinome_gef 155 IL15_UP.V1_UP 192 4.32E-02 
97_kinome_gef 155 IL2_UP.V1_UP 192 4.32E-02 
97_kinome_gef 155 VEGF_A_UP.V1_DN 193 4.32E-02 
97_kinome_gef 155 CYCLIN_D1_KE_.V1_DN 194 4.32E-02 
97_kinome_gef 155 PIGF_UP.V1_DN 194 4.32E-02 
97_kinome_gef 155 CAHOY_OLIGODENDROCUTIC 100 4.53E-02 
108_kinome_erl 118 TBK1.DF_UP 290 1.24E-04 
108_kinome_erl 118 TGFB_UP.V1_UP 192 8.10E-04 
108_kinome_erl 118 AKT_UP.V1_UP 172 4.28E-03 
108_kinome_erl 118 AKT_UP_MTOR_DN.V1_UP 184 4.28E-03 
108_kinome_erl 118 EIF4E_UP 100 4.28E-03 
108_kinome_erl 118 RAPA_EARLY_UP.V1_DN 191 3.88E-02 
108_kinome_erl 118 MEK_UP.V1_UP 196 3.88E-02 
108_kinome_gef 109 KRAS.600_UP.V1_UP 287 1.13E-03 
108_kinome_gef 109 KRAS.300_UP.V1_UP 146 2.56E-03 
108_kinome_gef 109 TBK1.DF_DN 287 4.19E-03 
108_kinome_gef 109 LEF1_UP.V1_UP 195 5.04E-03 
108_kinome_gef 109 KRAS.600_UP.V1_DN 289 2.45E-02 
108_kinome_gef 109 AKT_UP.V1_UP 172 2.45E-02 
108_kinome_gef 109 ESC_J1_UP_EARLY.V1_UP 183 2.64E-02 
Table 3-6. Gene sets enriched in individual Kinase library screens 
Gene set enrichment analysis was performed with significant genes from each kinome screen to 
identify significant overlap with gene sets in the “Hallmark”, “Motif”, “Go-Biological Process” 
and “Oncogene” databases with the molecular signatures database v5.1. Pivotal input variables 
used for network analysis in Cytoscape are shown. Node is the sample in the following format: 
‘cell line_library_drug’. Node Size is the number of input genes from the sample. Gene Set 
Name is the pathway enriched, with # of Genes in Gene Set being the number of genes in the 






































108_Gecko_GEF 1823 GO_NEGATIVE_REGULATION_OF_CELL_COMMUNICATION 1192 7.61E-32 
108_Gecko_GEF 1823 GO_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1360 5.05E-31 
108_Gecko_GEF 1823 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 2.90E-30 
108_Gecko_GEF 1823 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 2.90E-30 
108_Gecko_GEF 1823 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 8.92E-30 
108_Gecko_GEF 1823 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 1.19E-29 
108_Gecko_GEF 1823 GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 1805 1.19E-29 
108_Gecko_GEF 1823 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.19E-29 
108_Gecko_GEF 1823 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 1.42E-29 
108_Gecko_GEF 1823 
GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PR
OMOTER 1784 1.67E-28 
108_Gecko_GEF 1823 GO_REGULATION_OF_CELL_PROLIFERATION 1496 1.44E-25 
108_Gecko_GEF 1823 GO_REGULATION_OF_TRANSPORT 1804 2.85E-25 
108_Gecko_GEF 1823 GO_CATABOLIC_PROCESS 1773 2.85E-25 
108_Gecko_GEF 1823 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 5.49E-25 
108_Gecko_GEF 1823 GO_IMMUNE_SYSTEM_PROCESS 1984 7.47E-25 
108_Gecko_GEF 1823 GO_RESPONSE_TO_ENDOGENOUS_STIMULUS 1450 8.77E-25 
108_Gecko_GEF 1823 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 1.32E-24 
108_Gecko_GEF 1823 GO_CELLULAR_RESPONSE_TO_STRESS 1565 3.75E-24 
108_Gecko_GEF 1823 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 1493 5.22E-24 
108_Gecko_GEF 1823 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 7.43E-24 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 1.49E-40 
108_Gecko_ERL 1587 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 1.51E-33 
108_Gecko_ERL 1587 GO_IMMUNE_SYSTEM_PROCESS 1984 1.00E-32 
108_Gecko_ERL 1587 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 7.23E-32 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 3.22E-31 
108_Gecko_ERL 1587 GO_RESPONSE_TO_ENDOGENOUS_STIMULUS 1450 7.48E-31 
108_Gecko_ERL 1587 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 8.21E-31 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 9.57E-31 
108_Gecko_ERL 1587 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 1.99E-30 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 1805 1.99E-29 
108_Gecko_ERL 1587 GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 1275 7.36E-29 
108_Gecko_ERL 1587 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.46E-28 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 1.14E-26 
108_Gecko_ERL 1587 GO_CATABOLIC_PROCESS 1773 1.35E-26 
108_Gecko_ERL 1587 GO_CELLULAR_RESPONSE_TO_STRESS 1565 1.35E-26 
108_Gecko_ERL 1587 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 1.41E-26 
108_Gecko_ERL 1587 GO_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1360 3.11E-26 
108_Gecko_ERL 1587 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 1.21E-25 
108_Gecko_ERL 1587 
GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PR
OMOTER 1784 1.86E-25 
108_Gecko_ERL 1587 GO_CELL_DEVELOPMENT 1426 2.65E-25 
58_Gecko_GEF 1554 GO_RNA_PROCESSING 835 3.88E-36 
58_Gecko_GEF 1554 GO_MRNA_METABOLIC_PROCESS 611 2.67E-29 
58_Gecko_GEF 1554 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 9.25E-28 
58_Gecko_GEF 1554 GO_CATABOLIC_PROCESS 1773 4.76E-27 
58_Gecko_GEF 1554 GO_CELLULAR_CATABOLIC_PROCESS 1322 1.10E-25 
58_Gecko_GEF 1554 GO_PROTEIN_LOCALIZATION 1805 2.12E-25 
58_Gecko_GEF 1554 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 5.08E-25 
58_Gecko_GEF 1554 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 5.21E-24 
58_Gecko_GEF 1554 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.40E-23 
58_Gecko_GEF 1554 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 5.34E-23 
58_Gecko_GEF 1554 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 1423 5.34E-23 
58_Gecko_GEF 1554 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 6.04E-23 
58_Gecko_GEF 1554 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 7.05E-23 
58_Gecko_GEF 1554 GO_CELLULAR_RESPONSE_TO_STRESS 1565 1.32E-22 
58_Gecko_GEF 1554 GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL 1676 4.14E-22 
58_Gecko_GEF 1554 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 5.27E-22 
58_Gecko_GEF 1554 GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1492 8.86E-22 




58_Gecko_GEF 1554 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 1.73E-21 
58_Gecko_GEF 1554 GO_MACROMOLECULE_CATABOLIC_PROCESS 926 5.51E-21 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 1.11E-34 
58_Gecko_ERL 1656 GO_CELLULAR_RESPONSE_TO_STRESS 1565 1.66E-33 
58_Gecko_ERL 1656 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.87E-31 
58_Gecko_ERL 1656 GO_REGULATION_OF_TRANSPORT 1804 8.84E-30 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 1.57E-28 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 1805 1.84E-28 
58_Gecko_ERL 1656 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 4.52E-28 
58_Gecko_ERL 1656 GO_IMMUNE_SYSTEM_PROCESS 1984 7.09E-28 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 7.89E-28 
58_Gecko_ERL 1656 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 3.22E-27 
58_Gecko_ERL 1656 
GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PR
OMOTER 1784 6.32E-27 
58_Gecko_ERL 1656 GO_NEUROGENESIS 1402 1.62E-26 
58_Gecko_ERL 1656 GO_SYSTEM_PROCESS 1785 4.98E-26 
58_Gecko_ERL 1656 GO_PROTEIN_LOCALIZATION 1805 5.54E-26 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 1.76E-25 
58_Gecko_ERL 1656 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 2.28E-25 
58_Gecko_ERL 1656 GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 1618 1.15E-24 
58_Gecko_ERL 1656 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 1.15E-24 
58_Gecko_ERL 1656 GO_REGULATION_OF_HYDROLASE_ACTIVITY 1327 1.66E-24 
58_Gecko_ERL 1656 GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1492 1.71E-24 
49_Gecko_GEF 1579 GO_CATABOLIC_PROCESS 1773 1.27E-29 
49_Gecko_GEF 1579 
GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_P
ROCESS 1517 6.47E-28 
49_Gecko_GEF 1579 GO_PROTEIN_LOCALIZATION 1805 1.02E-26 
49_Gecko_GEF 1579 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 3.58E-26 
49_Gecko_GEF 1579 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 3.58E-26 
49_Gecko_GEF 1579 GO_IMMUNE_SYSTEM_PROCESS 1984 3.70E-25 
49_Gecko_GEF 1579 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 9.05E-25 
49_Gecko_GEF 1579 
GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PR
OMOTER 1784 1.85E-23 
49_Gecko_GEF 1579 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 4.35E-23 
49_Gecko_GEF 1579 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 1493 8.61E-23 
49_Gecko_GEF 1579 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 3.97E-22 
49_Gecko_GEF 1579 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 5.55E-22 
49_Gecko_GEF 1579 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 1.13E-21 
49_Gecko_GEF 1579 GO_CELLULAR_CATABOLIC_PROCESS 1322 2.05E-21 
49_Gecko_GEF 1579 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 7.59E-21 
49_Gecko_GEF 1579 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.23E-20 
49_Gecko_GEF 1579 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 1.42E-20 
49_Gecko_GEF 1579 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 3.84E-20 
49_Gecko_GEF 1579 GO_REGULATION_OF_CELL_DEATH 1472 7.26E-20 
49_Gecko_GEF 1579 GO_REGULATION_OF_TRANSPORT 1804 7.75E-20 
49_Gecko_ERL 806 GO_TISSUE_DEVELOPMENT 1518 8.99E-24 
49_Gecko_ERL 806 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 2.20E-23 
49_Gecko_ERL 806 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 6.66E-17 
49_Gecko_ERL 806 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.54E-15 
49_Gecko_ERL 806 GO_REGULATION_OF_CELL_DEATH 1472 1.80E-15 
49_Gecko_ERL 806 GO_PHOSPHORYLATION 1228 1.82E-15 
49_Gecko_ERL 806 GO_SYSTEM_PROCESS 1785 2.57E-15 
49_Gecko_ERL 806 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 2.99E-15 
49_Gecko_ERL 806 GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 1275 8.77E-15 
49_Gecko_ERL 806 GO_PROTEIN_PHOSPHORYLATION 944 2.79E-14 
49_Gecko_ERL 806 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 5.12E-14 
49_Gecko_ERL 806 GO_REPRODUCTION 1297 5.58E-14 
49_Gecko_ERL 806 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 5.94E-14 
49_Gecko_ERL 806 GO_SINGLE_ORGANISM_BIOSYNTHETIC_PROCESS 1340 7.38E-14 
49_Gecko_ERL 806 GO_LIPID_METABOLIC_PROCESS 1158 8.85E-14 
49_Gecko_ERL 806 GO_VESICLE_MEDIATED_TRANSPORT 1239 1.76E-13 
49_Gecko_ERL 806 GO_EMBRYO_DEVELOPMENT 894 3.75E-13 
49_Gecko_ERL 806 GO_IMMUNE_SYSTEM_PROCESS 1984 5.50E-13 
49_Gecko_ERL 806 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 6.13E-13 
49_Gecko_ERL 806 GO_EPITHELIUM_DEVELOPMENT 945 8.58E-13 




108_Gecko_GEF 1823 HALLMARK_E2F_TARGETS 200 
0.0000029
9 
108_Gecko_GEF 1823 HALLMARK_APICAL_JUNCTION 200 0.0000156 
108_Gecko_GEF 1823 HALLMARK_MYC_TARGETS_V1 200 0.0000156 
108_Gecko_GEF 1823 HALLMARK_P53_PATHWAY 200 0.0000156 
108_Gecko_GEF 1823 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 0.0000375 
108_Gecko_GEF 1823 HALLMARK_HYPOXIA 200 0.0000375 
108_Gecko_GEF 1823 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 0.0000645 
108_Gecko_GEF 1823 HALLMARK_COMPLEMENT 200 0.0000767 
108_Gecko_GEF 1823 HALLMARK_G2M_CHECKPOINT 200 0.0000767 
108_Gecko_GEF 1823 HALLMARK_IL2_STAT5_SIGNALING 200 0.0000767 
108_Gecko_GEF 1823 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 0.000121 
108_Gecko_GEF 1823 HALLMARK_INFLAMMATORY_RESPONSE 200 0.000173 
108_Gecko_GEF 1823 HALLMARK_KRAS_SIGNALING_DN 200 0.000173 
108_Gecko_GEF 1823 HALLMARK_MITOTIC_SPINDLE 200 0.000173 
108_Gecko_GEF 1823 HALLMARK_SPERMATOGENESIS 135 0.000296 
108_Gecko_GEF 1823 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 0.000371 
108_Gecko_GEF 1823 HALLMARK_ESTROGEN_RESPONSE_LATE 200 0.000371 
108_Gecko_GEF 1823 HALLMARK_GLYCOLYSIS 200 0.000371 
108_Gecko_GEF 1823 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 0.000371 
108_Gecko_ERL 1587 HALLMARK_FATTY_ACID_METABOLISM 158 2.07E-09 
108_Gecko_ERL 1587 HALLMARK_E2F_TARGETS 200 8.15E-07 
108_Gecko_ERL 1587 HALLMARK_ESTROGEN_RESPONSE_LATE 200 2.21E-06 
108_Gecko_ERL 1587 HALLMARK_COMPLEMENT 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_IL2_STAT5_SIGNALING 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_MYC_TARGETS_V1 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_P53_PATHWAY 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 2.87E-06 
108_Gecko_ERL 1587 HALLMARK_ADIPOGENESIS 200 9.58E-06 
108_Gecko_ERL 1587 HALLMARK_MYC_TARGETS_V2 58 1.87E-05 
108_Gecko_ERL 1587 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 2.42E-05 
108_Gecko_ERL 1587 HALLMARK_G2M_CHECKPOINT 200 2.42E-05 
108_Gecko_ERL 1587 HALLMARK_HEME_METABOLISM 200 2.42E-05 
108_Gecko_ERL 1587 HALLMARK_APICAL_JUNCTION 200 7.58E-05 
108_Gecko_ERL 1587 HALLMARK_BILE_ACID_METABOLISM 112 1.03E-04 
108_Gecko_ERL 1587 HALLMARK_UV_RESPONSE_DN 144 1.20E-04 
108_Gecko_ERL 1587 HALLMARK_CHOLESTEROL_HOMEOSTASIS 74 1.27E-04 
108_Gecko_ERL 1587 HALLMARK_MYOGENESIS 200 1.81E-04 
108_Gecko_ERL 1587 HALLMARK_XENOBIOTIC_METABOLISM 200 1.81E-04 
58_Gecko_GEF 1554 HALLMARK_E2F_TARGETS 200 1.80E-05 
58_Gecko_GEF 1554 HALLMARK_DNA_REPAIR 150 2.10E-05 
58_Gecko_GEF 1554 HALLMARK_MYOGENESIS 200 2.27E-05 
58_Gecko_GEF 1554 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 8.18E-05 
58_Gecko_GEF 1554 HALLMARK_G2M_CHECKPOINT 200 3.93E-04 
58_Gecko_GEF 1554 HALLMARK_MYC_TARGETS_V1 200 3.93E-04 
58_Gecko_GEF 1554 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 3.93E-04 
58_Gecko_GEF 1554 HALLMARK_ANDROGEN_RESPONSE 101 8.48E-04 
58_Gecko_GEF 1554 HALLMARK_MITOTIC_SPINDLE 200 8.48E-04 
58_Gecko_GEF 1554 HALLMARK_P53_PATHWAY 200 8.48E-04 
58_Gecko_GEF 1554 HALLMARK_ADIPOGENESIS 200 1.65E-03 
58_Gecko_GEF 1554 HALLMARK_APICAL_JUNCTION 200 1.65E-03 
58_Gecko_GEF 1554 HALLMARK_COMPLEMENT 200 1.65E-03 
58_Gecko_GEF 1554 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 1.65E-03 
58_Gecko_GEF 1554 HALLMARK_GLYCOLYSIS 200 1.65E-03 
58_Gecko_GEF 1554 HALLMARK_APICAL_SURFACE 44 2.00E-03 
58_Gecko_GEF 1554 HALLMARK_COAGULATION 138 2.50E-03 
58_Gecko_GEF 1554 HALLMARK_FATTY_ACID_METABOLISM 158 2.78E-03 
58_Gecko_GEF 1554 HALLMARK_INFLAMMATORY_RESPONSE 200 3.39E-03 
58_Gecko_GEF 1554 HALLMARK_KRAS_SIGNALING_DN 200 3.39E-03 
58_Gecko_ERL 1656 HALLMARK_UV_RESPONSE_DN 144 5.74E-07 
58_Gecko_ERL 1656 HALLMARK_ADIPOGENESIS 200 1.22E-06 
58_Gecko_ERL 1656 HALLMARK_APICAL_JUNCTION 200 1.22E-06 
58_Gecko_ERL 1656 HALLMARK_COAGULATION 138 2.71E-05 
58_Gecko_ERL 1656 HALLMARK_G2M_CHECKPOINT 200 2.71E-05 




58_Gecko_ERL 1656 HALLMARK_IL2_STAT5_SIGNALING 200 2.71E-05 
58_Gecko_ERL 1656 HALLMARK_PANCREAS_BETA_CELLS 40 6.24E-05 
58_Gecko_ERL 1656 HALLMARK_HYPOXIA 200 6.41E-05 
58_Gecko_ERL 1656 HALLMARK_KRAS_SIGNALING_DN 200 6.41E-05 
58_Gecko_ERL 1656 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.15E-04 
58_Gecko_ERL 1656 HALLMARK_E2F_TARGETS 200 1.59E-04 
58_Gecko_ERL 1656 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.59E-04 
58_Gecko_ERL 1656 HALLMARK_ANDROGEN_RESPONSE 101 2.52E-04 
58_Gecko_ERL 1656 HALLMARK_COMPLEMENT 200 3.49E-04 
58_Gecko_ERL 1656 HALLMARK_HEME_METABOLISM 200 3.49E-04 
58_Gecko_ERL 1656 HALLMARK_MITOTIC_SPINDLE 200 3.49E-04 
58_Gecko_ERL 1656 HALLMARK_MTORC1_SIGNALING 200 3.49E-04 
58_Gecko_ERL 1656 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 9.57E-04 
58_Gecko_ERL 1656 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 1.99E-03 
49_Gecko_GEF 1579 HALLMARK_ADIPOGENESIS 200 1.03E-06 
49_Gecko_GEF 1579 HALLMARK_SPERMATOGENESIS 135 1.03E-06 
49_Gecko_GEF 1579 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 1.03E-06 
49_Gecko_GEF 1579 HALLMARK_UV_RESPONSE_UP 158 1.61E-06 
49_Gecko_GEF 1579 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 4.73E-06 
49_Gecko_GEF 1579 HALLMARK_E2F_TARGETS 200 1.47E-05 
49_Gecko_GEF 1579 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 4.48E-05 
49_Gecko_GEF 1579 HALLMARK_COMPLEMENT 200 9.63E-05 
49_Gecko_GEF 1579 HALLMARK_G2M_CHECKPOINT 200 9.63E-05 
49_Gecko_GEF 1579 HALLMARK_HEME_METABOLISM 200 9.63E-05 
49_Gecko_GEF 1579 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 9.63E-05 
49_Gecko_GEF 1579 HALLMARK_PROTEIN_SECRETION 96 1.05E-04 
49_Gecko_GEF 1579 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 1.09E-04 
49_Gecko_GEF 1579 HALLMARK_ALLOGRAFT_REJECTION 200 2.42E-04 
49_Gecko_GEF 1579 HALLMARK_P53_PATHWAY 200 6.86E-04 
49_Gecko_GEF 1579 HALLMARK_APOPTOSIS 161 1.46E-03 
49_Gecko_GEF 1579 HALLMARK_INFLAMMATORY_RESPONSE 200 1.73E-03 
49_Gecko_GEF 1579 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 4.19E-03 
49_Gecko_GEF 1579 HALLMARK_MITOTIC_SPINDLE 200 4.19E-03 
49_Gecko_GEF 1579 HALLMARK_ANDROGEN_RESPONSE 101 6.31E-03 
49_Gecko_ERL 806 HALLMARK_ADIPOGENESIS 200 2.94E-05 
49_Gecko_ERL 806 HALLMARK_XENOBIOTIC_METABOLISM 200 7.34E-05 
49_Gecko_ERL 806 HALLMARK_ALLOGRAFT_REJECTION 200 2.28E-04 
49_Gecko_ERL 806 HALLMARK_IL2_STAT5_SIGNALING 200 5.94E-04 
49_Gecko_ERL 806 HALLMARK_MYOGENESIS 200 5.94E-04 
49_Gecko_ERL 806 HALLMARK_PEROXISOME 104 7.80E-04 
49_Gecko_ERL 806 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.70E-03 
49_Gecko_ERL 806 HALLMARK_MTORC1_SIGNALING 200 5.50E-03 
49_Gecko_ERL 806 HALLMARK_APOPTOSIS 161 1.20E-02 
49_Gecko_ERL 806 HALLMARK_G2M_CHECKPOINT 200 1.20E-02 
49_Gecko_ERL 806 HALLMARK_MYC_TARGETS_V1 200 1.20E-02 
49_Gecko_ERL 806 HALLMARK_P53_PATHWAY 200 1.20E-02 
49_Gecko_ERL 806 HALLMARK_COAGULATION 138 1.20E-02 
49_Gecko_ERL 806 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 1.55E-02 
49_Gecko_ERL 806 HALLMARK_DNA_REPAIR 150 1.72E-02 
49_Gecko_ERL 806 HALLMARK_PROTEIN_SECRETION 96 1.91E-02 
49_Gecko_ERL 806 HALLMARK_FATTY_ACID_METABOLISM 158 1.91E-02 
49_Gecko_ERL 806 HALLMARK_APICAL_SURFACE 44 1.91E-02 
49_Gecko_ERL 806 HALLMARK_COMPLEMENT 200 1.91E-02 
49_Gecko_ERL 806 HALLMARK_E2F_TARGETS 200 1.91E-02 
108_Gecko_GEF 1823 GGGCGGR_SP1_Q6 2940 2.03E-52 
108_Gecko_GEF 1823 CAGGTG_E12_Q6 2485 5.58E-40 
108_Gecko_GEF 1823 TTGTTT_FOXO4_01 2061 5.45E-34 
108_Gecko_GEF 1823 GGGAGGRR_MAZ_Q6 2274 1.29E-31 
108_Gecko_GEF 1823 AACTTT_UNKNOWN 1890 2.01E-30 
108_Gecko_GEF 1823 TGGAAA_NFAT_Q4_01 1896 1.77E-28 
108_Gecko_GEF 1823 CTTTGT_LEF1_Q2 1972 9.51E-28 
108_Gecko_GEF 1823 SCGGAAGY_ELK1_02 1199 3.8E-26 
108_Gecko_GEF 1823 TATAAA_TATA_01 1296 1.85E-22 
108_Gecko_GEF 1823 GGGTGGRR_PAX4_03 1294 1.07E-20 
108_Gecko_GEF 1823 RCGCANGCGY_NRF1_Q6 918 2.49E-18 




108_Gecko_GEF 1823 CAGCTG_AP4_Q5 1524 2.06E-16 
108_Gecko_GEF 1823 CTTTGA_LEF1_Q2 1232 2.2E-16 
108_Gecko_GEF 1823 CACGTG_MYC_Q2 1032 2.73E-16 
108_Gecko_GEF 1823 RYTTCCTG_ETS2_B 1085 2.96E-15 
108_Gecko_GEF 1823 TAATTA_CHX10_01 810 3.01E-15 
108_Gecko_GEF 1823 GATA4_Q3 249 5.39E-13 
108_Gecko_GEF 1823 WTGAAAT_UNKNOWN 616 5.87E-13 
108_Gecko_GEF 1823 GCANCTGNY_MYOD_Q6 924 7.75E-13 
108_Gecko_ERL 1587 CAGGTG_E12_Q6 2485 1.16E-39 
108_Gecko_ERL 1587 GGGCGGR_SP1_Q6 2940 6.36E-39 
108_Gecko_ERL 1587 CTTTGT_LEF1_Q2 1972 5.21E-27 
108_Gecko_ERL 1587 GGGAGGRR_MAZ_Q6 2274 4.64E-23 
108_Gecko_ERL 1587 TGGAAA_NFAT_Q4_01 1896 5.73E-19 
108_Gecko_ERL 1587 AACTTT_UNKNOWN 1890 5.85E-18 
108_Gecko_ERL 1587 GGGTGGRR_PAX4_03 1294 3.15E-17 
108_Gecko_ERL 1587 RCGCANGCGY_NRF1_Q6 918 1.06E-16 
108_Gecko_ERL 1587 CTTTAAR_UNKNOWN 972 3.46E-15 
108_Gecko_ERL 1587 GCANCTGNY_MYOD_Q6 924 1.17E-14 
108_Gecko_ERL 1587 CTTTGA_LEF1_Q2 1232 1.57E-14 
108_Gecko_ERL 1587 TATAAA_TATA_01 1296 2.29E-14 
108_Gecko_ERL 1587 TTGTTT_FOXO4_01 2061 2.78E-14 
108_Gecko_ERL 1587 TGANTCA_AP1_C 1121 2.98E-14 
108_Gecko_ERL 1587 RYTTCCTG_ETS2_B 1085 2.10E-13 
108_Gecko_ERL 1587 TGCCAAR_NF1_Q6 722 2.19E-13 
108_Gecko_ERL 1587 SCGGAAGY_ELK1_02 1199 2.31E-13 
108_Gecko_ERL 1587 CAGCTG_AP4_Q5 1524 2.45E-13 
108_Gecko_ERL 1587 TGACCTY_ERR1_Q2 1043 3.26E-13 
108_Gecko_ERL 1587 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 2.59E-11 
58_Gecko_GEF 1554 GGGCGGR_SP1_Q6 2940 1.20E-43 
58_Gecko_GEF 1554 CAGGTG_E12_Q6 2485 1.75E-29 
58_Gecko_GEF 1554 GGGAGGRR_MAZ_Q6 2274 2.65E-29 
58_Gecko_GEF 1554 CTTTGT_LEF1_Q2 1972 3.22E-28 
58_Gecko_GEF 1554 TTGTTT_FOXO4_01 2061 1.91E-27 
58_Gecko_GEF 1554 AACTTT_UNKNOWN 1890 3.22E-27 
58_Gecko_GEF 1554 CAGCTG_AP4_Q5 1524 1.08E-22 
58_Gecko_GEF 1554 SCGGAAGY_ELK1_02 1199 4.57E-20 
58_Gecko_GEF 1554 GATTGGY_NFY_Q6_01 1160 2.96E-19 
58_Gecko_GEF 1554 TGGAAA_NFAT_Q4_01 1896 6.78E-19 
58_Gecko_GEF 1554 RYTTCCTG_ETS2_B 1085 1.60E-18 
58_Gecko_GEF 1554 TGANTCA_AP1_C 1121 4.95E-18 
58_Gecko_GEF 1554 GGGYGTGNY_UNKNOWN 664 6.38E-18 
58_Gecko_GEF 1554 RNGTGGGC_UNKNOWN 766 1.14E-17 
58_Gecko_GEF 1554 CTTTAAR_UNKNOWN 972 1.84E-16 
58_Gecko_GEF 1554 TATAAA_TATA_01 1296 5.62E-16 
58_Gecko_GEF 1554 TTANTCA_UNKNOWN 952 1.30E-15 
58_Gecko_GEF 1554 TTTGCAC_MIR19A_MIR19B 516 1.44E-15 
58_Gecko_GEF 1554 GCCATNTTG_YY1_Q6 427 4.93E-15 
58_Gecko_GEF 1554 GTGACGY_E4F1_Q6 658 6.02E-15 
58_Gecko_ERL 1656 GGGCGGR_SP1_Q6 2940 1.86E-40 
58_Gecko_ERL 1656 CTTTGT_LEF1_Q2 1972 3.73E-36 
58_Gecko_ERL 1656 TTGTTT_FOXO4_01 2061 3.08E-31 
58_Gecko_ERL 1656 CAGGTG_E12_Q6 2485 6.34E-30 
58_Gecko_ERL 1656 TGGAAA_NFAT_Q4_01 1896 6.31E-29 
58_Gecko_ERL 1656 GGGAGGRR_MAZ_Q6 2274 3.04E-28 
58_Gecko_ERL 1656 AACTTT_UNKNOWN 1890 2.32E-27 
58_Gecko_ERL 1656 CACGTG_MYC_Q2 1032 2.60E-25 
58_Gecko_ERL 1656 TATAAA_TATA_01 1296 2.32E-24 
58_Gecko_ERL 1656 TTANTCA_UNKNOWN 952 2.94E-22 
58_Gecko_ERL 1656 GGGTGGRR_PAX4_03 1294 4.99E-22 
58_Gecko_ERL 1656 CTTTGA_LEF1_Q2 1232 1.81E-21 
58_Gecko_ERL 1656 CAGCTG_AP4_Q5 1524 5.47E-20 
58_Gecko_ERL 1656 RCGCANGCGY_NRF1_Q6 918 2.59E-19 
58_Gecko_ERL 1656 SCGGAAGY_ELK1_02 1199 9.05E-18 
58_Gecko_ERL 1656 TAATTA_CHX10_01 810 9.05E-18 
58_Gecko_ERL 1656 CTTTAAR_UNKNOWN 972 3.51E-17 




58_Gecko_ERL 1656 GCANCTGNY_MYOD_Q6 924 9.57E-16 
58_Gecko_ERL 1656 TGANTCA_AP1_C 1121 1.98E-15 
49_Gecko_GEF 1579 CAGGTG_E12_Q6 2485 4.03E-35 
49_Gecko_GEF 1579 CTTTGT_LEF1_Q2 1972 1.98E-34 
49_Gecko_GEF 1579 GGGAGGRR_MAZ_Q6 2274 4.72E-33 
49_Gecko_GEF 1579 GGGCGGR_SP1_Q6 2940 6.26E-32 
49_Gecko_GEF 1579 TTGTTT_FOXO4_01 2061 6.32E-29 
49_Gecko_GEF 1579 AACTTT_UNKNOWN 1890 1.99E-26 
49_Gecko_GEF 1579 TGGAAA_NFAT_Q4_01 1896 2.04E-25 
49_Gecko_GEF 1579 TATAAA_TATA_01 1296 3.33E-25 
49_Gecko_GEF 1579 RTAAACA_FREAC2_01 919 9.33E-23 
49_Gecko_GEF 1579 RYTTCCTG_ETS2_B 1085 5.57E-20 
49_Gecko_GEF 1579 CAGCTG_AP4_Q5 1524 1.28E-18 
49_Gecko_GEF 1579 GGGTGGRR_PAX4_03 1294 3.55E-17 
49_Gecko_GEF 1579 TGANTCA_AP1_C 1121 1.24E-16 
49_Gecko_GEF 1579 CTTTGA_LEF1_Q2 1232 4.25E-16 
49_Gecko_GEF 1579 GATTGGY_NFY_Q6_01 1160 1.10E-15 
49_Gecko_GEF 1579 TTANTCA_UNKNOWN 952 1.19E-15 
49_Gecko_GEF 1579 TGACCTY_ERR1_Q2 1043 3.51E-14 
49_Gecko_GEF 1579 TGAYRTCA_ATF3_Q6 538 8.08E-14 
49_Gecko_GEF 1579 CACGTG_MYC_Q2 1032 1.31E-13 
49_Gecko_GEF 1579 TAATTA_CHX10_01 810 1.77E-13 
49_Gecko_ERL 806 CAGGTG_E12_Q6 2485 2.04E-19 
49_Gecko_ERL 806 GGGAGGRR_MAZ_Q6 2274 2.74E-18 
49_Gecko_ERL 806 GGGCGGR_SP1_Q6 2940 3.70E-18 
49_Gecko_ERL 806 CAGCTG_AP4_Q5 1524 2.69E-16 
49_Gecko_ERL 806 RYTTCCTG_ETS2_B 1085 5.44E-16 
49_Gecko_ERL 806 CTTTGT_LEF1_Q2 1972 8.94E-15 
49_Gecko_ERL 806 AACTTT_UNKNOWN 1890 1.54E-14 
49_Gecko_ERL 806 CTTTGA_LEF1_Q2 1232 5.04E-14 
49_Gecko_ERL 806 TGANTCA_AP1_C 1121 9.13E-13 
49_Gecko_ERL 806 TGGAAA_NFAT_Q4_01 1896 9.13E-13 
49_Gecko_ERL 806 TGACAGNY_MEIS1_01 827 6.03E-11 
49_Gecko_ERL 806 TTGTTT_FOXO4_01 2061 1.72E-10 
49_Gecko_ERL 806 TGTTTGY_HNF3_Q6 738 1.93E-10 
49_Gecko_ERL 806 TGACCTY_ERR1_Q2 1043 4.87E-10 
49_Gecko_ERL 806 RNGTGGGC_UNKNOWN 766 5.69E-10 
49_Gecko_ERL 806 GGGYGTGNY_UNKNOWN 664 1.13E-09 
49_Gecko_ERL 806 GCANCTGNY_MYOD_Q6 924 1.88E-09 
49_Gecko_ERL 806 TGCCAAR_NF1_Q6 722 3.43E-09 
49_Gecko_ERL 806 TCANNTGAY_SREBP1_01 475 6.06E-09 
49_Gecko_ERL 806 YTATTTTNR_MEF2_02 697 1.38E-08 
108_Gecko_GEF 1823 TBK1.DF_DN 287 4.11E-08 
108_Gecko_GEF 1823 KRAS.600_UP.V1_DN 289 4.11E-08 
108_Gecko_GEF 1823 CYCLIN_D1_KE_.V1_DN 194 5.65E-08 
108_Gecko_GEF 1823 RPS14_DN.V1_UP 192 1.45E-07 
108_Gecko_GEF 1823 CYCLIN_D1_UP.V1_DN 191 4.35E-07 
108_Gecko_GEF 1823 KRAS.600.LUNG.BREAST_UP.V1_DN 289 5.81E-07 
108_Gecko_GEF 1823 AKT_UP_MTOR_DN.V1_UP 184 5.81E-07 
108_Gecko_GEF 1823 GCNP_SHH_UP_EARLY.V1_DN 169 1.59E-06 
108_Gecko_GEF 1823 NRL_DN.V1_DN 134 1.64E-06 
108_Gecko_GEF 1823 STK33_UP 293 1.64E-06 
108_Gecko_GEF 1823 ESC_V6.5_UP_LATE.V1_DN 186 1.86E-06 
108_Gecko_GEF 1823 E2F1_UP.V1_UP 189 2.33E-06 
108_Gecko_GEF 1823 PIGF_UP.V1_UP 191 2.53E-06 
108_Gecko_GEF 1823 STK33_DN 289 2.53E-06 
108_Gecko_GEF 1823 P53_DN.V1_DN 192 2.53E-06 
108_Gecko_GEF 1823 STK33_NOMO_DN 292 2.99E-06 
108_Gecko_GEF 1823 ESC_V6.5_UP_EARLY.V1_DN 172 4.19E-06 
108_Gecko_GEF 1823 ESC_J1_UP_LATE.V1_UP 191 7.09E-06 
108_Gecko_GEF 1823 ATF2_S_UP.V1_UP 193 8.12E-06 
108_Gecko_GEF 1823 STK33_NOMO_UP 294 8.45E-06 
108_Gecko_ERL 1587 KRAS.PROSTATE_UP.V1_DN 144 3.31E-08 
108_Gecko_ERL 1587 CSR_EARLY_UP.V1_UP 164 4.93E-08 
108_Gecko_ERL 1587 PRC2_EED_UP.V1_DN 193 2.26E-07 




108_Gecko_ERL 1587 PRC1_BMI_UP.V1_UP 192 5.40E-07 
108_Gecko_ERL 1587 TBK1.DF_DN 287 8.09E-07 
108_Gecko_ERL 1587 BMI1_DN.V1_UP 147 1.07E-06 
108_Gecko_ERL 1587 ESC_J1_UP_EARLY.V1_DN 179 1.61E-06 
108_Gecko_ERL 1587 MTOR_UP.N4.V1_UP 196 1.71E-06 
108_Gecko_ERL 1587 VEGF_A_UP.V1_UP 196 1.71E-06 
108_Gecko_ERL 1587 ATM_DN.V1_DN 149 4.03E-06 
108_Gecko_ERL 1587 E2F1_UP.V1_DN 193 4.29E-06 
108_Gecko_ERL 1587 CYCLIN_D1_KE_.V1_DN 194 4.35E-06 
108_Gecko_ERL 1587 STK33_DN 289 4.65E-06 
108_Gecko_ERL 1587 CRX_DN.V1_DN 134 1.15E-05 
108_Gecko_ERL 1587 KRAS.600.LUNG.BREAST_UP.V1_DN 289 1.30E-05 
108_Gecko_ERL 1587 RAF_UP.V1_UP 196 1.52E-05 
108_Gecko_ERL 1587 ERB2_UP.V1_DN 197 1.56E-05 
108_Gecko_ERL 1587 ESC_V6.5_UP_EARLY.V1_DN 172 2.34E-05 
108_Gecko_ERL 1587 NFE2L2.V2 481 2.37E-05 
58_Gecko_GEF 1554 ATF2_UP.V1_DN 187 1.62E-09 
58_Gecko_GEF 1554 TBK1.DF_DN 287 1.62E-09 
58_Gecko_GEF 1554 ATF2_S_UP.V1_DN 187 3.46E-07 
58_Gecko_GEF 1554 ESC_J1_UP_EARLY.V1_DN 179 4.92E-07 
58_Gecko_GEF 1554 ESC_V6.5_UP_LATE.V1_DN 186 8.40E-07 
58_Gecko_GEF 1554 STK33_NOMO_UP 294 8.82E-07 
58_Gecko_GEF 1554 STK33_SKM_UP 290 1.93E-06 
58_Gecko_GEF 1554 STK33_NOMO_DN 292 1.96E-06 
58_Gecko_GEF 1554 VEGF_A_UP.V1_UP 196 5.25E-06 
58_Gecko_GEF 1554 RB_P107_DN.V1_DN 128 6.41E-06 
58_Gecko_GEF 1554 ESC_J1_UP_LATE.V1_DN 186 6.77E-06 
58_Gecko_GEF 1554 LEF1_UP.V1_UP 195 1.40E-05 
58_Gecko_GEF 1554 EGFR_UP.V1_DN 196 1.41E-05 
58_Gecko_GEF 1554 CAMP_UP.V1_UP 200 1.84E-05 
58_Gecko_GEF 1554 TBK1.DF_UP 290 2.94E-05 
58_Gecko_GEF 1554 PDGF_ERK_DN.V1_UP 147 2.94E-05 
58_Gecko_GEF 1554 KRAS.DF.V1_UP 193 2.94E-05 
58_Gecko_GEF 1554 VEGF_A_UP.V1_DN 193 2.94E-05 
58_Gecko_GEF 1554 HOXA9_DN.V1_UP 194 2.97E-05 
58_Gecko_GEF 1554 HOXA9_DN.V1_DN 195 2.97E-05 
58_Gecko_ERL 1656 MEK_UP.V1_DN 196 2.39E-08 
58_Gecko_ERL 1656 ESC_V6.5_UP_EARLY.V1_DN 172 2.00E-07 
58_Gecko_ERL 1656 ALK_DN.V1_DN 148 2.00E-07 
58_Gecko_ERL 1656 CAMP_UP.V1_DN 200 2.00E-07 
58_Gecko_ERL 1656 PIGF_UP.V1_UP 191 2.58E-07 
58_Gecko_ERL 1656 TBK1.DF_DN 287 6.09E-07 
58_Gecko_ERL 1656 RAPA_EARLY_UP.V1_UP 183 1.43E-06 
58_Gecko_ERL 1656 CSR_LATE_UP.V1_UP 172 1.64E-06 
58_Gecko_ERL 1656 STK33_SKM_UP 290 1.77E-06 
58_Gecko_ERL 1656 RB_P107_DN.V1_DN 128 3.37E-06 
58_Gecko_ERL 1656 MTOR_UP.N4.V1_UP 196 3.37E-06 
58_Gecko_ERL 1656 IL15_UP.V1_DN 190 6.77E-06 
58_Gecko_ERL 1656 KRAS.DF.V1_UP 193 6.91E-06 
58_Gecko_ERL 1656 CAHOY_NEURONAL 100 6.91E-06 
58_Gecko_ERL 1656 EIF4E_DN 100 6.91E-06 
58_Gecko_ERL 1656 SRC_UP.V1_DN 179 6.91E-06 
58_Gecko_ERL 1656 CRX_NRL_DN.V1_UP 140 8.22E-06 
58_Gecko_ERL 1656 ERB2_UP.V1_DN 197 8.59E-06 
58_Gecko_ERL 1656 PDGF_UP.V1_UP 146 1.41E-05 
58_Gecko_GEF 1656 ATF2_UP.V1_UP 192 1.82E-05 
49_Gecko_GEF 1579 WNT_UP.V1_DN 170 2.09E-10 
49_Gecko_GEF 1579 SRC_UP.V1_DN 179 1.33E-06 
49_Gecko_GEF 1579 STK33_DN 289 1.70E-06 
49_Gecko_GEF 1579 SNF5_DN.V1_UP 177 2.10E-06 
49_Gecko_GEF 1579 ATF2_UP.V1_UP 192 2.10E-06 
49_Gecko_GEF 1579 PKCA_DN.V1_DN 167 2.23E-06 
49_Gecko_GEF 1579 IL2_UP.V1_DN 196 2.23E-06 
49_Gecko_GEF 1579 CSR_LATE_UP.V1_UP 172 3.07E-06 
49_Gecko_GEF 1579 DCA_UP.V1_UP 191 4.34E-06 




49_Gecko_GEF 1579 PRC1_BMI_UP.V1_DN 190 1.27E-05 
49_Gecko_GEF 1579 NOTCH_DN.V1_UP 193 1.44E-05 
49_Gecko_GEF 1579 KRAS.600.LUNG.BREAST_UP.V1_DN 289 1.44E-05 
49_Gecko_GEF 1579 TBK1.DF_UP 290 1.44E-05 
49_Gecko_GEF 1579 IL15_UP.V1_DN 190 3.37E-05 
49_Gecko_GEF 1579 PIGF_UP.V1_UP 191 3.37E-05 
49_Gecko_GEF 1579 PTEN_DN.V1_UP 191 3.37E-05 
49_Gecko_GEF 1579 MTOR_UP.N4.V1_DN 193 3.56E-05 
49_Gecko_GEF 1579 VEGF_A_UP.V1_DN 193 3.56E-05 
49_Gecko_GEF 1579 ESC_J1_UP_EARLY.V1_DN 179 3.81E-05 
49_Gecko_ERL 806 GCNP_SHH_UP_EARLY.V1_UP 174 1.66E-05 
49_Gecko_ERL 806 KRAS.600.LUNG.BREAST_UP.V1_UP 288 8.83E-05 
49_Gecko_ERL 806 JNK_DN.V1_DN 191 8.83E-05 
49_Gecko_ERL 806 P53_DN.V2_DN 145 8.83E-05 
49_Gecko_ERL 806 CAMP_UP.V1_DN 200 1.11E-04 
49_Gecko_ERL 806 RAPA_EARLY_UP.V1_DN 191 2.47E-04 
49_Gecko_ERL 806 PRC2_EED_UP.V1_DN 193 2.47E-04 
49_Gecko_ERL 806 VEGF_A_UP.V1_UP 196 2.57E-04 
49_Gecko_ERL 806 CAMP_UP.V1_UP 200 2.88E-04 
49_Gecko_ERL 806 NFE2L2.V2 481 3.41E-04 
49_Gecko_ERL 806 STK33_NOMO_UP 294 3.63E-04 
49_Gecko_ERL 806 PTEN_DN.V1_UP 191 5.67E-04 
49_Gecko_ERL 806 PRC1_BMI_UP.V1_UP 192 5.67E-04 
49_Gecko_ERL 806 STK33_SKM_DN 288 7.73E-04 
49_Gecko_ERL 806 STK33_DN 289 7.73E-04 
49_Gecko_ERL 806 JNK_DN.V1_UP 192 1.93E-03 
49_Gecko_ERL 806 RAF_UP.V1_DN 194 1.97E-03 
49_Gecko_ERL 806 KRAS.600_UP.V1_UP 287 1.97E-03 
49_Gecko_ERL 806 IL2_UP.V1_DN 196 1.97E-03 
49_Gecko_ERL 806 CSR_LATE_UP.V1_DN 170 2.02E-03 
Table 3-7. Gene sets enriched in individual GeCKO library screens 
Gene set enrichment analysis was performed with significant genes from each GeCKO screen to 
identify significant overlap with gene sets in the “Hallmark”, “Motif”, “Go-Biological Process” 
and “Oncogene” databases with the molecular signatures database v5.1. Pivotal input variables 
used for network analysis in Cytoscape are shown. Node is the sample in the following format: 
‘cell line_library_drug’. Node Size is the number of input genes from the sample. Gene Set 
Name is the pathway enriched, with # of Genes in Gene Set being the number of genes in the 
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Chapter 4: Investigating FGFR as a Common Resistance Mechanism to EGFR Inhibition 
in HNSCC 
Abstract 
In this chapter, we expand on our results from chapter three that nominated the FGF 
pathway as a compensatory mechanism to EGFR inhibition, and show that FGF is a more 
common compensatory pathway across 14/22 (63%) of UM-SCC cell lines across oral cavity and 
larynx subsites. Surprisingly, neither copy number or expression of FGFRs predict 
responsiveness to dual EGFR and FGFR inhibition. However, our generation of an EGFR 
knockout model using CRISPR/Cas9 demonstrated that FGFRs can compensate for the complete 
loss of EGFR. Additionally, dual inhibition of EGFR and FGFR significantly suppressed tumor 
growth in our mouse xenograft model, suggesting in vivo relevance of this combination for 
HNSCC. To further evaluate potential clinical relevance, we analyzed expression profiles of 
tumors from patients who received the EGFR inhibitor cetuximab. We observed changes in the 




The epidermal growth factor receptor (EGFR) is a known driver of cancer cell growth 
and proliferation in head and neck squamous cell carcinoma (HNSCC) as well as other cancer 
types. As such, several pathways have already been identified as contributing to resistance to 




MET (13, 14), and IGF1R(15-18). However, there are still no biomarkers to predict which 
pathway is driving compensation in a specific model, and as such makes it difficult to 
successfully advance combination therapies.  
Here, we further investigate the results of our last chapter that nominated the FGFR 
pathway as a potential compensatory mechanism to EGFR inhibition in a UM-SCC cell line. The 
FGF pathway consists of four cell-surface receptors, FGFR1-4, that contain tyrosine kinase 
domains that are activated upon ligand binding, and can in turn activate downstream effectors 
such as PI3K and MAPKs (19-21).  FGFR signaling has been proposed before as a compensatory 
mechanism to EGFR inhibition in both HNSCC and lung cancer, but specifically for cases of 
FGFR1 amplification(10, 22-24). Cases with FGFR1 amplification are thought to be reliant on 
FGFR1 and FGF signals, identifying these cases as potentially sensitive to dual inhibition of 
EGFR and FGFR. Interestingly, the UM-SCC cell line that nominated FGFR signaling as a 
compensatory mechanism, UM-SCC-49, has an FGFR1 deletion(25). As FGFRs activate similar 
downstream pathways (19), we believe this suggests that FGFR may be a more common 
compensatory mechanism to EGFR inhibition than only in models with FGFR1 amplification.  
In this chapter, we expand on our results from chapter three and investigate the extent 
that FGFR may be a common compensatory pathway in more HNSCC models. We also sought 
to identify a biomarker that would predict FGFR as a compensatory pathway given our genetic 
characterization of these models in chapter two. We then further explored the mechanism of 
FGFR compensation, including short-term inhibition of EGFR by small molecule inhibitors and 
long-term loss of EGFR by CRISPR knockout. Additionally, we sought to evaluate the in vivo 
relevance FGFR as a compensatory pathway to EGFR inhibition through the creation of mouse 






Cell Culture. Cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Invitrogen #11965) containing 10% fetal bovine serum (FBS, Sigma), 1% NEAA (Invitrogen 
15140122) and 7 µL/mL penicillin-streptomycin (Invitrogen 15140122) in a humidified 
atmosphere of 5% CO2 at 37°C.  Cells were tested for mycoplasma contamination using the 
MycoAlert detection kit (Lonza).  
 
Cell Viability assays. 2,000 cells per well were seeded in 384-well microplates using a Multiflo 
liquid handling dispensing system.  After 24 hours, cells were treated with compound or DMSO 
in a 10-point two-fold dilution series in quadruplicate.  96-well plates were prepared with 
compounds in 200X concentration and then diluted to 10X concentration in media in a second 
96-well plate using the Agilent Bravo Automated Liquid Handling Platform and VWorks 
Automation Control Software.  These compounds were then used to treat the cells with the 
desired drug concentration, again using liquid handling robotics.  Cells were stained with 
resazurin (Sigma) in PBS for 12-24 hours before fluorescent signal intensity was quantified 72 
hours after treatment using the Cytation3 fluorescence plate reader enabled with automatic 
stacking at excitation and emission wavelengths of 540 and 612 nm, respectively. All 
compounds were purchased from Selleck Chemicals.   10mM aliquots were stored -80 °C.  Each 





Trypan Blue assays. Cells were seeded in 24-well plates. After 24 hours, cells were treated with 
compound or DMSO. After 72 hours, cells were harvested and counted with trypan blue reagent 
(Invitrogen) using the Countess II Automated Cell Counter (ThermoFisher).  
 
Annexin V+ assay and statistics. Cells were seeded into 6-well plates. After 24 hours, cells 
were treated with compound or DMSO. After 48 hours, cells were prepared for Annexin V 
staining according to manufacturer recommendations (Invitrogen). Briefly, cells were harvested 
and then stained with propidium iodide and Alexa Fluor 488 annexin V before being analyzed on 
the Ze5 (Bio-Rad) at the University of Michigan Flow Cytometry core. Statistical significance 
was calculated on log-transformed data fitted with linear regression and interaction term. P-
values were adjusted with Bonferroni method.  
 
Immunoblotting. Western blot analysis was performed as previously described (25, 26). Briefly, 
UM-SCC cell lines at 70-80% confluency were rinsed with PBS and lysed in buffer (150 mM 
NaCl, 10% Glycerol, 1% NP40, 0.1% Triton X-100, 1 mM PIPES, 1 mM MgCl, 50 mM Tris) 
containing protease and phosphatase inhibitors (Thermo 186129, 1861277) as described (27).  
See Table 4-1 for primary and secondary antibodies used. 
 
Transcript analysis by qPCR. Cells were rinsed with PBS and then preserved in Qiazol 
(Qiagen) at -80°C until RNA extraction was performed using RNeasy Spin Kit (Qiagen) 
according to manufacturer recommendations. cDNA templates were then synthesized using 
random primers and SuperScript III Reverse Transcriptase (Invitrogen) according to 




Amplification by qPCR was performed with Quantitech Sybr Green (Qiagen) on QuantStudio5 
(Applied Biosystems) under the cycling conditions recommended by manufacturer. 
 
Generation of Clonal Knockout Lines. UM-SCC-92 was transduced with a lentiviral CRISPR 
construct targeting EGFR (Sigma Aldrich) and after antibiotic and GFP selection, individual 
clones were isolated. Individual clones were screened for knockout by sanger sequencing. DNA 
was extracted from clones (Qiagen, Gentra Puregene Cell Kit) and the gRNA region amplified 
by PCR using Platinum HiFi Taq (Invitrogen). Primers for amplification are in Table 4-2. PCR 
products were then ligated into pCR8 vector (ThermoFisher, K250020), transformed, and 
plasmid DNA extracted from individual colonies (Qiagen, QIAprep Spin Miniprep Kit) and 
submitted for sanger sequencing at the University of Michigan DNA Sequencing Core. 
Sequences were aligned using the DNASTAR Lasergene software suite. 
 
Exome Sequencing and Variant Calling. Genomic DNA from UM-SCC-92 and EGFR K/O 
cell line was extracted according to Gentra PureGene Handbook (Qiagen) and genotyped. Exome 
Capture Library Construction was done using the Roche NimbleGen V3, and paired-end 
sequencing (2x150 bp) of the captured exons was carried out on an Illumina HiSeq 2500 High-
Output at the University of Michigan DNA sequencing core according to standard protocol. 
Variant calling was performed as previously described (25). Variants reported were required to 
have at least 5 reads supporting the variant allele, and variants reported as intergenic or intronic 





RNA Sequencing and Bioinformatic Analysis. RNA was isolated with the Qiagen RNeasy 
Spin Prep Kit and submitted to the University of Michigan DNA sequencing core. Sequencing 
libraries were prepared according to manufacturer’s protocols with the Illumina TruSeq stranded 
mRNA kit and sequenced by paired end sequencing on the Illumina HiSeq 2500-Rapid. Read 
quality, alignment, and FPKM calculations were performed as previously described (25). 
 
Mouse Xenografts. UM-SCC-108 cells in log-phase growth were trypsinized and re-suspended 
in a 1:1 ratio of DMEM and Matrigel (Corning #354234). Nude athymic mice (Charles River 
Laboratories) were subcutaneously injected with 2 million cells per flank. When the average 
tumor size measured around 100mm3, mice were treated with either vehicle (0.5% 
methylcellulose, 0.2% Tween-80), 150mg/kg gefitinib, 30mg/kg BGJ398, or the combination of 
150mg/kg gefitinib and 30mg/kg BGJ398. Drugs were delivered by oral gavage.  
Changes to cell signaling were evaluated on tumors staged to approximately 350mm3 and 
treated in the four different groups indicated above for 6 hours, tumors were then homogenized 
by pestle in protein lysis buffer with inhibitors and protein lysates were evaluated by 
immunoblotting as described above.   
To monitor tumor growth, cell line xenografts were established and then treated over the 
course of twenty-one days using 16 tumors per treatment group in bilateral flanks, except for the 
combination arm which had 14 tumors due to the necessary euthanization of one mouse during 
treatment. During treatment, mice were dosed by oral gavage daily for five days then allowed to 
recover for two days. Tumors were measured twice weekly using calipers. Volume of tumor was 
calculated by (π/6)*(width x length x length) where length is defined by the longest measurement 




Because tumors were in bilateral flanks which could cause a dependence of the two 
tumors within the same mouse, significance was calculated using the linear mixed model with 
random intercept only on log2 scaled data. This model considers the dependence of the 
measurements of the tumors on the same mouse and was therefore the most appropriate test. Two 
outliers were identified in FGFR group for the log2 scaled data, the highest of which was 
removed from the analysis.  
 
Clinical specimens and clinical data. Formalin fixed paraffin embedded (FFPE) blocks were 
collected from a retrospective cohort of patients under an IRB-approved protocol for next 
generation sequencing of DNA and RNA (HUM00080561) from our recent clinical trial, “A 
Phase II Study of RT Concurrent with Cetuximab in Patients with Locally Advanced Head and 
Neck Squamous Cell Carcinoma Who Do Not Qualify For Standard Chemotherapy Due To 
Age>70 Or Co-Morbidities”, University identification number: UMCC 2009.009, 
clinicialtrials.gov identification number: NCT00904345.  Clinical variables of the cohort were 
previously described in (30). As previously noted, clinical, histologic, and outcome data was 
collected from medical records and death was documented from electronic medical record notes.  
Following hematoxylin and eosin staining of sections from each block, our HN pathologist 
J.B.M. identified blocks with >60% tumor content for coring and DNA/RNA isolation. In total, 
we identified 13 tumors and 4 adjacent normal tissues with sufficient material from both pre- and 
mid-cetuximab loading dose biopsy specimens for molecular analysis. DNA and RNA were 
simultaneously isolated using the Qiagen AllPrep kit as described (31) and advanced for NGS if 
it met our previously defined quality standards defined by Qubit and Bioanalyzer analysis (26, 





Clinical specimen transcriptome sequencing. Total RNA isolated using Allprep Kit (Qiagen) 
was submitted for library preparation and sequencing to the University of Michigan DNA 
sequencing core. Briefly, we used 500ng of RNA for library preparations or as much RNA as 
available with the Illumina TruSeq Stranded Total RNA library prep kit (Cat#: RS-122-2201/2). 
The protocol was followed according to the manufacturer’s recommendations, with a single 
modification in which we used 14 cycles of PCR to amplify the library prior to the final bead 
purification. The samples were then pooled and loaded on an Illumina HiSEQ4000 across 5 lanes 
and paired end sequenced to 75nt length. A summary of sequencing quality statistics including 
total unique mapped reads for each sample is provided in Table 4-3.  
 
Transcript Quantification and Statistical Analysis. Read quality was assessed using FastQC 
(v0.11.5). No quality issues were detected. The two-step STAR workflow was used to map the 
reads. In step 1, STAR (v2.5.3a) was used to generate the genome index database with the help 
of the reference human genome and annotated transcriptome files. In step 2, read mapping was 
guided by this generated genome index database generated in step 1. Only reads that map 
uniquely were retained by using samtools (v1.2). To compute FPKM, cufflinks (v2.2.1) was used 
with default parameters except for “--max-bundle-frags” which was changed to 100000000 to 
avoid raising of the HIDATA flag at loci that have more fragments than the pre-set threshold for 
every locus. 
Differential transcripts with greater or less than 2-log2 fold change between mid- and pre-
treatment samples were used to create up and down-regulated gene signature rank-lists for each 




assessed statistical enrichment over 1000 permutations with four different gene set databases: 
‘Hallmark’, ‘Motif’, ‘Go-Biological Process’ and ‘Oncogene’. Enrichments with FDR < 0.05, up 
to a maximum of 20 significant pathways per database, were then used to create statistically 
significant enrichment networks for each Cetuximab-regulated tumor gene set. Networks were 
then filtered for concepts enriched in greater than one tumor. We then loaded tumor networks 
into the Cytoscape3.7.1 desktop module, using the FDR P-value as edge weight and number of 
genes in a gene set as node diameter. Network concepts were clustered and highlighted based on 
similarity to significant Hallmark gene sets.  
 
Results 
Our results from chapter three nominated the FGFR signaling pathway as a potential 
compensatory mechanism to EGFR inhibition in UM-SCC-49. In this chapter, we wanted to test 
the hypothesis that FGFR signaling could be a more common compensatory mechanism and 
therefore challenged multiple UM-SCC cell lines from the oral cavity and larynx subsites with 
the combination of the EGFR and pan-FGFR inhibition. We observed that a subset of cell lines 
had decreased viability after three days of treatment with the drug combination in comparison to 
either monotherapy both by resaurzin (Fig 4-1A) and trypan blue (Fig 4-1B) assays. We 
observed that a total of 14/22 (63%) of UM-SCC cell lines had decreased viability when 
challenged with the combination of EGFR and FGFR inhibitors but not to the monotherapy 
treatments. Of the lines tested, 10/13 (77%) of the responders to the combination were derived 
from the oral cavity subsite and 4/9 (44%) of the responders were derived from the larynx. We 
also included the human oral keratinocyte cell line HOK16B to test if dual EGFR and FGFR 




undergo cell death when treated with EGFR and FGFR inhibitors alone or in combination (Fig 4-
1B), suggesting that there was specificity in the HNSCC cancer models.  
We next wanted to test the mechanism of cell death and focused on using oral cavity cell 
line models due to the high response rate of this subsite. We choose the cell lines UM-SCC-49 
and UM-SCC-108 which responded to the combination of EGFR and FGFR inhibition through 
decreased viability, as well as the non-responsive oral cavity cell line UM-SCC-97. We chose to 
analyze the amount of annexin V staining by flow cytometry, as annexin V is indicative of 
apoptosis(33) and a common mechanism of cell death. We observed that UM-SCC-49 and UM-
SCC-108 had significantly higher annexin V staining in the combination treatment (p-value ≤ 
0.05) as compared to the vehicle control or monotherapy treatments, while UM-SCC-97 did not 
(Fig 4-2). Accordingly, UM-SCC-49 and UM-SCC-108 had elevated levels of cleaved caspase-3 
in the combination treatment at 24 hours, while UM-SCC-97 did not (Fig 4-3). We also 
evaluated a panel of other proteins that play a role in cell death, such as BCL-2, MCL1, and 
BAD, but did not observe any distinguishing differences between the responsive and non-
responsive lines in their response to drug treatment.  
We then hypothesized that there might be a biomarker that could predict which cell lines 
would respond and undergo cell death when treated with dual EGFR and FGFR inhibition. We 
first evaluated the copy number status of a panel of cell lines, as we postulated that perhaps 
amplifications of FGFRs would predict response. However, the UM-SCC models had a range of 
amplifications and deletions across all FGFR receptors for both subsets and was not a 
distinguishing factor for either responsive or non-responsive models (Fig 4-4). The copy number 
of EGFR was high across UM-SCC models with the exception of UM-SCC-55, a responder. As 




other known resistance mechanisms, we evaluated copy numbers of ERBB2 and IGF1R. Copy 
numbers of both ERBB2 and IGF1R varied between subsets, suggesting that we can’t identify 
FGFR is the compensatory mechanism to EGFR inhibition because of a lack of ERBB2 or 
IGF1R amplification. We next evaluated the transcriptome to test if RNA expression could be a 
biomarker that predicts response to EGFR and FGFR inhibition. We observed that for the FGF 
receptors, expression varied for each receptor and did not distinguish between responsive and 
non-responsive models (Fig 4-5). Expression of EGFR remained high across all cell lines, and 
expression of ERBB2 and IGF1R varied.  
We next evaluated downstream signaling mechanisms in response to EGFR and FGFR 
inhibition alone and in combination to determine if activation of a downstream effector might 
differentiate between responsive and non-responsive models. In a panel of oral cavity models, 
we observed decreases in phosphorylation of notable downstream effectors such as AKT, 
ERK1/2, and MEK1/2 in response to the inhibitors regardless of a responsive or non-responsive 
model (Fig 4-6). We also noted limited changes in phosphorylation of STAT1 or STAT3 across 
treatments, suggesting that STATs have a limited role in the effect of the EGFR and FGFR 
response. Notably, the phosphorylation of MET, another known resistance pathway to EGFR 
inhibition, did not change in response to EGFR inhibition for either the models that respond to 
the EGFR and FGFR combination, or UM-SCC-97. The lack of induction of MET 
phosphorylation in response may indicate that MET is not a compensatory pathway in these 
models. Overall, we did not observe any distinguishing factor that differentiated a responsive cell 
line model from a non-responsive model.  
We hypothesized that the responsive cell lines might display a greater reliance on FGF 




genetic level or through FGFR expression during normal cell growth. Unfortunately, due to 
technical issues with specificity of phospho-antibodies, we were unable to directly assess the 
phosphorylation status of the FGF receptors. As we were unable to evaluate any induction of the 
FGF pathway by immunoblotting, we turned to assess the transcript levels of the receptors. After 
treatment of EGFR inhibitor, we observed no upregulation of FGF receptors in the responsive 
model UM-SCC-92 as compared to vehicle control (Fig 4-7). However, the responsive model 
UM-SCC-49 did have an upregulation of FGFR3 transcript at 12 hours.  
These modest changes in FGFR transcript levels due to short-term inhibition of EGFR 
led us to postulate that long-term loss of EGFR signaling might give significant clues to 
compensatory pathways in the cell lines. We hypothesized that a complete loss of EGFR 
signaling may lead to reliance on FGF signaling if the FGF signaling pathway was a primary 
compensatory pathway for the cell line. To test this hypothesis, we used CRISPR/Cas9 to 
generate a knockout of EGFR in UM-SCC cell lines. We successfully derived a clonal cell line 
in UM-SCC-92 for which all three alleles of EGFR contained deletions leading to deleterious 
frame-shifts (Fig 4-8A), and for which we observed no expression of EGFR by immunoblot (Fig 
4-8B). This EGFR knockout (EGFR K/O) cell line has a significantly slower proliferation rate 
than the parental UM-SCC-92 cell line (p-value ≤ 0.0001) (Fig 4-9A), which was not surprising 
given the known role of EGFR in cell growth and proliferation. We also observed morphological 
differences in the EGFR K/O cell line as compared to the parental UM-SCC-92 cell line, where 
the EGFR K/O cell line has a broader, stretched out cell body perhaps indicative of a more 
mesenchymal phenotype (Fig 4-9B). 
As the EGFR K/O cell line, while slower growing, was capable of surviving without 




for this loss of EGFR signaling. We first postulated that a gain of function mutation might have 
occurred during the CRISPR/Cas9 and cloning process which helped the EGFR K/O cell line 
survive. We submitted the EGFR K/O cell line for exome sequencing and found an additional 18 
synonymous mutations and 89 non-synonymous mutations not in parental UM-SCC-92 cell line 
(25). The non-synonymous mutations are categorized by effect in Table 4-4. Importantly, we did 
not see any gain of function mutations in notable kinases such as Ras, PIK3CA, or even the FGF 
receptors. We then analyzed the transcriptome of the EGFR K/O cell line, hypothesizing that a 
compensatory pathway may be upregulated in response to the loss of EGFR. We focused on 
kinases and receptors that were upregulated in the EGFR K/O as compared to UM-SCC-92 
wildtype cell line, as we thought these genes would be more likely to have small molecule 
inhibitors available for further experimentation. There were 23 kinases and receptors that had >3 
differential expression in the EGFR K/O as compared to UM-SCC-92 wildtype cell line and are 
listed in Table 4-5. We saw that FGFR1 was ranked 8th highest of the upregulated kinases in the 
EGFR K/O cell line, and so we also assessed if there were changes in the expression of FGFR2 
and FGFR3. Interestingly, while FGFR1 was highly upregulated, FGFR2 and FGFR3 were 
downregulated (Fig 4-10A). PIK3CA, a known compensatory signaling mechanism to loss of 
EGFR, showed no transcriptome changes, while we saw the expected decrease of EGFR 
transcripts. We then confirmed the upregulation of FGFR1 and downregulation of FGFR2 by 
qPCR, though we saw a slight upregulation of FGFR3 (Fig 4-10B). We also confirmed the 
decrease in EGFR transcript with primers that were upstream or downstream of the gRNA cut 
site. Next, we used immunoblotting to evaluate any changes in cell signaling between UM-SCC-
92 and the EGFR K/O cell lines. We observed that downstream activation of effectors such as 




also saw an increase in FGFR1 protein expression in the EGFR K/O, corroborating the 
upregulated transcription of FGFR1, while we did not see any significant changes in either 
phospho or total MET protein.  
While the parental UM-SCC-92 cell line is responsive to EGFR and FGFR inhibitors, 
UM-SCC-92 undergoes cell death only when treated with the combination and not the 
monotherapies. Given the upregulation of FGFR1 in the EGFR K/O cell line, we hypothesized 
that if FGFR signaling is compensating for the lack of EGFR, then FGFR inhibitors as a 
monotherapy should be able to cause cell death in the EGFR K/O cell line. Additionally, the 
EGFR K/O cell line should not respond to EGFR inhibition. To test this, we challenged the 
EGFR K/O cell line with the EGFR inhibitor gefitinib, multiple FGFR inhibitors, and a MET 
inhibitor. We postulated that if the EGFR K/O cell line relied specifically on FGF signaling as 
compensation, then the cell line should not undergo cell death by inhibiting MET. In our results, 
we saw no decrease in viability in the EGFR K/O cell line in response to EGFR inhibition or 
MET inhibition. However, when used as monotherapies, both pan-FGFR inhibitors BGJ398 and 
AZD4547 as well as the FGFR1 selective inhibitor PD173074 resulted in decreased viability in 
the EGFR K/O cell line (Fig 4-12).  
We also wanted to further evaluate the response of the EGFR K/O cell line to the EGFR 
inhibitor gefitinib. As the EGFR inhibitor does not result in cell death in the wildtype cell line, 
we would not expect a decrease in viability in the EGFR K/O cell line regardless of EGFR 
expression. However, EGFR inhibition does result in decreased cell growth in UM-SCC-92, and 
so we analyzed cell growth of the EGFR K/O cell line after being challenged with the EGFR 




inhibition, the EGFR K/O cell line does not (Fig 4-13) confirming that the EGFR K/O cell line 
does not respond to EGFR inhibition.  
As our data nominated FGFR signaling as a robust compensatory pathway to EGFR 
inhibition, we hypothesized that the combination of EGFR and FGFR inhibition could be 
effective in vivo. As neither UM-SCC-92 nor UM-SCC-49 formed cell line xenograft models, we 
chose UM-SCC-108 to implant subcutaneously into the bilateral flanks of nude athymic mice. 
After establishing the cell line xenografts, we first wanted to determine that the EGFR inhibitor 
gefitinib and pan-FGFR inhibitor BGJ398 would affect cell signaling of the tumor. After dosing 
mice with vehicle, gefitinib, BGJ398, or the combination, we harvested tumors six hours post-
treatment. We analyzed the protein content of the tumor by immunoblotting and observed 
decreased phosphorylation of EGFR and other downstream effectors in the mice receiving drug 
(Fig 4-14).  
Given the success of the drugs to affect cell signaling of the tumors, we established 
additional xenograft models and monitored tumor size over the course of 21 days for each 
treatment. At the end of treatment, we observed no significant effect of the EGFR or FGFR 
inhibitor as a monotherapy. The tumor volumes in the mice receiving the combination of EGFR 
and FGFR inhibitors were significantly decreased in size as compared to the vehicle control and 
FGFR monotherapy (p-values ≤ 0.01), and EGFR monotherapy (p-value ≤ 0.05) (Fig 4-15). 
Additionally, at the end of treatment we visually observed that the tumors from the mice 
receiving the combination had less vascularization (Fig 4-16). To monitor for potential toxicity, 
we also measured the weight of the mice during the course of treatment. Towards the end of the 
treatment course, we did observe a dip in weight for mice in the combination arm while the mice 




To test the clinical relevance of FGFR as a compensatory mechanism to EGFR inhibition, 
through collaboration with Dr. Nyati we obtained tissue blocks from a recent clinical study of 
patients with locally advanced HNSCC that were treated with cetuximab for one week prior to 
moving on to a more complex clinical care regimen. Importantly, this study included biopsies 
that were taken before and after the single cetuximab treatment for each patient, creating a 
unique opportunity to study the molecular compensation mechanisms in human tumors. Thus, we 
performed comprehensive transcriptome sequencing on 14 formalin fixed paraffin embedded 
(FFPE) HNSCC tissue pairs and 4 FFPE normal tissues pre- and mid-cetuximab treatment.  
Overall, we generated an average of 74,709,217 reads per sample of which an average of 
71% uniquely mapped to the reference (Table 4-3). On average, we identified 19,913 genes per 
sample with an FPKM >1 indicating high quality RNAseq libraries. Thus, following FPKM 
analysis, we performed gene set enrichment analysis (GSEA) and network analysis to look for 
gene set concepts that were differentially regulated following cetuximab treatment in multiple 
tumors. Consistent with previous in vitro studies from our work and others, gene set concepts 
associated with PI3K/mTOR signaling, cell survival, cell cycle and angiogenesis were strongly 
upregulated in the tumors, supporting that the analysis defined relevant gene set concepts (Fig 4-
18). Surprisingly, however, the data also showed a strong enrichment of gene sets associated 
with KRAS signaling. Comparison of gene sets identified in our UM-SCC-92 EGFR K/O model 
showed similar significant gene set enrichments, including KRAS signaling, epithelial to 
mesenchymal transition, and TNFalpha signaling through NFKB, supporting the postulate that 
KRAS adaption in HNSCC tumors occurs in tumor cells. GSEA outputs for the individual 
HNSCC tumors and EGFR K/O cell are in Table 4-6, 4-7. We then de-constructed the network 




responses per sample. Notably, HNSCC-10 exhibited marked decreases in expression for 
FGFR1, PIK3CA, and MAP3K8 while HNSCC-11 had marked increases in expression (Fig 4-
19). HNSCC-3 had a specific marked increase in PI3KCA, while overall changes in FGFR1 and 
FGF3 expression varied per sample. Collectively, this analysis highlights the continued need to 
monitor individual samples during response to treatment. 
 
Discussion 
In HNSCC, monotherapies have been broadly ineffective. While inhibition of EGFR with 
cetuximab treatment has been effective, resistance and recurrence are still common. We 
investigated the hypothesis that there are signaling pathways compensating when EGFR is 
inhibited, and that co-targeting EGFR and this compensatory pathway will be more effective. In 
this chapter we present the results of investigating the FGF signaling pathway as a common 
compensatory mechanism to EGFR inhibition, where we expanded this finding to nominate 
>50% of cells lines having FGFR signaling as a compensatory response. Our results suggest that 
FGFR may be a more common compensatory mechanism than previously realized, and not 
limited to cases with FGFR1 amplification.  
Unfortunately, we were unable to find a biomarker that predicted which UM-SCC cell 
lines would respond and undergo cell death when challenged with the combination of EGFR and 
FGFR inhibitors. We expected that copy number amplifications or expression of the FGF 
receptors would identify models that may be reliant on FGF signaling in the absence of EGFR, 
such as the case for this combination in lung cancer (22, 23). Additionally, our interrogation of 
the downstream signaling pathways was unable to find a differential marker between cell lines 




in using elastic net analysis (34) to identify differential genetic mutations, copy number changes, 
or transcriptome markers between responsive and non-responsive models would be useful. 
However, for this global analysis to be robust, ideally hundreds of more lines would be tested to 
identify a biomarker of sensitivity or resistance (35), which was not possible for this thesis work. 
Instead, we did a preliminary investigation to identify compensatory pathways based on the 
response of a cell line to EGFR inhibition. As we had difficulty interrogating the activation of 
FGFRs by immunoblotting, we assessed transcript levels of FGFRs after EGFR inhibition. Our 
results were conflicting. We expected that responsive cell lines either would not change, 
suggesting that we could not use transcript expression of FGFRs to identify responsive models, 
or that both cell lines would see an increase in at least one of the FGF receptors. Further 
investigation is warranted to evaluate if response to EGFR inhibition, such as upregulating the 
FGFRs, may predict response to dual EGFR and FGFR inhibition. We then postulated that 
perhaps the short-term inhibition of EGFR by gefitinib made it difficult to observe any changes 
in FGFR signaling, and we hypothesized that long-term inhibition or complete loss of EGFR 
signaling might highlight the reliance on the compensatory pathway. Thus, we used 
CRISPR/Cas9 to successfully engineer an EGFR K/O cell line. This complete loss of EGFR 
expression led to an upregulation of FGFR1 expression and sensitivity to FGFR inhibition as a 
monotherapy, supporting the hypothesis that FGFR is a compensatory mechanism when EGFR is 
inhibited or completely lost.  
Excitingly, our mouse model supports the translational potential of dual EGFR and FGFR 
inhibition. The tumors from mice receiving the combination arm were significantly smaller and 
containing less visible vasculature, potentially due to inhibiting FGFRs’ role in vascularization 




toxicity issues for this combination that were not observed in either monotherapy arm. Indeed, a 
clinical trial testing the combination of the EGFR inhibitor erlotinib and the pan-FGFR inhibitor 
dovitinib was halted early due to toxicity (37).  
Of interest is the significant changes in KRAS signaling mid-cetuximab treatment for 
HNSCC patients. While genetic disruption of KRAS is a well-known driver of cetuximab-
resistance in colorectal and other cancers (5, 38-40), compensatory KRAS signaling has not 
previously been described to play a significant role in HNSCC. This compensatory activation of 
KRAS signaling was supported in our EGFR K/O model, as the EGFR K/O model showed 
increased KRAS signaling but had no acquired or inherent Ras mutations. Importantly, the 
discovery of compensatory KRAS signaling is also consistent with our CRISPR genome and 
CRISPR kinome network analysis from chapter three that also identified KRAS-related gene 
knockouts as EGFR inhibitor sensitizers in HNSCC cell line. Thus, we believe that this is the 
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Figure 4-1. Cell line responses to EGFR and FGFR combination treatment 
A) Each dot indicates an IC50 value for each drug listed on x-axis, for each cell line as indicated 
in the legend, plotted on a log-scale. Cell lines that respond to EGFR and FGFR combination 
treatment have decreased IC50 values in the presence of both inhibitors, and are highlighted by 
color. Cell lines that do not respond to the combination are greyed out. B) Each dot indicates a 
percent cell viability for each drug on the x-axis, for each cell line as indicated in the legend. Cell 
lines that respond to EGFR and FGFR combination treatment have decreased cell viability in the 
presence of both inhibitors, and are highlighted by color. Cell lines that do not respond to the 





Figure 4-2. Cell death by annexin V+ staining 
Graph represents the percentage of cells positive for annexin V staining, which is indicative of 
early or late state apoptosis. Cell lines were treated with DMSO (black), 5 µM gefitinib (green), 
2.5 µM BGJ398 (blue), or the combination of 5 µM gefitinib and 2.5 µM BGJ398 (red). For 
UM-SCC-49 and UM-SCC-108, the combination treatment had significantly higher cell death 







Figure 4-3. Immunoblot of UM-SCC lines, 24 hour post-treatment  
UM-SCC cell lines were treated with 1 µM of each compound listed above with lysates 







Figure 4-4. Copy number analysis of UM-SCC lines 
Heatmap of relative copy number of genes as listed. Values plotted are two raised to the power 
of the probe median of the gene. Heatmap was generated using the Morpheus webtool available 






Figure 4-5. Expression analysis of UM-SCC lines 
Heatmap depicting expression values of each gene listed, plotted as FPKM +1 on a log2 scale. 
Yellow indicates low expression, and blue indicates higher expression. Heatmap was generated 







Figure 4-6. Immunoblot of UM-SCC cell lines, 1 hour post-treatment 
UM-SCC cell lines were treated with 1 µM of each compound listed above with lysates 








Figure 4-7. FGFR transcript analysis during EGFR inhibition 
Graph plots the changes in transcript expression for each gene listed after treatment with 5 µM 
gefitinib. Values were determined by fold change to the DMSO vehicle control treatment. 
Lysates were collected and analyzed at 12 or 24 hours post-treatment with gefitinib for UM-
SCC-92 (blue) and UM-SCC-49 (red). Note, FGFR2 transcript was undetectable for UM-SCC-






Figure 4-8. Genetic and protein confirmation of EGFR K/O cell line 
A) Schematic of sanger sequencing results of the EGFR K/O cell line as compared to wildtype 
sequence. The gRNA targeted exon 7 of EGFR is underlined in red, and PAM sequence colored 
red. Three allelic deletions are depicted, with 8bp, 41bp, or 1bp deletion. B) Immunoblot of 
parental UM-SCC-92 cell line and EGFR K/O line evaluating EGFR protein expression and 







Figure 4-9. Phenotype of EGFR K/O cell line 
A) Graph representative of number of lives cells after 4 day’s growth. Cells were counted and 
seeded for 16,000 cells on day zero. Asteriscks depict a significant difference between UM-SCC-
92 parental line (WT) and EGFR K/O (p-value ≤ 0.0001). B) Representative images taken at 








Figure 4-10. Transcript analysis of EGFR K/O compared to WT 
A) Bar graph showing transcriptional changes in the EGFR K/O model. Value shown is 
differential expression in the EGFR K/O compared to UM-SCC-92 (WT) for EGFR, FGFRs 1-3, 
and PIK3CA. B) Bar graph showing qPCR confirmation of transcriptional changes in the EGFR 
K/O model. Value shown is the fold change of the EGFR K/O cell line as compared to UM-
SCC-92 (WT) shown on a log2 scale. There were two primer sets used to evaluate EGFR 








Figure 4-11. Signaling changes in EGFR K/O model by immunoblot 
Lysates harvested during log-phase growth for UM-SCC-92 and EGFR K/O cell line and 







Figure 4-12. Response of EGFR K/O cell line to FGFR monotherapy 
Cell viability of the EGFR K/O cell line after challenge with inhibitors, as tested by trypan blue 
assay. Inhibitors are the gefitinib (blue), BGJ398 (red), PD173074 (green), AZD4547 (purple), 







Figure 4-13. No response of EGFR K/O to EGFR inhibition 
Graph of live cell counts after 3 days of treatment listed on x-axis for UM-SCC-92 (black) or 







Figure 4-14. Cell signaling effects of inhibitors in mouse xenograft model 
Western blot results of xenograft tumors that were harvested six hours after mice were dosed 
with vehicle, 150mg/kg gefitinib, 30mg/kg BGJ398, or 150mg/kg gefitinib and 30mg/kg 








Figure 4-15. Tumor volumes of mouse xenografts 
Tumor volumes were normalized to starting tumor growth on Day 0 of treatment, and then put 
on a log-scale go accommodate the linear mixed model that was used to analyze significance. 
Data points represent average tumor volume of the cohort, while the bars represent standard 







Figure 4-16. Representative pictures of mouse xenograft tumors harvested at 21 days 
Images were taken of six tumors from each cohort as indicated, with ruler shown for scale. 







Figure 4-17. Mouse weights during xenograft experiment 
The average weight of the cohort is plotted over the course of treatment, while bars indicate 







Figure 4-18. Gene set enrichment analysis of 13 HNSCC tumors treated with cetuximab 
and EGFR K/O cell line 
Cytoscape network plot shows significant enrichments of gene sets significantly upregulated (A) 
or downregulated (B) following cetuximab treatment in each of the 13 HNSCC tumors as well as 
the genes upregulated in UM-SCC-92_EGFR knockout compared to control (each gene set is 
represented by labeled blue circular nodes in the center of the plot) with annotated gene sets 
downloaded from the molecular signatures data bases v5.1 (red nodes = “Hallmark” gene sets, 
black nodes = “Motif” gene sets, green nodes = “Go-biological process” gene sets and yellow 
nodes = “Oncogene” gene sets). The size of each node is proportional to the number of genes in 
the gene set. Lines connecting each node are proportional to the significance of overlap between 
the gene sets, determined by false discovery rate (FDR), with more significant interactions 
represented by thicker edge weights. All interactions shown have FDR < 0.05. Recurrent and 
selected concepts are grouped within the transparent geometric shapes to highlight network 





Figure 4-19. Heatmap of expression changes in cetuximab-treated samples 
Heatmap shows the changes in expression mid-cetuximab treatment, where blue indicates an 
increase in expression and yellow indicates a decrease. Values were calculated by subtracting the 
pre-cetuximab treatment FPKM value from the mid-cetuximab treatment and plotted on a log2 










Antibody Catalog # 
p-EGFR Y1068 CST 3777 
EGFR CST 8504 
p-AKT CST 4060 
AKT CST 4685 
p-ERK1/2 T202/Y204 CST4370 
ERK1/2 CST 4695 
p-MEK 1/2 CST 9121 
MEK 1/2 CST 8727 
HSP90 CST 4877 
BCL 2 CST 4223 
Cleaved Caspase 3 CST 9664 
Total Caspase 3 CST 9665 
CDK4 CST 12790 
p21 CST 2947 
p-CDC2 Y15 CST 4539 
pBAD S136 CST 4366 
pRb S807/811 CST 8516 
MCL1 CST 5453 
STAT1 CST 14994 
pSTAT1 CST 8826 
MET CST 8198 
pMET (Tyr1234/1235) CST 3077 
pSTAT3 CST p145 
STAT3 CST 30835 
FGFR1 CST 9740 
Actin CST 4970 
Anti-Rabbit Secondary Jackson Research 111-035-045 
Anti-Mouse Secondary  Jackson Research 715-035-151 



























EGFR 5' of 




EGFR 3' of 





region of gRNA 
Fwd GGCTTTCTGACGGGAGTCAA 
Rev CTGTATTTGCCCTCGGGGTT 










HNSCC1_PreCetux 59,437,572 74.8 18,570 
HNSCC1_MidCetux 70,180,145 73.8 23,233 
HNSCC2_PreCetux 73,637,010 76.2 22,027 
HNSCC2_MidCetux 85,593,958 74.3 23,081 
HNSCC3_PreCetux 67,433,628 69.3 15,188 
HNSCC4_MidCetux 69,187,588 70.1 16,006 
HNSCC4_PreCetux 60,105,607 70 22,357 
HNSCC4_MidCetux 66,802,892 78.3 22,619 
HNSCC5_PreCetux 102,630,698 77.5 18,356 
HNSCC5_MidCetux 67,844,060 69.4 18,351 
HNSCC6_PreCetux 80,559,807 73.9 19,920 
HNSCC6_MidCetux 62,010,165 78.1 20,359 
HNSCC7_PreCetux 92,414,717 70.2 15,500 
HNSCC7_MidCetux 69,861,669 65.9 16,081 
HNSCC8_PreCetux 82,439,705 72.8 25,287 
HNSCC8_MidCetux 108,845,855 67.3 27,069 
HNSCC9_PreCetux 61,249,773 72.7 19,526 
HNSCC9_MidCetux 62,636,343 76.1 23,890 
HNSCC10_PreCetux 85,138,732 60.3 19,236 
HNSCC10_MidCetux 62,163,895 56.6 10,527 
HNSCC11_PreCetux 73,325,291 62.6 8,029 
HNSCC11_MidCetux 74,545,093 67.5 19,522 
HNSCC12_PreCetux 83,414,271 69.6 21,841 
HNSCC12_MidCetux 57,730,761 74.2 18,024 
HNSCC13_PreCetux 90,893,707 63.9 21,667 
HNSCC13_MidCetux 74,441,825 78.5 25,184 
Table 4-3. Sequencing statistics for samples from patients receiving cetuximab 
Total reads generated by RNAseq per sample, with percent of reads uniquely mapped shown. 






























ZSCAN20 1:33957209 G/T 
ZNF804A 2:185801336 G/T  LOC100288142 1:148312431  A/G 
FAM71B 5:156589997 C/A  NUP210L 1:154061969  C/T 
CNGB3 8:87683195 G/T  EFNA1 1:155103912  A/T 












SORCS2 4:7706012 G/C  SLC30A3 2:27480837 C/T 
SLIT2 4:20259487 T/C  HOXD9 2:176988779  G/T 
PRKG2 4:82027093 G/A  DNAH7 2:196801403  T/G 
FBXW7 4:153271186 A/C  VWC2L 2:215301391  T/A 










C1orf158 1:12806253 C/G  LTF 3:46480969 T/A 
PAFAH2 1:26288379 G/T  ACAD11 3:132294638  A/G 
LRP8 1:53711735 G/C  MUC4 3:195506747  C/T 
KCNA2 1:111136289 T/C  MUC4 3:195506750  G/C 
LAD1 1:201350285 G/A  GABRA1 5:161317947  G/T 
EPAS1 2:46612626 C/G  AKAP9 7:91730186 T/G 
CCDC88A 2:55517271 T/C  CFTR 7:117232191  G/C 
CTNNA2,LRRTM1 2:80529217 T/C  KIAA1967 8:22464533 A/G 
SI 3:164697131 C/T  CCDC171 9:15784553 A/C 
KCNMB3 3:178984521 G/A  SURF6 9:136198772  C/G 
TMPRSS11A 4:68776852 A/T  DBH 9:136523451  T/A 
SMAP1,B3GAT2 6:71571694 T/A  KIF20B 10:91492669  G/A 
VOPP1 7:55540132 G/A  PDE3B 11:14665679  G/A 
GRM8 7:126078821 G/A  PDE3B 11:14665680  C/T 
LZTS1 8:20106576 C/A  FAT3 11:92257971  C/A 
MAK16,TTI2 8:33358270 G/A  PUS7L 12:44139903  T/C 
CLVS1 8:62212374 G/T  KRT75 12:52818456 C/T 
IL33 9:6257454 T/C  FAM222A 12:110207009  G/T 
GKAP1 9:86421470 T/C  GOLGA3 12:133360800  T/C 
DFNB31 9:117164510 G/A  TPP2 13:103326642  C/G 
PRKG1 10:54053983 T/G  TDRD9 14:104498355  C/A 
NPAP1 15:24927196 G/T  ADAMTS7 15:79059746  G/T 
FAM174B 15:93162549 G/A  WDR90 16:699835 G/A 
HSPB6 19:36246418 C/G  MMP2 16:55522595  C/T 
TMEM230 20:5093724 C/A  CNOT1 16:58568254  A/T 
MAP7D2 X:20025422 A/C  NF1 17:29652938  A/G 
TAB3 X:30846292 C/T  KANSL1 17:44110456  G/A 







HTATSF1 X:135593004 G/A  ZNF665 19:53668122  G/T 
HCFC1 X:153217337 T/A  ZNF837 19:58880235  G/T 
HCFC1 X:153222905 G/A  ID1 20:30193215  G/A 
SERPINB13 18:61264276 G/T  DGCR2 22:19076897  G/C 
FLJ22184 19:7935863 G/T  SSX2 X:52734778 C/A 
APOC1 19:45419485 G/C  SSX2B X:52781779 G/T 






Table 4-4. Non-synonymous mutations in EGFR K/O cell line 
Non-synonymous mutations found in the EGFR K/O cell line that are not present in UM-SCC-92 





Rank Gene FPKM_WT FPKM_K/O DE 
1 PGK1 0 312.318 8.29 
2 NCOA4 0 108.671 6.78 
3 CSNK2B 0 88.6994 6.49 
4 IRAK1 0 80.1222 6.34 
5 CDK7 0 51.4813 5.71 
6 PPIP5K2 0 37.4859 5.27 
7 CDK16 0 29.5537 4.93 
8 FGFR1 1.57785 54.1979 4.42 
9 TK2 0 19.0733 4.33 
10 IFNGR2 0 18.915 4.32 
11 MAPKAPK2 0 14.9457 4 
12 LIMK1 0 13.4991 3.86 
13 FYN 2.88515 47.403 3.64 
14 RXRB 0 11.0631 3.59 
15 GPR107 0 9.72812 3.42 
16 DCLK1 0.305365 12.8606 3.41 
17 TNIK 0.467579 14.2765 3.38 
18 DDR1 0 8.84388 3.3 
19 AGK 0 8.45822 3.24 
20 TLR4 0.0960775 8.6858 3.14 
21 ALPK2 0.214953 9.39677 3.1 
22 DYRK3 0 7.35272 3.06 
23 STK19 0 7.18523 3.03 
Table 4-5. Kinases and receptors upregulated in the EGFR K/O cell line 
Table of kinases and receptors that are upregulated in the EGFR K/O cell line as compared to 
wildtype, with a differential expression of at least three. Genes are ranked by upregulation, and 
show the FPKM of UM-SCC-92 (FPKM_WT), FPKM in the EGFR K/O (FPKM_K/O), and 






































HNSCC1_cetux_up 337 HALLMARK_MYOGENESIS 200 1.68E-16 
HNSCC1_cetux_up 337 HALLMARK_ESTROGEN_RESPONSE_LATE 200 9.10E-08 
HNSCC1_cetux_up 337 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 5.91E-07 
HNSCC1_cetux_up 337 HALLMARK_KRAS_SIGNALING_UP 200 3.23E-05 
HNSCC1_cetux_up 337 HALLMARK_COAGULATION 138 7.64E-04 
HNSCC1_cetux_up 337 HALLMARK_HYPOXIA 200 8.96E-04 
HNSCC1_cetux_up 337 HALLMARK_XENOBIOTIC_METABOLISM 200 8.96E-04 
HNSCC1_cetux_up 337 HALLMARK_COMPLEMENT 200 4.07E-03 
HNSCC1_cetux_up 337 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 4.07E-03 
HNSCC1_cetux_up 337 HALLMARK_ANDROGEN_RESPONSE 101 4.59E-03 
HNSCC1_cetux_up 337 HALLMARK_FATTY_ACID_METABOLISM 158 5.22E-03 
HNSCC1_cetux_up 337 TGCCAAR_NF1_Q6 722 1.10E-07 
HNSCC1_cetux_up 337 TTGTTT_FOXO4_01 2061 1.10E-07 
HNSCC1_cetux_up 337 CAGGTG_E12_Q6 2485 2.82E-07 
HNSCC1_cetux_up 337 TATAAA_TATA_01 1296 6.18E-07 
HNSCC1_cetux_up 337 CAGCTG_AP4_Q5 1524 1.92E-06 
HNSCC1_cetux_up 337 SOX9_B1 237 3.14E-06 
HNSCC1_cetux_up 337 MEF2_03 238 3.14E-06 
HNSCC1_cetux_up 337 GCANCTGNY_MYOD_Q6 924 3.14E-06 
HNSCC1_cetux_up 337 TGACCTY_ERR1_Q2 1043 7.37E-06 
HNSCC1_cetux_up 337 GGGAGGRR_MAZ_Q6 2274 1.03E-05 
HNSCC1_cetux_up 337 WTGAAAT_UNKNOWN 616 1.52E-05 
HNSCC1_cetux_up 337 CAGGTA_AREB6_01 792 3.70E-05 
HNSCC1_cetux_up 337 CTAWWWATA_RSRFC4_Q2 361 3.70E-05 
HNSCC1_cetux_up 337 TGGAAA_NFAT_Q4_01 1896 3.88E-05 
HNSCC1_cetux_up 337 TGATTTRY_GFI1_01 294 1.22E-04 
HNSCC1_cetux_up 337 FOXO3_01 245 1.22E-04 
HNSCC1_cetux_up 337 TFIIA_Q6 251 1.44E-04 
HNSCC1_cetux_up 337 OCT1_05 254 1.50E-04 
HNSCC1_cetux_up 337 SRY_02 255 1.50E-04 
HNSCC1_cetux_up 337 GGGTGGRR_PAX4_03 1294 1.83E-04 
HNSCC1_cetux_up 337 GO_COMPLEMENT_ACTIVATION 76 3.02E-29 
HNSCC1_cetux_up 337 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATIN
G_IMMUNOGLOBULIN 69 7.33E-29 
HNSCC1_cetux_up 337 GO_PROTEIN_ACTIVATION_CASCADE 99 2.87E-28 
HNSCC1_cetux_up 337 GO_HUMORAL_IMMUNE_RESPONSE 187 1.26E-26 
HNSCC1_cetux_up 337 GO_B_CELL_MEDIATED_IMMUNITY 99 3.83E-25 
HNSCC1_cetux_up 337 GO_PHAGOCYTOSIS_RECOGNITION 34 7.07E-23 




OBULIN_SUPERFAMILY_DOMAINS 154 1.23E-20 
HNSCC1_cetux_up 337 GO_LEUKOCYTE_MEDIATED_IMMUNITY 189 6.42E-20 
HNSCC1_cetux_up 337 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 2.09E-18 
HNSCC1_cetux_up 337 GO_PHAGOCYTOSIS_ENGULFMENT 38 3.30E-18 
HNSCC1_cetux_up 337 GO_DEFENSE_RESPONSE_TO_BACTERIUM 237 1.10E-17 
HNSCC1_cetux_up 337 GO_REGULATION_OF_IMMUNE_RESPONSE 858 5.24E-17 
HNSCC1_cetux_up 337 GO_DEFENSE_RESPONSE 1231 5.24E-17 
HNSCC1_cetux_up 337 GO_ACTIVATION_OF_IMMUNE_RESPONSE 427 6.54E-17 
HNSCC1_cetux_up 337 GO_MEMBRANE_INVAGINATION 48 1.06E-16 
HNSCC1_cetux_up 337 GO_IMMUNE_RESPONSE 1100 1.40E-16 
HNSCC1_cetux_up 337 GO_PHAGOCYTOSIS 190 2.83E-16 
HNSCC1_cetux_up 337 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 3.76E-16 
HNSCC1_cetux_up 337 GO_B_CELL_RECEPTOR_SIGNALING_PATHWAY 54 5.48E-16 
HNSCC1_cetux_up 337 BMI1_DN_MEL18_DN.V1_DN 147 1.34E-08 
HNSCC1_cetux_up 337 ATF2_UP.V1_DN 187 1.34E-08 
HNSCC1_cetux_up 337 MEL18_DN.V1_DN 148 9.23E-07 
HNSCC1_cetux_up 337 ATF2_S_UP.V1_DN 187 7.64E-06 
HNSCC1_cetux_up 337 BMI1_DN.V1_DN 144 4.97E-05 




HNSCC1_cetux_up 337 AKT_UP_MTOR_DN.V1_DN 183 2.53E-04 
HNSCC1_cetux_up 337 PTEN_DN.V1_UP 191 3.12E-04 
HNSCC1_cetux_up 337 PKCA_DN.V1_UP 170 8.45E-04 
HNSCC1_cetux_up 337 SNF5_DN.V1_UP 177 9.84E-04 
HNSCC1_cetux_up 337 KRAS.600.LUNG.BREAST_UP.V1_DN 289 9.84E-04 
HNSCC1_cetux_up 337 ESC_J1_UP_EARLY.V1_UP 183 9.84E-04 
HNSCC1_cetux_up 337 MTOR_UP.V1_DN 184 9.84E-04 
HNSCC1_cetux_up 337 AKT_UP.V1_DN 187 9.84E-04 
HNSCC1_cetux_up 337 IL15_UP.V1_DN 190 9.84E-04 
HNSCC1_cetux_up 337 PRC1_BMI_UP.V1_UP 192 9.84E-04 
HNSCC1_cetux_up 337 E2F1_UP.V1_DN 193 9.84E-04 
HNSCC1_cetux_up 337 CAHOY_ASTROGLIAL 100 9.84E-04 
HNSCC1_cetux_up 337 KRAS.KIDNEY_UP.V1_UP 145 9.84E-04 
HNSCC1_cetux_up 337 KRAS.LUNG.BREAST_UP.V1_DN 145 9.84E-04 
HNSCC2_cetux_up 152 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 1.89E-06 
HNSCC2_cetux_up 152 HALLMARK_E2F_TARGETS 200 1.26E-04 
HNSCC2_cetux_up 152 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 9.61E-04 
HNSCC2_cetux_up 152 HALLMARK_G2M_CHECKPOINT 200 7.00E-03 
HNSCC2_cetux_up 152 HALLMARK_KRAS_SIGNALING_DN 200 3.61E-02 
HNSCC2_cetux_up 152 HALLMARK_ANDROGEN_RESPONSE 101 3.61E-02 
HNSCC2_cetux_up 152 HALLMARK_PEROXISOME 104 3.61E-02 
HNSCC2_cetux_up 152 ISRE_01 247 1.30E-04 
HNSCC2_cetux_up 152 MAZR_01 220 3.29E-04 
HNSCC2_cetux_up 152 AREB6_01 271 1.04E-03 
HNSCC2_cetux_up 152 CAGGTG_E12_Q6 2485 1.62E-03 
HNSCC2_cetux_up 152 IRF_Q6 242 2.91E-03 
HNSCC2_cetux_up 152 GGGCGGR_SP1_Q6 2940 5.22E-03 
HNSCC2_cetux_up 152 KRCTCNNNNMANAGC_UNKNOWN 66 7.47E-03 
HNSCC2_cetux_up 152 CAGGTA_AREB6_01 792 7.47E-03 
HNSCC2_cetux_up 152 E2F1DP1RB_01 231 1.18E-02 
HNSCC2_cetux_up 152 GGGAGGRR_MAZ_Q6 2274 1.63E-02 
HNSCC2_cetux_up 152 DR4_Q2 260 1.71E-02 
HNSCC2_cetux_up 152 CTTTGA_LEF1_Q2 1232 1.71E-02 
HNSCC2_cetux_up 152 STTTCRNTTT_IRF_Q6 188 2.72E-02 
HNSCC2_cetux_up 152 AACTTT_UNKNOWN 1890 3.32E-02 
HNSCC2_cetux_up 152 COMP1_01 115 3.33E-02 
HNSCC2_cetux_up 152 RP58_01 207 3.42E-02 
HNSCC2_cetux_up 152 MEF2_02 228 3.79E-02 
HNSCC2_cetux_up 152 TTTNNANAGCYR_UNKNOWN 133 3.79E-02 
HNSCC2_cetux_up 152 E2F1_Q6 232 3.79E-02 
HNSCC2_cetux_up 152 E2F_Q6 232 3.79E-02 
HNSCC2_cetux_up 152 GO_CELL_CYCLE 1316 3.76E-03 
HNSCC2_cetux_up 152 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 1493 3.76E-03 
HNSCC2_cetux_up 152 
GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METAB
OLIC_PROCESS 1517 3.76E-03 
HNSCC2_cetux_up 152 GO_CELL_CYCLE_PROCESS 1081 3.76E-03 
HNSCC2_cetux_up 152 GO_CHROMOSOME_ORGANIZATION 1009 6.48E-03 
HNSCC2_cetux_up 152 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOP
MENT 1672 8.54E-03 
HNSCC2_cetux_up 152 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.85E-02 
HNSCC2_cetux_up 152 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 112 1.85E-02 
HNSCC2_cetux_up 152 GO_DNA_CONFORMATION_CHANGE 273 1.85E-02 
HNSCC2_cetux_up 152 GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT 750 1.95E-02 
HNSCC2_cetux_up 152 GO_REGULATION_OF_NOTCH_SIGNALING_PATHWAY 67 2.67E-02 
HNSCC2_cetux_up 152 GO_RESPONSE_TO_TYPE_I_INTERFERON 68 2.67E-02 
HNSCC2_cetux_up 152 GO_GENE_SILENCING 212 2.67E-02 
HNSCC2_cetux_up 152 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATIN
G_IMMUNOGLOBULIN 69 2.67E-02 
HNSCC2_cetux_up 152 GO_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 229 3.38E-02 
HNSCC2_cetux_up 152 GO_COMPLEMENT_ACTIVATION 76 3.38E-02 
HNSCC2_cetux_up 152 GO_RENAL_TUBULE_DEVELOPMENT 78 3.38E-02 
HNSCC2_cetux_up 152 GO_REGULATION_OF_CELL_DIFFERENTIATION 1492 3.38E-02 
HNSCC2_cetux_up 152 GO_KIDNEY_MORPHOGENESIS 82 3.84E-02 
HNSCC2_cetux_up 152 GO_RESPONSE_TO_BIOTIC_STIMULUS 886 4.12E-02 
HNSCC2_cetux_up 152 PIGF_UP.V1_DN 194 7.81E-04 




HNSCC2_cetux_up 152 CSR_LATE_UP.V1_DN 170 1.47E-03 
HNSCC2_cetux_up 152 IL15_UP.V1_DN 190 1.89E-03 
HNSCC2_cetux_up 152 HOXA9_DN.V1_DN 195 1.89E-03 
HNSCC2_cetux_up 152 ATM_DN.V1_UP 146 4.14E-03 
HNSCC2_cetux_up 152 IL21_UP.V1_DN 187 8.05E-03 
HNSCC2_cetux_up 152 PRC2_EED_UP.V1_DN 193 8.05E-03 
HNSCC2_cetux_up 152 LEF1_UP.V1_UP 195 8.05E-03 
HNSCC2_cetux_up 152 E2F3_UP.V1_UP 196 8.05E-03 
HNSCC2_cetux_up 152 EGFR_UP.V1_DN 196 8.05E-03 
HNSCC2_cetux_up 152 MEK_UP.V1_DN 196 8.05E-03 
HNSCC2_cetux_up 152 KRAS.300_UP.V1_DN 143 1.96E-02 
HNSCC2_cetux_up 152 KRAS.600_UP.V1_DN 289 3.45E-02 
HNSCC2_cetux_up 152 SRC_UP.V1_DN 179 3.45E-02 
HNSCC2_cetux_up 152 GCNP_SHH_UP_LATE.V1_DN 180 3.45E-02 
HNSCC2_cetux_up 152 RAPA_EARLY_UP.V1_UP 183 3.45E-02 
HNSCC2_cetux_up 152 ATF2_UP.V1_UP 192 3.45E-02 
HNSCC2_cetux_up 152 JNK_DN.V1_UP 192 3.45E-02 
HNSCC2_cetux_up 152 KRAS.DF.V1_UP 193 3.45E-02 
HNSCC3_cetux_up 729 HALLMARK_MYC_TARGETS_V1 200 7.77E-06 
HNSCC3_cetux_up 729 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 1.11E-04 
HNSCC3_cetux_up 729 HALLMARK_G2M_CHECKPOINT 200 2.87E-04 
HNSCC3_cetux_up 729 HALLMARK_PROTEIN_SECRETION 96 2.87E-04 
HNSCC3_cetux_up 729 HALLMARK_DNA_REPAIR 150 3.01E-04 
HNSCC3_cetux_up 729 HALLMARK_GLYCOLYSIS 200 6.75E-04 
HNSCC3_cetux_up 729 HALLMARK_XENOBIOTIC_METABOLISM 200 6.75E-04 
HNSCC3_cetux_up 729 HALLMARK_APOPTOSIS 161 1.68E-03 
HNSCC3_cetux_up 729 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 2.15E-03 
HNSCC3_cetux_up 729 HALLMARK_UV_RESPONSE_DN 144 2.58E-03 
HNSCC3_cetux_up 729 HALLMARK_UV_RESPONSE_UP 158 4.55E-03 
HNSCC3_cetux_up 729 HALLMARK_COMPLEMENT 200 4.81E-03 
HNSCC3_cetux_up 729 HALLMARK_E2F_TARGETS 200 4.81E-03 
HNSCC3_cetux_up 729 HALLMARK_IL2_STAT5_SIGNALING 200 4.81E-03 
HNSCC3_cetux_up 729 HALLMARK_KRAS_SIGNALING_UP 200 4.81E-03 
HNSCC3_cetux_up 729 HALLMARK_TGF_BETA_SIGNALING 54 5.16E-03 
HNSCC3_cetux_up 729 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 6.54E-03 
HNSCC3_cetux_up 729 HALLMARK_HEME_METABOLISM 200 1.17E-02 
HNSCC3_cetux_up 729 HALLMARK_MITOTIC_SPINDLE 200 1.17E-02 
HNSCC3_cetux_up 729 HALLMARK_MYOGENESIS 200 1.17E-02 
HNSCC3_cetux_up 729 GGGCGGR_SP1_Q6 2940 2.98E-31 
HNSCC3_cetux_up 729 TGANTCA_AP1_C 1121 1.12E-14 
HNSCC3_cetux_up 729 CAGGTG_E12_Q6 2485 3.33E-14 
HNSCC3_cetux_up 729 TGGAAA_NFAT_Q4_01 1896 3.21E-10 
HNSCC3_cetux_up 729 SCGGAAGY_ELK1_02 1199 5.67E-10 
HNSCC3_cetux_up 729 CTTTGT_LEF1_Q2 1972 1.36E-09 
HNSCC3_cetux_up 729 TTGCCAA_MIR182 327 3.04E-09 
HNSCC3_cetux_up 729 TTGTTT_FOXO4_01 2061 3.06E-09 
HNSCC3_cetux_up 729 TGACCTY_ERR1_Q2 1043 6.37E-09 
HNSCC3_cetux_up 729 GGGAGGRR_MAZ_Q6 2274 6.37E-09 
HNSCC3_cetux_up 729 GATTGGY_NFY_Q6_01 1160 7.28E-09 
HNSCC3_cetux_up 729 TAATTA_CHX10_01 810 9.87E-07 
HNSCC3_cetux_up 729 CAGCTG_AP4_Q5 1524 1.25E-06 
HNSCC3_cetux_up 729 TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P 579 1.30E-06 
HNSCC3_cetux_up 729 TGAATGT_MIR181A_MIR181B_MIR181C_MIR181D 484 1.37E-06 
HNSCC3_cetux_up 729 CACGTG_MYC_Q2 1032 2.04E-06 
HNSCC3_cetux_up 729 CTTTGA_LEF1_Q2 1232 2.04E-06 
HNSCC3_cetux_up 729 ERR1_Q2 259 2.04E-06 
HNSCC3_cetux_up 729 RYTTCCTG_ETS2_B 1085 2.51E-06 
HNSCC3_cetux_up 729 CTTTAAR_UNKNOWN 972 2.60E-06 
HNSCC3_cetux_up 729 GO_PROTEIN_LOCALIZATION 1805 1.60E-21 
HNSCC3_cetux_up 729 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 3.85E-19 
HNSCC3_cetux_up 729 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 8.12E-19 
HNSCC3_cetux_up 729 GO_CELLULAR_MACROMOLECULE_LOCALIZATION 1234 8.12E-19 
HNSCC3_cetux_up 729 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 1423 2.32E-18 
HNSCC3_cetux_up 729 GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL 1676 1.40E-17 






S 1977 2.07E-16 
HNSCC3_cetux_up 729 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 1.33E-15 
HNSCC3_cetux_up 729 GO_REGULATION_OF_ORGANELLE_ORGANIZATION 1178 2.16E-15 
HNSCC3_cetux_up 729 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 5.67E-15 
HNSCC3_cetux_up 729 GO_TISSUE_DEVELOPMENT 1518 7.05E-15 
HNSCC3_cetux_up 729 GO_INTRACELLULAR_PROTEIN_TRANSPORT 781 8.81E-15 
HNSCC3_cetux_up 729 
GO_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGAN
IZATION 1152 1.16E-13 
HNSCC3_cetux_up 729 GO_CATABOLIC_PROCESS 1773 6.43E-13 
HNSCC3_cetux_up 729 GO_CELLULAR_RESPONSE_TO_STRESS 1565 9.47E-13 
HNSCC3_cetux_up 729 GO_INTRACELLULAR_SIGNAL_TRANSDUCTION 1572 1.11E-12 
HNSCC3_cetux_up 729 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 1.58E-12 
HNSCC3_cetux_up 729 GO_SINGLE_ORGANISM_CELLULAR_LOCALIZATION 898 1.65E-12 
HNSCC3_cetux_up 729 GO_REGULATION_OF_CELL_PROLIFERATION 1496 2.76E-12 
HNSCC3_cetux_up 729 E2F1_UP.V1_DN 193 4.48E-07 
HNSCC3_cetux_up 729 RPS14_DN.V1_UP 192 8.37E-06 
HNSCC3_cetux_up 729 MEK_UP.V1_DN 196 2.52E-05 
HNSCC3_cetux_up 729 MEK_UP.V1_UP 196 2.52E-05 
HNSCC3_cetux_up 729 MTOR_UP.N4.V1_UP 196 2.52E-05 
HNSCC3_cetux_up 729 TBK1.DF_UP 290 3.62E-05 
HNSCC3_cetux_up 729 E2F1_UP.V1_UP 189 6.19E-05 
HNSCC3_cetux_up 729 RAF_UP.V1_UP 196 4.07E-04 
HNSCC3_cetux_up 729 STK33_UP 293 4.63E-04 
HNSCC3_cetux_up 729 PDGF_ERK_DN.V1_UP 147 4.72E-04 
HNSCC3_cetux_up 729 MYC_UP.V1_DN 182 6.55E-04 
HNSCC3_cetux_up 729 AKT_UP.V1_DN 187 7.81E-04 
HNSCC3_cetux_up 729 LTE2_UP.V1_UP 190 8.41E-04 
HNSCC3_cetux_up 729 LEF1_UP.V1_UP 195 1.00E-03 
HNSCC3_cetux_up 729 STK33_NOMO_UP 294 1.07E-03 
HNSCC3_cetux_up 729 ESC_V6.5_UP_LATE.V1_DN 186 2.25E-03 
HNSCC3_cetux_up 729 ATF2_UP.V1_DN 187 2.25E-03 
HNSCC3_cetux_up 729 SINGH_KRAS_DEPENDENCY_SIGNATURE_ 20 2.25E-03 
HNSCC3_cetux_up 729 LEF1_UP.V1_DN 190 2.25E-03 
HNSCC3_cetux_up 729 ERB2_UP.V1_UP 191 2.25E-03 
HNSCC4_cetux_up 129 HALLMARK_INFLAMMATORY_RESPONSE 200 4.25E-05 
HNSCC4_cetux_up 129 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 4.25E-05 
HNSCC4_cetux_up 129 HALLMARK_APOPTOSIS 161 1.90E-02 
HNSCC4_cetux_up 129 HALLMARK_ALLOGRAFT_REJECTION 200 2.09E-02 
HNSCC4_cetux_up 129 HALLMARK_COMPLEMENT 200 2.09E-02 
HNSCC4_cetux_up 129 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 2.09E-02 
HNSCC4_cetux_up 129 PEA3_Q6 255 5.75E-04 
HNSCC4_cetux_up 129 AML_Q6 266 4.66E-02 
HNSCC4_cetux_up 129 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 1.54E-13 
HNSCC4_cetux_up 129 GO_REGULATION_OF_CELL_ACTIVATION 484 2.85E-13 
HNSCC4_cetux_up 129 GO_ADAPTIVE_IMMUNE_RESPONSE 288 2.85E-13 
HNSCC4_cetux_up 129 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 2.85E-13 
HNSCC4_cetux_up 129 GO_REGULATION_OF_IMMUNE_RESPONSE 858 2.98E-13 
HNSCC4_cetux_up 129 GO_IMMUNE_SYSTEM_PROCESS 1984 4.10E-13 
HNSCC4_cetux_up 129 GO_PHAGOCYTOSIS_ENGULFMENT 38 7.10E-13 
HNSCC4_cetux_up 129 GO_REGULATION_OF_B_CELL_ACTIVATION 121 7.10E-13 
HNSCC4_cetux_up 129 GO_IMMUNE_RESPONSE 1100 3.29E-12 
HNSCC4_cetux_up 129 GO_MEMBRANE_INVAGINATION 48 5.52E-12 




OBULIN_SUPERFAMILY_DOMAINS 154 8.96E-12 
HNSCC4_cetux_up 129 GO_B_CELL_RECEPTOR_SIGNALING_PATHWAY 54 1.33E-11 
HNSCC4_cetux_up 129 GO_PHAGOCYTOSIS_RECOGNITION 34 1.67E-11 
HNSCC4_cetux_up 129 GO_POSITIVE_REGULATION_OF_B_CELL_ACTIVATION 86 1.86E-11 
HNSCC4_cetux_up 129 GO_PHAGOCYTOSIS 190 8.36E-11 
HNSCC4_cetux_up 129 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATIN
G_IMMUNOGLOBULIN 69 1.01E-10 
HNSCC4_cetux_up 129 GO_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY 195 1.01E-10 






R_SIGNALING_PATHWAY 323 1.13E-10 
HNSCC4_cetux_up 129 BMI1_DN_MEL18_DN.V1_UP 145 1.11E-02 
HNSCC4_cetux_up 129 NOTCH_DN.V1_DN 189 1.14E-02 
HNSCC4_cetux_up 129 PRC1_BMI_UP.V1_UP 192 1.14E-02 
HNSCC4_cetux_up 129 IL2_UP.V1_DN 196 1.14E-02 
HNSCC4_cetux_up 129 BRCA1_DN.V1_UP 141 2.36E-02 
HNSCC4_cetux_up 129 P53_DN.V2_UP 148 2.36E-02 
HNSCC4_cetux_up 129 HINATA_NFKB_IMMU_INF 17 2.36E-02 
HNSCC4_cetux_up 129 KRAS.600.LUNG.BREAST_UP.V1_DN 289 2.36E-02 
HNSCC4_cetux_up 129 AKT_UP.V1_UP 172 2.36E-02 
HNSCC4_cetux_up 129 AKT_UP_MTOR_DN.V1_UP 184 2.36E-02 
HNSCC4_cetux_up 129 LEF1_UP.V1_DN 190 2.36E-02 
HNSCC4_cetux_up 129 ERB2_UP.V1_UP 191 2.36E-02 
HNSCC4_cetux_up 129 IL15_UP.V1_UP 192 2.36E-02 
HNSCC4_cetux_up 129 IL2_UP.V1_UP 192 2.36E-02 
HNSCC4_cetux_up 129 JNK_DN.V1_UP 192 2.36E-02 
HNSCC4_cetux_up 129 RPS14_DN.V1_UP 192 2.36E-02 
HNSCC4_cetux_up 129 DCA_UP.V1_DN 193 2.36E-02 
HNSCC4_cetux_up 129 CYCLIN_D1_KE_.V1_DN 194 2.36E-02 
HNSCC4_cetux_up 129 CAMP_UP.V1_DN 200 2.50E-02 
HNSCC5_cetux_up 384 HALLMARK_ESTROGEN_RESPONSE_LATE 200 9.29E-09 
HNSCC5_cetux_up 384 HALLMARK_P53_PATHWAY 200 4.63E-08 
HNSCC5_cetux_up 384 HALLMARK_APICAL_JUNCTION 200 2.85E-07 
HNSCC5_cetux_up 384 HALLMARK_KRAS_SIGNALING_DN 200 1.22E-06 
HNSCC5_cetux_up 384 HALLMARK_MYOGENESIS 200 1.22E-06 
HNSCC5_cetux_up 384 HALLMARK_XENOBIOTIC_METABOLISM 200 1.22E-06 
HNSCC5_cetux_up 384 HALLMARK_KRAS_SIGNALING_UP 200 8.15E-06 
HNSCC5_cetux_up 384 HALLMARK_G2M_CHECKPOINT 200 3.28E-04 
HNSCC5_cetux_up 384 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 1.68E-03 
HNSCC5_cetux_up 384 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 5.97E-03 
HNSCC5_cetux_up 384 HALLMARK_GLYCOLYSIS 200 5.97E-03 
HNSCC5_cetux_up 384 HALLMARK_HYPOXIA 200 5.97E-03 
HNSCC5_cetux_up 384 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 5.97E-03 
HNSCC5_cetux_up 384 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 6.91E-03 
HNSCC5_cetux_up 384 HALLMARK_APICAL_SURFACE 44 1.98E-02 
HNSCC5_cetux_up 384 HALLMARK_E2F_TARGETS 200 2.05E-02 
HNSCC5_cetux_up 384 HALLMARK_HEME_METABOLISM 200 2.05E-02 
HNSCC5_cetux_up 384 CAGGTG_E12_Q6 2485 2.91E-16 
HNSCC5_cetux_up 384 CTTTGT_LEF1_Q2 1972 3.75E-14 
HNSCC5_cetux_up 384 TGANTCA_AP1_C 1121 2.29E-09 
HNSCC5_cetux_up 384 GGGCGGR_SP1_Q6 2940 1.11E-08 
HNSCC5_cetux_up 384 GGGTGGRR_PAX4_03 1294 2.19E-07 
HNSCC5_cetux_up 384 GGGAGGRR_MAZ_Q6 2274 2.19E-07 
HNSCC5_cetux_up 384 CAGCTG_AP4_Q5 1524 3.31E-07 
HNSCC5_cetux_up 384 RYTTCCTG_ETS2_B 1085 1.55E-06 
HNSCC5_cetux_up 384 TATAAA_TATA_01 1296 6.12E-06 
HNSCC5_cetux_up 384 KRCTCNNNNMANAGC_UNKNOWN 66 6.95E-06 
HNSCC5_cetux_up 384 WGGAATGY_TEF1_Q6 378 6.70E-05 
HNSCC5_cetux_up 384 WTGAAAT_UNKNOWN 616 9.94E-05 
HNSCC5_cetux_up 384 TTANTCA_UNKNOWN 952 1.36E-04 
HNSCC5_cetux_up 384 TGACAGNY_MEIS1_01 827 1.44E-04 
HNSCC5_cetux_up 384 TGGAAA_NFAT_Q4_01 1896 2.74E-04 
HNSCC5_cetux_up 384 TGGTGCT_MIR29A_MIR29B_MIR29C 521 5.32E-04 
HNSCC5_cetux_up 384 SOX5_01 265 7.98E-04 
HNSCC5_cetux_up 384 CTTTGA_LEF1_Q2 1232 7.98E-04 
HNSCC5_cetux_up 384 CCCNNGGGAR_OLF1_01 320 7.98E-04 
HNSCC5_cetux_up 384 GATTGGY_NFY_Q6_01 1160 7.98E-04 
HNSCC5_cetux_up 384 GO_EPIDERMIS_DEVELOPMENT 253 1.61E-20 
HNSCC5_cetux_up 384 GO_TISSUE_DEVELOPMENT 1518 1.06E-18 
HNSCC5_cetux_up 384 GO_EPITHELIUM_DEVELOPMENT 945 1.48E-18 
HNSCC5_cetux_up 384 GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 1275 3.02E-17 
HNSCC5_cetux_up 384 GO_BIOLOGICAL_ADHESION 1032 2.02E-13 
HNSCC5_cetux_up 384 GO_CELL_MOTILITY 835 6.15E-12 
HNSCC5_cetux_up 384 GO_LOCOMOTION 1114 9.53E-12 




HNSCC5_cetux_up 384 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 1.76E-10 
HNSCC5_cetux_up 384 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 2.08E-10 
HNSCC5_cetux_up 384 GO_EPITHELIAL_CELL_DIFFERENTIATION 495 4.73E-10 
HNSCC5_cetux_up 384 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 6.20E-10 
HNSCC5_cetux_up 384 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOP
MENT 1672 2.40E-09 
HNSCC5_cetux_up 384 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 2.96E-09 
HNSCC5_cetux_up 384 GO_REGULATION_OF_CELL_PROLIFERATION 1496 2.96E-09 
HNSCC5_cetux_up 384 GO_CELLULAR_RESPONSE_TO_STRESS 1565 3.08E-09 
HNSCC5_cetux_up 384 GO_REGULATION_OF_HYDROLASE_ACTIVITY 1327 3.94E-09 
HNSCC5_cetux_up 384 GO_EPIDERMAL_CELL_DIFFERENTIATION 142 4.67E-09 
HNSCC5_cetux_up 384 GO_SINGLE_ORGANISM_BIOSYNTHETIC_PROCESS 1340 4.67E-09 
HNSCC5_cetux_up 384 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 4.67E-09 
HNSCC5_cetux_up 384 KRAS.LUNG_UP.V1_DN 145 2.15E-16 
HNSCC5_cetux_up 384 KRAS.600.LUNG.BREAST_UP.V1_DN 289 4.74E-08 
HNSCC5_cetux_up 384 KRAS.600_UP.V1_DN 289 2.45E-07 
HNSCC5_cetux_up 384 CSR_LATE_UP.V1_UP 172 1.31E-06 
HNSCC5_cetux_up 384 KRAS.LUNG.BREAST_UP.V1_DN 145 1.69E-06 
HNSCC5_cetux_up 384 AKT_UP.V1_DN 187 1.89E-06 
HNSCC5_cetux_up 384 RPS14_DN.V1_DN 187 1.89E-06 
HNSCC5_cetux_up 384 CYCLIN_D1_KE_.V1_UP 190 1.63E-05 
HNSCC5_cetux_up 384 KRAS.DF.V1_DN 194 1.68E-05 
HNSCC5_cetux_up 384 LEF1_UP.V1_UP 195 1.68E-05 
HNSCC5_cetux_up 384 ATF2_UP.V1_DN 187 7.72E-05 
HNSCC5_cetux_up 384 STK33_DN 289 1.09E-04 
HNSCC5_cetux_up 384 SNF5_DN.V1_DN 164 1.59E-04 
HNSCC5_cetux_up 384 SNF5_DN.V1_UP 177 2.72E-04 
HNSCC5_cetux_up 384 AKT_UP_MTOR_DN.V1_DN 183 3.26E-04 
HNSCC5_cetux_up 384 ATF2_S_UP.V1_DN 187 3.26E-04 
HNSCC5_cetux_up 384 JAK2_DN.V1_UP 188 3.26E-04 
HNSCC5_cetux_up 384 IL15_UP.V1_DN 190 3.26E-04 
HNSCC5_cetux_up 384 STK33_SKM_DN 288 3.26E-04 
HNSCC5_cetux_up 384 DCA_UP.V1_DN 193 3.26E-04 
HNSCC6_cetux_up 242 HALLMARK_COMPLEMENT 200 4.97E-03 
HNSCC6_cetux_up 242 KRCTCNNNNMANAGC_UNKNOWN 66 4.78E-11 
HNSCC6_cetux_up 242 TTTNNANAGCYR_UNKNOWN 133 1.09E-06 
HNSCC6_cetux_up 242 TTCYNRGAA_STAT5B_01 335 2.23E-02 
HNSCC6_cetux_up 242 TGANTCA_AP1_C 1121 4.98E-02 
HNSCC6_cetux_up 242 CIZ_01 246 4.98E-02 
HNSCC6_cetux_up 242 ETS_Q4 247 4.98E-02 
HNSCC6_cetux_up 242 STAT_01 253 4.98E-02 
HNSCC6_cetux_up 242 GO_IMMUNE_RESPONSE 1100 1.73E-10 
HNSCC6_cetux_up 242 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 1.78E-09 
HNSCC6_cetux_up 242 GO_IMMUNE_SYSTEM_PROCESS 1984 9.16E-09 
HNSCC6_cetux_up 242 GO_REGULATION_OF_IMMUNE_RESPONSE 858 2.70E-07 
HNSCC6_cetux_up 242 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 112 4.27E-07 
HNSCC6_cetux_up 242 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 1.24E-06 
HNSCC6_cetux_up 242 GO_CHROMATIN_SILENCING 95 1.35E-06 
HNSCC6_cetux_up 242 GO_DEFENSE_RESPONSE 1231 1.35E-06 
HNSCC6_cetux_up 242 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATIN
G_IMMUNOGLOBULIN 69 1.65E-06 
HNSCC6_cetux_up 242 GO_ADAPTIVE_IMMUNE_RESPONSE 288 2.23E-06 
HNSCC6_cetux_up 242 GO_HUMORAL_IMMUNE_RESPONSE 187 2.23E-06 
HNSCC6_cetux_up 242 GO_COMPLEMENT_ACTIVATION 76 2.70E-06 
HNSCC6_cetux_up 242 GO_RESPONSE_TO_BIOTIC_STIMULUS 886 4.42E-06 
HNSCC6_cetux_up 242 GO_CHROMOSOME_ORGANIZATION 1009 8.02E-06 
HNSCC6_cetux_up 242 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 1.15E-05 
HNSCC6_cetux_up 242 GO_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 229 1.24E-05 
HNSCC6_cetux_up 242 GO_B_CELL_MEDIATED_IMMUNITY 99 1.47E-05 
HNSCC6_cetux_up 242 GO_PROTEIN_ACTIVATION_CASCADE 99 1.47E-05 
HNSCC6_cetux_up 242 GO_LYMPHOCYTE_MEDIATED_IMMUNITY 147 2.29E-05 
HNSCC6_cetux_up 242 GO_GENE_SILENCING 212 4.86E-05 
HNSCC6_cetux_up 242 LEF1_UP.V1_UP 195 5.52E-03 
HNSCC6_cetux_up 242 EGFR_UP.V1_DN 196 5.52E-03 
HNSCC6_cetux_up 242 MEK_UP.V1_DN 196 5.52E-03 




HNSCC6_cetux_up 242 PRC2_EED_UP.V1_DN 193 2.00E-02 
HNSCC6_cetux_up 242 LTE2_UP.V1_DN 196 2.00E-02 
HNSCC7_cetux_up 412 HALLMARK_E2F_TARGETS 200 9.75E-07 
HNSCC7_cetux_up 412 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 9.75E-07 
HNSCC7_cetux_up 412 HALLMARK_ADIPOGENESIS 200 2.81E-05 
HNSCC7_cetux_up 412 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 2.81E-05 
HNSCC7_cetux_up 412 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 2.84E-04 
HNSCC7_cetux_up 412 HALLMARK_MYC_TARGETS_V1 200 7.46E-04 
HNSCC7_cetux_up 412 HALLMARK_MYC_TARGETS_V2 58 1.25E-03 
HNSCC7_cetux_up 412 HALLMARK_UV_RESPONSE_DN 144 1.05E-02 
HNSCC7_cetux_up 412 HALLMARK_APICAL_JUNCTION 200 1.05E-02 
HNSCC7_cetux_up 412 HALLMARK_G2M_CHECKPOINT 200 1.05E-02 
HNSCC7_cetux_up 412 HALLMARK_P53_PATHWAY 200 1.05E-02 
HNSCC7_cetux_up 412 HALLMARK_ANGIOGENESIS 36 1.71E-02 
HNSCC7_cetux_up 412 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 2.84E-02 
HNSCC7_cetux_up 412 HALLMARK_ALLOGRAFT_REJECTION 200 2.84E-02 
HNSCC7_cetux_up 412 HALLMARK_KRAS_SIGNALING_UP 200 2.84E-02 
HNSCC7_cetux_up 412 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 2.84E-02 
HNSCC7_cetux_up 412 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 2.84E-02 
HNSCC7_cetux_up 412 HALLMARK_TGF_BETA_SIGNALING 54 3.46E-02 
HNSCC7_cetux_up 412 HALLMARK_ANDROGEN_RESPONSE 101 3.46E-02 
HNSCC7_cetux_up 412 HALLMARK_PEROXISOME 104 3.63E-02 
HNSCC7_cetux_up 412 GGGCGGR_SP1_Q6 2940 5.48E-14 
HNSCC7_cetux_up 412 GATTGGY_NFY_Q6_01 1160 2.81E-06 
HNSCC7_cetux_up 412 AACTTT_UNKNOWN 1890 2.81E-06 
HNSCC7_cetux_up 412 GGGAGGRR_MAZ_Q6 2274 3.33E-06 
HNSCC7_cetux_up 412 CACGTG_MYC_Q2 1032 1.34E-05 
HNSCC7_cetux_up 412 RCGCANGCGY_NRF1_Q6 918 1.34E-05 
HNSCC7_cetux_up 412 CTTTGT_LEF1_Q2 1972 7.76E-05 
HNSCC7_cetux_up 412 SCGGAAGY_ELK1_02 1199 1.84E-04 
HNSCC7_cetux_up 412 TGANTCA_AP1_C 1121 4.03E-04 
HNSCC7_cetux_up 412 CAGGTG_E12_Q6 2485 5.83E-04 
HNSCC7_cetux_up 412 TGGAAA_NFAT_Q4_01 1896 7.01E-04 
HNSCC7_cetux_up 412 GTGACGY_E4F1_Q6 658 7.01E-04 
HNSCC7_cetux_up 412 POU3F2_02 260 1.72E-03 
HNSCC7_cetux_up 412 HNF4_Q6 263 1.77E-03 
HNSCC7_cetux_up 412 EFC_Q6 268 1.96E-03 
HNSCC7_cetux_up 412 CHX10_01 225 2.13E-03 
HNSCC7_cetux_up 412 USF_C 279 2.49E-03 
HNSCC7_cetux_up 412 TATAAA_TATA_01 1296 2.53E-03 
HNSCC7_cetux_up 412 SP1_01 237 2.77E-03 
HNSCC7_cetux_up 412 GGGYGTGNY_UNKNOWN 664 4.91E-03 
HNSCC7_cetux_up 412 GO_IMMUNE_SYSTEM_PROCESS 1984 8.90E-13 
HNSCC7_cetux_up 412 GO_DEFENSE_RESPONSE 1231 1.02E-12 
HNSCC7_cetux_up 412 GO_RESPONSE_TO_BIOTIC_STIMULUS 886 2.09E-11 
HNSCC7_cetux_up 412 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 5.86E-11 
HNSCC7_cetux_up 412 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 9.96E-11 
HNSCC7_cetux_up 412 GO_DEFENSE_RESPONSE_TO_OTHER_ORGANISM 505 1.48E-10 
HNSCC7_cetux_up 412 GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 1710 2.44E-09 
HNSCC7_cetux_up 412 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 5.57E-09 
HNSCC7_cetux_up 412 GO_LOCOMOTION 1114 6.16E-09 
HNSCC7_cetux_up 412 GO_CELLULAR_RESPONSE_TO_STRESS 1565 1.38E-08 
HNSCC7_cetux_up 412 GO_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 771 5.21E-08 
HNSCC7_cetux_up 412 GO_IMMUNE_EFFECTOR_PROCESS 486 5.21E-08 
HNSCC7_cetux_up 412 
GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCES
S 1977 5.79E-08 
HNSCC7_cetux_up 412 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 5.92E-08 
HNSCC7_cetux_up 412 GO_REGULATION_OF_CELL_DIFFERENTIATION 1492 8.92E-08 
HNSCC7_cetux_up 412 GO_POSITIVE_REGULATION_OF_LOCOMOTION 420 9.29E-08 
HNSCC7_cetux_up 412 GO_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 926 1.33E-07 
HNSCC7_cetux_up 412 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 1.36E-07 
HNSCC7_cetux_up 412 GO_PROTEIN_LOCALIZATION 1805 1.96E-07 
HNSCC7_cetux_up 412 GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 1381 3.00E-07 
HNSCC7_cetux_up 412 STK33_NOMO_UP 294 1.66E-05 
HNSCC7_cetux_up 412 BMI1_DN.V1_DN 144 4.94E-04 




HNSCC7_cetux_up 412 RPS14_DN.V1_UP 192 4.94E-04 
HNSCC7_cetux_up 412 KRAS.600.LUNG.BREAST_UP.V1_DN 289 5.04E-04 
HNSCC7_cetux_up 412 STK33_UP 293 5.04E-04 
HNSCC7_cetux_up 412 PKCA_DN.V1_UP 170 6.58E-04 
HNSCC7_cetux_up 412 CSR_LATE_UP.V1_UP 172 6.58E-04 
HNSCC7_cetux_up 412 RB_P107_DN.V1_UP 140 8.73E-04 
HNSCC7_cetux_up 412 LEF1_UP.V1_UP 195 1.32E-03 
HNSCC7_cetux_up 412 LTE2_UP.V1_DN 196 1.32E-03 
HNSCC7_cetux_up 412 MTOR_UP.V1_UP 170 2.54E-03 
HNSCC7_cetux_up 412 AKT_UP.V1_UP 172 2.54E-03 
HNSCC7_cetux_up 412 SNF5_DN.V1_UP 177 2.87E-03 
HNSCC7_cetux_up 412 AKT_UP_MTOR_DN.V1_UP 184 3.49E-03 
HNSCC7_cetux_up 412 KRAS.LUNG_UP.V1_DN 145 3.60E-03 
HNSCC7_cetux_up 412 EGFR_UP.V1_UP 193 3.60E-03 
HNSCC7_cetux_up 412 KRAS.DF.V1_UP 193 3.60E-03 
HNSCC7_cetux_up 412 P53_DN.V1_UP 194 3.60E-03 
HNSCC7_cetux_up 412 ALK_DN.V1_DN 148 3.60E-03 
HNSCC8_cetux_up 201 HALLMARK_KRAS_SIGNALING_UP 200 1.40E-05 
HNSCC8_cetux_up 201 HALLMARK_ALLOGRAFT_REJECTION 200 6.14E-03 
HNSCC8_cetux_up 201 HALLMARK_COAGULATION 138 6.14E-03 
HNSCC8_cetux_up 201 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 1.94E-02 




OBULIN_SUPERFAMILY_DOMAINS 154 2.43E-35 
HNSCC8_cetux_up 201 GO_ADAPTIVE_IMMUNE_RESPONSE 288 5.39E-35 
HNSCC8_cetux_up 201 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATIN
G_IMMUNOGLOBULIN 69 2.24E-34 
HNSCC8_cetux_up 201 GO_COMPLEMENT_ACTIVATION 76 2.32E-33 
HNSCC8_cetux_up 201 GO_B_CELL_RECEPTOR_SIGNALING_PATHWAY 54 3.99E-33 
HNSCC8_cetux_up 201 GO_B_CELL_MEDIATED_IMMUNITY 99 1.36E-30 
HNSCC8_cetux_up 201 GO_PROTEIN_ACTIVATION_CASCADE 99 1.36E-30 
HNSCC8_cetux_up 201 GO_HUMORAL_IMMUNE_RESPONSE 187 2.80E-30 
HNSCC8_cetux_up 201 GO_PHAGOCYTOSIS 190 3.91E-30 
HNSCC8_cetux_up 201 GO_REGULATION_OF_IMMUNE_RESPONSE 858 5.92E-30 
HNSCC8_cetux_up 201 GO_IMMUNE_RESPONSE 1100 5.92E-30 
HNSCC8_cetux_up 201 GO_LYMPHOCYTE_MEDIATED_IMMUNITY 147 5.92E-30 
HNSCC8_cetux_up 201 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 7.44E-30 
HNSCC8_cetux_up 201 GO_IMMUNE_SYSTEM_PROCESS 1984 4.15E-29 
HNSCC8_cetux_up 201 GO_POSITIVE_REGULATION_OF_IMMUNE_RESPONSE 563 1.75E-28 
HNSCC8_cetux_up 201 
GO_IMMUNE_RESPONSE_REGULATING_CELL_SURFACE_RECEPTO
R_SIGNALING_PATHWAY 323 2.96E-28 
HNSCC8_cetux_up 201 GO_ACTIVATION_OF_IMMUNE_RESPONSE 427 2.61E-27 
HNSCC8_cetux_up 201 GO_LEUKOCYTE_MEDIATED_IMMUNITY 189 2.99E-27 
HNSCC8_cetux_up 201 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 1.40E-26 
HNSCC8_cetux_up 201 GO_FC_GAMMA_RECEPTOR_SIGNALING_PATHWAY 95 7.10E-26 
HNSCC8_cetux_up 201 KRAS.600.LUNG.BREAST_UP.V1_UP 288 4.31E-03 
HNSCC8_cetux_up 201 KRAS.LUNG.BREAST_UP.V1_UP 145 4.31E-03 
HNSCC8_cetux_up 201 PKCA_DN.V1_DN 167 6.28E-03 
HNSCC8_cetux_up 201 ALK_DN.V1_UP 145 2.18E-02 
HNSCC8_cetux_up 201 HINATA_NFKB_MATRIX 10 3.16E-02 
HNSCC8_cetux_up 201 IL21_UP.V1_UP 193 4.68E-02 
HNSCC8_cetux_up 201 KRAS.600_UP.V1_UP 287 4.68E-02 
HNSCC9_cetux_up 176 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 3.29E-04 
HNSCC9_cetux_up 176 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 3.29E-04 
HNSCC9_cetux_up 176 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.29E-03 
HNSCC9_cetux_up 176 HALLMARK_KRAS_SIGNALING_UP 200 1.29E-03 
HNSCC9_cetux_up 176 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 1.29E-03 
HNSCC9_cetux_up 176 HALLMARK_APOPTOSIS 161 2.93E-02 
HNSCC9_cetux_up 176 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 3.30E-02 
HNSCC9_cetux_up 176 HALLMARK_MYOGENESIS 200 3.83E-02 
HNSCC9_cetux_up 176 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 3.83E-02 
HNSCC9_cetux_up 176 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 3.83E-02 
HNSCC9_cetux_up 176 HALLMARK_ANGIOGENESIS 36 3.83E-02 
HNSCC9_cetux_up 176 KRCTCNNNNMANAGC_UNKNOWN 66 5.77E-06 




HNSCC9_cetux_up 176 TTTNNANAGCYR_UNKNOWN 133 2.48E-04 
HNSCC9_cetux_up 176 NGFIC_01 255 1.28E-03 
HNSCC9_cetux_up 176 AREB6_03 258 1.28E-03 
HNSCC9_cetux_up 176 CTTTGT_LEF1_Q2 1972 3.34E-03 
HNSCC9_cetux_up 176 TGGAAA_NFAT_Q4_01 1896 5.17E-03 
HNSCC9_cetux_up 176 CAGGTG_E12_Q6 2485 8.71E-03 
HNSCC9_cetux_up 176 TGANTCA_AP1_C 1121 3.50E-02 
HNSCC9_cetux_up 176 GATA4_Q3 249 3.50E-02 
HNSCC9_cetux_up 176 CATTGTYY_SOX9_B1 358 3.73E-02 
HNSCC9_cetux_up 176 SOX5_01 265 4.05E-02 
HNSCC9_cetux_up 176 GO_REGULATION_OF_CELL_DIFFERENTIATION 1492 1.04E-07 
HNSCC9_cetux_up 176 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOP
MENT 1672 1.27E-07 
HNSCC9_cetux_up 176 GO_CHROMATIN_SILENCING_AT_RDNA 37 1.42E-07 
HNSCC9_cetux_up 176 GO_CHROMATIN_SILENCING 95 1.42E-07 
HNSCC9_cetux_up 176 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 3.51E-07 
HNSCC9_cetux_up 176 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 112 4.18E-07 
HNSCC9_cetux_up 176 
GO_DNA_REPLICATION_DEPENDENT_NUCLEOSOME_ORGANIZATI
ON 32 1.53E-06 
HNSCC9_cetux_up 176 GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT 750 3.07E-06 
HNSCC9_cetux_up 176 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 3.07E-06 
HNSCC9_cetux_up 176 GO_PROTEIN_HETEROTETRAMERIZATION 38 3.20E-06 
HNSCC9_cetux_up 176 GO_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 771 3.55E-06 
HNSCC9_cetux_up 176 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 78 8.32E-06 
HNSCC9_cetux_up 176 GO_REGULATION_OF_CELL_DEVELOPMENT 836 9.72E-06 
HNSCC9_cetux_up 176 GO_CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 177 1.01E-05 
HNSCC9_cetux_up 176 GO_REGULATION_OF_NEURON_DIFFERENTIATION 554 1.07E-05 
HNSCC9_cetux_up 176 GO_PROTEIN_TETRAMERIZATION 135 1.60E-05 
HNSCC9_cetux_up 176 GO_DNA_PACKAGING 194 1.82E-05 
HNSCC9_cetux_up 176 GO_PROTEIN_COMPLEX_BIOGENESIS 1132 2.12E-05 
HNSCC9_cetux_up 176 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 2.59E-05 
HNSCC9_cetux_up 176 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 2.59E-05 
HNSCC9_cetux_up 176 KRAS.LUNG.BREAST_UP.V1_UP 145 1.06E-06 
HNSCC9_cetux_up 176 KRAS.600.LUNG.BREAST_UP.V1_UP 288 1.83E-05 
HNSCC9_cetux_up 176 RB_DN.V1_DN 126 3.89E-05 
HNSCC9_cetux_up 176 BMI1_DN.V1_UP 147 8.21E-05 
HNSCC9_cetux_up 176 ATF2_S_UP.V1_UP 193 2.92E-04 
HNSCC9_cetux_up 176 KRAS.DF.V1_UP 193 2.92E-04 
HNSCC9_cetux_up 176 RAF_UP.V1_DN 194 2.92E-04 
HNSCC9_cetux_up 176 ALK_DN.V1_UP 145 4.73E-04 
HNSCC9_cetux_up 176 KRAS.BREAST_UP.V1_UP 146 4.73E-04 
HNSCC9_cetux_up 176 HINATA_NFKB_IMMU_INF 17 6.82E-04 
HNSCC9_cetux_up 176 ESC_V6.5_UP_LATE.V1_UP 190 1.52E-03 
HNSCC9_cetux_up 176 P53_DN.V1_DN 192 1.52E-03 
HNSCC9_cetux_up 176 KRAS.DF.V1_DN 194 1.52E-03 
HNSCC9_cetux_up 176 HOXA9_DN.V1_DN 195 1.52E-03 
HNSCC9_cetux_up 176 STK33_SKM_UP 290 1.73E-03 
HNSCC9_cetux_up 176 CRX_DN.V1_UP 136 2.20E-03 
HNSCC9_cetux_up 176 CTIP_DN.V1_UP 138 2.20E-03 
HNSCC9_cetux_up 176 RB_P107_DN.V1_UP 140 2.20E-03 
HNSCC9_cetux_up 176 KRAS.LUNG_UP.V1_UP 141 2.20E-03 
HNSCC9_cetux_up 176 BMI1_DN_MEL18_DN.V1_UP 145 2.38E-03 
HNSCC10_cetux_up 146 TGGAAA_NFAT_Q4_01 1896 5.02E-03 
HNSCC10_cetux_up 146 ELF1_Q6 244 5.02E-03 
HNSCC10_cetux_up 146 TEF_Q6 255 5.02E-03 
HNSCC10_cetux_up 146 TTAYRTAA_E4BP4_01 265 5.02E-03 
HNSCC10_cetux_up 146 CAGGTG_E12_Q6 2485 1.70E-02 
HNSCC10_cetux_up 146 E2A_Q2 243 1.70E-02 
HNSCC10_cetux_up 146 NFAT_Q6 246 1.70E-02 
HNSCC10_cetux_up 146 CTTTGA_LEF1_Q2 1232 1.70E-02 
HNSCC10_cetux_up 146 RTAAACA_FREAC2_01 919 1.70E-02 
HNSCC10_cetux_up 146 YGACNNYACAR_UNKNOWN 96 2.16E-02 
HNSCC10_cetux_up 146 CTTTAAR_UNKNOWN 972 2.24E-02 
HNSCC10_cetux_up 146 GATTGGY_NFY_Q6_01 1160 2.45E-02 
HNSCC10_cetux_up 146 GGGCGGR_SP1_Q6 2940 2.68E-02 




HNSCC10_cetux_up 146 RYTTCCTG_ETS2_B 1085 4.08E-02 
HNSCC10_cetux_up 146 PU1_Q6 234 4.81E-02 
HNSCC10_cetux_up 146 TTANTCA_UNKNOWN 952 4.81E-02 
HNSCC10_cetux_up 146 HNF1_01 245 4.81E-02 
HNSCC10_cetux_up 146 CAGCTG_AP4_Q5 1524 4.81E-02 
HNSCC10_cetux_up 146 AP2_Q3 251 4.81E-02 
HNSCC10_cetux_up 146 GO_SINGLE_ORGANISM_BIOSYNTHETIC_PROCESS 1340 5.13E-03 
HNSCC10_cetux_up 146 GO_VESICLE_MEDIATED_TRANSPORT 1239 5.13E-03 
HNSCC10_cetux_up 146 GO_MITOCHONDRION_ORGANIZATION 594 5.15E-03 
HNSCC10_cetux_up 146 GO_EXOCYTOSIS 310 8.18E-03 
HNSCC10_cetux_up 146 GO_ION_HOMEOSTASIS 576 1.27E-02 
HNSCC10_cetux_up 146 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 1.27E-02 
HNSCC10_cetux_up 146 GO_CHEMICAL_HOMEOSTASIS 874 1.58E-02 
HNSCC10_cetux_up 146 GO_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS 1047 1.79E-02 
HNSCC10_cetux_up 146 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 2.45E-02 
HNSCC10_cetux_up 146 GO_ORGANIC_ACID_METABOLIC_PROCESS 953 2.55E-02 
HNSCC10_cetux_up 146 GO_LIPID_METABOLIC_PROCESS 1158 3.60E-02 
HNSCC10_cetux_up 146 GO_SECRETION 588 4.38E-02 
HNSCC10_cetux_up 146 GO_WNT_SIGNALING_PATHWAY 351 4.77E-02 
HNSCC10_cetux_up 146 GO_NUCLEIC_ACID_PHOSPHODIESTER_BOND_HYDROLYSIS 254 4.83E-02 
HNSCC10_cetux_up 146 GO_CELLULAR_LIPID_METABOLIC_PROCESS 913 4.83E-02 
HNSCC10_cetux_up 146 GO_SECRETION_BY_CELL 486 4.83E-02 
HNSCC10_cetux_up 146 CSR_EARLY_UP.V1_UP 164 2.86E-03 
HNSCC11_cetux_up 2568 HALLMARK_MYC_TARGETS_V1 200 8.13E-87 
HNSCC11_cetux_up 2568 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 1.34E-43 
HNSCC11_cetux_up 2568 HALLMARK_E2F_TARGETS 200 7.08E-39 
HNSCC11_cetux_up 2568 HALLMARK_G2M_CHECKPOINT 200 7.08E-39 
HNSCC11_cetux_up 2568 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 7.08E-39 
HNSCC11_cetux_up 2568 HALLMARK_MTORC1_SIGNALING 200 5.67E-37 
HNSCC11_cetux_up 2568 HALLMARK_P53_PATHWAY 200 4.27E-35 
HNSCC11_cetux_up 2568 HALLMARK_MITOTIC_SPINDLE 200 1.48E-29 
HNSCC11_cetux_up 2568 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 2.25E-24 
HNSCC11_cetux_up 2568 HALLMARK_PROTEIN_SECRETION 96 2.26E-24 
HNSCC11_cetux_up 2568 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 3.93E-23 
HNSCC11_cetux_up 2568 HALLMARK_PI3K_AKT_MTOR_SIGNALING 105 1.08E-22 
HNSCC11_cetux_up 2568 HALLMARK_APOPTOSIS 161 1.33E-22 
HNSCC11_cetux_up 2568 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 2.34E-22 
HNSCC11_cetux_up 2568 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 2.30E-21 
HNSCC11_cetux_up 2568 HALLMARK_ESTROGEN_RESPONSE_LATE 200 2.30E-21 
HNSCC11_cetux_up 2568 HALLMARK_UV_RESPONSE_UP 158 2.30E-21 
HNSCC11_cetux_up 2568 HALLMARK_APICAL_JUNCTION 200 7.90E-20 
HNSCC11_cetux_up 2568 HALLMARK_HEME_METABOLISM 200 4.17E-19 
HNSCC11_cetux_up 2568 HALLMARK_HYPOXIA 200 4.17E-19 
HNSCC11_cetux_up 2568 GGGCGGR_SP1_Q6 2940 6.71E-172 
HNSCC11_cetux_up 2568 GGGAGGRR_MAZ_Q6 2274 4.60E-106 
HNSCC11_cetux_up 2568 CTTTGT_LEF1_Q2 1972 1.17E-90 
HNSCC11_cetux_up 2568 GCCATNTTG_YY1_Q6 427 7.83E-83 
HNSCC11_cetux_up 2568 SCGGAAGY_ELK1_02 1199 9.30E-82 
HNSCC11_cetux_up 2568 CAGGTG_E12_Q6 2485 1.70E-76 
HNSCC11_cetux_up 2568 GATTGGY_NFY_Q6_01 1160 7.27E-74 
HNSCC11_cetux_up 2568 GGGTGGRR_PAX4_03 1294 8.15E-68 
HNSCC11_cetux_up 2568 RCGCANGCGY_NRF1_Q6 918 2.09E-67 
HNSCC11_cetux_up 2568 CACGTG_MYC_Q2 1032 2.50E-66 
HNSCC11_cetux_up 2568 TGANTCA_AP1_C 1121 3.47E-64 
HNSCC11_cetux_up 2568 TTGTTT_FOXO4_01 2061 4.09E-59 
HNSCC11_cetux_up 2568 TGGAAA_NFAT_Q4_01 1896 1.02E-54 
HNSCC11_cetux_up 2568 GTGACGY_E4F1_Q6 658 1.51E-54 
HNSCC11_cetux_up 2568 AACTTT_UNKNOWN 1890 1.84E-51 
HNSCC11_cetux_up 2568 RYTTCCTG_ETS2_B 1085 4.86E-49 
HNSCC11_cetux_up 2568 NFMUE1_Q6 245 1.93E-46 
HNSCC11_cetux_up 2568 MGGAAGTG_GABP_B 757 1.93E-45 
HNSCC11_cetux_up 2568 CTTTGTA_MIR524 433 2.82E-44 
HNSCC11_cetux_up 2568 GGGYGTGNY_UNKNOWN 664 1.19E-40 
HNSCC11_cetux_up 2568 GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL 1676 4.72E-175 
HNSCC11_cetux_up 2568 GO_PROTEIN_LOCALIZATION 1805 1.27E-146 




HNSCC11_cetux_up 2568 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 1423 2.70E-141 
HNSCC11_cetux_up 2568 GO_CELLULAR_MACROMOLECULE_LOCALIZATION 1234 1.51E-130 
HNSCC11_cetux_up 2568 GO_MACROMOLECULE_CATABOLIC_PROCESS 926 3.71E-130 
HNSCC11_cetux_up 2568 GO_CATABOLIC_PROCESS 1773 2.84E-127 
HNSCC11_cetux_up 2568 GO_CELLULAR_CATABOLIC_PROCESS 1322 6.78E-123 
HNSCC11_cetux_up 2568 GO_MRNA_METABOLIC_PROCESS 611 7.69E-123 
HNSCC11_cetux_up 2568 GO_INTRACELLULAR_PROTEIN_TRANSPORT 781 1.46E-113 
HNSCC11_cetux_up 2568 GO_SINGLE_ORGANISM_CELLULAR_LOCALIZATION 898 8.50E-110 
HNSCC11_cetux_up 2568 GO_MEMBRANE_ORGANIZATION 899 5.78E-108 
HNSCC11_cetux_up 2568 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 6.24E-108 
HNSCC11_cetux_up 2568 GO_IMMUNE_SYSTEM_PROCESS 1984 2.68E-107 
HNSCC11_cetux_up 2568 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 2.95E-107 
HNSCC11_cetux_up 2568 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 1493 1.54E-105 
HNSCC11_cetux_up 2568 GO_CELLULAR_RESPONSE_TO_STRESS 1565 4.13E-103 
HNSCC11_cetux_up 2568 GO_CELL_CYCLE 1316 8.28E-103 
HNSCC11_cetux_up 2568 GO_RNA_PROCESSING 835 3.71E-102 
HNSCC11_cetux_up 2568 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 5.98E-100 
HNSCC11_cetux_up 2568 CAMP_UP.V1_UP 200 4.48E-28 
HNSCC11_cetux_up 2568 SIRNA_EIF4GI_UP 95 3.81E-21 
HNSCC11_cetux_up 2568 TBK1.DF_DN 287 1.34E-18 
HNSCC11_cetux_up 2568 CAMP_UP.V1_DN 200 1.34E-18 
HNSCC11_cetux_up 2568 STK33_SKM_UP 290 3.78E-17 
HNSCC11_cetux_up 2568 MEK_UP.V1_UP 196 6.89E-17 
HNSCC11_cetux_up 2568 CYCLIN_D1_KE_.V1_UP 190 8.61E-17 
HNSCC11_cetux_up 2568 EGFR_UP.V1_UP 193 1.40E-16 
HNSCC11_cetux_up 2568 RB_P107_DN.V1_DN 128 1.40E-16 
HNSCC11_cetux_up 2568 P53_DN.V1_UP 194 1.48E-16 
HNSCC11_cetux_up 2568 LTE2_UP.V1_DN 196 2.09E-16 
HNSCC11_cetux_up 2568 GCNP_SHH_UP_LATE.V1_UP 183 3.31E-16 
HNSCC11_cetux_up 2568 E2F1_UP.V1_DN 193 5.03E-16 
HNSCC11_cetux_up 2568 MEK_UP.V1_DN 196 8.87E-16 
HNSCC11_cetux_up 2568 RB_DN.V1_DN 126 2.40E-15 
HNSCC11_cetux_up 2568 EGFR_UP.V1_DN 196 2.08E-14 
HNSCC11_cetux_up 2568 CSR_LATE_UP.V1_UP 172 1.04E-13 
HNSCC11_cetux_up 2568 STK33_UP 293 1.45E-12 
HNSCC11_cetux_up 2568 RB_P130_DN.V1_DN 139 1.93E-12 
HNSCC11_cetux_up 2568 ERB2_UP.V1_UP 191 3.50E-12 
HNSCC13_cetux_up 81 HALLMARK_INFLAMMATORY_RESPONSE 200 3.40E-26 
HNSCC13_cetux_up 81 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 4.50E-14 
HNSCC13_cetux_up 81 HALLMARK_ALLOGRAFT_REJECTION 200 4.57E-08 
HNSCC13_cetux_up 81 HALLMARK_COMPLEMENT 200 5.87E-07 
HNSCC13_cetux_up 81 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 5.87E-07 
HNSCC13_cetux_up 81 HALLMARK_KRAS_SIGNALING_UP 200 5.87E-07 
HNSCC13_cetux_up 81 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 1.27E-04 
HNSCC13_cetux_up 81 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 1.82E-04 
HNSCC13_cetux_up 81 HALLMARK_ANGIOGENESIS 36 2.01E-04 
HNSCC13_cetux_up 81 HALLMARK_COAGULATION 138 9.52E-03 
HNSCC13_cetux_up 81 HALLMARK_APOPTOSIS 161 1.34E-02 
HNSCC13_cetux_up 81 HALLMARK_HYPOXIA 200 2.25E-02 
HNSCC13_cetux_up 81 GO_DEFENSE_RESPONSE 1231 1.27E-17 
HNSCC13_cetux_up 81 GO_IMMUNE_SYSTEM_PROCESS 1984 3.38E-17 
HNSCC13_cetux_up 81 GO_IMMUNE_RESPONSE 1100 1.57E-15 
HNSCC13_cetux_up 81 GO_INFLAMMATORY_RESPONSE 454 4.81E-15 
HNSCC13_cetux_up 81 GO_LOCOMOTION 1114 2.00E-14 
HNSCC13_cetux_up 81 GO_TAXIS 464 6.85E-11 
HNSCC13_cetux_up 81 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 1.08E-10 
HNSCC13_cetux_up 81 GO_CELL_CHEMOTAXIS 162 1.88E-10 
HNSCC13_cetux_up 81 GO_REGULATION_OF_RESPONSE_TO_WOUNDING 413 2.20E-10 
HNSCC13_cetux_up 81 GO_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 926 2.20E-10 
HNSCC13_cetux_up 81 GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 1275 2.72E-10 
HNSCC13_cetux_up 81 GO_LEUKOCYTE_CHEMOTAXIS 117 2.72E-10 
HNSCC13_cetux_up 81 GO_LEUKOCYTE_MIGRATION 259 4.30E-10 
HNSCC13_cetux_up 81 GO_CELL_MOTILITY 835 4.34E-10 
HNSCC13_cetux_up 81 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.33E-09 
HNSCC13_cetux_up 81 GO_MYELOID_LEUKOCYTE_MIGRATION 99 2.72E-09 




HNSCC13_cetux_up 81 GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 1381 6.72E-09 
HNSCC13_cetux_up 81 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 7.25E-09 
HNSCC13_cetux_up 81 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 7.82E-09 
HNSCC13_cetux_up 81 STK33_NOMO_UP 294 3.52E-10 
HNSCC13_cetux_up 81 STK33_UP 293 5.40E-08 
HNSCC13_cetux_up 81 STK33_SKM_UP 290 8.94E-05 
HNSCC13_cetux_up 81 ESC_V6.5_UP_EARLY.V1_DN 172 3.86E-04 
HNSCC13_cetux_up 81 P53_DN.V1_UP 194 6.12E-04 
HNSCC13_cetux_up 81 PTEN_DN.V2_UP 143 1.49E-03 
HNSCC13_cetux_up 81 KRAS.DF.V1_UP 193 4.36E-03 
HNSCC13_cetux_up 81 MEK_UP.V1_UP 196 4.36E-03 
HNSCC13_cetux_up 81 RAF_UP.V1_UP 196 4.36E-03 
HNSCC13_cetux_up 81 RELA_DN.V1_DN 141 1.17E-02 
HNSCC13_cetux_up 81 BMI1_DN.V1_UP 147 1.24E-02 
HNSCC13_cetux_up 81 KRAS.600_UP.V1_UP 287 1.78E-02 
HNSCC13_cetux_up 81 TBK1.DF_UP 290 1.78E-02 
HNSCC13_cetux_up 81 ESC_V6.5_UP_LATE.V1_DN 186 1.86E-02 
HNSCC13_cetux_up 81 CYCLIN_D1_KE_.V1_UP 190 1.86E-02 
HNSCC13_cetux_up 81 ESC_V6.5_UP_LATE.V1_UP 190 1.86E-02 
HNSCC13_cetux_up 81 LEF1_UP.V1_DN 190 1.86E-02 
HNSCC13_cetux_up 81 ESC_J1_UP_LATE.V1_UP 191 1.86E-02 
HNSCC13_cetux_up 81 EGFR_UP.V1_UP 193 1.86E-02 
HNSCC13_cetux_up 81 VEGF_A_UP.V1_DN 193 1.86E-02 
UMSCC92_EGFR_KO 766 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 1.16E-40 
UMSCC92_EGFR_KO 766 HALLMARK_UV_RESPONSE_DN 144 8.91E-23 
UMSCC92_EGFR_KO 766 HALLMARK_COAGULATION 138 2.62E-09 
UMSCC92_EGFR_KO 766 HALLMARK_APICAL_JUNCTION 200 2.62E-09 
UMSCC92_EGFR_KO 766 HALLMARK_COMPLEMENT 200 6.40E-08 
UMSCC92_EGFR_KO 766 HALLMARK_HYPOXIA 200 6.40E-08 
UMSCC92_EGFR_KO 766 HALLMARK_KRAS_SIGNALING_UP 200 6.40E-08 
UMSCC92_EGFR_KO 766 HALLMARK_GLYCOLYSIS 200 1.88E-06 
UMSCC92_EGFR_KO 766 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 7.91E-06 
UMSCC92_EGFR_KO 766 HALLMARK_XENOBIOTIC_METABOLISM 200 7.91E-06 
UMSCC92_EGFR_KO 766 HALLMARK_ANGIOGENESIS 36 8.67E-06 
UMSCC92_EGFR_KO 766 HALLMARK_ADIPOGENESIS 200 2.77E-05 
UMSCC92_EGFR_KO 766 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 2.77E-05 
UMSCC92_EGFR_KO 766 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 2.77E-05 
UMSCC92_EGFR_KO 766 HALLMARK_IL2_STAT5_SIGNALING 200 1.18E-04 
UMSCC92_EGFR_KO 766 HALLMARK_APOPTOSIS 161 2.79E-04 
UMSCC92_EGFR_KO 766 HALLMARK_ALLOGRAFT_REJECTION 200 4.40E-04 
UMSCC92_EGFR_KO 766 HALLMARK_PROTEIN_SECRETION 96 5.64E-04 
UMSCC92_EGFR_KO 766 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 5.64E-04 
UMSCC92_EGFR_KO 766 HALLMARK_DNA_REPAIR 150 5.64E-04 
UMSCC92_EGFR_KO 766 GGGCGGR_SP1_Q6 2940 2.67E-39 
UMSCC92_EGFR_KO 766 TGGAAA_NFAT_Q4_01 1896 6.04E-32 
UMSCC92_EGFR_KO 766 GGGAGGRR_MAZ_Q6 2274 1.20E-29 
UMSCC92_EGFR_KO 766 CTTTGT_LEF1_Q2 1972 3.04E-21 
UMSCC92_EGFR_KO 766 CAGGTG_E12_Q6 2485 5.83E-20 
UMSCC92_EGFR_KO 766 GATTGGY_NFY_Q6_01 1160 2.24E-19 
UMSCC92_EGFR_KO 766 GGGTGGRR_PAX4_03 1294 2.15E-17 
UMSCC92_EGFR_KO 766 TATAAA_TATA_01 1296 1.07E-15 
UMSCC92_EGFR_KO 766 TTGTTT_FOXO4_01 2061 3.65E-15 
UMSCC92_EGFR_KO 766 TGANTCA_AP1_C 1121 2.33E-14 
UMSCC92_EGFR_KO 766 GGGYGTGNY_UNKNOWN 664 2.41E-13 
UMSCC92_EGFR_KO 766 AACTTT_UNKNOWN 1890 8.71E-13 
UMSCC92_EGFR_KO 766 SCGGAAGY_ELK1_02 1199 4.49E-12 
UMSCC92_EGFR_KO 766 GCCATNTTG_YY1_Q6 427 5.18E-12 
UMSCC92_EGFR_KO 766 CACGTG_MYC_Q2 1032 1.28E-11 
UMSCC92_EGFR_KO 766 CAGCTG_AP4_Q5 1524 1.63E-11 
UMSCC92_EGFR_KO 766 TAATTA_CHX10_01 810 4.32E-11 
UMSCC92_EGFR_KO 766 CAGTATT_MIR200B_MIR200C_MIR429 469 2.75E-10 
UMSCC92_EGFR_KO 766 CTTTAAR_UNKNOWN 972 5.02E-10 
UMSCC92_EGFR_KO 766 RTAAACA_FREAC2_01 919 2.61E-09 
UMSCC92_EGFR_KO 766 GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE 1848 3.38E-19 
UMSCC92_EGFR_KO 766 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOP




UMSCC92_EGFR_KO 766 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 2.27E-18 
UMSCC92_EGFR_KO 766 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 5.17E-18 
UMSCC92_EGFR_KO 766 GO_PROTEIN_LOCALIZATION 1805 6.18E-18 
UMSCC92_EGFR_KO 766 
GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCES
S 1977 6.18E-18 
UMSCC92_EGFR_KO 766 GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL 1676 6.37E-18 
UMSCC92_EGFR_KO 766 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 1.01E-17 
UMSCC92_EGFR_KO 766 GO_REGULATION_OF_CELL_DIFFERENTIATION 1492 2.80E-17 
UMSCC92_EGFR_KO 766 GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 1527 2.80E-17 
UMSCC92_EGFR_KO 766 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 2.80E-17 
UMSCC92_EGFR_KO 766 GO_TISSUE_DEVELOPMENT 1518 6.28E-17 
UMSCC92_EGFR_KO 766 GO_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1360 6.84E-17 
UMSCC92_EGFR_KO 766 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 9.90E-17 
UMSCC92_EGFR_KO 766 GO_EXTRACELLULAR_STRUCTURE_ORGANIZATION 304 1.20E-16 
UMSCC92_EGFR_KO 766 GO_CATABOLIC_PROCESS 1773 3.20E-16 
UMSCC92_EGFR_KO 766 GO_IMMUNE_SYSTEM_PROCESS 1984 9.55E-16 
UMSCC92_EGFR_KO 766 GO_BIOLOGICAL_ADHESION 1032 1.39E-15 
UMSCC92_EGFR_KO 766 GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 1805 2.57E-15 
UMSCC92_EGFR_KO 766 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 7.37E-15 
UMSCC92_EGFR_KO 766 BMI1_DN.V1_UP 147 5.81E-17 
UMSCC92_EGFR_KO 766 BMI1_DN_MEL18_DN.V1_UP 145 2.68E-16 
UMSCC92_EGFR_KO 766 MEL18_DN.V1_UP 141 1.15E-15 
UMSCC92_EGFR_KO 766 TBK1.DF_UP 290 8.74E-13 
UMSCC92_EGFR_KO 766 LEF1_UP.V1_UP 195 6.90E-10 
UMSCC92_EGFR_KO 766 ESC_V6.5_UP_EARLY.V1_DN 172 2.52E-08 
UMSCC92_EGFR_KO 766 RB_P107_DN.V1_UP 140 4.00E-07 
UMSCC92_EGFR_KO 766 KRAS.DF.V1_UP 193 7.49E-07 
UMSCC92_EGFR_KO 766 CAMP_UP.V1_DN 200 1.12E-06 
UMSCC92_EGFR_KO 766 KRAS.600_UP.V1_UP 287 1.91E-06 
UMSCC92_EGFR_KO 766 ESC_J1_UP_LATE.V1_UP 191 2.76E-06 
UMSCC92_EGFR_KO 766 VEGF_A_UP.V1_UP 196 3.60E-06 
UMSCC92_EGFR_KO 766 STK33_DN 289 7.45E-06 
UMSCC92_EGFR_KO 766 STK33_NOMO_UP 294 8.96E-06 
UMSCC92_EGFR_KO 766 CSR_EARLY_UP.V1_UP 164 9.47E-06 
UMSCC92_EGFR_KO 766 P53_DN.V1_UP 194 1.28E-05 
UMSCC92_EGFR_KO 766 KRAS.600.LUNG.BREAST_UP.V1_UP 288 2.32E-05 
UMSCC92_EGFR_KO 766 PTEN_DN.V1_DN 187 3.75E-05 
UMSCC92_EGFR_KO 766 CYCLIN_D1_UP.V1_UP 188 3.78E-05 
UMSCC92_EGFR_KO 766 CORDENONSI_YAP_CONSERVED_SIGNATURE 57 4.06E-05 
Table 4-6. Upregulated gene sets enriched in each of the 13 cetuximab-treated gene sets and 
EGFR K/O gene sets 
Gene set enrichment analysis was performed with significantly upregulated genes from each of 
the 14 gene sets to identify significant overlap with gene sets in the “Hallmark”, “Motif”, “Go-
Biological Process” and “Oncogene” databases with the molecular signatures database v5.1. 
Node is the sample, and Node Size is the number of input genes from the sample. Gene Set 
Name is the pathway enriched, with # of Genes in Gene Set being the number of genes in the 






































HNSCC1_cetux_down 120 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 5.37E-08 
HNSCC1_cetux_down 120 HALLMARK_ESTROGEN_RESPONSE_LATE 200 5.37E-08 
HNSCC1_cetux_down 120 HALLMARK_P53_PATHWAY 200 5.37E-08 
HNSCC1_cetux_down 120 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 7.74E-07 
HNSCC1_cetux_down 120 HALLMARK_APICAL_JUNCTION 200 8.71E-06 
HNSCC1_cetux_down 120 HALLMARK_HYPOXIA 200 8.71E-06 
HNSCC1_cetux_down 120 HALLMARK_KRAS_SIGNALING_DN 200 1.18E-03 
HNSCC1_cetux_down 120 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 1.18E-03 
HNSCC1_cetux_down 120 HALLMARK_KRAS_SIGNALING_UP 200 1.07E-02 
HNSCC1_cetux_down 120 HALLMARK_COAGULATION 138 2.88E-02 
HNSCC1_cetux_down 120 TGANTCA_AP1_C 1121 1.27E-14 
HNSCC1_cetux_down 120 AP1_Q2_01 275 7.86E-08 
HNSCC1_cetux_down 120 CAGGTG_E12_Q6 2485 3.00E-07 
HNSCC1_cetux_down 120 BACH1_01 263 7.22E-06 
HNSCC1_cetux_down 120 BACH2_01 271 7.46E-06 
HNSCC1_cetux_down 120 TTANTCA_UNKNOWN 952 1.11E-03 
HNSCC1_cetux_down 120 GGGCGGR_SP1_Q6 2940 2.82E-03 
HNSCC1_cetux_down 120 P53_DECAMER_Q2 256 5.12E-03 
HNSCC1_cetux_down 120 SREBP_Q3 258 5.12E-03 
HNSCC1_cetux_down 120 GGGYGTGNY_UNKNOWN 664 5.12E-03 
HNSCC1_cetux_down 120 AP1_Q4_01 261 5.12E-03 
HNSCC1_cetux_down 120 AP1_Q4 271 5.75E-03 
HNSCC1_cetux_down 120 GGGAGGRR_MAZ_Q6 2274 5.75E-03 
HNSCC1_cetux_down 120 MZF1_01 236 2.41E-02 
HNSCC1_cetux_down 120 WGGAATGY_TEF1_Q6 378 2.76E-02 
HNSCC1_cetux_down 120 TATAAA_TATA_01 1296 3.10E-02 
HNSCC1_cetux_down 120 YCATTAA_UNKNOWN 556 3.10E-02 
HNSCC1_cetux_down 120 NFAT_Q4_01 266 3.10E-02 
HNSCC1_cetux_down 120 AP1_01 267 3.10E-02 
HNSCC1_cetux_down 120 GO_TISSUE_DEVELOPMENT 1518 1.20E-14 
HNSCC1_cetux_down 120 GO_EPIDERMIS_DEVELOPMENT 253 5.34E-13 
HNSCC1_cetux_down 120 GO_BIOLOGICAL_ADHESION 1032 5.01E-11 
HNSCC1_cetux_down 120 GO_EPITHELIUM_DEVELOPMENT 945 6.90E-11 
HNSCC1_cetux_down 120 GO_INTERMEDIATE_FILAMENT_BASED_PROCESS 43 1.88E-10 
HNSCC1_cetux_down 120 GO_HEMIDESMOSOME_ASSEMBLY 12 1.88E-10 
HNSCC1_cetux_down 120 GO_CELL_JUNCTION_ORGANIZATION 185 1.68E-09 
HNSCC1_cetux_down 120 GO_CELL_SUBSTRATE_JUNCTION_ASSEMBLY 41 8.03E-09 
HNSCC1_cetux_down 120 GO_CELL_JUNCTION_ASSEMBLY 129 3.23E-08 
HNSCC1_cetux_down 120 GO_EXTRACELLULAR_STRUCTURE_ORGANIZATION 304 2.41E-07 
HNSCC1_cetux_down 120 GO_EXTRACELLULAR_MATRIX_DISASSEMBLY 76 2.12E-05 
HNSCC1_cetux_down 120 GO_RESPONSE_TO_INORGANIC_SUBSTANCE 479 2.18E-05 
HNSCC1_cetux_down 120 GO_INTERMEDIATE_FILAMENT_ORGANIZATION 20 7.08E-05 
HNSCC1_cetux_down 120 GO_RESPONSE_TO_WOUNDING 563 9.32E-05 
HNSCC1_cetux_down 120 GO_CELL_MOTILITY 835 9.32E-05 
HNSCC1_cetux_down 120 GO_RESPONSE_TO_ZINC_ION 55 9.70E-05 
HNSCC1_cetux_down 120 GO_CELL_CELL_ADHESION 608 1.64E-04 
HNSCC1_cetux_down 120 
GO_MULTICELLULAR_ORGANISMAL_MACROMOLECULE_METABOLI
C_PROCESS 79 5.31E-04 
HNSCC1_cetux_down 120 GO_RESPONSE_TO_TRANSITION_METAL_NANOPARTICLE 148 6.35E-04 
HNSCC1_cetux_down 120 GO_RESPONSE_TO_METAL_ION 333 6.44E-04 
HNSCC1_cetux_down 120 RB_DN.V1_DN 126 2.84E-10 
HNSCC1_cetux_down 120 KRAS.LUNG.BREAST_UP.V1_DN 145 1.77E-08 
HNSCC1_cetux_down 120 KRAS.600_UP.V1_DN 289 3.29E-07 
HNSCC1_cetux_down 120 ESC_V6.5_UP_EARLY.V1_DN 172 9.09E-07 
HNSCC1_cetux_down 120 P53_DN.V1_UP 194 1.85E-06 
HNSCC1_cetux_down 120 KRAS.600.LUNG.BREAST_UP.V1_DN 289 2.43E-06 
HNSCC1_cetux_down 120 KRAS.LUNG_UP.V1_DN 145 3.21E-06 
HNSCC1_cetux_down 120 AKT_UP.V1_DN 187 1.57E-05 
HNSCC1_cetux_down 120 KRAS.300_UP.V1_DN 143 4.68E-05 




HNSCC1_cetux_down 120 SINGH_KRAS_DEPENDENCY_SIGNATURE_ 20 3.29E-04 
HNSCC1_cetux_down 120 RB_P130_DN.V1_DN 139 5.28E-04 
HNSCC1_cetux_down 120 MEL18_DN.V1_UP 141 5.28E-04 
HNSCC1_cetux_down 120 BMI1_DN_MEL18_DN.V1_UP 145 5.61E-04 
HNSCC1_cetux_down 120 SNF5_DN.V1_DN 164 9.39E-04 
HNSCC1_cetux_down 120 WNT_UP.V1_UP 180 1.36E-03 
HNSCC1_cetux_down 120 AKT_UP_MTOR_DN.V1_DN 183 1.39E-03 
HNSCC1_cetux_down 120 EGFR_UP.V1_UP 193 1.68E-03 
HNSCC1_cetux_down 120 MEK_UP.V1_UP 196 1.71E-03 
HNSCC1_cetux_down 120 KRAS.50_UP.V1_DN 49 2.77E-03 
HNSCC2_cetux_down 77 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 1.82E-17 
HNSCC2_cetux_down 77 HALLMARK_HYPOXIA 200 1.24E-06 
HNSCC2_cetux_down 77 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.93E-05 
HNSCC2_cetux_down 77 HALLMARK_UV_RESPONSE_UP 158 9.12E-05 
HNSCC2_cetux_down 77 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 3.06E-03 
HNSCC2_cetux_down 77 HALLMARK_P53_PATHWAY 200 3.06E-03 
HNSCC2_cetux_down 77 HALLMARK_COMPLEMENT 200 2.60E-02 
HNSCC2_cetux_down 77 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 2.60E-02 
HNSCC2_cetux_down 77 HALLMARK_KRAS_SIGNALING_DN 200 2.60E-02 
HNSCC2_cetux_down 77 CREBP1_Q2 254 6.93E-09 
HNSCC2_cetux_down 77 ATF_01 259 6.93E-09 
HNSCC2_cetux_down 77 CREB_Q2 263 6.93E-09 
HNSCC2_cetux_down 77 SRF_01 50 5.68E-08 
HNSCC2_cetux_down 77 E4F1_Q6 289 2.52E-07 
HNSCC2_cetux_down 77 SRF_C 211 3.86E-07 
HNSCC2_cetux_down 77 CREB_Q2_01 220 4.59E-07 
HNSCC2_cetux_down 77 GGGAGGRR_MAZ_Q6 2274 4.89E-07 
HNSCC2_cetux_down 77 SRF_Q6 241 7.29E-07 
HNSCC2_cetux_down 77 GTGACGY_E4F1_Q6 658 1.13E-06 
HNSCC2_cetux_down 77 CREB_01 262 1.14E-06 
HNSCC2_cetux_down 77 CREB_Q4 268 1.25E-06 
HNSCC2_cetux_down 77 ATF_B 187 2.01E-06 
HNSCC2_cetux_down 77 CREB_Q4_01 211 4.26E-06 
HNSCC2_cetux_down 77 SRF_Q4 221 5.45E-06 
HNSCC2_cetux_down 77 TAXCREB_01 137 6.54E-06 
HNSCC2_cetux_down 77 TATAAA_TATA_01 1296 1.14E-05 
HNSCC2_cetux_down 77 ATF4_Q2 258 1.26E-05 
HNSCC2_cetux_down 77 CREBP1CJUN_01 259 1.26E-05 
HNSCC2_cetux_down 77 AML_Q6 266 1.43E-05 
HNSCC2_cetux_down 77 GO_REGULATION_OF_PROTEOLYSIS 711 6.02E-08 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_REACTIVE_OXYGEN_SPECIES 191 8.58E-08 
HNSCC2_cetux_down 77 GO_REGULATION_OF_CELL_DEATH 1472 4.06E-07 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_OXIDATIVE_STRESS 352 4.06E-07 
HNSCC2_cetux_down 77 GO_TISSUE_DEVELOPMENT 1518 4.06E-07 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 1381 7.31E-07 
HNSCC2_cetux_down 77 GO_REGULATION_OF_PEPTIDASE_ACTIVITY 392 7.61E-07 
HNSCC2_cetux_down 77 GO_NEGATIVE_REGULATION_OF_PROTEOLYSIS 329 2.58E-06 
HNSCC2_cetux_down 77 GO_POSITIVE_REGULATION_OF_CELL_DEATH 605 2.82E-06 
HNSCC2_cetux_down 77 GO_NEGATIVE_REGULATION_OF_PEPTIDASE_ACTIVITY 245 3.96E-06 
HNSCC2_cetux_down 77 GO_NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY 397 8.70E-06 
HNSCC2_cetux_down 77 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 1493 8.70E-06 
HNSCC2_cetux_down 77 GO_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 1087 1.01E-05 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_HYDROGEN_PEROXIDE 109 1.01E-05 
HNSCC2_cetux_down 77 GO_PEPTIDE_CROSS_LINKING 56 1.22E-05 
HNSCC2_cetux_down 77 
GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POL
YMERASE_II_PROMOTER 740 1.24E-05 
HNSCC2_cetux_down 77 GO_SKIN_DEVELOPMENT 211 1.86E-05 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_INORGANIC_SUBSTANCE 479 2.86E-05 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_ABIOTIC_STIMULUS 1024 3.19E-05 
HNSCC2_cetux_down 77 GO_RESPONSE_TO_STEROID_HORMONE 497 3.44E-05 
HNSCC2_cetux_down 77 RELA_DN.V1_UP 149 3.89E-05 
HNSCC2_cetux_down 77 CORDENONSI_YAP_CONSERVED_SIGNATURE 57 2.54E-04 
HNSCC2_cetux_down 77 PDGF_UP.V1_UP 146 3.13E-04 
HNSCC2_cetux_down 77 ESC_J1_UP_LATE.V1_UP 191 8.62E-04 
HNSCC2_cetux_down 77 BMI1_DN.V1_DN 144 2.90E-03 




HNSCC2_cetux_down 77 MEL18_DN.V1_DN 148 2.90E-03 
HNSCC2_cetux_down 77 STK33_SKM_UP 290 2.90E-03 
HNSCC2_cetux_down 77 STK33_UP 293 2.90E-03 
HNSCC2_cetux_down 77 MTOR_UP.V1_DN 184 4.85E-03 
HNSCC2_cetux_down 77 CYCLIN_D1_UP.V1_UP 188 4.85E-03 
HNSCC2_cetux_down 77 EGFR_UP.V1_UP 193 4.85E-03 
HNSCC2_cetux_down 77 HOXA9_DN.V1_DN 195 4.85E-03 
HNSCC2_cetux_down 77 CAMP_UP.V1_DN 200 4.96E-03 
HNSCC2_cetux_down 77 BMI1_DN_MEL18_DN.V1_UP 145 2.28E-02 
HNSCC2_cetux_down 77 BMI1_DN_MEL18_DN.V1_DN 147 2.28E-02 
HNSCC2_cetux_down 77 PDGF_ERK_DN.V1_DN 149 2.28E-02 
HNSCC2_cetux_down 77 ESC_V6.5_UP_EARLY.V1_DN 172 2.81E-02 
HNSCC2_cetux_down 77 ESC_J1_UP_EARLY.V1_DN 179 2.81E-02 
HNSCC2_cetux_down 77 AKT_UP_MTOR_DN.V1_DN 183 2.81E-02 
HNSCC3_cetux_down 242 HALLMARK_GLYCOLYSIS 200 1.77E-02 
HNSCC3_cetux_down 242 HALLMARK_XENOBIOTIC_METABOLISM 200 1.77E-02 
HNSCC3_cetux_down 242 HALLMARK_FATTY_ACID_METABOLISM 158 2.59E-02 
HNSCC3_cetux_down 242 HALLMARK_MYC_TARGETS_V2 58 3.07E-02 
HNSCC3_cetux_down 242 HALLMARK_ADIPOGENESIS 200 3.07E-02 
HNSCC3_cetux_down 242 HALLMARK_G2M_CHECKPOINT 200 3.07E-02 
HNSCC3_cetux_down 242 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 3.07E-02 
HNSCC3_cetux_down 242 SCGGAAGY_ELK1_02 1199 7.09E-04 
HNSCC3_cetux_down 242 GGGCGGR_SP1_Q6 2940 7.09E-04 
HNSCC3_cetux_down 242 MGGAAGTG_GABP_B 757 7.09E-04 
HNSCC3_cetux_down 242 SGCGSSAAA_E2F1DP2_01 168 7.09E-04 
HNSCC3_cetux_down 242 TGGAAA_NFAT_Q4_01 1896 1.35E-03 
HNSCC3_cetux_down 242 TGACAGNY_MEIS1_01 827 1.35E-03 
HNSCC3_cetux_down 242 CYTAGCAAY_UNKNOWN 147 1.67E-03 
HNSCC3_cetux_down 242 E2F1_Q6 232 2.31E-03 
HNSCC3_cetux_down 242 TEL2_Q6 233 2.31E-03 
HNSCC3_cetux_down 242 ATAAGCT_MIR21 116 2.31E-03 
HNSCC3_cetux_down 242 E2F1DP1_01 235 2.31E-03 
HNSCC3_cetux_down 242 E2F1DP2_01 235 2.31E-03 
HNSCC3_cetux_down 242 E2F4DP2_01 235 2.31E-03 
HNSCC3_cetux_down 242 E2F_02 235 2.31E-03 
HNSCC3_cetux_down 242 E2F4DP1_01 239 2.42E-03 
HNSCC3_cetux_down 242 YYCATTCAWW_UNKNOWN 191 3.89E-03 
HNSCC3_cetux_down 242 ER_Q6_01 269 4.88E-03 
HNSCC3_cetux_down 242 E2F_Q6 232 1.15E-02 
HNSCC3_cetux_down 242 E2F_Q4 234 1.15E-02 
HNSCC3_cetux_down 242 WTGAAAT_UNKNOWN 616 1.98E-02 
HNSCC3_cetux_down 242 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 4.27E-03 
HNSCC3_cetux_down 242 GO_CHROMOSOME_ORGANIZATION 1009 4.27E-03 
HNSCC3_cetux_down 242 GO_PROTEIN_COMPLEX_BIOGENESIS 1132 4.27E-03 
HNSCC3_cetux_down 242 GO_RECEPTOR_MEDIATED_ENDOCYTOSIS 231 4.76E-03 
HNSCC3_cetux_down 242 GO_ORGANELLE_FUSION 131 5.85E-03 
HNSCC3_cetux_down 242 GO_CELLULAR_MACROMOLECULAR_COMPLEX_ASSEMBLY 727 6.42E-03 
HNSCC3_cetux_down 242 GO_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS 1047 8.37E-03 
HNSCC3_cetux_down 242 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 9.54E-03 
HNSCC3_cetux_down 242 GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 1527 1.08E-02 
HNSCC3_cetux_down 242 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 1.08E-02 
HNSCC3_cetux_down 242 GO_DEFENSE_RESPONSE 1231 1.34E-02 
HNSCC3_cetux_down 242 GO_BIOLOGICAL_ADHESION 1032 1.34E-02 
HNSCC3_cetux_down 242 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.34E-02 
HNSCC3_cetux_down 242 GO_CHROMATIN_ORGANIZATION 663 1.84E-02 
HNSCC3_cetux_down 242 GO_SINGLE_ORGANISM_MEMBRANE_FUSION 128 1.88E-02 
HNSCC3_cetux_down 242 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 2.43E-02 
HNSCC3_cetux_down 242 GO_CELLULAR_PROTEIN_COMPLEX_ASSEMBLY 346 2.66E-02 
HNSCC3_cetux_down 242 GO_VESICLE_MEDIATED_TRANSPORT 1239 2.82E-02 
HNSCC3_cetux_down 242 GO_METHYLATION 284 3.21E-02 
HNSCC3_cetux_down 242 GO_IMMUNE_SYSTEM_PROCESS 1984 3.21E-02 
HNSCC3_cetux_down 242 CRX_NRL_DN.V1_UP 140 1.93E-03 
HNSCC3_cetux_down 242 ESC_V6.5_UP_LATE.V1_UP 190 5.54E-03 
HNSCC3_cetux_down 242 NRL_DN.V1_UP 136 5.54E-03 
HNSCC3_cetux_down 242 PTEN_DN.V2_UP 143 5.54E-03 




HNSCC3_cetux_down 242 E2F1_UP.V1_DN 193 1.67E-02 
HNSCC3_cetux_down 242 HOXA9_DN.V1_DN 195 1.67E-02 
HNSCC4_cetux_down 255 HALLMARK_MYOGENESIS 200 2.40E-72 
HNSCC4_cetux_down 255 HALLMARK_KRAS_SIGNALING_DN 200 3.99E-08 
HNSCC4_cetux_down 255 HALLMARK_APICAL_JUNCTION 200 2.59E-06 
HNSCC4_cetux_down 255 HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 200 2.59E-06 
HNSCC4_cetux_down 255 HALLMARK_ESTROGEN_RESPONSE_LATE 200 1.14E-03 
HNSCC4_cetux_down 255 HALLMARK_HYPOXIA 200 1.14E-03 
HNSCC4_cetux_down 255 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 6.61E-03 
HNSCC4_cetux_down 255 CAGCTG_AP4_Q5 1524 9.31E-41 
HNSCC4_cetux_down 255 CAGGTG_E12_Q6 2485 8.18E-33 
HNSCC4_cetux_down 255 YTATTTTNR_MEF2_02 697 2.71E-29 
HNSCC4_cetux_down 255 CTAWWWATA_RSRFC4_Q2 361 5.61E-29 
HNSCC4_cetux_down 255 GCANCTGNY_MYOD_Q6 924 1.14E-27 
HNSCC4_cetux_down 255 MEF2_02 228 3.61E-24 
HNSCC4_cetux_down 255 RSRFC4_01 245 4.61E-18 
HNSCC4_cetux_down 255 RSRFC4_Q2 214 9.66E-17 
HNSCC4_cetux_down 255 TGACCTY_ERR1_Q2 1043 1.87E-15 
HNSCC4_cetux_down 255 TAAWWATAG_RSRFC4_Q2 165 6.29E-15 
HNSCC4_cetux_down 255 MEF2_Q6_01 244 1.61E-14 
HNSCC4_cetux_down 255 AMEF2_Q6 259 4.46E-14 
HNSCC4_cetux_down 255 E12_Q6 262 5.09E-14 
HNSCC4_cetux_down 255 TGGAAA_NFAT_Q4_01 1896 5.17E-14 
HNSCC4_cetux_down 255 GGGTGGRR_PAX4_03 1294 1.16E-13 
HNSCC4_cetux_down 255 MEF2_03 238 1.16E-13 
HNSCC4_cetux_down 255 MEF2_01 144 2.14E-13 
HNSCC4_cetux_down 255 TGANTCA_AP1_C 1121 3.46E-13 
HNSCC4_cetux_down 255 HMEF2_Q6 138 2.31E-12 
HNSCC4_cetux_down 255 TATAAA_TATA_01 1296 3.18E-12 
HNSCC4_cetux_down 255 GO_MUSCLE_CONTRACTION 233 1.66E-45 
HNSCC4_cetux_down 255 GO_MUSCLE_SYSTEM_PROCESS 282 2.33E-45 
HNSCC4_cetux_down 255 GO_MUSCLE_STRUCTURE_DEVELOPMENT 432 5.94E-43 
HNSCC4_cetux_down 255 GO_ACTIN_MYOSIN_FILAMENT_SLIDING 38 2.13E-37 
HNSCC4_cetux_down 255 GO_ACTIN_FILAMENT_BASED_PROCESS 450 1.91E-35 
HNSCC4_cetux_down 255 GO_MUSCLE_CELL_DEVELOPMENT 128 5.13E-32 
HNSCC4_cetux_down 255 GO_MUSCLE_CELL_DIFFERENTIATION 237 8.67E-32 
HNSCC4_cetux_down 255 GO_ACTIN_MEDIATED_CELL_CONTRACTION 74 1.46E-29 
HNSCC4_cetux_down 255 GO_MUSCLE_ORGAN_DEVELOPMENT 277 3.01E-28 
HNSCC4_cetux_down 255 GO_ACTIN_FILAMENT_BASED_MOVEMENT 93 3.54E-27 
HNSCC4_cetux_down 255 GO_TISSUE_DEVELOPMENT 1518 3.64E-27 
HNSCC4_cetux_down 255 GO_MYOFIBRIL_ASSEMBLY 48 3.15E-26 
HNSCC4_cetux_down 255 GO_ACTOMYOSIN_STRUCTURE_ORGANIZATION 77 1.36E-25 
HNSCC4_cetux_down 255 GO_STRIATED_MUSCLE_CELL_DIFFERENTIATION 173 1.73E-25 
HNSCC4_cetux_down 255 GO_SYSTEM_PROCESS 1785 8.37E-24 
HNSCC4_cetux_down 255 GO_STRIATED_MUSCLE_CONTRACTION 99 2.89E-23 
HNSCC4_cetux_down 255 GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 1275 1.06E-20 
HNSCC4_cetux_down 255 GO_REGULATION_OF_SYSTEM_PROCESS 507 1.55E-20 
HNSCC4_cetux_down 255 GO_MUSCLE_TISSUE_DEVELOPMENT 275 3.31E-19 
HNSCC4_cetux_down 255 GO_CYTOSKELETON_ORGANIZATION 838 5.25E-19 
HNSCC4_cetux_down 255 MTOR_UP.V1_DN 184 7.01E-08 
HNSCC4_cetux_down 255 ATF2_S_UP.V1_DN 187 7.01E-08 
HNSCC4_cetux_down 255 AKT_UP.V1_DN 187 5.99E-07 
HNSCC4_cetux_down 255 KRAS.600.LUNG.BREAST_UP.V1_DN 289 4.01E-06 
HNSCC4_cetux_down 255 ESC_J1_UP_LATE.V1_UP 191 4.01E-06 
HNSCC4_cetux_down 255 KRAS.LUNG_UP.V1_DN 145 4.01E-06 
HNSCC4_cetux_down 255 IL21_UP.V1_UP 193 4.01E-06 
HNSCC4_cetux_down 255 SNF5_DN.V1_DN 164 9.16E-06 
HNSCC4_cetux_down 255 ESC_V6.5_UP_EARLY.V1_DN 172 1.22E-05 
HNSCC4_cetux_down 255 STK33_SKM_DN 288 1.41E-05 
HNSCC4_cetux_down 255 KRAS.LUNG.BREAST_UP.V1_DN 145 2.86E-05 
HNSCC4_cetux_down 255 ALK_DN.V1_DN 148 3.06E-05 
HNSCC4_cetux_down 255 KRAS.600_UP.V1_DN 289 8.34E-05 
HNSCC4_cetux_down 255 ATF2_UP.V1_DN 187 1.47E-04 
HNSCC4_cetux_down 255 CYCLIN_D1_UP.V1_DN 191 1.50E-04 
HNSCC4_cetux_down 255 ERB2_UP.V1_UP 191 1.50E-04 




HNSCC4_cetux_down 255 LEF1_UP.V1_UP 195 1.55E-04 
HNSCC4_cetux_down 255 PTEN_DN.V2_UP 143 1.63E-04 
HNSCC4_cetux_down 255 NFE2L2.V2 481 1.69E-04 
HNSCC5_cetux_down 352 HALLMARK_ALLOGRAFT_REJECTION 200 9.49E-05 
HNSCC5_cetux_down 352 HALLMARK_KRAS_SIGNALING_UP 200 9.49E-05 
HNSCC5_cetux_down 352 HALLMARK_COMPLEMENT 200 4.46E-04 
HNSCC5_cetux_down 352 HALLMARK_ADIPOGENESIS 200 2.92E-02 
HNSCC5_cetux_down 352 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 2.92E-02 
HNSCC5_cetux_down 352 HALLMARK_ESTROGEN_RESPONSE_LATE 200 2.92E-02 
HNSCC5_cetux_down 352 HALLMARK_MYOGENESIS 200 2.92E-02 
HNSCC5_cetux_down 352 HALLMARK_APICAL_SURFACE 44 2.92E-02 
HNSCC5_cetux_down 352 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 49 3.51E-02 
HNSCC5_cetux_down 352 HALLMARK_APOPTOSIS 161 4.11E-02 
HNSCC5_cetux_down 352 RGAGGAARY_PU1_Q6 502 4.51E-05 
HNSCC5_cetux_down 352 PEA3_Q6 255 4.51E-05 
HNSCC5_cetux_down 352 CAGGTG_E12_Q6 2485 9.11E-04 
HNSCC5_cetux_down 352 RYTTCCTG_ETS2_B 1085 9.11E-04 
HNSCC5_cetux_down 352 ETS1_B 259 1.00E-03 
HNSCC5_cetux_down 352 ELK1_01 269 1.19E-03 
HNSCC5_cetux_down 352 RTAAACA_FREAC2_01 919 1.26E-02 
HNSCC5_cetux_down 352 ELF1_Q6 244 1.26E-02 
HNSCC5_cetux_down 352 NERF_Q2 247 1.26E-02 
HNSCC5_cetux_down 352 GGGTGGRR_PAX4_03 1294 1.60E-02 
HNSCC5_cetux_down 352 TEL2_Q6 233 3.37E-02 
HNSCC5_cetux_down 352 PU1_Q6 234 3.37E-02 
HNSCC5_cetux_down 352 ETS_Q4 247 4.43E-02 
HNSCC5_cetux_down 352 GO_IMMUNE_SYSTEM_PROCESS 1984 2.18E-26 
HNSCC5_cetux_down 352 GO_IMMUNE_RESPONSE 1100 4.01E-18 
HNSCC5_cetux_down 352 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 4.95E-17 
HNSCC5_cetux_down 352 GO_ADAPTIVE_IMMUNE_RESPONSE 288 6.55E-16 
HNSCC5_cetux_down 352 GO_REGULATION_OF_CELL_ACTIVATION 484 2.01E-15 
HNSCC5_cetux_down 352 GO_ACTIVATION_OF_IMMUNE_RESPONSE 427 5.36E-14 
HNSCC5_cetux_down 352 
GO_IMMUNE_RESPONSE_REGULATING_CELL_SURFACE_RECEPTOR_
SIGNALING_PATHWAY 323 6.76E-14 
HNSCC5_cetux_down 352 GO_POSITIVE_REGULATION_OF_IMMUNE_RESPONSE 563 7.76E-14 
HNSCC5_cetux_down 352 GO_B_CELL_RECEPTOR_SIGNALING_PATHWAY 54 1.03E-13 
HNSCC5_cetux_down 352 GO_LEUKOCYTE_ACTIVATION 414 1.44E-13 
HNSCC5_cetux_down 352 GO_HUMORAL_IMMUNE_RESPONSE 187 2.27E-13 
HNSCC5_cetux_down 352 GO_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY 195 4.55E-13 
HNSCC5_cetux_down 352 GO_B_CELL_MEDIATED_IMMUNITY 99 5.59E-13 
HNSCC5_cetux_down 352 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 5.75E-13 
HNSCC5_cetux_down 352 GO_LYMPHOCYTE_ACTIVATION 342 1.19E-12 
HNSCC5_cetux_down 352 GO_REGULATION_OF_IMMUNE_RESPONSE 858 2.22E-12 




N_SUPERFAMILY_DOMAINS 154 2.02E-11 
HNSCC5_cetux_down 352 GO_IMMUNE_EFFECTOR_PROCESS 486 2.64E-11 
HNSCC5_cetux_down 352 GO_LEUKOCYTE_MEDIATED_IMMUNITY 189 3.30E-11 
HNSCC5_cetux_down 352 CYCLIN_D1_KE_.V1_DN 194 6.81E-05 
HNSCC5_cetux_down 352 KRAS.600.LUNG.BREAST_UP.V1_DN 289 1.38E-03 
HNSCC5_cetux_down 352 LEF1_UP.V1_UP 195 1.38E-03 
HNSCC5_cetux_down 352 SNF5_DN.V1_UP 177 3.43E-03 
HNSCC5_cetux_down 352 PTEN_DN.V2_UP 143 3.68E-03 
HNSCC5_cetux_down 352 ATF2_UP.V1_UP 192 3.68E-03 
HNSCC5_cetux_down 352 KRAS.LUNG.BREAST_UP.V1_UP 145 3.68E-03 
HNSCC5_cetux_down 352 KRAS.600.LUNG.BREAST_UP.V1_UP 288 8.81E-03 
HNSCC5_cetux_down 352 STK33_SKM_DN 288 8.81E-03 
HNSCC5_cetux_down 352 AKT_UP_MTOR_DN.V1_UP 184 1.00E-02 
HNSCC5_cetux_down 352 CYCLIN_D1_UP.V1_DN 191 1.00E-02 
HNSCC5_cetux_down 352 JNK_DN.V1_UP 192 1.00E-02 
HNSCC5_cetux_down 352 PRC1_BMI_UP.V1_UP 192 1.00E-02 
HNSCC5_cetux_down 352 RPS14_DN.V1_UP 192 1.00E-02 
HNSCC5_cetux_down 352 VEGF_A_UP.V1_UP 196 1.06E-02 
HNSCC5_cetux_down 352 KRAS.LUNG_UP.V1_DN 145 1.09E-02 




HNSCC5_cetux_down 352 CSR_LATE_UP.V1_DN 170 2.18E-02 
HNSCC5_cetux_down 352 PTEN_DN.V1_DN 187 3.13E-02 
HNSCC5_cetux_down 352 ESC_V6.5_UP_LATE.V1_UP 190 3.13E-02 
HNSCC6_cetux_down 157 HALLMARK_APICAL_SURFACE 44 8.71E-03 
HNSCC6_cetux_down 157 HALLMARK_IL2_STAT5_SIGNALING 200 8.71E-03 
HNSCC6_cetux_down 157 HALLMARK_ESTROGEN_RESPONSE_LATE 200 3.89E-02 
HNSCC6_cetux_down 157 HALLMARK_KRAS_SIGNALING_DN 200 3.89E-02 
HNSCC6_cetux_down 157 TGANTCA_AP1_C 1121 3.85E-05 
HNSCC6_cetux_down 157 TATAAA_TATA_01 1296 7.38E-04 
HNSCC6_cetux_down 157 GO_KERATINOCYTE_DIFFERENTIATION 101 2.37E-14 
HNSCC6_cetux_down 157 GO_KERATINIZATION 50 7.61E-13 
HNSCC6_cetux_down 157 GO_EPIDERMAL_CELL_DIFFERENTIATION 142 7.61E-13 
HNSCC6_cetux_down 157 GO_PEPTIDE_CROSS_LINKING 56 1.39E-12 
HNSCC6_cetux_down 157 GO_EPIDERMIS_DEVELOPMENT 253 1.61E-12 
HNSCC6_cetux_down 157 GO_SKIN_DEVELOPMENT 211 6.65E-11 
HNSCC6_cetux_down 157 GO_EPITHELIAL_CELL_DIFFERENTIATION 495 1.10E-10 
HNSCC6_cetux_down 157 GO_TISSUE_DEVELOPMENT 1518 1.34E-08 
HNSCC6_cetux_down 157 GO_EPITHELIUM_DEVELOPMENT 945 3.31E-08 
HNSCC6_cetux_down 157 GO_SEQUESTERING_OF_METAL_ION 11 1.86E-03 
HNSCC6_cetux_down 157 GO_PROTEOLYSIS 1208 6.63E-03 
HNSCC6_cetux_down 157 GO_IMMUNE_SYSTEM_PROCESS 1984 9.84E-03 
HNSCC6_cetux_down 157 GO_ZINC_ION_HOMEOSTASIS 21 1.13E-02 
HNSCC6_cetux_down 157 GO_CELLULAR_TRANSITION_METAL_ION_HOMEOSTASIS 77 2.74E-02 
HNSCC6_cetux_down 157 GO_IMMUNE_RESPONSE 1100 3.54E-02 
HNSCC6_cetux_down 157 KRAS.PROSTATE_UP.V1_DN 144 2.20E-09 
HNSCC6_cetux_down 157 KRAS.LUNG_UP.V1_DN 145 2.20E-09 
HNSCC6_cetux_down 157 KRAS.50_UP.V1_DN 49 4.98E-07 
HNSCC6_cetux_down 157 KRAS.600_UP.V1_DN 289 1.30E-04 
HNSCC6_cetux_down 157 KRAS.300_UP.V1_DN 143 1.58E-04 
HNSCC6_cetux_down 157 KRAS.BREAST_UP.V1_UP 146 1.58E-04 
HNSCC6_cetux_down 157 P53_DN.V2_UP 148 1.58E-04 
HNSCC6_cetux_down 157 EGFR_UP.V1_UP 193 6.24E-04 
HNSCC6_cetux_down 157 AKT_UP.V1_UP 172 3.65E-03 
HNSCC6_cetux_down 157 RAPA_EARLY_UP.V1_UP 183 4.03E-03 
HNSCC6_cetux_down 157 AKT_UP_MTOR_DN.V1_UP 184 4.03E-03 
HNSCC6_cetux_down 157 PTEN_DN.V1_DN 187 4.03E-03 
HNSCC6_cetux_down 157 ERB2_UP.V1_UP 191 4.09E-03 
HNSCC6_cetux_down 157 P53_DN.V1_UP 194 4.09E-03 
HNSCC6_cetux_down 157 RB_P130_DN.V1_DN 139 1.01E-02 
HNSCC6_cetux_down 157 RELA_DN.V1_DN 141 1.01E-02 
HNSCC6_cetux_down 157 PTEN_DN.V2_UP 143 1.01E-02 
HNSCC6_cetux_down 157 KRAS.LUNG.BREAST_UP.V1_DN 145 1.01E-02 
HNSCC6_cetux_down 157 KRAS.600.LUNG.BREAST_UP.V1_DN 289 1.73E-02 
HNSCC6_cetux_down 157 TBK1.DF_UP 290 1.73E-02 
HNSCC7_cetux_down 404 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 9.31E-05 
HNSCC7_cetux_down 404 HALLMARK_E2F_TARGETS 200 4.24E-03 
HNSCC7_cetux_down 404 HALLMARK_MYC_TARGETS_V1 200 4.24E-03 
HNSCC7_cetux_down 404 HALLMARK_MYOGENESIS 200 4.24E-03 
HNSCC7_cetux_down 404 HALLMARK_P53_PATHWAY 200 4.24E-03 
HNSCC7_cetux_down 404 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 49 7.60E-03 
HNSCC7_cetux_down 404 HALLMARK_ADIPOGENESIS 200 1.48E-02 
HNSCC7_cetux_down 404 HALLMARK_APOPTOSIS 161 1.77E-02 
HNSCC7_cetux_down 404 HALLMARK_BILE_ACID_METABOLISM 112 1.77E-02 
HNSCC7_cetux_down 404 HALLMARK_APICAL_JUNCTION 200 4.01E-02 
HNSCC7_cetux_down 404 HALLMARK_COMPLEMENT 200 4.01E-02 
HNSCC7_cetux_down 404 GGGCGGR_SP1_Q6 2940 3.60E-07 
HNSCC7_cetux_down 404 MGGAAGTG_GABP_B 757 3.59E-05 
HNSCC7_cetux_down 404 CAGGTG_E12_Q6 2485 3.59E-05 
HNSCC7_cetux_down 404 AACTTT_UNKNOWN 1890 5.56E-05 
HNSCC7_cetux_down 404 ETS_Q4 247 5.56E-05 
HNSCC7_cetux_down 404 GGGAGGRR_MAZ_Q6 2274 5.56E-05 
HNSCC7_cetux_down 404 STAT6_02 258 6.88E-05 
HNSCC7_cetux_down 404 CTTTGA_LEF1_Q2 1232 6.88E-05 
HNSCC7_cetux_down 404 TTGCACT_MIR130A_MIR301_MIR130B 403 6.88E-05 
HNSCC7_cetux_down 404 CAGCTG_AP4_Q5 1524 7.26E-05 




HNSCC7_cetux_down 404 STAT_Q6 260 2.75E-04 
HNSCC7_cetux_down 404 RORA1_01 242 7.38E-04 
HNSCC7_cetux_down 404 CTGCAGY_UNKNOWN 765 1.11E-03 
HNSCC7_cetux_down 404 RCGCANGCGY_NRF1_Q6 918 1.50E-03 
HNSCC7_cetux_down 404 GATTGGY_NFY_Q6_01 1160 2.30E-03 
HNSCC7_cetux_down 404 TGACAGNY_MEIS1_01 827 2.70E-03 
HNSCC7_cetux_down 404 TTTGCAC_MIR19A_MIR19B 516 2.96E-03 
HNSCC7_cetux_down 404 E2F1_Q3_01 247 3.16E-03 
HNSCC7_cetux_down 404 TAL1BETAE47_01 248 3.16E-03 
HNSCC7_cetux_down 404 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 6.00E-12 
HNSCC7_cetux_down 404 GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 1791 2.37E-11 
HNSCC7_cetux_down 404 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 2.37E-11 
HNSCC7_cetux_down 404 GO_POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 867 2.37E-11 
HNSCC7_cetux_down 404 GO_OXIDATION_REDUCTION_PROCESS 898 2.74E-10 
HNSCC7_cetux_down 404 GO_REGULATION_OF_IMMUNE_RESPONSE 858 3.19E-10 
HNSCC7_cetux_down 404 GO_IMMUNE_SYSTEM_PROCESS 1984 5.80E-09 
HNSCC7_cetux_down 404 GO_PROTEIN_LOCALIZATION 1805 6.91E-09 
HNSCC7_cetux_down 404 GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 1518 1.09E-08 
HNSCC7_cetux_down 404 GO_POSITIVE_REGULATION_OF_IMMUNE_RESPONSE 563 2.48E-08 
HNSCC7_cetux_down 404 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 4.79E-08 
HNSCC7_cetux_down 404 GO_ACTIVATION_OF_IMMUNE_RESPONSE 427 1.16E-07 
HNSCC7_cetux_down 404 GO_IMMUNE_RESPONSE 1100 1.16E-07 
HNSCC7_cetux_down 404 GO_RNA_PROCESSING 835 7.14E-07 
HNSCC7_cetux_down 404 GO_CATABOLIC_PROCESS 1773 7.56E-07 
HNSCC7_cetux_down 404 
GO_IMMUNE_RESPONSE_REGULATING_CELL_SURFACE_RECEPTOR_
SIGNALING_PATHWAY 323 1.54E-06 
HNSCC7_cetux_down 404 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 1423 1.54E-06 
HNSCC7_cetux_down 404 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.79E-06 
HNSCC7_cetux_down 404 GO_CELLULAR_CATABOLIC_PROCESS 1322 2.32E-06 
HNSCC7_cetux_down 404 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 4.26E-06 
HNSCC7_cetux_down 404 KRAS.600.LUNG.BREAST_UP.V1_DN 289 1.10E-02 
HNSCC7_cetux_down 404 TBK1.DF_DN 287 1.14E-02 
HNSCC7_cetux_down 404 IL21_UP.V1_DN 187 1.14E-02 
HNSCC7_cetux_down 404 PTEN_DN.V1_DN 187 1.14E-02 
HNSCC7_cetux_down 404 CYCLIN_D1_KE_.V1_UP 190 1.14E-02 
HNSCC7_cetux_down 404 WNT_UP.V1_DN 170 2.56E-02 
HNSCC7_cetux_down 404 STK33_SKM_UP 290 2.87E-02 
HNSCC7_cetux_down 404 STK33_UP 293 2.87E-02 
HNSCC7_cetux_down 404 ESC_J1_UP_LATE.V1_DN 186 2.87E-02 
HNSCC7_cetux_down 404 IL15_UP.V1_DN 190 2.90E-02 
HNSCC7_cetux_down 404 KRAS.DF.V1_UP 193 2.90E-02 
HNSCC7_cetux_down 404 RAF_UP.V1_UP 196 2.90E-02 
HNSCC8_cetux_down 334 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 3.78E-14 
HNSCC8_cetux_down 334 HALLMARK_ESTROGEN_RESPONSE_LATE 200 7.66E-09 
HNSCC8_cetux_down 334 HALLMARK_P53_PATHWAY 200 5.45E-08 
HNSCC8_cetux_down 334 HALLMARK_APOPTOSIS 161 4.13E-06 
HNSCC8_cetux_down 334 HALLMARK_APICAL_SURFACE 44 9.85E-05 
HNSCC8_cetux_down 334 HALLMARK_IL2_STAT5_SIGNALING 200 9.85E-05 
HNSCC8_cetux_down 334 HALLMARK_KRAS_SIGNALING_DN 200 9.85E-05 
HNSCC8_cetux_down 334 HALLMARK_KRAS_SIGNALING_UP 200 9.85E-05 
HNSCC8_cetux_down 334 HALLMARK_MYOGENESIS 200 9.85E-05 
HNSCC8_cetux_down 334 HALLMARK_COMPLEMENT 200 5.36E-04 
HNSCC8_cetux_down 334 HALLMARK_HYPOXIA 200 5.36E-04 
HNSCC8_cetux_down 334 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 2.90E-03 
HNSCC8_cetux_down 334 HALLMARK_COAGULATION 138 1.28E-02 
HNSCC8_cetux_down 334 HALLMARK_APICAL_JUNCTION 200 1.28E-02 
HNSCC8_cetux_down 334 HALLMARK_ANDROGEN_RESPONSE 101 2.15E-02 
HNSCC8_cetux_down 334 HALLMARK_GLYCOLYSIS 200 4.40E-02 
HNSCC8_cetux_down 334 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 4.40E-02 
HNSCC8_cetux_down 334 HALLMARK_XENOBIOTIC_METABOLISM 200 4.40E-02 
HNSCC8_cetux_down 334 TGANTCA_AP1_C 1121 1.28E-22 
HNSCC8_cetux_down 334 CAGGTG_E12_Q6 2485 3.95E-13 
HNSCC8_cetux_down 334 GGGAGGRR_MAZ_Q6 2274 1.34E-12 
HNSCC8_cetux_down 334 GGGTGGRR_PAX4_03 1294 8.58E-11 
HNSCC8_cetux_down 334 TATAAA_TATA_01 1296 1.01E-07 




HNSCC8_cetux_down 334 RYTTCCTG_ETS2_B 1085 1.01E-06 
HNSCC8_cetux_down 334 BACH1_01 263 1.01E-06 
HNSCC8_cetux_down 334 TTANTCA_UNKNOWN 952 1.01E-06 
HNSCC8_cetux_down 334 AP1_01 267 1.06E-06 
HNSCC8_cetux_down 334 TTGTTT_FOXO4_01 2061 1.51E-06 
HNSCC8_cetux_down 334 WGGAATGY_TEF1_Q6 378 1.05E-05 
HNSCC8_cetux_down 334 CAGGTA_AREB6_01 792 3.02E-05 
HNSCC8_cetux_down 334 AP1_Q4_01 261 3.42E-05 
HNSCC8_cetux_down 334 BACH2_01 271 4.75E-05 
HNSCC8_cetux_down 334 AP1_Q2_01 275 5.19E-05 
HNSCC8_cetux_down 334 TGCCAAR_NF1_Q6 722 9.13E-05 
HNSCC8_cetux_down 334 MYOGENIN_Q6 255 1.46E-04 
HNSCC8_cetux_down 334 TGGAAA_NFAT_Q4_01 1896 1.75E-04 
HNSCC8_cetux_down 334 TEF1_Q6 226 2.95E-04 
HNSCC8_cetux_down 334 GO_EPIDERMIS_DEVELOPMENT 253 1.49E-27 
HNSCC8_cetux_down 334 GO_EPITHELIUM_DEVELOPMENT 945 1.34E-25 
HNSCC8_cetux_down 334 GO_TISSUE_DEVELOPMENT 1518 1.77E-24 
HNSCC8_cetux_down 334 GO_EPITHELIAL_CELL_DIFFERENTIATION 495 4.19E-24 
HNSCC8_cetux_down 334 GO_KERATINOCYTE_DIFFERENTIATION 101 2.20E-23 
HNSCC8_cetux_down 334 GO_EPIDERMAL_CELL_DIFFERENTIATION 142 1.92E-21 
HNSCC8_cetux_down 334 GO_SKIN_DEVELOPMENT 211 9.59E-19 
HNSCC8_cetux_down 334 GO_KERATINIZATION 50 6.03E-18 
HNSCC8_cetux_down 334 GO_PEPTIDE_CROSS_LINKING 56 3.72E-17 
HNSCC8_cetux_down 334 GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 1381 1.31E-06 
HNSCC8_cetux_down 334 GO_REGULATION_OF_HYDROLASE_ACTIVITY 1327 1.68E-06 
HNSCC8_cetux_down 334 GO_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 1656 2.31E-06 
HNSCC8_cetux_down 334 GO_PROTEOLYSIS 1208 2.31E-06 
HNSCC8_cetux_down 334 GO_CELL_DEATH 1001 2.31E-06 
HNSCC8_cetux_down 334 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 3.03E-06 
HNSCC8_cetux_down 334 GO_CELL_JUNCTION_ORGANIZATION 185 3.58E-06 
HNSCC8_cetux_down 334 GO_BIOLOGICAL_ADHESION 1032 3.58E-06 
HNSCC8_cetux_down 334 GO_CELL_JUNCTION_ASSEMBLY 129 1.01E-05 
HNSCC8_cetux_down 334 GO_REGULATION_OF_RESPONSE_TO_STRESS 1468 1.02E-05 
HNSCC8_cetux_down 334 GO_REGULATION_OF_CELL_ADHESION 629 1.12E-05 
HNSCC8_cetux_down 334 KRAS.LUNG_UP.V1_DN 145 5.72E-19 
HNSCC8_cetux_down 334 P53_DN.V1_UP 194 6.32E-13 
HNSCC8_cetux_down 334 KRAS.600_UP.V1_DN 289 3.83E-11 
HNSCC8_cetux_down 334 MYC_UP.V1_DN 182 3.25E-10 
HNSCC8_cetux_down 334 AKT_UP.V1_UP 172 1.56E-09 
HNSCC8_cetux_down 334 ERB2_UP.V1_UP 191 5.25E-09 
HNSCC8_cetux_down 334 KRAS.PROSTATE_UP.V1_DN 144 2.12E-08 
HNSCC8_cetux_down 334 KRAS.300_UP.V1_DN 143 2.20E-07 
HNSCC8_cetux_down 334 RAF_UP.V1_DN 194 4.82E-07 
HNSCC8_cetux_down 334 RB_P107_DN.V1_DN 128 7.22E-07 
HNSCC8_cetux_down 334 KRAS.50_UP.V1_DN 49 1.14E-06 
HNSCC8_cetux_down 334 PTEN_DN.V2_UP 143 1.72E-06 
HNSCC8_cetux_down 334 KRAS.BREAST_UP.V1_UP 146 1.89E-06 
HNSCC8_cetux_down 334 ESC_V6.5_UP_LATE.V1_DN 186 1.89E-06 
HNSCC8_cetux_down 334 ALK_DN.V1_DN 148 1.90E-06 
HNSCC8_cetux_down 334 LTE2_UP.V1_UP 190 2.05E-06 
HNSCC8_cetux_down 334 EGFR_UP.V1_UP 193 2.13E-06 
HNSCC8_cetux_down 334 IL21_UP.V1_UP 193 2.13E-06 
HNSCC8_cetux_down 334 PRC2_EZH2_UP.V1_UP 194 2.13E-06 
HNSCC8_cetux_down 334 MEK_UP.V1_UP 196 2.15E-06 
HNSCC9_cetux_down 53 GO_PEPTIDE_CROSS_LINKING 56 2.72E-05 
HNSCC9_cetux_down 53 GO_KERATINOCYTE_DIFFERENTIATION 101 2.72E-04 
HNSCC9_cetux_down 53 GO_KERATINIZATION 50 5.16E-04 
HNSCC9_cetux_down 53 GO_EPIDERMAL_CELL_DIFFERENTIATION 142 7.41E-04 
HNSCC9_cetux_down 53 GO_SKIN_DEVELOPMENT 211 4.14E-03 
HNSCC9_cetux_down 53 GO_EPIDERMIS_DEVELOPMENT 253 8.31E-03 
HNSCC9_cetux_down 53 KRAS.BREAST_UP.V1_UP 146 4.79E-03 
HNSCC10_cetux_down 2476 HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 2.96E-19 
HNSCC10_cetux_down 2476 HALLMARK_MYC_TARGETS_V1 200 9.02E-19 
HNSCC10_cetux_down 2476 HALLMARK_E2F_TARGETS 200 1.76E-14 
HNSCC10_cetux_down 2476 HALLMARK_ADIPOGENESIS 200 2.15E-13 




HNSCC10_cetux_down 2476 HALLMARK_MTORC1_SIGNALING 200 2.15E-13 
HNSCC10_cetux_down 2476 HALLMARK_DNA_REPAIR 150 9.65E-13 
HNSCC10_cetux_down 2476 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 113 1.23E-12 
HNSCC10_cetux_down 2476 HALLMARK_HEME_METABOLISM 200 1.39E-11 
HNSCC10_cetux_down 2476 HALLMARK_UV_RESPONSE_DN 144 1.52E-10 
HNSCC10_cetux_down 2476 HALLMARK_MITOTIC_SPINDLE 200 2.06E-10 
HNSCC10_cetux_down 2476 HALLMARK_APOPTOSIS 161 5.55E-10 
HNSCC10_cetux_down 2476 HALLMARK_PROTEIN_SECRETION 96 4.35E-09 
HNSCC10_cetux_down 2476 HALLMARK_UV_RESPONSE_UP 158 2.33E-08 
HNSCC10_cetux_down 2476 HALLMARK_HYPOXIA 200 3.30E-08 
HNSCC10_cetux_down 2476 HALLMARK_FATTY_ACID_METABOLISM 158 8.17E-08 
HNSCC10_cetux_down 2476 HALLMARK_XENOBIOTIC_METABOLISM 200 1.03E-07 
HNSCC10_cetux_down 2476 HALLMARK_ANDROGEN_RESPONSE 101 2.33E-07 
HNSCC10_cetux_down 2476 HALLMARK_ESTROGEN_RESPONSE_LATE 200 2.84E-07 
HNSCC10_cetux_down 2476 HALLMARK_IL2_STAT5_SIGNALING 200 2.84E-07 
HNSCC10_cetux_down 2476 GGGCGGR_SP1_Q6 2940 1.49E-113 
HNSCC10_cetux_down 2476 SCGGAAGY_ELK1_02 1199 5.72E-82 
HNSCC10_cetux_down 2476 CTTTGT_LEF1_Q2 1972 5.43E-64 
HNSCC10_cetux_down 2476 TTGTTT_FOXO4_01 2061 2.10E-63 
HNSCC10_cetux_down 2476 RCGCANGCGY_NRF1_Q6 918 6.23E-62 
HNSCC10_cetux_down 2476 TGGAAA_NFAT_Q4_01 1896 1.66E-53 
HNSCC10_cetux_down 2476 AACTTT_UNKNOWN 1890 3.38E-48 
HNSCC10_cetux_down 2476 GGGAGGRR_MAZ_Q6 2274 3.39E-45 
HNSCC10_cetux_down 2476 MGGAAGTG_GABP_B 757 9.05E-44 
HNSCC10_cetux_down 2476 GATTGGY_NFY_Q6_01 1160 9.07E-40 
HNSCC10_cetux_down 2476 CAGGTG_E12_Q6 2485 2.08E-39 
HNSCC10_cetux_down 2476 TTGCACT_MIR130A_MIR301_MIR130B 403 3.62E-39 
HNSCC10_cetux_down 2476 TTTGCAC_MIR19A_MIR19B 516 2.77E-38 
HNSCC10_cetux_down 2476 CTTTAAR_UNKNOWN 972 4.37E-35 
HNSCC10_cetux_down 2476 TGCCTTA_MIR124A 552 2.66E-33 
HNSCC10_cetux_down 2476 CACGTG_MYC_Q2 1032 5.57E-32 
HNSCC10_cetux_down 2476 TGACCTY_ERR1_Q2 1043 5.57E-32 
HNSCC10_cetux_down 2476 GCCATNTTG_YY1_Q6 427 1.43E-29 
HNSCC10_cetux_down 2476 ACCAAAG_MIR9 499 2.22E-29 
HNSCC10_cetux_down 2476 GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D 595 4.63E-29 
HNSCC10_cetux_down 2476 GO_PROTEIN_LOCALIZATION 1805 1.21E-82 
HNSCC10_cetux_down 2476 GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL 1676 7.40E-82 
HNSCC10_cetux_down 2476 GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS 1977 1.83E-74 
HNSCC10_cetux_down 2476 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 1423 3.44E-70 
HNSCC10_cetux_down 2476 GO_CATABOLIC_PROCESS 1773 3.99E-68 
HNSCC10_cetux_down 2476 GO_CELLULAR_RESPONSE_TO_STRESS 1565 5.40E-65 
HNSCC10_cetux_down 2476 GO_CELLULAR_CATABOLIC_PROCESS 1322 2.07E-64 
HNSCC10_cetux_down 2476 GO_RNA_PROCESSING 835 3.37E-64 
HNSCC10_cetux_down 2476 GO_CELLULAR_MACROMOLECULE_LOCALIZATION 1234 3.82E-62 
HNSCC10_cetux_down 2476 GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS 1796 2.36E-61 
HNSCC10_cetux_down 2476 GO_CELL_CYCLE 1316 1.41E-60 
HNSCC10_cetux_down 2476 GO_CHROMOSOME_ORGANIZATION 1009 6.00E-60 
HNSCC10_cetux_down 2476 GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 1398 1.45E-58 
HNSCC10_cetux_down 2476 GO_SMALL_MOLECULE_METABOLIC_PROCESS 1767 1.91E-57 
HNSCC10_cetux_down 2476 GO_SINGLE_ORGANISM_BIOSYNTHETIC_PROCESS 1340 2.43E-57 
HNSCC10_cetux_down 2476 GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 1527 5.66E-53 
HNSCC10_cetux_down 2476 GO_CELL_CYCLE_PROCESS 1081 5.78E-53 
HNSCC10_cetux_down 2476 GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1733 3.91E-51 
HNSCC10_cetux_down 2476 
GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II
_PROMOTER 1784 2.91E-50 
HNSCC10_cetux_down 2476 GO_MACROMOLECULE_CATABOLIC_PROCESS 926 3.06E-50 
HNSCC10_cetux_down 2476 TBK1.DF_DN 287 3.65E-23 
HNSCC10_cetux_down 2476 ERB2_UP.V1_DN 197 4.22E-20 
HNSCC10_cetux_down 2476 MEK_UP.V1_DN 196 1.68E-16 
HNSCC10_cetux_down 2476 E2F1_UP.V1_UP 189 1.68E-16 
HNSCC10_cetux_down 2476 TBK1.DF_UP 290 6.37E-16 
HNSCC10_cetux_down 2476 PIGF_UP.V1_UP 191 2.89E-14 
HNSCC10_cetux_down 2476 LTE2_UP.V1_DN 196 6.65E-14 
HNSCC10_cetux_down 2476 STK33_SKM_UP 290 1.28E-13 
HNSCC10_cetux_down 2476 HOXA9_DN.V1_UP 194 1.78E-13 




HNSCC10_cetux_down 2476 VEGF_A_UP.V1_DN 193 5.95E-13 
HNSCC10_cetux_down 2476 STK33_NOMO_UP 294 2.33E-12 
HNSCC10_cetux_down 2476 STK33_UP 293 7.07E-12 
HNSCC10_cetux_down 2476 ERB2_UP.V1_UP 191 3.38E-11 
HNSCC10_cetux_down 2476 GCNP_SHH_UP_LATE.V1_UP 183 3.67E-11 
HNSCC10_cetux_down 2476 SIRNA_EIF4GI_UP 95 4.30E-11 
HNSCC10_cetux_down 2476 CAMP_UP.V1_DN 200 1.20E-10 
HNSCC10_cetux_down 2476 EGFR_UP.V1_DN 196 2.57E-10 
HNSCC10_cetux_down 2476 CYCLIN_D1_KE_.V1_UP 190 4.03E-10 
HNSCC10_cetux_down 2476 MTOR_UP.N4.V1_DN 193 6.09E-10 
HNSCC12_cetux_down 133 HALLMARK_DNA_REPAIR 150 4.90E-02 
HNSCC12_cetux_down 133 KRCTCNNNNMANAGC_UNKNOWN 66 8.19E-07 
HNSCC12_cetux_down 133 TTTNNANAGCYR_UNKNOWN 133 1.11E-03 
HNSCC12_cetux_down 133 WTTGKCTG_UNKNOWN 516 5.86E-03 
HNSCC12_cetux_down 133 GO_KERATINOCYTE_DIFFERENTIATION 101 8.83E-13 
HNSCC12_cetux_down 133 GO_EPIDERMAL_CELL_DIFFERENTIATION 142 2.92E-11 
HNSCC12_cetux_down 133 GO_KERATINIZATION 50 3.62E-11 
HNSCC12_cetux_down 133 GO_SKIN_DEVELOPMENT 211 1.67E-09 
HNSCC12_cetux_down 133 GO_PEPTIDE_CROSS_LINKING 56 4.46E-09 
HNSCC12_cetux_down 133 GO_EPIDERMIS_DEVELOPMENT 253 9.39E-09 
HNSCC12_cetux_down 133 GO_EPITHELIAL_CELL_DIFFERENTIATION 495 1.60E-05 
HNSCC12_cetux_down 133 GO_CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 177 2.98E-05 
HNSCC12_cetux_down 133 GO_DNA_PACKAGING 194 5.13E-05 
HNSCC12_cetux_down 133 GO_DNA_CONFORMATION_CHANGE 273 5.13E-05 
HNSCC12_cetux_down 133 GO_CHROMOSOME_ORGANIZATION 1009 1.06E-04 
HNSCC12_cetux_down 133 GO_CHROMATIN_SILENCING 95 1.32E-04 
HNSCC12_cetux_down 133 GO_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 229 1.32E-04 
HNSCC12_cetux_down 133 GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 112 3.09E-04 
HNSCC12_cetux_down 133 GO_PROTEIN_COMPLEX_BIOGENESIS 1132 3.26E-04 
HNSCC12_cetux_down 133 GO_REGULATION_OF_MEGAKARYOCYTE_DIFFERENTIATION 28 3.61E-04 
HNSCC12_cetux_down 133 GO_TELOMERE_CAPPING 29 3.93E-04 
HNSCC12_cetux_down 133 GO_ANATOMICAL_STRUCTURE_HOMEOSTASIS 285 4.90E-04 
HNSCC12_cetux_down 133 GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 1527 5.09E-04 
HNSCC12_cetux_down 133 GO_DEFENSE_RESPONSE_TO_OTHER_ORGANISM 505 5.27E-04 
HNSCC13_cetux_down 151 HALLMARK_KRAS_SIGNALING_DN 200 2.42E-04 
HNSCC13_cetux_down 151 TGANTCA_AP1_C 1121 4.04E-03 
HNSCC13_cetux_down 151 
GO_HUMORAL_IMMUNE_RESPONSE_MEDIATED_BY_CIRCULATING_I
MMUNOGLOBULIN 69 5.95E-22 
HNSCC13_cetux_down 151 GO_COMPLEMENT_ACTIVATION 76 1.55E-21 
HNSCC13_cetux_down 151 GO_PROTEIN_ACTIVATION_CASCADE 99 1.55E-21 
HNSCC13_cetux_down 151 GO_B_CELL_MEDIATED_IMMUNITY 99 8.09E-20 
HNSCC13_cetux_down 151 GO_PHAGOCYTOSIS_RECOGNITION 34 4.63E-19 




N_SUPERFAMILY_DOMAINS 154 1.80E-18 
HNSCC13_cetux_down 151 GO_LYMPHOCYTE_MEDIATED_IMMUNITY 147 3.05E-17 
HNSCC13_cetux_down 151 GO_MEMBRANE_INVAGINATION 48 3.14E-17 
HNSCC13_cetux_down 151 GO_HUMORAL_IMMUNE_RESPONSE 187 3.68E-17 
HNSCC13_cetux_down 151 GO_B_CELL_RECEPTOR_SIGNALING_PATHWAY 54 1.25E-16 
HNSCC13_cetux_down 151 GO_LEUKOCYTE_MEDIATED_IMMUNITY 189 1.23E-15 
HNSCC13_cetux_down 151 GO_PHAGOCYTOSIS 190 1.23E-15 
HNSCC13_cetux_down 151 GO_ADAPTIVE_IMMUNE_RESPONSE 288 1.77E-15 
HNSCC13_cetux_down 151 GO_FC_GAMMA_RECEPTOR_SIGNALING_PATHWAY 95 2.51E-15 
HNSCC13_cetux_down 151 GO_POSITIVE_REGULATION_OF_B_CELL_ACTIVATION 86 3.49E-14 
HNSCC13_cetux_down 151 GO_KERATINOCYTE_DIFFERENTIATION 101 2.45E-13 
HNSCC13_cetux_down 151 GO_KERATINIZATION 50 2.45E-13 
HNSCC13_cetux_down 151 GO_DEFENSE_RESPONSE_TO_BACTERIUM 237 7.02E-13 
HNSCC13_cetux_down 151 GO_EPIDERMIS_DEVELOPMENT 253 1.75E-12 
HNSCC13_cetux_down 151 KRAS.PROSTATE_UP.V1_DN 144 1.08E-08 
HNSCC13_cetux_down 151 KRAS.LUNG_UP.V1_DN 145 1.37E-07 
HNSCC13_cetux_down 151 KRAS.600_UP.V1_DN 289 2.33E-07 
HNSCC13_cetux_down 151 KRAS.50_UP.V1_DN 49 6.70E-07 
HNSCC13_cetux_down 151 KRAS.300_UP.V1_DN 143 1.95E-05 
HNSCC13_cetux_down 151 ESC_V6.5_UP_EARLY.V1_DN 172 5.62E-05 




HNSCC13_cetux_down 151 PTEN_DN.V2_UP 143 2.56E-02 
HNSCC13_cetux_down 151 KRAS.LUNG.BREAST_UP.V1_DN 145 2.56E-02 
HNSCC13_cetux_down 151 MEL18_DN.V1_DN 148 2.56E-02 
HNSCC13_cetux_down 151 P53_DN.V2_UP 148 2.56E-02 
HNSCC13_cetux_down 151 PKCA_DN.V1_DN 167 3.64E-02 
HNSCC13_cetux_down 151 KRAS.600_UP.V1_UP 287 3.89E-02 
HNSCC13_cetux_down 151 PTEN_DN.V1_DN 187 4.00E-02 
HNSCC13_cetux_down 151 IL15_UP.V1_DN 190 4.00E-02 
HNSCC13_cetux_down 151 RAPA_EARLY_UP.V1_DN 191 4.00E-02 
HNSCC13_cetux_down 151 P53_DN.V1_DN 192 4.00E-02 
HNSCC13_cetux_down 151 RPS14_DN.V1_UP 192 4.00E-02 
HNSCC13_cetux_down 151 LEF1_UP.V1_UP 195 4.01E-02 
UMSCC92_EGFR_KO
_down 516 HALLMARK_ESTROGEN_RESPONSE_LATE 200 8.84E-27 
UMSCC92_EGFR_KO
_down 516 HALLMARK_ESTROGEN_RESPONSE_EARLY 200 2.45E-16 
UMSCC92_EGFR_KO
_down 516 HALLMARK_APICAL_JUNCTION 200 1.82E-14 
UMSCC92_EGFR_KO
_down 516 HALLMARK_P53_PATHWAY 200 1.82E-14 
UMSCC92_EGFR_KO
_down 516 HALLMARK_KRAS_SIGNALING_UP 200 1.29E-08 
UMSCC92_EGFR_KO
_down 516 HALLMARK_INFLAMMATORY_RESPONSE 200 8.48E-08 
UMSCC92_EGFR_KO
_down 516 HALLMARK_APOPTOSIS 161 2.92E-07 
UMSCC92_EGFR_KO
_down 516 HALLMARK_GLYCOLYSIS 200 4.68E-07 
UMSCC92_EGFR_KO
_down 516 HALLMARK_INTERFERON_ALPHA_RESPONSE 97 8.52E-07 
UMSCC92_EGFR_KO
_down 516 HALLMARK_IL2_STAT5_SIGNALING 200 2.32E-06 
UMSCC92_EGFR_KO
_down 516 HALLMARK_INTERFERON_GAMMA_RESPONSE 200 2.32E-06 
UMSCC92_EGFR_KO
_down 516 HALLMARK_ALLOGRAFT_REJECTION 200 1.34E-05 
UMSCC92_EGFR_KO
_down 516 HALLMARK_TNFA_SIGNALING_VIA_NFKB 200 7.15E-05 
UMSCC92_EGFR_KO
_down 516 HALLMARK_KRAS_SIGNALING_DN 200 3.51E-04 
UMSCC92_EGFR_KO
_down 516 HALLMARK_ANDROGEN_RESPONSE 101 4.99E-04 
UMSCC92_EGFR_KO
_down 516 HALLMARK_UV_RESPONSE_UP 158 1.31E-03 
UMSCC92_EGFR_KO
_down 516 HALLMARK_HYPOXIA 200 1.31E-03 
UMSCC92_EGFR_KO
_down 516 HALLMARK_MTORC1_SIGNALING 200 1.31E-03 
UMSCC92_EGFR_KO
_down 516 HALLMARK_MYOGENESIS 200 5.32E-03 
UMSCC92_EGFR_KO
_down 516 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 49 5.58E-03 
UMSCC92_EGFR_KO
_down 516 CAGGTG_E12_Q6 2485 9.57E-38 
UMSCC92_EGFR_KO
_down 516 TGANTCA_AP1_C 1121 4.66E-27 
UMSCC92_EGFR_KO
_down 516 GGGAGGRR_MAZ_Q6 2274 7.32E-19 
UMSCC92_EGFR_KO
_down 516 TTGTTT_FOXO4_01 2061 9.66E-16 
UMSCC92_EGFR_KO
_down 516 CAGGTA_AREB6_01 792 6.81E-13 
UMSCC92_EGFR_KO
_down 516 TGTTTGY_HNF3_Q6 738 1.69E-10 
UMSCC92_EGFR_KO





_down 516 AACTTT_UNKNOWN 1890 2.10E-10 
UMSCC92_EGFR_KO
_down 516 AREB6_01 271 5.80E-10 
UMSCC92_EGFR_KO
_down 516 TGGNNNNNNKCCAR_UNKNOWN 424 2.06E-09 
UMSCC92_EGFR_KO
_down 516 TATAAA_TATA_01 1296 2.61E-09 
UMSCC92_EGFR_KO
_down 516 AP1_Q2_01 275 4.06E-09 
UMSCC92_EGFR_KO
_down 516 CAGCTG_AP4_Q5 1524 4.06E-09 
UMSCC92_EGFR_KO
_down 516 GGGTGGRR_PAX4_03 1294 6.48E-09 
UMSCC92_EGFR_KO
_down 516 AREB6_02 254 6.48E-09 
UMSCC92_EGFR_KO
_down 516 TGGAAA_NFAT_Q4_01 1896 9.60E-09 
UMSCC92_EGFR_KO
_down 516 HNF4_Q6 263 1.03E-08 
UMSCC92_EGFR_KO
_down 516 TTANTCA_UNKNOWN 952 1.66E-08 
UMSCC92_EGFR_KO
_down 516 WGGAATGY_TEF1_Q6 378 2.19E-08 
UMSCC92_EGFR_KO
_down 516 CTTTGT_LEF1_Q2 1972 3.16E-08 
UMSCC92_EGFR_KO
_down 516 GO_TISSUE_DEVELOPMENT 1518 3.81E-30 
UMSCC92_EGFR_KO
_down 516 GO_EPIDERMIS_DEVELOPMENT 253 6.28E-29 
UMSCC92_EGFR_KO
_down 516 GO_IMMUNE_SYSTEM_PROCESS 1984 2.72E-27 
UMSCC92_EGFR_KO
_down 516 GO_EPITHELIUM_DEVELOPMENT 945 6.77E-26 
UMSCC92_EGFR_KO
_down 516 GO_BIOLOGICAL_ADHESION 1032 2.46E-22 
UMSCC92_EGFR_KO
_down 516 GO_CELL_JUNCTION_ORGANIZATION 185 1.20E-21 
UMSCC92_EGFR_KO
_down 516 GO_RESPONSE_TO_EXTERNAL_STIMULUS 1821 1.77E-19 
UMSCC92_EGFR_KO
_down 516 GO_DEFENSE_RESPONSE 1231 2.16E-19 
UMSCC92_EGFR_KO
_down 516 GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 1929 3.90E-18 
UMSCC92_EGFR_KO
_down 516 GO_IMMUNE_RESPONSE 1100 1.47E-17 
UMSCC92_EGFR_KO
_down 516 GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 1532 1.88E-17 
UMSCC92_EGFR_KO
_down 516 GO_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 771 1.88E-17 
UMSCC92_EGFR_KO
_down 516 GO_REGULATION_OF_CELL_PROLIFERATION 1496 9.90E-17 
UMSCC92_EGFR_KO
_down 516 GO_CELL_JUNCTION_ASSEMBLY 129 5.77E-16 
UMSCC92_EGFR_KO
_down 516 GO_SKIN_DEVELOPMENT 211 8.19E-16 
UMSCC92_EGFR_KO
_down 516 GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 1403 5.50E-15 
UMSCC92_EGFR_KO
_down 516 GO_REGULATION_OF_HYDROLASE_ACTIVITY 1327 7.87E-15 
UMSCC92_EGFR_KO
_down 516 GO_REGULATION_OF_PEPTIDASE_ACTIVITY 392 6.18E-14 
UMSCC92_EGFR_KO
_down 516 GO_CELL_DEATH 1001 2.56E-13 
UMSCC92_EGFR_KO
_down 516 GO_ORGAN_MORPHOGENESIS 841 2.67E-13 
UMSCC92_EGFR_KO





_down 516 MEK_UP.V1_UP 196 3.06E-18 
UMSCC92_EGFR_KO
_down 516 ERB2_UP.V1_UP 191 1.51E-17 
UMSCC92_EGFR_KO
_down 516 SINGH_KRAS_DEPENDENCY_SIGNATURE_ 20 1.94E-17 
UMSCC92_EGFR_KO
_down 516 LEF1_UP.V1_DN 190 1.11E-16 
UMSCC92_EGFR_KO
_down 516 AKT_UP_MTOR_DN.V1_UP 184 7.76E-15 
UMSCC92_EGFR_KO
_down 516 AKT_UP.V1_UP 172 1.82E-14 
UMSCC92_EGFR_KO
_down 516 ESC_V6.5_UP_EARLY.V1_DN 172 1.82E-14 
UMSCC92_EGFR_KO
_down 516 MEL18_DN.V1_DN 148 1.52E-13 
UMSCC92_EGFR_KO
_down 516 ESC_J1_UP_LATE.V1_UP 191 1.48E-10 
UMSCC92_EGFR_KO
_down 516 KRAS.LUNG_UP.V1_DN 145 1.78E-10 
UMSCC92_EGFR_KO
_down 516 RAF_UP.V1_UP 196 1.86E-10 
UMSCC92_EGFR_KO
_down 516 BMI1_DN_MEL18_DN.V1_DN 147 1.86E-10 
UMSCC92_EGFR_KO
_down 516 RB_P107_DN.V1_DN 128 2.60E-10 
UMSCC92_EGFR_KO
_down 516 EGFR_UP.V1_UP 193 1.10E-09 
UMSCC92_EGFR_KO
_down 516 STK33_SKM_DN 288 1.68E-09 
UMSCC92_EGFR_KO
_down 516 TBK1.DF_UP 290 1.78E-09 
UMSCC92_EGFR_KO
_down 516 ATF2_UP.V1_DN 187 5.06E-09 
UMSCC92_EGFR_KO
_down 516 ATF2_S_UP.V1_DN 187 4.06E-08 
UMSCC92_EGFR_KO
_down 516 LTE2_UP.V1_UP 190 4.80E-08 
Table 4-7. Downregulated gene sets enriched in each of the 13 cetuximab-treated gene sets 
and EGFR K/O gene sets 
Gene set enrichment analysis was performed with significantly downregulated genes from each 
of the 14 gene sets to identify significant overlap with gene sets in the “Hallmark”, “Motif”, 
“Go-Biological Process” and “Oncogene” databases with the molecular signatures database v5.1. 
Node is the sample, and Node Size is the number of input genes from the sample. Gene Set 
Name is the pathway enriched, with # of Genes in Gene Set being the number of genes in the 
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Chapter 5: Summary and Perspectives 
Summary 
My thesis examined the hypothesis that co-targeting the epidermal growth factor receptor 
(EGFR) and a compensatory pathway could be an effective combination to cause cell death in 
head and neck squamous cell carcinoma (HNSCC). My work first characterized the genetics of a 
panel of UM-SCC cell lines, which are frequently used models for HNSCC. I then used CRISPR 
libraries to identify genes and pathways that compensate during inhibition of EGFR, leading to 
the nomination of the fibroblast growth factor (FGF) pathway as a common compensatory 
mechanism in HNSCC. Further, I evaluated the mechanism of dual inhibition of EGFR and 
FGFR, and also tested this combination in a mouse xenograft model. Here, I review the main 
findings of my thesis, identify remaining questions, and discuss possible directions for future 
work.  
 
Section 1: Challenges to precision medicine in HNSCC 
Head and neck squamous cell carcinoma (HNSCC) remains a disease with poor outcomes 
(1). To generate new, effective strategies to improve patient survival, much work has been done 
to develop precision medicine protocols – protocols that use genetic understandings of the cancer 
to affect the course of treatment.  Notably, The Cancer Genome Atlas (TCGA)(2) as well as 
others (3, 4) have made strides to identify genetic mutations and copy number alterations, 
offering genetic insight into HNSCC. In chapter one of this thesis, I reviewed genetic signatures 




for that cohort. This genetic information, for HNSCC as well as other cancer types, has allowed 
for significant strides in designing and implementing effective precision medicine approaches. 
Several groups have enrolled patients with metastatic or recurrent cancer into clinical trials that 
use sequencing information to identify actionable mutations to inform treatment decisions (5-7). 
While the rate of success has not been overwhelming, with the highest rate being Gustave 
Roussy with 10/68 (15%)(5), the metastatic and recurrent setting makes turnaround time of 
sequencing results and maintaining health for clinical trial eligibility a challenge (5, 6). Still, this 
is a promising precedent that when biomarkers are found, they can be effectively leveraged even 
in metastatic and recurrent cancers.   
 The need for biomarkers is especially apparent given the results of the clinical trial 
RTOG 1016 which evaluated the possible de-escalation of oropharyngeal carcinoma that are 
positive for human papillomavirus (HPV). As HPV-positive cancers generally do well under 
treatment (8), this de-escalation evaluated if radiotherapy plus cetuximab would offer similar 
outcomes as the standard, but more toxic (9), treatment of radiotherapy plus cisplatin. 
Unfortunately, patients receiving radiotherapy plus cetuximab had worse overall survival and 
progression-free survival compared to patients who received radiotherapy plus cisplatin(10). The 
failure of this de-escalation trial illuminates a need to understand biomarkers of response and be 
able to match tumors to therapy to prevent failures from future trials. For example, if we had a 
biomarker of known response to cetuximab, then HPV+ cancers containing this biomarker would 
more likely respond to cetuximab plus radiotherapy than cisplatin plus radiotherapy. 
Alternatively, if the tumor had a biomarker for known sensitivity to cisplatin, then the most 
effective therapy may likely be cisplatin plus radiotherapy. In fact, in another trial that evaluated 




efficacies (11). Notably, this trial is underpowered with 70 patients compared to the 987 patients 
enrolled in RTOG 1016, but there is potential for higher efficacy with both cetuximab and 
cisplatin in early stage HNSCC with the utilization of appropriate biomarkers, hence why I 
focused on EGFR inhibition and cisplatin therapy in my thesis work. My results from chapter 
three suggest that evaluating NOTCH1 genetic status, or the activity of the Notch signaling 
pathway, may be useful as a biomarker for cisplatin sensitivity. As previously discussed, 
advancement of a combination therapy of cisplatin and Notch inhibition is unlikely due to 
toxicity, but Notch status may prove an effective marker for response to cisplatin therapy.  
 In the quest to identify biomarkers and advance precision medicine strategies, the genetic 
complexity of most of HNSCC tumors has been a challenge. The high number of alterations 
spanning across multiple pathways in HNSCC (2-4, 12, 13) makes interpretation and 
prioritization of actionable alterations difficult. Therefore, to develop and advance biomarkers, 
we need to identify and use models that represent this genetic complexity of HNSCC. While the 
identification of genetic alterations from the TCGA as well as other cohorts have made great 
contributions to understanding the genetic landscape of HNSCC, we now need to combine this 
understanding with phenotypic responses. Thus, in chapter two of my thesis, I characterized the 
genetic landscape of 14 oral cavity UM-SCC cell lines. These UM-SCC cell lines have been used 
as models in HNSCC research for decades, and we now have the ability to combine the 
phenotypic information gathered with the underlining genetic processes in the cell lines. We now 
know that these UM-SCC cell lines have very similar genetic alterations to each other, such 
amplification of EGFR and PIK3CA and mutations in TP53. Surprisingly, the cell lines had 
multiple genetic events along the same pathway, and this redundancy means that overall the cell 




suggesting a need for developing additional models for study. However, although these cell lines 
are derived largely from primary untreated disease, they tend to represent the genetic 
composition of tumors from metastatic HNSCC with their high mutational burden, and therefore 
may be particularly useful in the study of resistance. As discussed in chapter two, other available 
HNSCC cell line models do not seem to have the diversity or number of mutations that are in the 
UM-SCC cell lines, such as frequent NOTCH1 or TP53 mutations. However, evaluating 
therapeutic resistance and advancement of biomarkers in this challenging setting of high, 
recurrent mutational loads within the UM-SCC cell lines is a relevant struggle to translating 
results for clinical benefit in HNSCC.  
 
Section 2: Utilizing CRISPR screens to identify co-dependent genes and/or pathways 
Advances in the CRISPR/Cas9 system, still new enough to be considered recent, have 
made CRISPR and genetic engineering a more widespread phenomenon. Along with the 
technological advances for CRISPR/Cas9 came CRISPR screening libraries, powerful 
alternatives to siRNA or shRNA libraries. 2014 saw the first of the CRISPR screening libraries 
in both mouse and human cell lines (14-17). These first papers represent both positive and 
negative selection screens, for example identifying genes that create resistance to thioguanine in 
a sensitive CML cell line(16) or vemurafenib in a BRAF mutant melanoma cell line(14).  
For my thesis, I adapted new CRISPR screening strategies that had only just been 
developed to identify genes and pathways that were co-dependent with EGFR signaling and 
cisplatin therapy. I used these initial screens to set the parameters of my own CRISPR screening. 
Notably, that a vehicle control is run alongside the treatment group for comparison of loss or 




previous setups of 12-14 days in the literature. In Shalem et al, they observed more distinctive 
shifts in gRNA representation at 14 days than after 7 days of treatment(14).  
We chose to use the MAGeCK algorithm(18) as it was one of the first pipelines for 
CRISPR analysis that was publicly available, and that the MAGeCK algorithm can be used for 
negative selection screen comparisons of treatment versus control groups. For comparison, some 
analysis pipelines such as BAGEL(19) require comparison to an earlier passage of the library 
pre-treatment. Additionally, other publicly available tools such as caRpool (20) are not as well-
cited (caRpool’s <10 citations compared to >100 for MAGeCK). Additionally, MAGeCK is 
supposed to be robust and able to make accurate calls even when there are fewer gRNAs per 
gene in the screen, though as discussed in chapter three we still struggled with prioritizing targets 
in the genome-wide screens that had less gRNA coverage.  
In looking to compare our data with the literature we modeled our screens after, it is 
important to note that the MAGeCK pipeline was not available for the initial published CRISPR 
screens. However, Li et al. re-analyzed both Wang et al. and Shalem et al.’s results to show the 
utility of MAGeCK (18). As such, it allows for comparison of the results of my CRISPR screens 
to these initial papers. In the original publication, Wang et al. used the Kolmogorov-Smirov test 
with p-value correction, and noted 2 genes of significance in their negative selection screen (16). 
Shalem et al. used the RNAi analysis method RIGER, and noted 6 genes of significance (14). 
Neither study mentioned the total number of genes, only the genes they highlighted for further 
validation. The MAGeCK algorithm identified >100 more significant genes with a p-value <0.05 
for both studies (18). Unfortunately, the complete analysis was not published, only the top 100 




GeCKO library of ~3 gRNAs/gene as similar to my data, or ~100 significant genes for the library 
of 10gRNAs/gene like the kinome.      
While analysis pipelines attempt to be robust and make accurate calls when there are few 
gRNAs per gene, it provides much more confidence in the results when multiple gRNAs exhibit 
the desired phenotype. We found the results of the kinome library easier to prioritize given the 
expected recurrence of genes across our EGFR inhibitors and cell lines, and we expect this is due 
to the relatively large number of gRNAs per gene. Although, the Cancer Dependency Map, 
which screened a large CRISPR library with an average of 4 gRNAs per gene across 342 cancer 
cell lines, has the depth of data for robust analysis (21). However, this scale of experiment was 
infeasible for my thesis, and so we found more utility out of the kinome library with 10 gRNAs 
per gene than the genome-wide library with 3 gRNAs, at least when considering each library on 
its own. Combined, we’ve generated a wealth of data that we have explored to answer our 
primary scientific question, which can be mined by many future researchers. 
An additional, interesting direction would have been setting up a positive selection screen 
and identifying genetic knockouts that created resistance to EGFR inhibition. This approach 
would have offered the benefits of generating the mechanistic models of interest for subsequent 
validation. After treatment with EGFR inhibition, a portion of cells could have been preserved 
for cloning out and further mechanistic work. For the negative selection model, the knockouts of 
most interest are a small population among the majority or are missing entirely because the 
knockouts underwent cell death in response to EGFR inhibition. For my validation, it required 
remaking the individual genetic knockouts for further experimentation and mechanistic work. 




gefitinib or erlotinib and therefore were not the appropriate models to address this question of 
using a positive selection approach.  
 
Section 3: Identifying & Validating Resistance Mechanisms 
In using CRISPR screens to identify genes that, when lost, generate sensitivity to 
HNSCC therapies, we assume that one gene plays a major role in resistance. In some cases, this 
appears to be true. In our CRISPR screen to identify genetic knockouts that create sensitivity to 
cisplatin, we identified several genes in the Notch pathway as significantly depleted. We then 
went on to validate that NOTCH1 loss specifically created sensitivity to cisplatin, and despite 
changes in expression of Notch2, the other Notch receptors were unable to compensate for the 
lack of Notch1. We also identified FGFR3 alone as a sensitizer to EGFR inhibition. Like the 
Notch receptors, FGFR3 is a part of a family of receptors that are generally understood to 
activate similar downstream pathways. The genetic knockout of FGFR3 alone was enough to 
cause sensitivity to EGFR inhibition. However, in the case of FGFR3 knockouts, cell death was 
significantly higher when a pan-FGFR inhibitor was in combination with EGFR inhibition, and 
not simply EGFR inhibition and FGFR3 loss. While we did not observe any upregulation of the 
other FGFRs in response to the FGFR3 knockout, there does seem to be compensation from the 
other FGFRs when EGFR is inhibited.  
As CRISPR screens designed to knockout a single gene have generated targets and 
validated hits, both ours and others, the data suggest that one gene can play a major role in 
resistance. Notably, the results of genetic knockouts that were clonally derived, such as in this 
work, may be caveated as representing only a subset of the heterogeneity in the cell line. 




genetic knockouts also significantly affected the heterogenous wildtype model. Creating genetic 
knockouts in cell line models with heterogeneity may be a concern, but our work suggests that 
impactful results can still be generated. However, we can’t ignore that additional compensation 
can and still happens. While we did not see compensation for the loss of NOTCH1 when treated 
with cisplatin, we did see compensation from other FGFRs during EGFR inhibition when 
FGFR3 was knocked out. Then, when we generated the EGFR knockout model and treated the 
cell line with FGFR inhibitors, we did not get complete cell death and kill every cell. Eventually, 
cells can compensate under inhibition and genetic loss, and resistance occurs. Perhaps then it is 
better to target pathways, and more broadly shut down cellular signals to prevent the chance for 
compensation. Our CRISPR screens identify individual genes, but we are able to collate that 
information into understanding pathways that play a role in resistance – such as KRAS signaling. 
Targeting pathways in attempts to circumvent compensation early may help improve efficacy of 
inhibitors and improve patient survival. Broader-based therapies targeting pathways rather than 
specific genes may be especially needed for patients with metastatic or recurrent cancer, which 
for HNSCC is a common presentation (22). The additional mutational burden in HNSCC cancers 
lend to giving tumors multiple options and opportunities for compensation. While our work in 
UM-SCC models - that we characterized with a large mutational load and still containing 
heterogeneity - supports that targeted therapy combinations can be effective, it is most likely that 
resistance and compensation will continue to be a challenge.  
Some work on the dual inhibition of EGFR and FGFR has already been accomplished, 
mostly in lung cancer but also HNSCC (23-27). This inhibition was founded based on the noted 
frequent amplification of FGFR1 in both cancer types. Amplification and overexpression of 




sensitive to FGFR inhibition (24, 27, 28). Multiple FGFR-targeted therapies are approved for 
treatment (23, 29), and it had been noted that EGFR signaling is a possible resistance mechanism 
to FGFR monotherapy (30). While none of the UM-SCC models that were tested for my thesis 
were sensitive to FGFR inhibition as a monotherapy, our results suggest that FGFR may be a 
more common compensatory mechanism than previously realized. Cell lines that responded to 
dual inhibition had a mix of amplifications and deletions of each FGFR receptor, as well as cell 
lines that remained resistant. Even expression profiles of the receptors did not predict sensitivity 
to combined EGFR and FGFR inhibition, though we did not evaluate different isoforms of the 
FGFRs that may be expressed. Our data suggest that FGFR1 amplification is not the biomarker 
of FGFR compensation, and that this dual inhibition may be effective in a broader selection of 
patients.  
However, the most limiting factor in translating this combination to the clinic is the 
toxicity of combining EGFR and FGFR inhibitors. A trial of the EGFR inhibitor erlotinib and 
pan-FGFR inhibitor dovitinib in metastatic non-small cell lung cancer was halted early given 
dose limiting toxicities (31), and no other combination of EGFR and FGFR inhibitors has been 
attempted in a trial since. However, no biomarker was used to restrict patient eligibility, and the 
status of the FGF receptors were unknown. One patient of the nine enrolled in the study had a 
partial response, indicating that the combination of EGFR and FGFR could be effective without 
the unexpected toxicity for this combination. Unfortunately, further investigation into the 
combination of EGFR and FGFR inhibitors may be halted for the time being. While multiple 
FGFR inhibitors are approved for use and cetuximab would have a different toxicity profile than 
erlotinib, it is unlikely for such a study to be attempted without additional work investigating 




Of potential future interest is anlotinib, a new inhibitor that targeted FGFR, vascular 
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), 
and c-kit (32). Given the signaling similarities of FGFR, VEGF, and PDGF (33), it is possible 
that VEGF and PDGF may be secondary or tertiary compensatory mechanisms to EGFR and 
FGFR dual inhibition. As discussed above, a broad-based tyrosine kinase inhibitor targeting 
multiple pathways may be especially beneficial in metastatic settings, though again toxicity will 
be a major concern. Several trials are recruiting or will be recruiting for the combination 
treatment of an EGFR inhibitor including gefitinib, erlotinib, or icotininb, along with anlotinib 
(NCT03736837, NCT03720873, NCT03766490, NCT03461185), and it will be interesting to see 
the results. These trials are for non-small cell lung cancer, and the biomarkers for eligibility 
include EGFR del19 or L858R, EGFR mutations known to be sensitive to EGFR inhibitors, and 
an absence of EGFR T790M, a known mutation that prevents first generation EGFR inhibitors 
from binding to EGFR.  
It would be interesting to test our UM-SCC models with the combination of EGFR 
inhibition and anlotinib, and determine if lines respond. I would expect cell lines that respond to 
EGFR and FGFR inhibition to also respond to EGFR inhibition and anlotinib, perhaps with even 
greater sensitivity. If so, this could speak to a common downstream node from these receptors 
that would illuminate the mechanism behind this pathway compensation. Additionally, perhaps 
cell lines that do not respond to dual EGFR and FGFR inhibition may respond to EGFR, FGFR, 
VEGF, and PDGF inhibition, suggesting that VEGF and PDGF are compensating during EGFR 
and FGFR inhibition. 
One possible mechanism for FGFR compensation during EGFR inhibition that was noted 




samples as well, with another group noticing loss of AKT and ERK inhibition under dual 
inhibition (25). Our investigation of the MAPK pathway, including AKT and ERK 
phosphorylation, showed decreases in activation of these downstream effectors, but the 
combination treatment did not have observable differences from EGFR inhibition alone. 
Additionally, UM-SCC cell lines that do not undergo cell death under dual inhibition of EGFR 
and FGFR also had decreased phosphorylation and activation of these downstream effectors in 
the combination treatment. If it is reactivation of the Ras-MAPK pathway that is a key player in 
the compensatory response, then perhaps additional timepoints to observe the reactivation in the 
non-responsive models will need to be investigated. Additionally, perhaps a more wide-spread 
approach, such as a phospho-proteomics screen, would help illuminate critical downstream 
effectors of this response.  
An interesting mechanism of FGFR compensation to EGFR inhibition that was observed 
in lung adenocarcinoma is the physical interaction of EGFR and FGFR1 (26), suggesting that 
FGF ligands can then stimulate EGFR and EGF ligands can stimulate FGFR1. However, this 
mechanism does not seem applicable to my work in HNSCC. The EGFR K/O model, with the 
complete loss of EGFR, still upregulated FGFR1 expression and was sensitive to FGFR 
inhibition. If a physical interaction and co-activation of EGFR and FGFR1 was essential to 
compensation, then inhibition of FGFR should not have affected cell survival.   
For colon and lung cancer, a frequent resistance mechanism to cetuximab treatment is the 
acquiring of somatic mutations (35), but these are infrequently seen in HNSCC (2, 12, 13). 
Instead, focus for HNSCC has been observing changes in expression, such as the frequent 
overexpression of MET, FGFR1, or AXL either intrinsic or in response to EGFR inhibition. As 




uncovering mutations. However, there are known Ras signaling expression signatures from work 
done in colon and breast cancer (36), and it would be interesting to compare the expression 
profile to the pre- and post- cetuximab treated transcriptomes in HNSCC. For samples that had a 
significant enrichment of up- or down-regulated Ras genes post-treatment, then it would suggest 
that other cancer treatments to circumvent Ras activation or suppress Ras signaling may also be 
effective in HNSCC. Additionally, the Ras expression profile could serve as a biomarker for 
adapting treatment for known Ras-mediated resistance.  
 
Section 4. Future Directions 
Future work that I think would be exciting to explore is an in-depth look at heterogeneity 
within a tumor or cell line and how this might factor into response. More specifically, an 
experimental approach that could address if differential compensation mechanisms arise from the 
same tumor due to heterogeneity. Given the mutational load in metastatic and recurrent HNSCC, 
as well as the multiple potential resistance mechanisms, it’s possible that a tumor may contain 
60% of cells that rely on FGFR signaling for compensation and 40% on MET signaling, for 
example. Single cell sequencing of a heterogenous population after EGFR inhibition would be 
one method to address this question. If a heterogenous population responds similarly to EGFR 
inhibition, then it would shift focus onto identifying and targeting the primary compensation 
pathway, with more focus on sequential resistance mechanisms. If there are differential 
populations after EGFR inhibition, then it’s possible that multiple compensatory pathways will 
need to be targeted in combination such as EGFR, FGFR, and MET signaling as in the example 
discussed above. If only two of the three pathways are targeted, then the sub-population will 




I anticipate that work will continue on identifying and validating combination therapies 
for potential advancement into HNSCC. The data of my thesis supports the hypothesis that 
targeted therapies in combination can be more effective than monotherapies. Strides in clinical 
benefits are yet to be seen, however, and it will continue to be difficult to prove efficacy in 
metastatic and recurrent settings where combination therapies are usually tested. Biomarkers will 
be of particular importance to restrict enrollment and include patients that have a chance at 
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